U.S. patent application number 16/844262 was filed with the patent office on 2020-10-01 for heterocyclic compounds as monoacylglycerol lipase inhibitors.
This patent application is currently assigned to Hoffmann-La Roche Inc.. The applicant listed for this patent is Hoffmann-La Roche Inc.. Invention is credited to Charles BELL, Joerg BENZ, Luca GOBBI, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Benoit HORNSPERGER, Buelent KOCER, Carsten KROLL, Bernd KUHN, Martin KURATLI, Marius Daniel Rinaldo LUTZ, Fionn O'HARA, Hans RICHTER, Martin RITTER, Didier ROMBACH.
Application Number | 20200308190 16/844262 |
Document ID | / |
Family ID | 1000004896722 |
Filed Date | 2020-10-01 |
![](/patent/app/20200308190/US20200308190A1-20201001-C00001.png)
![](/patent/app/20200308190/US20200308190A1-20201001-C00002.png)
![](/patent/app/20200308190/US20200308190A1-20201001-C00003.png)
![](/patent/app/20200308190/US20200308190A1-20201001-C00004.png)
![](/patent/app/20200308190/US20200308190A1-20201001-C00005.png)
![](/patent/app/20200308190/US20200308190A1-20201001-C00006.png)
![](/patent/app/20200308190/US20200308190A1-20201001-C00007.png)
![](/patent/app/20200308190/US20200308190A1-20201001-C00008.png)
![](/patent/app/20200308190/US20200308190A1-20201001-C00009.png)
![](/patent/app/20200308190/US20200308190A1-20201001-C00010.png)
![](/patent/app/20200308190/US20200308190A1-20201001-C00011.png)
View All Diagrams
United States Patent
Application |
20200308190 |
Kind Code |
A1 |
BELL; Charles ; et
al. |
October 1, 2020 |
HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS
Abstract
The invention provides new heterocyclic compounds having the
general formula ##STR00001## wherein A, L, X, m, n, R.sup.1 and
R.sup.2 are as described herein, compositions including the
compounds, processes of manufacturing the compounds and methods of
using the compounds.
Inventors: |
BELL; Charles; (Basel,
CH) ; BENZ; Joerg; (Basel, CH) ; GOBBI;
Luca; (Basel, CH) ; GRETHER; Uwe; (Basel,
CH) ; GROEBKE ZBINDEN; Katrin; (Basel, CH) ;
HORNSPERGER; Benoit; (Basel, CH) ; KOCER;
Buelent; (Basel, CH) ; KROLL; Carsten; (Basel,
CH) ; KUHN; Bernd; (Basel, CH) ; LUTZ; Marius
Daniel Rinaldo; (Basel, CH) ; O'HARA; Fionn;
(Basel, CH) ; RICHTER; Hans; (Basel, CH) ;
RITTER; Martin; (Basel, CH) ; ROMBACH; Didier;
(Basel, CH) ; KURATLI; Martin; (Basel,
CH) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Hoffmann-La Roche Inc. |
Little Falls |
NJ |
US |
|
|
Assignee: |
Hoffmann-La Roche Inc.
Little Falls
NJ
|
Family ID: |
1000004896722 |
Appl. No.: |
16/844262 |
Filed: |
April 9, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
PCT/EP2019/071520 |
Aug 12, 2019 |
|
|
|
16844262 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 519/00 20130101;
C07D 498/04 20130101 |
International
Class: |
C07D 498/04 20060101
C07D498/04; C07D 519/00 20060101 C07D519/00 |
Foreign Application Data
Date |
Code |
Application Number |
Aug 13, 2018 |
EP |
18188681.3 |
Claims
1-56. (canceled)
57. A compound of formula (I): ##STR00324## or a pharmaceutically
acceptable salt thereof, wherein: (i) X is C--R.sup.3; m is 0 or 1;
n is selected from 0, 1 and 2; and L is selected from
--(CH.sub.2).sub.p--, --O--, --OCH.sub.2--, --CH.sub.2OCH.sub.2--,
--CF.sub.2CH.sub.2--, --CH.sub.2.dbd.CH.sub.2--,
--(CR.sup.16R.sup.17).sub.q--CH.sub.2O--, and --CH.sub.2CF.sub.2--;
or (ii) X is N; m is 1; n is 1 or 2; and L is --(CH.sub.2).sub.p--
or --CF.sub.2CH.sub.2--; p is selected from 1, 2, and 3; q is 0 or
1; A is selected from: (i) C.sub.6-C.sub.14-aryl substituted with
R.sup.4, R.sup.5, and R.sup.6; (ii) 5- to 14-membered heteroaryl
substituted with R.sup.7, R.sup.8, and R.sup.9; and (iii) 3- to
14-membered heterocycloalkyl substituted with R.sup.10, R.sup.11,
and R.sup.12; R.sup.1 is hydrogen or C.sub.1-6-alkyl; R.sup.2 is
selected from hydrogen, C.sub.1-6-alkyl, and
hydroxy-C.sub.1-6-alkyl; R.sup.3 is selected from hydrogen,
halogen, hydroxy, C.sub.1-6-alkoxy, C.sub.1-6-alkyl, and
halo-C.sub.1-6-alkyl; each of R.sup.4, R.sup.5, R.sup.6, R.sup.7,
R.sup.8, R.sup.9, R.sup.10, R.sup.11 and R.sup.12 is independently
selected from hydrogen, halogen, cyano, hydroxy, C.sub.1-6-alkyl,
halo-C.sub.1-6-alkyl, hydroxy-C.sub.1-6-alkyl, C.sub.1-6-alkanoyl,
halo-C.sub.1-5-alkyl-CH(OH)--, C.sub.1-6-alkoxy,
halo-C.sub.1-6-alkoxy, SF.sub.5, CH.sub.3SO.sub.2,
C.sub.3-10-cycloalkyl, C.sub.3-10-cycloalkyl substituted with
R.sup.13, 3- to 14-membered heterocycloalkyl, 3- to 14-membered
heterocycloalkyl substituted with R.sup.14 and R.sup.15, 5- to
14-membered heteroaryl, C.sub.6-C.sub.14-aryl,
C.sub.6-C.sub.14-aryloxy, halo-C.sub.6-C.sub.14-aryl, and
halo-C.sub.6-C.sub.14-aryloxy; each of R.sup.13, R.sup.14, and
R.sup.15 is independently selected from C.sub.1-6-alkyl,
C.sub.1-6-alkoxy, halo-C.sub.1-6-alkyl, halo-C.sub.1-6-alkoxy,
halogen, and hydroxy; and R.sup.16 and R.sup.17, taken together
with the carbon atom to which they are attached, form a
C.sub.3-10-cycloalkyl.
58. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein the compound of formula (I) is a compound of
formula (Ia): ##STR00325## wherein A, L, X, m, n, R.sup.1, and
R.sup.2 are as defined in claim 57.
59. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein the compound of formula (I) is a compound of
formula (Ib): ##STR00326## wherein A, L, X, m, n, R.sup.1, and
R.sup.2 are as defined in claim 57.
60. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein: (i) X is C--R.sup.3; m is 0 or 1; n is selected
from 0, 1, and 2; and L is selected from --(CH.sub.2).sub.p--,
--O--, --OCH.sub.2--, --CF.sub.2CH.sub.2--,
--CH.sub.2.dbd.CH.sub.2--,
--(CR.sup.16R.sup.17).sub.q--CH.sub.2O--, and
--CH.sub.2OCH.sub.2--; or (ii) X is N; m and n are both 1; and L is
--(CH.sub.2).sub.p--.
61. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein: X is C--R.sup.3; m and n are both 0; or m and n
are both 1; and L is selected from --(CH.sub.2).sub.p--, --O--,
--OCH.sub.2-- and --CH.sub.2O--.
62. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein p is 1 or 2.
63. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein p is 2.
64. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein q is 0 or 1.
65. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein q is 0.
66. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein A is selected from: (i) C.sub.6-C.sub.14-aryl
substituted with R.sup.4, R.sup.5 and R.sup.6; and (ii) 5- to
14-membered heteroaryl substituted with R.sup.7, R.sup.8 and
R.sup.9.
67. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein A is selected from: (i) phenyl substituted with
R.sup.4, R.sup.5, and R.sup.6; (ii) oxazolyl substituted with
R.sup.7, R.sup.8, and R.sup.9; and (iii) pyridyl substituted with
R.sup.7, R.sup.8, and R.sup.9.
68. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.1 is hydrogen.
69. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.2 is hydrogen or C.sub.1-6-alkyl.
70. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.2 is hydrogen or methyl.
71. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.3 is selected from hydrogen, halogen,
C.sub.1-6-alkyl, and halo-C.sub.1-6-alkyl.
72. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.3 is selected from hydrogen, halogen, and
C.sub.1-6-alkyl.
73. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.3 is selected from hydrogen, fluoro, and
methyl.
74. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.4 is selected from hydrogen, halogen,
hydroxy, cyano, C.sub.1-6-alkyl, C.sub.1-6-alkanoyl, SF.sub.5,
C.sub.1-6-alkoxy, halo-C.sub.1-6-alkoxy, halo-C.sub.1-6-alkyl,
C.sub.3-10-cycloalkyl, 3- to 14-membered heterocyclyl, 3- to
14-membered heterocycloalkyl substituted with R.sup.14 and
R.sup.15, 5- to 14-membered heteroaryl, C.sub.6-C.sub.14-aryloxy,
and halo-C.sub.6-C.sub.14-aryl.
75. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.4 is selected from halogen, SF.sub.5,
C.sub.1-6-alkyl, C.sub.1-6-alkoxy, halo-C.sub.1-6-alkoxy,
halo-C.sub.1-6-alkyl, C.sub.3-10-cycloalkyl, and 3- to 14-membered
heterocycloalkyl.
76. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.4 is selected from chloro, SF.sub.5, methyl,
methoxy, OCF.sub.3, CF.sub.3, cyclopropyl, and
2-azaspiro[3.3]heptan-2-yl.
77. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.5 is selected from hydrogen, cyano, halogen,
C.sub.1-6-alkyl, halo-C.sub.1-6-alkyl, C.sub.1-6-alkoxy, 3- to
14-membered heterocycloalkyl, C.sub.3-10-cycloalkyl, 5- to
14-membered heteroaryl, and halo-C.sub.6-C.sub.14-aryl.
78. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.5 is selected from hydrogen, cyano, halogen,
C.sub.1-6-alkyl, halo-C.sub.1-6-alkyl, 3- to 14-membered
heterocycloalkyl, C.sub.3-10-cycloalkyl, and
halo-C.sub.6-C.sub.14-aryl.
79. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.5 is selected from hydrogen, cyano, fluoro,
chloro, methyl, CF.sub.3, pyrrolidinyl, cyclopentyl, cyclopropyl,
and chlorophenyl.
80. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.6 is hydrogen or halogen.
81. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.6 is hydrogen.
82. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.7 is selected from hydrogen,
C.sub.1-6-alkyl, C.sub.6-C.sub.14-aryl, halo-C.sub.6-C.sub.14-aryl,
halo-C.sub.6-C.sub.14-aryloxy, and halo-C.sub.1-6-alkyl.
83. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.7 is C.sub.1-6-alkyl or
halo-C.sub.1-6-alkyl.
84. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.7 is tert-butyl or CF.sub.3.
85. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.8 is selected from hydrogen, halogen,
C.sub.1-6-alkyl, and halo-C.sub.1-6-alkyl.
86. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.8 is hydrogen or halo-C.sub.1-6-alkyl.
87. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.8 is hydrogen or CF.sub.3.
88. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.9 is hydrogen.
89. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.10 is halogen.
90. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.11 is halogen.
91. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.12 is hydrogen.
92. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.14 is selected from C.sub.1-6-alkyl,
C.sub.1-6-alkoxy, and halogen.
93. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein R.sup.15 is hydrogen or halogen.
94. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein: (i) X is C--R.sup.3; m is 0 or 1; n is selected
from 0, 1, and 2; and L is selected from --(CH.sub.2).sub.p--,
--O--, --OCH.sub.2--, --(CR.sup.16R.sup.17).sub.q--CH.sub.2O--,
--CH.sub.2OCH.sub.2--, --CF.sub.2CH.sub.2--, and
--CH.sub.2.dbd.CH.sub.2--; or (ii) X is N; m and n are both 1; and
L is --(CH.sub.2).sub.p--; p is 1 or 2; q is 0 or 1; A is selected
from: (i) C.sub.6-C.sub.14-aryl substituted with R.sup.4, R.sup.5,
and R.sup.6; (ii) 5- to 14-membered heteroaryl substituted with
R.sup.7, R.sup.8, and R.sup.9; and (iii) 3- to 14-membered
heterocycloalkyl substituted with R.sup.10, R.sup.11, and R.sup.12;
R.sup.1 is hydrogen or C.sub.1-6-alkyl; R.sup.2 is hydrogen or
C.sub.1-6-alkyl; R.sup.3 is selected from hydrogen, halogen,
C.sub.1-6-alkyl, and halo-C.sub.1-6-alkyl; R.sup.4 is selected from
hydrogen, halogen, cyano, SF.sub.5, C.sub.1-6-alkyl,
C.sub.1-6-alkanoyl, C.sub.1-6-alkoxy, halo-C.sub.1-6-alkoxy,
halo-C.sub.1-6-alkyl, C.sub.3-10-cycloalkyl, 3- to 14-membered
heterocycloalkyl, 3- to 14-membered heterocycloalkyl substituted
with R.sup.14 and R.sup.15, 5- to 14-membered heteroaryl,
halo-C.sub.6-C.sub.14-aryl, and C.sub.6-C.sub.14-aryloxy; R.sup.5
is selected from hydrogen, cyano, halogen, C.sub.1-6-alkyl,
halo-C.sub.1-6-alkyl, C.sub.1-6-alkoxy, 3- to 14-membered
heterocycloalkyl, C.sub.1-10-cycloalkyl, 5- to 14-membered
heteroaryl, and halo-C.sub.6-C.sub.14-aryl; R.sup.6 is hydrogen or
halogen; R.sup.7 is selected from hydrogen, C.sub.1-6-alkyl,
C.sub.6-C.sub.14-aryl, halo-C.sub.6-C.sub.14-aryl,
halo-C.sub.6-C.sub.14-aryloxy, and halo-C.sub.1-6-alkyl; R.sup.8 is
selected from hydrogen, halogen, C.sub.1-6-alkyl, and
halo-C.sub.1-6-alkyl; R.sup.9 is hydrogen; R.sup.10 is halogen;
R.sup.11 is halogen; R.sup.12 is hydrogen; R.sup.14 is selected
from halogen, C.sub.1-6-alkyl, and C.sub.1-6-alkoxy; R.sup.15 is
hydrogen or halogen; and R.sup.16 and R.sup.17, taken together with
the carbon atom to which they are attached, form a
C.sub.3-10-cycloalkyl.
95. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein: X is C--R.sup.3; m and n are both 0; or m and n
are both 1; L is selected from --(CH.sub.2).sub.p--, --O--,
--OCH.sub.2-- and --CH.sub.2O--; p is 1 or 2; A is selected from:
(i) C.sub.6-C.sub.14-aryl substituted with R.sup.4, R.sup.5 and
R.sup.6; and (ii) 5- to 14-membered heteroaryl substituted with
R.sup.7, R.sup.8 and R.sup.9; R.sup.1 is hydrogen; R.sup.2 is
hydrogen or C.sub.1-6-alkyl; R.sup.3 is selected from hydrogen,
halogen and C.sub.1-6-alkyl; R.sup.4 is selected from halogen,
SF.sub.5, C.sub.1-6-alkyl, C.sub.1-6-alkoxy, halo-C.sub.1-6-alkoxy,
halo-C.sub.1-6-alkyl, C.sub.3-10-cycloalkyl, and 3- to 14-membered
heterocycloalkyl; R.sup.5 is selected from hydrogen, cyano,
halogen, C.sub.1-6-alkyl, halo-C.sub.1-6-alkyl, 3- to 14-membered
heterocycloalkyl, C.sub.3-10-cycloalkyl and
halo-C.sub.6-C.sub.14-aryl; R.sup.6 is hydrogen; R.sup.7 is
C.sub.1-6-alkyl or halo-C.sub.1-6-alkyl; R.sup.8 is hydrogen or
halo-C.sub.1-6-alkyl; and R.sup.9 is hydrogen.
96. The compound of claim 57, or a pharmaceutically acceptable salt
thereof, wherein: X is C--R.sup.3; m and n are both 0; or m and n
are both 1; L is selected from --(CH.sub.2).sub.p--, --O--,
--OCH.sub.2-- and --CH.sub.2O--; p is 1 or 2; A is selected from:
(i) phenyl substituted with R.sup.4, R.sup.5, and R.sup.6; (ii)
oxazolyl substituted with R.sup.7, R.sup.8, and R.sup.9; and (iii)
pyridyl substituted with R.sup.7, R.sup.8, and R.sup.9; R.sup.1 is
hydrogen; R.sup.2 is hydrogen or methyl; R.sup.3 is selected from
hydrogen, fluoro and methyl; R.sup.4 is selected from chloro,
SF.sub.5, methyl, methoxy, OCF.sub.3, CF.sub.3, cyclopropyl, and
2-azaspiro[3.3]heptan-2-yl; R.sup.5 is selected from hydrogen,
cyano, fluoro, chloro, methyl, CF.sub.3, pyrrolidinyl, cyclopentyl,
cyclopropyl and chlorophenyl; R.sup.6 is hydrogen; R.sup.7 is
selected from tert-butyl, methyl, and CF.sub.3; R.sup.8 is hydrogen
or CF.sub.3; and R.sup.9 is hydrogen.
97. A compound of claim 57, or a pharmaceutically acceptable salt
thereof, selected from the compounds disclosed in Table 1.
98. A compound of claim 57, wherein the compound is:
(+)-(4aR,8aS)-6-(4-((4-(tert-Butyl)oxazol-2-yl)methyl)piperidine-1-carbon-
yl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(+)-(4aR,8aS)-6-[4-[[4-(Trifluoromethyl)phenyl]methyl]piperidine-1-carbon-
yl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(+)-(4aR,8aS)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)piperidine-1-carbony-
l)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
rac-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)azetidine-1-c-
arbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or
(-)-(4aR,8aS)-6-(3-((2-Chloro-4-fluorobenzyl)oxy)azetidine-1-carbonyl)hex-
ahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or
(-)-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)azetidine-1-c-
arbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or
(-)-(4aR,8aS)-6-(4-(4-(Trifluoromethoxy)benzyl)piperidine-1-carbonyl)hexa-
hydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or
(-)-(4aR,8aS)-6-(4-(4-Chloro-3-fluorobenzyl)piperidine-1-carbonyl)hexahyd-
ro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or
(-)-(4aR,8aS)-6-(4-(2-Chloro-4-(trifluoromethyl)phenoxy)piperidine-1-carb-
onyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or
(-)-(4aR,8aS)-6-(4-(3-(Trifluoromethyl)phenoxy)piperidine-1-carbonyl)hexa-
hydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or
(-)-(4aR,8aS)-6-[4-[[2-Chloro-4-(trifluoromethoxy)phenoxy]methyl]piperidi-
ne-1-carbonyl]-4,4a
5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)- or
(-)-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethyl)phenoxy)methyl)azetid-
ine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(+)- or
(-)-(4aR,8aS)-6-(4-((4-Chloro-2-fluorophenoxy)methyl)piperidine-1-carbony-
l)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or
(-)-(4aR,8aS)-6-(4-((4-Fluoro-2-(trifluoromethyl)phenoxy)methyl)piperidin-
e-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)-
or
(-)-(4aR,8aS)-6-(4-((2-Fluoro-4-(trifluoromethyl)phenoxy)methyl)piperidin-
e-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)-
or
(-)-(4aR,8aS)-6-(4-(2-(Pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperid-
ine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(+)- or
(-)-(4aR,8aS)-6-4-((2-Chloro-4-(trifluoromethyl)phenoxy)methyl)piperidine-
-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)-
or
(-)-(4aR,8aS)-6-[4-[[2-Cyclopentyl-4-(trifluoromethyl)phenyl]methyl]piper-
idine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(+)- or
(-)-3-Chloro-4-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4-
]oxazine-6-carbonyl)piperidin-4-yl)methoxy)benzonitrile; (+)- or
(-)-(4aR,8aS)-6-(3-((2-Chloro-4-(trifluoromethyl)phenoxy)methyl)azetidine-
-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)-
or
(-)-(4aR,8aS)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)-4-fluoropiperidine--
1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or
(-)-(4aR,8aS)-6-(4-((4',6-Dichloro-[1,1'-biphenyl]-3-yl)oxy)piperidine-1--
carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or
(-)-(4aR,8aS)-6-(cis-4-((2-Chloro-4-fluorophenoxy)methyl)-3-methylpiperid-
ine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(+)- or
(-)-(4aR,8aS)-6-(3-((2-Chloro-4-(trifluoromethyl)benzyl)oxy)azetidine-1-c-
arbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or
(-)-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethoxy)benzyl)oxy)azetidine-1--
carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or
(-)-(4aR,8aS)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)-4-methylpiperidine--
1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(4aR,8aS)-6-[3-[(2,4-Dichlorophenyl)methoxy]azetidine-1-carbonyl]-4,4a,5,-
7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[4-[[2-Fluoro-4-(trifluoromethyl)phenyl]methyl]piperidine-1-c-
arbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[4-[[2-Cyclopropyl-4-(trifluoromethyl)phenyl]methyl]piperidin-
e-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[[3-Chloro-4-(trifluoromethyl)phenyl]methoxy]azetidine-1-c-
arbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[[2-Fluoro-5-(trifluoromethyl)phenyl]methoxy]azetidine-1-c-
arbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[2-[2-Fluoro-6-(trifluoromethyl)phenyl]ethyl]azetidine-1-c-
arbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-(3-(2-fluoro-4-(trifluoromethyl)phenethyl)azetidine-1-carbony-
l)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
6-(3-((2,4-bis(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro--
2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(4aR,8aS)-6-[4-[3-chloro-4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl-
]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-(3-methyl-4-(((5-methyl-6-(trifluoromethyl)pyridin-3-yl)oxy)m-
ethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on-
e;
(4aR,8aS)-6-(3-((3,4-dichlorobenzyl)oxy)azetidine-1-carbonyl)hexahydro--
2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(4aR,8aS)-6-(3-((2,5-dichlorobenzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-
-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
rac-(4aR,8aS)-6(2-methyl-3-((4-methyl-3-(trifluoromethyl)benzyl)oxy)azeti-
dine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(4aR,8aS)-6-(3-(((4,5-bis(trifluoromethyl)pyridin-2-yl)oxy)methyl)azetidi-
ne-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
rac-(4aR,8aS)-6-(3-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)-2-methyl
azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(4aR,8aS)-6-(3-((2-fluoro-4-(pentafluoro-16-sulfaneyl)benzyl)oxy)azetidin-
e-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(4aR,8aS)-6-(3-((4-methyl-2-(trifluoromethoxy)benzyl)oxy)azetidine-1-carb-
onyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(4aR,8aS)-6-[4-[3-cyclopropyl-4-(trifluoromethyl)phenoxy]piperidine-1-car-
bonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[2-(2-fluoro-4-methyl-phenyl)ethyl]azetidine-1-carbonyl]-4-
,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[2-[4-methoxy-2-(trifluoromethyl)phenyl]ethyl]azetidine-1--
carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[3-(2-azaspiro[3.3]heptan-2-yl)-4-(trifluoromethyl)phenoxy-
]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-o-
ne;
(4aR,8aS)-6-[3-[2-[4-methyl-2-(trifluoromethyl)phenyl]ethyl]azetidine--
1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-(3-((4-methyl-3-(trifluoromethyl)benzyl)oxy)azetidine-1-carbo-
nyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
(4aR,8aS)-6-(3-((2-methyl-3-(trifluoromethyl)benzyl)oxy)azetidine-1-carbo-
nyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
rac-(4aR,8aS)-6-[2-methyl-3-[[2-methyl-4-(trifluoromethoxy)phenyl]methoxy-
]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-o-
ne;
rac-(4aR,8aS)-6-[2-methyl-3-[[2-methyl-3-(trifluoromethyl)phenyl]metho-
xy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-
-one;
(4aR,8aS)-6-[3-(4-chloro-3-cyclopropylphenoxy)azetidine-1-carbonyl]--
4,4# a!,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[4-[2-chloro-3-(trifluoromethyl)phenoxy]piperidine-1-carbonyl-
]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-(2-chloro-3-cyclopropyl-phenoxy)azetidine-1-carbonyl]-4,4a-
,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[3-(2-azaspiro[3.3]heptan-2-yl)-2-chloro-phenoxy]azetidine-
-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[2-chloro-3-(5-oxa-2-azaspiro[3.5]nonan-2-yl)phenoxy]azeti-
dine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-[3-[(E)-2-(2-fluoro-4-methyl-phenyl)vinyl]azetidine-1-carbony-
l]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
(4aR,8aS)-6-(3-((E)-2-fluoro-6-(trifluoromethyl)styryl)azetidine-1-carbon-
yl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; or
(4aR,8aS)-6-(3-((4-methyl-3-(trifluoromethyl)benzyl)oxy)azetidine-1-carbo-
nyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one, or a
pharmaceutically acceptable salt thereof.
99. A process of manufacturing a compound of claim 57, or a
pharmaceutically acceptable salt thereof, the process comprising:
reacting a first amine of formula 1, wherein R.sup.1 is as
described in claim 57: ##STR00327## with a second amine 2, wherein
A, L, m, n, X and R.sup.2 are as described in claim 57:
##STR00328## in the presence of a base and a urea forming reagent,
to form said compound of claim 57, or a pharmaceutically acceptable
salt thereof.
100. A compound of claim 57, or a pharmaceutically acceptable salt
thereof, when manufactured by a process comprising: reacting a
first amine of formula 1, wherein R.sup.1 is as described in claim
57: ##STR00329## with a second amine 2, wherein A, L, m, n, X and
R.sup.2 are as described in claim 57: ##STR00330## in the presence
of a base and a urea forming reagent, to form said compound of
claim 57, or a pharmaceutically acceptable salt thereof.
101. The compound of claim 57, or a pharmaceutically acceptable
salt thereof, wherein said compound has an IC.sub.50 for
monoacylglycerol lipase below 10 .mu.M.
102. A pharmaceutical composition, comprising a compound of claim
57, or a pharmaceutically acceptable salt thereof, and a
therapeutically inert carrier.
103. A pharmaceutical composition, comprising a compound of claim
98, or a pharmaceutically acceptable salt thereof, and a
therapeutically inert carrier.
104. A method for the treatment or prophylaxis of a condition in a
mammal, wherein the condition is neuroinflammation, a
neurodegenerative disease, pain, cancer, or a mental disorder, the
method comprising administering an effective amount of a compound
of claim 57, or a pharmaceutically acceptable salt thereof, to the
mammal.
105. A method for the treatment or prophylaxis of a condition in a
mammal, wherein the condition is neuroinflammation, a
neurodegenerative disease, pain, cancer, or a mental disorder, the
method comprising administering an effective amount of a compound
of claim 98, or a pharmaceutically acceptable salt thereof, to the
mammal.
106. A method for the treatment or prophylaxis of a condition in a
mammal, wherein the condition is multiple sclerosis, Alzheimer's
disease, Parkinson's disease, amyotrophic lateral sclerosis,
traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety,
migraine, depression, hepatocellular carcinoma, colon
carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy
induced neuropathy, acute pain, chronic pain, or spasticity
associated with pain, the method comprising administering an
effective amount of a compound of claim 57, or a pharmaceutically
acceptable salt thereof, to the mammal.
107. A method for the treatment or prophylaxis of a condition in a
mammal, wherein the condition is multiple sclerosis, Alzheimer's
disease, Parkinson's disease, amyotrophic lateral sclerosis,
traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety,
migraine, depression, hepatocellular carcinoma, colon
carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy
induced neuropathy, acute pain, chronic pain, or spasticity
associated with pain, the method comprising administering an
effective amount of a compound of claim 98, or a pharmaceutically
acceptable salt thereof, to the mammal.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of International
Application No. PCT/EP2019/071520, filed Aug. 12, 2019, which
claims priority to EP Application No. 18188681.3, filed Aug. 13,
2018, the disclosure of each of which is incorporated herein by
reference in its entirety.
FIELD OF THE INVENTION
[0002] The present invention relates to organic compounds useful
for therapy or prophylaxis in a mammal, and in particular to
monoacylglycerol lipase (MAGL) inhibitors for the treatment or to
prophylaxis of neuroinflammation, neurodegenerative diseases, pain,
cancer, mental disorders, multiple sclerosis, Alzheimer's disease,
Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain
injury, neurotoxicity, stroke, epilepsy, anxiety, migraine and/or
depression in a mammal.
BACKGROUND OF THE INVENTION
[0003] Endocannabinoids (ECs) are signaling lipids that exert their
biological actions by interacting with cannabinoid receptors
(CBRs), CB1 and CB2. They modulate multiple physiological processes
including neuroinflammation, neurodegeneration and tissue
regeneration (Iannotti, F. A., et al., Progress in lipid research
2016, 62, 107-28). In the brain, the main endocannabinoid,
2-arachidonoylglycerol (2-AG), is produced by diacyglycerol lipases
(DAGL) and hydrolyzed by the monoacylglycerol lipase, MAGL. MAGL
hydrolyses 85% of 2-AG; the remaining 15% being hydrolysed by ABHD6
and ABDH12 (Nomura, D. K., et al., Science 2011, 334, 809). MAGL is
expressed throughout the brain and in most brain cell types,
including neurons, astrocytes, oligodendrocytes and microglia cells
(Chanda, P. K., et al., Molecular pharmacology 2010, 78, 996;
Viader, A., et al., Cell reports 2015, 12, 798). 2-AG hydrolysis
results in the formation of arachidonic acid (AA), the precursor of
prostaglandins (PGs) and leukotrienes (LTs). Oxidative metabolism
of AA is increased in inflamed tissues. There are two principal
enzyme pathways of arachidonic acid oxygenation involved in
inflammatory processes, the cyclo-oxygenase which produces PGs and
the 5-lipoxygenase which produces LTs. Of the various
cyclooxygenase products formed during inflammation, PGE2 is one of
the most important. These products have been detected at sites of
inflammation, e.g. in the cerebrospinal fluid of patients suffering
from neurodegenerative disorders and are believed to contribute to
inflammatory response and disease progression. Mice lacking MAGL
(MgII-/-) exhibit dramatically reduced 2-AG hydrolase activity and
elevated 2-AG levels in the nervous system while other
arachidonoyl-containing phospho- and neutral lipid species
including anandamide (AEA), as well as other free fatty acids, are
unaltered. Conversely, levels of AA and AA-derived prostaglandins
and other eicosanoids, including prostaglandin E2 (PGE2), D2
(PGD2), F2 (PGF2), and thromboxane B2 (TXB2), are strongly
decreased. Phospholipase A.sub.2 (PLA.sub.2) enzymes have been
viewed as the principal source of AA, but cPLA.sub.2-deficient mice
have unaltered AA levels in their brain, reinforcing the key role
of MAGL in the brain for AA production and regulation of the brain
inflammatory process.
[0004] Neuroinflammation is a common pathological change
characteristic of diseases of the brain including, but not
restricted to, neurodegenerative diseases (e.g. multiple sclerosis,
Alzheimer's disease. Parkinson disease, amyotrophic lateral
sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy
and mental disorders such as anxiety and migraine). In the brain,
production of eicosanoids and prostaglandins controls the
neuroinflammation process. The pro-inflammatory agent
lipopolysaccharide (LPS) produces a robust, time-dependent increase
in brain eicosanoids that is markedly blunted in MgII-/- mice. LPS
treatment also induces a widespread elevation in pro-inflammatory
cytokines including interleukin-1-a (IL-1-a), IL-1b, IL-6, and
tumor necrosis factor-a (TNF-a) that is prevented in MgII-/-
mice.
[0005] Neuroinflammation is characterized by the activation of the
innate immune cells of the central nervous system, the microglia
and the astrocytes. It has been reported that anti-inflammatory
drugs can suppress in preclinical models the activation of glia
cells and the progression of disease including Alzheimer's disease
and multiple sclerosis (Lleo A., Cell Mol Life Sci. 2007, 64,
1403). Importantly, genetic and/or pharmacological disruption of
MAGL activity also blocks LPS-induced activation of microglial
cells in the brain (Nomura, D. K., et al., Science 2011, 334,
809).
[0006] In addition, genetic and/or pharmacological disruption of
MAGL activity was shown to be protective in several animal models
of neurodegeneration including, but not restricted to, Alzheimer's
disease, Parkinson's disease and multiple sclerosis. For example,
an irreversible MAGL inhibitor has been widely used in preclinical
models of neuroinflammation and neurodegeneration (Long, J. Z., et
al., Nature chemical biology 2009, 5, 37). Systemic injection of
such inhibitor recapitulates the MgII-/- mice phenotype in the
brain, including an increase in 2-AG levels, a reduction in AA
levels and related eicosanoids production, as well as the
prevention of cytokines production and microglia activation
following LPS-induced neuroinflammation (Nomura, D. K., et al.,
Science 2011, 334, 809), altogether confirming that MAGL is a
druggable target.
[0007] Consecutive to the genetic and/or pharmacological disruption
of MAGL activity, the endogenous levels of the MAGL natural
substrate in the brain, 2-AG, are increased. 2-AG has been reported
to show beneficial effects on pain with, for example,
anti-nociceptive effects in mice (Ignatowska-Jankowska B. et al.,
J. Pharmacol. Exp. Ther. 2015, 353, 424.) and on mental disorders,
such as depression in chronic stress models (Zhong P. et al.,
Neuropsychopharmacology 2014, 39, 1763.).
[0008] Furthermore, oligodendrocytes (OLs), the myelinating cells
of the central nervous system, and their precursors (OPCs) express
the cannabinoid receptor 2 (CB2) on their membrane. 2-AG is the
endogenous ligand of CB1 and CB2 receptors. It has been reported
that both cannabinoids and pharmacological inhibition of MAGL
attenuate OLs's and OPCs's vulnerability to excitotoxic insults and
therefore may be neuroprotective (Bernal-Chico, A., et al., Glia
2015, 63, 163.). Additionally, pharmacological inhibition of MAGL
increases the number of myelinating OLs in the brain of mice,
suggesting that MAGL inhibition may promote differentiation of OPCs
in myelinating OLs in vivo (Alpar, A., et al., Nature
communications 2014, 5, 4421.). Inhibition of MAGL was also shown
to promote remyelination and functional recovery in a mouse model
of progressive multiple sclerosis (Feliu A. et al., Journal of
Neuroscience 2017, 37 (35), 8385.).
[0009] Finally, in recent years, metabolism is talked highly
important in cancer research, especially the lipid metabolism.
Researchers believe that the de novo fatty acid synthesis plays an
important role in tumor development. Many studies illustrated that
endocannabinoids have anti-tumorigenic actions, including
anti-proliferation, apoptosis induction and anti-metastatic
effects. MAGL as an important decomposing enzyme for both lipid
metabolism and the endocannabinoids system, additionally as a part
of a gene expression signature, contributes to different aspects of
tumourigenesis (Qin, H., et al., Cell Biochem. Biophys. 2014, 70,
33: Nomura D K et al., Cell 2009, 140(1), 49-61; Nomura D K et al.,
Chem. Biol. 2011, 18(7), 846-856).
[0010] In conclusion, suppressing the action and/or the activation
of MAGL is a promising new therapeutic strategy for the treatment
or prevention of neuroinflammation, neurodegenerative diseases,
pain, cancer and mental disorders. Furthermore, suppressing the
action and/or the activation of MAGL is a promising new therapeutic
strategy for providing neuroprotection and myelin regeneration.
Accordingly, there is a high unmet medical need for new MAGL
inhibitors.
SUMMARY OF THE INVENTION
[0011] In a first aspect, the present invention provides a compound
of formula (I)
##STR00002## [0012] or a pharmaceutically acceptable salt thereof,
wherein A, L, X, m, n, R.sup.1 and R.sup.2 are as described
herein.
[0013] In one aspect, the present invention provides a process of
manufacturing the urea compounds of formula (I) described herein,
comprising: [0014] reacting a first amine of formula 1, wherein
R.sup.1 is as described herein, preferably wherein R.sup.1 is
hydrogen,
[0014] ##STR00003## [0015] with a second amine 2, wherein A, L, m,
n, X and R.sup.2 are as described herein
[0015] ##STR00004## [0016] in the presence of a base and a urea
forming reagent, form said compound of formula (I).
[0017] In a further aspect, the present invention provides a
compound of formula (I) as described herein, when manufactured
according to the processes described herein.
[0018] In a further aspect, the present invention provides a
compound of formula (I) as described herein, for use as
therapeutically active substance.
[0019] In a further aspect, the present invention provides a
pharmaceutical composition comprising a compound of formula (I) as
described herein and a therapeutically inert carrier.
[0020] In a further aspect, the present invention provides the use
of a compound of formula (I) as described herein or of a
pharmaceutical composition described herein for inhibiting
monoacylglycerol lipase (MAGL) in a mammal.
[0021] In a further aspect, the present invention provides the use
of a compound of formula (I) as described herein or of a
pharmaceutical composition described herein for the treatment or
prophylaxis of neuroinflammation, neurodegenerative diseases, pain,
cancer and/or mental disorders in a mammal.
[0022] In a further aspect, the present invention provides the use
of a compound of formula (I) as described herein or of a
pharmaceutical composition described herein for the treatment or to
prophylaxis of multiple sclerosis. Alzheimer's disease, Parkinson's
disease, amyotrophic lateral sclerosis, traumatic brain injury,
neurotoxicity, stroke, epilepsy, anxiety, migraine, depression,
hepatocellular carcinoma, colon carcinogenesis, ovarian cancer,
neuropathic pain, chemotherapy induced neuropathy, acute pain,
chronic pain and/or spasticity associated with pain in a
mammal.
[0023] In a further aspect, the present invention provides a
compound of formula (I) as described herein or a pharmaceutical
composition described herein for use in a method of inhibiting
monoacylglycerol lipase in a mammal.
[0024] In a further aspect, the present invention provides a
compound of formula (I) as described herein or a pharmaceutical
composition described herein for use in the treatment or
prophylaxis of neuroinflammation, neurodegenerative diseases, pain,
cancer and/or mental disorders in a mammal.
[0025] In a further aspect, the present invention provides a
compound of formula (I) as described herein or a pharmaceutical
composition described herein, for use in the treatment or
prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's
disease, amyotrophic lateral sclerosis, traumatic brain injury,
neurotoxicity, stroke, epilepsy, anxiety, migraine, depression,
hepatocellular carcinoma, colon carcinogenesis, ovarian cancer,
neuropathic pain, chemotherapy induced neuropathy, acute pain,
chronic pain and/or spasticity associated with pain in a
mammal.
[0026] In a further aspect, the present invention provides the use
of a compound of formula (I) as described herein for the
preparation of a medicament for inhibiting monoacylglycerol lipase
in a mammal.
[0027] In a further aspect, the present invention provides the use
of a compound of formula (I) as described herein for the
preparation of a medicament for the treatment or prophylaxis of
neuroinflammation, neurodegenerative diseases, pain, cancer and/or
mental disorders in a mammal.
[0028] In a further aspect, the present invention provides the use
of a compound of formula (I) as described herein for the
preparation of a medicament for the treatment or prophylaxis of
multiple sclerosis, Alzheimer's disease, Parkinson's disease,
amyotrophic lateral sclerosis, traumatic brain injury,
neurotoxicity, stroke, epilepsy, anxiety, migraine, depression,
hepatocellular carcinoma, colon carcinogenesis, ovarian cancer,
neuropathic pain, chemotherapy induced neuropathy, acute pain,
chronic pain and/or spasticity associated with pain in a
mammal.
[0029] In a further aspect, the present invention provides a method
for inhibiting monoacylglycerol lipase in a mammal, which method
comprises administering an effective amount of a compound of
formula (I) as described herein or of a pharmaceutical composition
described herein to the mammal.
[0030] In a further aspect, the present invention provides a method
for the treatment or prophylaxis of neuroinflammation,
neurodegenerative diseases, pain, cancer and/or mental disorders in
a mammal, which method comprises administering an effective amount
of a compound of formula (I) as described herein or of a
pharmaceutical composition described herein to the mammal.
[0031] In a further aspect, the present invention provides a method
for the treatment or prophylaxis of multiple sclerosis, Alzheimer's
disease, Parkinson's disease, amyotrophic lateral sclerosis,
traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety,
migraine, depression, hepatocellular carcinoma, colon
carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy
induced neuropathy, acute pain, chronic pain and/or spasticity
associated with pain in a mammal, which method comprises
administering an effective amount of a compound of formula (I) as
described herein or of a pharmaceutical composition described
herein to the mammal.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0032] Features, integers, characteristics, compounds, chemical
moieties or groups described in conjunction with a particular
aspect, embodiment or example of the invention are to be understood
to be applicable to any other aspect, embodiment or example
described herein, unless incompatible therewith. All of the
features disclosed in this specification (including any
accompanying claims, abstract and drawings), and/or all of the
steps of any method or process so disclosed, may be combined in any
combination, except combinations where at least some of such
features and/or steps are mutually exclusive. The invention is not
restricted to the details of any foregoing embodiments. The
invention extends to any novel one, or any novel combination, of
the features disclosed in this specification (including any
accompanying claims, abstract and drawings), or to any novel one,
or any novel combination, of the steps of any method or process so
disclosed.
[0033] The term "alkyl" refers to a mono- or multivalent, e.g., a
mono- or bivalent, linear or branched saturated hydrocarbon group
of 1 to 12 carbon atoms. In some preferred embodiments, the alkyl
group contains 1 to 6 carbon atoms ("C.sub.1-6-alkyl"), e.g., 1, 2,
3, 4, 5, or 6 carbon atoms. In other embodiments, the alkyl group
contains 1 to 3 carbon atoms, e.g., 1, 2 or 3 carbon atoms. Some
non-limiting examples of alkyl include methyl, ethyl, propyl,
2-propyl (isopropyl), n-butyl, iso-butyl, sec-butyl, tert-butyl,
and 2,2-dimethylpropyl. Particularly preferred, yet non-limiting
examples of alkyl are methyl and tert-butyl.
[0034] The term "alkoxy" refers to an alkyl group, as previously
defined, attached to the parent molecular moiety via an oxygen
atom. Unless otherwise specified, the alkoxy group contains 1 to 12
carbon atoms. In some preferred embodiments, the alkoxy group
contains 1 to 6 carbon atoms ("C.sub.1-6-alkoxy"). In other
embodiments, the alkoxy group contains 1 to 4 carbon atoms. In
still other embodiments, the alkoxy group contains 1 to 3 carbon
atoms. Some non-limiting examples of alkoxy groups include methoxy,
ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy and tert-butoxy.
A particularly preferred, yet non-limiting example of alkoxy is
methoxy.
[0035] The term "halogen" or "halo" refers to fluoro (F), chloro
(Cl), bromo (Br), or iodo (I). Preferably, the term "halogen" or
"halo" refers to fluoro (F), chloro (Cl) or bromo (Br).
Particularly preferred, yet non-limiting examples of "halogen" or
"halo" are fluoro (F) and chloro (Cl).
[0036] The term "cycloalkyl" as used herein refers to a saturated
or partly unsaturated monocyclic or bicyclic hydrocarbon group of 3
to 10 ring carbon atoms. In some preferred embodiments, the
cycloalkyl group is a saturated monocyclic hydrocarbon group of 3
to 8 ring carbon atoms. "Bicyclic cycloalkyl" refers to cycloalkyl
moieties consisting of two saturated carbocycles having two carbon
atoms in common, i.e., the bridge separating the two rings is
either a single bond or a chain of one or two ring atoms, and to
spirocyclic moieties, i.e., the two rings are connected via one
common ring atom. Preferably, the cycloalkyl group is a saturated
monocyclic hydrocarbon group of 3 to 6 ring carbon atoms, e.g., of
3, 4, 5 or 6 carbon atoms. Some non-limiting examples of cycloalkyl
include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and
cycloheptyl.
[0037] The terms "heterocyclyl" and "heterocycloalkyl" are used
herein interchangeably and refer to a saturated or partly
unsaturated mono- or bicyclic, preferably monocyclic ring system of
3 to 10 ring atoms, preferably 3 to 8 ring atoms, wherein 1, 2, or
3 of said ring atoms are heteroatoms selected from N, O and S, the
remaining ring atoms being carbon. Preferably, 1 to 2 of said ring
atoms are selected from N and O, the remaining ring atoms being
carbon. "Bicyclic heterocyclyl" refers to heterocyclic moieties
consisting of two cycles having two ring atoms in common, i.e., the
bridge separating the two rings is either a single bond or a chain
of one or two ring atoms, and to spirocyclic moieties, i.e., the
two rings are connected via one common ring atom. Some non-limiting
examples of monocyclic heterocyclyl groups include azetidin-3-yl,
azetidin-2-yl, oxetan-3-yl, oxetan-2-yl, l-piperidyl, 2-piperidyl,
3-piperidyl, 4-piperidyl, 2-oxopyrrolidin-1-yl,
2-oxopyrrolidin-3-yl, 5-oxopyrrolidin-2-yl, 5-oxopyrrolidin-3-yl,
2-oxo-1-piperidyl, 2-oxo-3-piperidyl, 2-oxo-4-piperidyl,
6-oxo-2-piperidyl, 6-oxo-3-piperidyl, morpholino, morpholin-2-yl
and morpholin-3-yl.
[0038] The term "aryl" refers to a monocyclic, bicyclic, or
tricyclic carbocyclic ring system having a total of 6 to 14 ring
members, preferably, 6 to 12 ring members, and more preferably 6 to
10 ring members, and wherein at least one ring in the system is
aromatic. Some non-limiting examples of aryl include phenyl and
9H-fluorenyl (e.g, 9H-fluoren-9-yl). A particularly preferred, yet
non-limiting example of aryl is phenyl.
[0039] The term "heteroaryl" refers to a mono- or multivalent,
monocyclic or bicyclic ring system having a total of 5 to 14 ring
members, preferably, 5 to 12 ring members, and more preferably 5 to
10 ring members, wherein at least one ring in the system is
aromatic, and at least one ring in the system contains one or more
heteroatoms. Preferably, "heteroaryl" refers to a 5-10 membered
heteroaryl comprising 1, 2, 3 or 4 heteroatoms independently
selected from O, S and N. Most preferably, "heteroaryl" refers to a
5-10 membered heteroaryl comprising 1 to 2 heteroatoms
independently selected from O, S and N. Some preferred, yet
non-limiting examples of heteroaryl include thiazolyl (e.g.
thiazol-2-yl); oxazolyl (e.g. oxazol-2-yl);
5,6-dihydro-4H-cyclopenta[d]thiazol-2-yl; 1,2,4-oxadiazol-5-yl;
pyridyl (e.g, 2-pyridyl); pyrazolyl (e.g. pyrazol-1-yl); imidazolyl
(e.g. imidazole-1-yl); benzoxazolyl (e.g. benzoxazol-2-yl) and
oxazolo[5,4-c]pyridin-2-yl.
[0040] The term "hydroxy" refers to an --OH group.
[0041] The term "cyano" refers to a --CN (nitrile) group.
[0042] The term "haloalkyl" refers to an alkyl group, wherein at
least one of the hydrogen atoms of the alkyl group has been
replaced by a halogen atom, preferably fluoro. Preferably.
"haloalkyl" refers to an alkyl group wherein 1, 2 or 3 hydrogen
atoms of the alkyl group have been replaced by a halogen atom, most
preferably fluoro. Particularly preferred, yet non-limiting
examples of haloalkyl are trifluoromethyl (CF.sub.3) and
trifluoroethyl (e.g, 2,2,2-trifluoroethyl).
[0043] The term "haloalkoxy" refers to an alkoxy group, wherein at
least one of the hydrogen atoms of the alkoxy group has been
replaced by a halogen atom, preferably fluoro. Preferably,
"haloalkoxy" refers to an alkoxy group wherein 1, 2 or 3 hydrogen
atoms of the alkoxy group have been replaced by a halogen atom,
most preferably fluoro. A particularly preferred, yet non-limiting
example of haloalkoxy is trifluoromethoxy (--OCF.sub.3).
[0044] The term "hydroxyalkyl" refers to an alkyl group, wherein at
least one of the hydrogen atoms of the alkyl group has been
replaced by a hydroxy group. Preferably, "hydroxyalkyl" refers to
an alkyl group wherein 1, 2 or 3 hydrogen atoms, most preferably 1
hydrogen atom of the alkyl group have been replaced by a hydroxy
group. Preferred, yet non-limiting examples of hydroxyalkyl are
hydroxymethyl and hydroxyethyl (e.g, 2-hydroxyethyl). A
particularly preferred, yet non-limiting example of hydroxyalkyl is
hydroxymethyl.
[0045] The term "haloaryl" refers to an aryl group, wherein at
least one of the hydrogen atoms of the aryl group has been replaced
by a halogen atom. Preferably, "haloaryl" refers to an aryl group
wherein 1, 2 or 3 hydrogen atoms, more preferably 1 or 2 hydrogen
atoms, most preferably 1 hydrogen atom of the aryl group have been
replaced by a halogen atom. A particularly preferred, yet
non-limiting example of haloaryl is chlorophenyl, in particular
4-chlorophenyl.
[0046] The term "aryloxy" refers to an aryl group, as previously
defined, attached to the parent molecular moiety via an oxygen
atom. A preferred, yet non-limiting example of aryloxy is
phenoxy.
[0047] The term "haloaryloxy" refers to a haloaryl group, as
previously defined, attached to the parent molecular moiety via an
oxygen atom. A preferred, yet non-limiting example of haloaryloxy
is 4-fluorophenoxy.
[0048] The term "pharmaceutically acceptable salt" refers to those
salts which retain the biological effectiveness and properties of
the free bases or free acids, which are not biologically or
otherwise undesirable. The salts are formed with inorganic acids
such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric
acid, phosphoric acid and the like, in particular hydrochloric
acid, and organic acids such as acetic acid, propionic acid,
glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic
acid, succinic acid, fumaric acid, tartaric acid, citric acid,
benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid,
ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid,
N-acetylcystein and the like. In addition these salts may be
prepared by addition of an inorganic base or an organic base to the
free acid. Salts derived from an inorganic base include, but are
not limited to, the sodium, potassium, lithium, ammonium, calcium,
magnesium salts and the like. Salts derived from organic bases
include, but are not limited to salts of primary, secondary, and
tertiary amines, substituted amines including naturally occurring
substituted amines, cyclic amines and basic ion exchange resins,
such as isopropylamine, trimethylamine, diethylamine,
triethylamine, tripropylamine, ethanolamine, lysine, arginine,
N-ethylpiperidine, piperidine, polyimine resins and the like.
Particular pharmaceutically acceptable salts of compounds of
formula (I) are hydrochloride salts.
[0049] The term "pharmaceutically acceptable ester" refers to
esters that hydrolyze in vivo and include those that break down
readily in the human body to leave the parent compound or a salt
thereof. Suitable ester groups include, for example, those derived
from pharmaceutically acceptable aliphatic carboxylic acids,
particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic
acids, in which each alkyl or alkenyl moiety advantageously has not
more than 6 carbon atoms. Representative examples of particular
esters include, but are not limited to, formates, acetates,
propionates, butyrates, acrylates and ethylsuccinates. Examples of
pharmaceutically acceptable prodrug types are described in Higuchi
and Stella. Pro-drugs as Novel Delivery Systems, Vol. 14 of the
A.C.S. Symposium Series, and in Roche, ed., Bioreversible Carriers
in Drug Design, American Pharmaceutical Association and Pergamon
Press, 1987.
[0050] The term "protective group" (PG) denotes the group which
selectively blocks a reactive site in a multifunctional compound
such that a chemical reaction can be carried out selectively at
another unprotected reactive site in the meaning conventionally
associated with it in synthetic chemistry. Protective groups can be
removed at the appropriate point. Exemplary protective groups are
amino-protective groups, carboxy-protective groups or
hydroxy-protective groups. Particular protective groups are the
tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz),
fluorenylmethoxycarbonyl (Fmoc) and benzyl (Bn). Further particular
protective groups are the tert-butoxycarbonyl (Boc) and the
fluorenylmethoxycarbonyl (Fmoc). More particular protective group
is the tert-butoxycarbonyl (Boc). Exemplary protective groups and
their application in organic synthesis are described, for example,
in "Protective Groups in Organic Chemistry" by T. W. Greene and P.
G. M. Wutts, 5th Ed., 2014, John Wiley & Sons, N.Y.
[0051] The term "urea forming reagent" refers to a chemical
compound that is able to render a first amine to a species that
will react with a second amine, thereby forming an urea derivative.
Non-limiting examples of urea forming reagents include
bis(trichloromethyl) carbonate, phosgene, trichloromethyl
chloroformate, (4-nitrophenyl)carbonate and
1,1'-carbonyldiimidazole. The urea forming reagents described in G.
Sartori et al., Green Chemistry 2000, 2, 140 are incorporated
herein by reference.
[0052] The compounds of formula (I) can contain several asymmetric
centers and can be present in the form of optically pure
enantiomers, mixtures of enantiomers such as, for example,
racemates, optically pure diastereoisomers, mixtures of
diastereoisomers, diastereoisomeric racemates or mixtures of
diastereoisomeric racemates. In a preferred embodiment, the
compound of formula (I) according to the invention is a
cis-enantiomer of formula (Ia) or (Ib), respectively, as described
herein.
[0053] According to the Cahn-Ingold-Prelog Convention, the
asymmetric carbon atom can be of the "R" or "S" configuration.
[0054] The abbreviation "MAGL" refers to the enzyme
monoacylglycerol lipase. The terms "MAGL" and "monoacylglycerol
lipase" are used herein interchangeably.
[0055] The term "treatment" as used herein includes: (1) inhibiting
the state, disorder or condition (e.g. arresting, reducing or
delaying the development of the disease, or a relapse thereof in
case of maintenance treatment, of at least one clinical or
subclinical symptom thereof); and/or (2) relieving the condition
(i.e., causing regression of the state, disorder or condition or at
least one of its clinical or subclinical symptoms). The benefit to
a patient to be treated is either statistically significant or at
least perceptible to the patient or to the physician. However, it
will be appreciated that when a medicament is administered to a
patient to treat a disease, the outcome may not always be effective
treatment.
[0056] The term "prophylaxis" as used herein includes: preventing
or delaying the appearance of clinical symptoms of the state,
disorder or condition developing in a mammal and especially a human
that may be afflicted with or predisposed to the state, disorder or
condition but does not yet experience or display clinical or
subclinical symptoms of the state, disorder or condition.
[0057] The term "neuroinflammation" as used herein relates to acute
and chronic inflammation of the nervous tissue, which is the main
tissue component of the two parts of the nervous system; the brain
and spinal cord of the central nervous system (CNS), and the
branching peripheral nerves of the peripheral nervous system (PNS).
Chronic neuroinflammation is associated with neurodegenerative
diseases such as Alzheimer's disease, Parkinson's disease and
multiple sclerosis. Acute neuroinflammation usually follows injury
to the central nervous system immediately, e.g., as a result of
traumatic brain injury (TBI).
[0058] The term "traumatic brain injury" ("TBI", also known as
"intracranial injury"), relates to damage to the brain resulting
from external mechanical force, such as rapid acceleration or
deceleration, impact, blast waves, or penetration by a
projectile.
[0059] The term "neurodegenerative diseases" relates to diseases
that are related to the progressive loss of structure or function
of neurons, including death of neurons. Examples of
neurodegenerative diseases include, but are not limited to,
multiple sclerosis, Alzheimer's disease, Parkinson's disease and
amyotrophic lateral sclerosis.
[0060] The term "mental disorders" (also called mental illnesses or
psychiatric disorders) relates to behavioral or mental patterns
that may cause suffering or a poor ability to function in life.
Such features may be persistent, relapsing and remitting, or occur
as a single episode. Examples of mental disorders include, but are
not limited to, anxiety and depression.
[0061] The term "pain" relates to an unpleasant sensory and
emotional experience associated with actual or potential tissue
damage. Examples of pain include, but are not limited to,
nociceptive pain, chronic pain (including idiopathic pain),
neuropathic pain including chemotherapy induced neuropathy, phantom
pain and phsychogenic pain. A particular example of pain is
neuropathic pain, which is caused by damage or disease affecting
any part of the nervous system involved in bodily feelings (i.e.,
the somatosensory system). In one embodiment, "pain" is neuropathic
pain resulting from amputation or thoracotomy. In one embodiment,
"pain" is chemotherapy induced neuropathy.
[0062] The term "neurotoxicity" relates to toxicity in the nervous
system. It occurs when exposure to natural or artificial toxic
substances (neurotoxins) alter the normal activity of the nervous
system in such a way as to cause damage to nervous tissue. Examples
of neurotoxicity include, but are not limited to, neurotoxicity
resulting from exposure to substances used in chemotherapy,
radiation treatment, drug therapies, drug abuse, and organ
transplants, as well as exposure to heavy metals, certain foods and
food additives, pesticides, industrial and/or cleaning solvents,
cosmetics, and some naturally occurring substances.
[0063] The term "cancer" refers to a disease characterized by the
presence of a neoplasm or tumor resulting from abnormal
uncontrolled growth of cells (such cells being "cancer cells"). As
used herein, the term cancer explicitly includes, but is not
limited to, hepatocellular carcinoma, colon carcinogenesis and
ovarian cancer.
[0064] The term "mammal" as used herein includes both humans and
non-humans and includes but is not limited to humans, non-human
primates, canines, felines, murines, bovines, equines, and
porcines. In a particularly preferred embodiment, the term "mammal"
refers to humans.
[0065] Compounds of the Invention
[0066] In a first aspect, the present invention provides a compound
of formula (I)
##STR00005## [0067] or a pharmaceutically acceptable salt thereof,
[0068] wherein: [0069] (i) X is C--R.sup.3; m is 0 or 1; n is
selected from 0, 1 and 2; and L is selected from
--(CH.sub.2).sub.p--, --O--, --OCH.sub.2--, --CH.sub.2O--,
--CH.sub.2OCH.sub.2--, --CF.sub.2CH.sub.2--, and
--CH.sub.2CF.sub.2--; or [0070] (ii) X is N; m is 1; n is 1 or 2;
and L is --(CH.sub.2).sub.p-- or --CF.sub.2CH.sub.2--; [0071] p is
selected from 1, 2 and 3: [0072] A is selected from: [0073] (i)
aryl substituted with R.sup.4, R.sup.5 and R.sup.6; [0074] (ii)
heteroaryl substituted with R.sup.7, R.sup.8 and R.sup.9; and
[0075] (iii) heterocycloalkyl substituted with R.sup.10, R.sup.11
and R.sup.12; [0076] R.sup.1 is hydrogen or C.sub.1-6-alkyl; [0077]
R.sup.2 is selected from hydrogen, C.sub.1-6-alkyl and
hydroxy-C.sub.1-6-alkyl; [0078] R.sup.3 is selected from hydrogen,
halogen, hydroxy, C.sub.1-6-alkoxy, C.sub.1-6-alkyl and
halo-C.sub.1-6-alkyl; [0079] each of R.sup.4, R.sup.5, R.sup.6,
R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11 and R.sup.12 is
independently selected from hydrogen, halogen, cyano, hydroxy,
C.sub.1-6-alkyl, halo-C.sub.1-6-alkyl, hydroxy-C.sub.1-6-alkyl,
halo-C.sub.1-5-alkyl-CH(OH)--, C.sub.1-6-alkoxy,
halo-C.sub.1-6-alkoxy, SF.sub.5, CH.sub.3SO.sub.2,
C.sub.3-10-cycloalkyl, C.sub.3-10-cycloalkyl substituted with
R.sup.13, heterocycloalkyl, heterocycloalkyl substituted with
R.sup.14, heteroaryl, aryl and haloaryl; and [0080] each of
R.sup.13 and R.sup.14 is independently C.sub.1-6-alkyl,
halo-C.sub.1-6-alkyl or hydroxy.
[0081] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein the compound of formula (I) is a
compound of formula (Ia):
##STR00006## [0082] wherein A, L, X, m, n, R.sup.1 and R.sup.2 are
as defined herein. Preferably, said compound of formula (Ia) has an
enantiomeric excess (ee) of >80%, more preferably >90%, in
particular >99%.
[0083] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein the compound of formula (I) is a
compound of formula (Ib):
##STR00007## [0084] wherein A, L, X, m, n, R.sup.1 and R.sup.2 are
as defined herein. Preferably, said compound of formula (Ib) has an
enantiomeric excess (ee) of >80%, more preferably >90%, in
particular >99%.
[0085] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein the compound of formula (I) is a
compound of formula (Ic):
##STR00008##
wherein A, L, X, m, n, R.sup.1 and R.sup.2 are as defined herein.
Preferably, said compound of formula (Ic) has an enantiomeric
excess (ee) of >80%, more preferably >90%, in particular
>99%.
[0086] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein the compound of formula (I) is a
compound of formula (Id):
##STR00009##
wherein A, L, X, m, n, R.sup.1 and R.sup.2 are as defined herein.
Preferably, said compound of formula (Id) has an enantiomeric
excess (ee) of >80%, more preferably >90%, in particular
>99%.
[0087] In one embodiment, there is provided a compound of formula
(I) as described herein, wherein when X is C--R.sup.3 and R.sup.3
is hydroxy or halogen, L is not --O-- or --CH.sub.2O--.
[0088] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein: [0089] (i) X is C--R.sup.3; m is
0 or 1; n is selected from 0, 1 and 2; and L is selected from
--(CH.sub.2).sub.p--, --O--, --OCH.sub.2--, --CH.sub.2O-- and
--CH.sub.2OCH.sub.2--; or [0090] (ii) X is N; m and n are both 1;
and L is --(CH.sub.2).sub.p--.
[0091] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein: [0092] X is C--R.sup.3: [0093] m
and n are both 0; or [0094] m and n are both 1; and [0095] L is
selected from --(CH.sub.2).sub.p--, --O--, --OCH.sub.2-- and
--CH.sub.2O--.
[0096] In another preferred embodiment, the present invention
provides a compound of formula (I) as described herein, or a
pharmaceutically acceptable salt thereof, wherein: [0097] X is
C--R.sup.3; [0098] m and n are both 0; or [0099] m and n are both
1; [0100] L is selected from --(CH.sub.2).sub.p--, --O--,
--OCH.sub.2-- and --CH.sub.2O--; [0101] R.sup.3 is selected from
hydrogen, C.sub.1-6-alkyl and halogen; and [0102] p is 1 or 2.
[0103] In a particularly preferred embodiment, the present
invention provides a compound of formula (I) as described herein,
or a pharmaceutically acceptable salt thereof, wherein: [0104] X is
C--R.sup.3; [0105] m and n are both 0; or [0106] m and n are both
1; [0107] L is selected from --(CH.sub.2).sub.p--, --O--,
--OCH.sub.2-- and --CH.sub.2--; [0108] R.sup.3 is hydrogen; and
[0109] p is 1 or 2.
[0110] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein p is 1 or 2.
[0111] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein A is selected from: [0112] (i)
aryl substituted with R.sup.4, R.sup.5 and R.sup.6; and [0113] (ii)
heteroaryl substituted with R.sup.7, R.sup.8 and R.sup.9.
[0114] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein A is selected from: [0115] (i)
phenyl substituted with R.sup.4, R.sup.5 and R.sup.6; and [0116]
(ii) oxazolyl substituted with R.sup.7, R.sup.8 and R.sup.9.
[0117] In another preferred embodiment, the present invention
provides a compound of formula (I) as described herein, or a
pharmaceutically acceptable salt thereof, wherein A is aryl
substituted with R.sup.4, R.sup.5 and R.sup.6.
[0118] In a particularly preferred embodiment, the present
invention provides a compound of formula (I) as described herein,
or a pharmaceutically acceptable salt thereof, wherein A is phenyl
substituted with R.sup.4, R.sup.5 and R.sup.6.
[0119] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein: A is selected from: [0120] (i)
aryl substituted with R.sup.4, R.sup.5 and R.sup.6; and [0121] (ii)
heteroaryl substituted with R.sup.7, R.sup.8 and R.sup.9; [0122]
R.sup.4 is selected from hydrogen, halogen, halo-C.sub.1-6-alkoxy
and halo-C.sub.1-6-alkyl; [0123] R.sup.5 is selected from hydrogen,
cyano, halogen, C.sub.1-6-alkyl, C.sub.1-6-alkoxy,
heterocycloalkyl, C.sub.3-10-cycloalkyl, heteroaryl and haloaryl;
[0124] R.sup.6 is hydrogen or halogen; [0125] R.sup.7 is selected
from hydrogen, C.sub.1-6-alkyl, aryl and halo-C.sub.1-6-alkyl;
[0126] R.sup.8 is hydrogen or C.sub.1-6-alkyl; and [0127] R.sup.9
is hydrogen.
[0128] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein: A is selected from: [0129] (i)
aryl substituted with R.sup.4, R.sup.5 and R.sup.6; and [0130] (ii)
heteroaryl substituted with R.sup.7, R.sup.8 and R.sup.9; [0131]
R.sup.4 is selected from halogen, halo-C.sub.1-6-alkoxy and
halo-C.sub.1-6-alkyl; [0132] R.sup.5 is selected from hydrogen,
cyano, halogen, heterocycloalkyl, C.sub.3-10-cycloalkyl and
haloaryl; [0133] R.sup.6 is hydrogen: [0134] R.sup.7 is
C.sub.1-6-alkyl; [0135] R.sup.8 is hydrogen; and [0136] R.sup.9 is
hydrogen.
[0137] In a particularly preferred embodiment, the present
invention provides a compound of formula (I) as described herein,
or a pharmaceutically acceptable salt thereof, wherein: A is
selected from: [0138] (i) phenyl substituted with R.sup.4, R.sup.5
and R.sup.6; and [0139] (ii) oxazolyl substituted with R.sup.7,
R.sup.8 and R.sup.9; [0140] R.sup.4 is selected from chloro
OCF.sub.3 and CF.sub.3; [0141] R.sup.5 is selected from hydrogen,
cyano, fluoro, chloro, pyrrolidinyl, cyclopentyl, cyclopropyl and
chlorophenyl; [0142] R.sup.6 is hydrogen: [0143] R.sup.7 is
tert-butyl; [0144] R.sup.8 is hydrogen; and [0145] R.sup.9 is
hydrogen.
[0146] In a further particularly preferred embodiment, the present
invention provides a compound of formula (I) as described herein,
or a pharmaceutically acceptable salt thereof, wherein A is
selected from phenyl, 4-tert-butylthiazol-2-yl,
4-tert-butyloxazol-2-yl, 2-chloro-4-fluoro-phenyl,
4-(trifluoromethyl)phenyl, 4-(trifluoromethoxy)phenyl,
4-chlorophenyl, 5,6-dihydro-4H-cyclopenta[d]thiazol-2-yl,
3-phenyl-1,2,4-oxadiazol-5-yl, 5-(trifluoromethyl)-2-pyridyl,
4-(trifluoromethyl)pyrazol-1-yl,
2-fluoro-4-(trifluoromethyl)phenyl, 2,4-difluorophenyl,
4-chloro-3-fluoro-phenyl, 4-cyanophenyl, 4,4-difluoro-1-piperidyl.
5-tert-butyloxazol-2-yl. 4-methoxy-2-fluoro-phenyl,
2-chloro-4(trifluoromethyl)phenyl, 6-(trifluoromethyl)-3-pyridyl,
3-(trifluoromethyl)phenyl, 2-chloro-4-(trifluoromethoxy)phenyl,
4-chloro-2-fluoro-phenyl, 4-fluoro-2-(trifluoromethyl)phenyl,
2-pyrrolidin-1-yl-4-(trifluoromethyl)phenyl,
4-fluoro-2-cyano-phenyl, 2-cyclopentyl-4-(trifluoromethyl)phenyl,
2-chloro-4-cyanophenyl, 4-(trifluoromethyl)imidazol-1-yl,
4-fluoro-2-methyl-phenyl, 4-tert-butylpyrazol-1-yl,
1,3-benzoxazol-2-yl, 4-chloro-3-(4-chlorophenyl)phenyl,
2-(1H-pyrazol-4-vl)-4-(trifluoromethyl)phenyl, 2,4-dichlorophenyl,
3-methoxy-4-(trifluoromethyl)phenyl,
5-methyl-6-(trifluoromethyl)-3-pyridyl, 3-chlorophenyl,
2-chlorophenyl, 2-cyclopropyl-4-(trifluoromethyl)phenyl,
2-methyl-4-(trifluoromethyl)phenyl,
3-fluoro-5-(trifluoromethyl)phenyl,
2-fluoro-6-(trifluoromethyl)phenyl,
3-chloro-4-(trifluoromethyl)phenyl,
2,4-difluoro-5-(trifluoromethyl)phenyl,
2-fluoro-5-(trifluoromethyl)phenyl,
2-methoxy-4-(trifluoromethyl)phenyl,
4-chloro-2-(trifluoromethyl)phenyl,
4-chloro-3-(trifluoromethyl)phenyl. 4-chloro-3-cyclopropyl-phenyl,
4-chloro-3-morpholino-phenyl, 2-cyano-4-(trifluoromethyl)phenyl,
oxazolo[5,4-c]pyridin-2-yl, 4-Methyl-3-(trifluoromethyl)phenyl,
3-cyclopropyl-4-(trifluoromethyl)phenyl, 2-fluoro-4-methyl-phenyl,
4-methoxy-2-(trifluoromethyl)phenyl,
4-methyl-2-(trifluoromethyl)phenyl, 3,4-dichlorophenyl,
2,5-dichlorophenyl, 5-methyl-6-(trifluoromethyl)-3-pyridyl,
4,5-bis(trifluoromethyl)-2-pyridyl,
2-fluoro-4-(trifluoromethyl)-phenyl.
2-fluoro-4-(pentafluoro-lambda6-sulfanyl)phenyl,
2,4-bis(trifluoromethyl)phenyl, 2-methyl-3-(trifluoromethyl)phenyl,
2-methyl-4-(trifluoromethoxy)phenyl,
3-chloro-4-(trifluoromethyl)phenyl, 3-cyclopropyl-4-chloro-phenyl,
2-chloro-3-(trifluoromethyl)phenyl, 2-chloro-3-cyclopropyl-phenyl,
3-(2-azaspiro[3.3]heptan-2-yl)-4-(trifluoromethyl)phenyl,
2-chloro-3-(2-azaspiro[3.3]heptan-2-yl)-phenyl,
2-chloro-3-(5-oxa-2-azaspiro[3.5]nonan-2-yl)phenyl,
2-fluoro-4-(trifluoromethtly)phenyl, 2-fluoro-4-methyl-phenyl,
2-fluoro-6-(trifluoromethyl)phenyl, and
2-(trifluoromethyl)-4-methyl-phenyl.
[0147] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.1 is hydrogen or methyl.
[0148] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.1 is hydrogen.
[0149] In one embodiment, the present invention provides a compound
of formula (I) as described to herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.2 is hydrogen or
C.sub.1-6-alkyl.
[0150] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.2 is hydrogen or methyl.
[0151] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.3 is selected from hydrogen,
halogen, C.sub.1-6-alkyl and halo-C.sub.1-6-alkyl.
[0152] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.3 is selected from hydrogen,
halogen and C.sub.1-6-alkyl.
[0153] In a particularly preferred embodiment, the present
invention provides a compound of formula (I) as described herein,
or a pharmaceutically acceptable salt thereof, wherein R.sup.3 is
selected from hydrogen, fluoro and methyl.
[0154] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.3 is selected from hydrogen,
methyl, fluoro and trifluoromethyl.
[0155] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.4 is selected from hydrogen,
halogen, halo-C.sub.1-6-alkoxy and halo-C.sub.1-6-alkyl.
[0156] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.4 is selected from halogen,
halo-C.sub.1-6-alkoxy and halo-C.sub.1-6-alkyl.
[0157] In a particularly preferred embodiment, the present
invention provides a compound of formula (I) as described herein,
or a pharmaceutically acceptable salt thereof, wherein R.sup.4 is
selected from chloro, OCF.sub.3 and CF.sub.3.
[0158] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.4 is selected from hydrogen,
chloro, fluoro, OCF.sub.3 and CF.sub.3.
[0159] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.5 is selected from hydrogen,
cyano, halogen, C.sub.1-6-alkyl, C.sub.1-6-alkoxy,
heterocycloalkyl, C.sub.3-10-cycloalkyl, heteroaryl and
haloaryl.
[0160] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.5 is selected from hydrogen,
cyano, halogen, heterocycloalkyl, C.sub.3-10-cycloalkyl and
haloaryl.
[0161] In a particularly preferred embodiment, the present
invention provides a compound of formula (I) as described herein,
or a pharmaceutically acceptable salt thereof, wherein R.sup.5 is
selected from hydrogen, cyano, fluoro, chloro, pyrrolidinyl,
cyclopentyl, cyclopropyl and chlorophenyl.
[0162] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.5 is selected from hydrogen,
methyl, methoxy, cyano, fluoro, chloro, pyrolidinyl, morpholinyl,
pyrazolyl, cyclopentyl, cyclopropyl and 4-chlorophenyl.
[0163] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.6 is hydrogen or
halogen.
[0164] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.6 is hydrogen or fluoro.
[0165] In a particularly preferred embodiment, the present
invention provides a compound of formula (I) as described herein,
or a pharmaceutically acceptable salt thereof, wherein R.sup.6 is
hydrogen.
[0166] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.7 is selected from hydrogen,
C.sub.1-6-alkyl, aryl and halo-C.sub.1-6-alkyl.
[0167] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.7 is C.sub.1-6-alkyl.
[0168] In a particularly preferred embodiment, the present
invention provides a compound of formula (I) as described herein,
or a pharmaceutically acceptable salt thereof, wherein R.sup.7 is
tert-butyl.
[0169] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.7 is selected from hydrogen,
tert-butyl, phenyl and CF.sub.3.
[0170] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.8 is hydrogen or
C.sub.1-6-alkyl.
[0171] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.8 is hydrogen or methyl.
[0172] In a particularly preferred embodiment, the present
invention provides a compound of formula (I) as described herein,
or a pharmaceutically acceptable salt thereof, wherein R.sup.8 is
hydrogen.
[0173] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.9 is hydrogen.
[0174] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.10 is halogen.
[0175] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.10 is fluoro.
[0176] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.11 is halogen.
[0177] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.11 is fluoro.
[0178] In a particularly preferred embodiment, the present
invention provides a compound of formula (I) as described herein,
or a pharmaceutically acceptable salt thereof, wherein R.sup.10 and
R.sup.11 are both fluoro.
[0179] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.12 is hydrogen.
[0180] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein: [0181] (i) X is C--R.sup.3; m is
0 or 1; n is selected from 0, 1 and 2; and L is selected from
--(CH.sub.2).sub.p--, --O--, --OCH.sub.2--, --CH.sub.2O-- and
--CH.sub.2OCH.sub.2--; or [0182] (ii) X is N; m and n are both 1;
and L is --(CH.sub.2).sub.p--; [0183] p is 1 or 2; [0184] A is
selected from: [0185] (i) aryl substituted with R.sup.4, R.sup.5
and R.sup.6: [0186] (ii) heteroaryl substituted with R.sup.7,
R.sup.8 and R.sup.9; and [0187] (iii) heterocycloalkyl substituted
with R.sup.10, R.sup.11 and R.sup.12; [0188] R.sup.1 is hydrogen or
C.sub.1-6-alkyl; [0189] R.sup.2 is selected from hydrogen or
C.sub.1-6-alkyl; [0190] R.sup.3 is selected from hydrogen, halogen,
C.sub.1-6-alkyl and halo-C.sub.1-6-alkyl; [0191] R.sup.4 is
selected from hydrogen, halogen, halo-C.sub.1-6-alkoxy and
halo-C.sub.1-6-alkyl; [0192] R.sup.5 is selected from hydrogen,
cyano, halogen, C.sub.1-6-alkyl, C.sub.1-6-alkoxy,
heterocycloalkyl, C.sub.3-10-cycloalkyl, heteroaryl and haloaryl;
[0193] R.sup.6 is hydrogen or halogen: [0194] R.sup.7 is selected
from hydrogen, C.sub.1-6-alkyl, aryl and halo-C.sub.1-6-alkyl;
[0195] R.sup.8 is hydrogen or C.sub.1-6-alkyl; [0196] R.sup.9 is
hydrogen; [0197] R.sup.10 is halogen; [0198] R.sup.11 is halogen,
and [0199] R.sup.12 is hydrogen.
[0200] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein: [0201] X is C--R.sup.3: [0202] m
and n are both 0; or [0203] m and n are both 1; [0204] L is
selected from --(CH.sub.2).sub.p--, --O--, --OCH.sub.2-- and
--CH.sub.2O--; [0205] p is 1 or 2; [0206] A is selected from:
[0207] (i) aryl substituted with R.sup.4, R.sup.5 and R.sup.6; and
[0208] (ii) heteroaryl substituted with R.sup.7, R.sup.8 and
R.sup.9; [0209] R.sup.1 is hydrogen; [0210] R.sup.2 is selected
from hydrogen or C.sub.1-6-alkyl; [0211] R.sup.1 is selected from
hydrogen, halogen and C.sub.1-6-alkyl; [0212] R.sup.4 is selected
from halogen, halo-C.sub.1-6-alkoxy and halo-C.sub.1-6-alkyl;
[0213] R.sup.5 is selected from hydrogen, cyano, halogen,
heterocycloalkyl, C.sub.3-10-cycloalkyl and haloaryl; [0214]
R.sup.6 is hydrogen; [0215] R.sup.7 is C.sub.1-6-alkyl; [0216]
R.sup.8 is hydrogen; and [0217] R.sup.9 is hydrogen.
[0218] In a particularly preferred embodiment, the present
invention provides a compound of formula (I) as described herein,
or a pharmaceutically acceptable salt thereof, wherein: [0219] X is
C--R.sup.3: [0220] m and n are both 0; or [0221] m and n are both
1; [0222] L is selected from --(CH.sub.2).sub.p--, --O--,
--OCH.sub.2-- and --CH.sub.2O--; [0223] p is 1 or 2; [0224] A is
selected from: [0225] (i) phenyl substituted with R.sup.4, R.sup.5
and R.sup.6; and [0226] (ii) oxazolyl substituted with R.sup.7,
R.sup.8 and R.sup.9; [0227] R.sup.1 is hydrogen; [0228] R.sup.2 is
selected from hydrogen or methyl; [0229] R.sup.1 is selected from
hydrogen, fluoro and methyl; [0230] R.sup.4 is selected from
chloro, OCF.sub.3 and CF.sub.3; [0231] R.sup.5 is selected from
hydrogen, cyano, fluoro, chloro, pyrrolidinyl, cyclopentyl,
cyclopropyl and chlorophenyl; [0232] R.sup.6 is hydrogen: [0233]
R.sup.7 is tert-butyl; [0234] R.sup.8 is hydrogen; and [0235]
R.sup.9 is hydrogen.
[0236] In one aspect, the present invention provides a compound of
formula (I), or a pharmaceutically acceptable salt thereof,
wherein: [0237] (i) X is C--R.sup.3; m is 0 or 1; n is selected
from 0, 1 and 2; and L is selected from --(CH.sub.2).sub.p--,
--O--, --OCH.sub.2--, --CH.sub.2OCH.sub.2--, --CF.sub.2CH.sub.2--,
--CH.sub.2.dbd.CH.sub.2--,
--(CR.sup.16R.sup.17).sub.q--CH.sub.2O--, and --CH.sub.2CF.sub.2--;
or [0238] (ii) X is N; m is 1; n is 1 or 2; and L is
--(CH.sub.2).sub.p-- or --CF.sub.2CH.sub.2--; [0239] p is selected
from 1, 2 and 3: [0240] q is 0 or 1; [0241] A is selected from:
[0242] (i) C.sub.6-C.sub.14-aryl substituted with R.sup.4, R.sup.5
and R.sup.6; [0243] (ii) 5- to 14-membered heteroaryl substituted
with R.sup.7, R.sup.8 and R.sup.9; and [0244] (iii) 3- to
14-membered heterocycloalkyl substituted with R.sup.10, R.sup.11
and R.sup.12; [0245] R.sup.1 is hydrogen or C.sub.1-6-alkyl; [0246]
R.sup.2 is selected from hydrogen, C.sub.1-6-alkyl and
hydroxy-C.sub.1-6-alkyl; [0247] R.sup.3 is selected from hydrogen,
halogen, hydroxy, C.sub.1-6-alkoxy, C.sub.1-6-alkyl and
halo-C.sub.1-6-alkyl; [0248] each of R.sup.4, R.sup.5, R.sup.6,
R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11 and R.sup.12 is
independently selected from hydrogen, halogen, cyano, hydroxy,
C.sub.1-6-alkyl, halo-C.sub.1-6-alkyl, hydroxy-C.sub.1-6-alkyl,
C.sub.1-6-alkanoyl, halo-C.sub.3-5-alkyl-CH(OH)--,
C.sub.1-6-alkoxy, halo-C.sub.1-6-alkoxy, SF.sub.5,
CH.sub.3SO.sub.2, C.sub.3-10-cycloalkyl, C.sub.3-10-cycloalkyl
substituted with R.sup.13, 3- to 14-membered heterocycloalkyl, 3-
to 14-membered heterocycloalkyl substituted with R.sup.14 and
R.sup.15, 5- to 14-membered heteroaryl, C.sub.6-C.sub.14-aryl,
C.sub.6-C.sub.14-aryloxy, halo-C.sub.6-C.sub.14-aryl, and
halo-C.sub.6-C.sub.14-aryloxy; [0249] each of R.sup.13, R.sup.14,
and R.sup.15 is independently selected from C.sub.3-6-alkyl,
C.sub.1-6-alkoxy, halo-C.sub.1-6-alkyl, halo-C.sub.1-6-alkoxy,
halogen, and hydroxy; and [0250] R.sup.16 and R.sup.17, taken
together with the carbon atom to which they are attached, form a
C.sub.3-10-cycloalkyl.
[0251] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein: [0252] (i) X is C--R.sup.3; m is
0 or 1; n is selected from 0, 1 and 2; and L is selected from
--(CH.sub.2).sub.p--, --O--, --OCH.sub.2--, --CF.sub.2CH.sub.2--,
--CH.sub.2.dbd.CH.sub.2--,
--(CR.sup.16R.sup.17).sub.q--CH.sub.2O--, and
--CH.sub.2OCH.sub.2--; or [0253] (ii) X is N; m and n are both 1;
and L is --(CH.sub.2).sub.p--.
[0254] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein p is 2.
[0255] In one embodiment, the present invention provides a compound
of formula (I) as described to herein, or a pharmaceutically
acceptable salt thereof, wherein q is 0 or 1.
[0256] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein q is 0.
[0257] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein A is selected from: [0258] (i)
C.sub.6-C.sub.14-aryl substituted with R.sup.4, R.sup.5 and
R.sup.6; and [0259] (ii) 5- to 14-membered heteroaryl substituted
with R.sup.7, R.sup.8 and R.sup.9.
[0260] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein A is selected from: [0261] (i)
phenyl substituted with R.sup.4, R.sup.5 and R.sup.6; [0262] (ii)
oxazolyl substituted with R.sup.7, R.sup.8 and R.sup.9; and [0263]
(iii) pyridyl substituted with R.sup.7, R.sup.8 and R.sup.9.
[0264] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.4 is selected from hydrogen,
halogen, hydroxy, cyano, C.sub.1-6-alkyl, C.sub.1-6-alkanoyl,
SF.sub.5, C.sub.1-6-alkoxy, halo-C.sub.1-6-alkoxy,
halo-C.sub.1-6-alkyl, C.sub.3-10-cycloalkyl, 3- to 14-membered
heterocyclyl, 3- to 14-membered heterocycloalkyl substituted with
R.sup.14 and R.sup.15, 5- to 14-membered heteroaryl,
C.sub.6-C.sub.14-aryloxy, and halo-C.sub.6-C.sub.14-aryl.
[0265] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.4 is selected from halogen,
SF.sub.5, C.sub.1-6-alkyl, C.sub.1-6-alkoxy, halo-C.sub.1-6-alkoxy,
halo-C.sub.1-6-alkyl, C.sub.3-10-cycloalkyl, and 3- to 14-membered
heterocycloalkyl.
[0266] In a particularly preferred embodiment, the present
invention provides a compound of formula (I) as described herein,
or a pharmaceutically acceptable salt thereof, wherein R.sup.4 is
selected from chloro, SF.sub.5, methyl, methoxy, OCF.sub.3,
CF.sub.3, cyclopropyl, and 2-azaspiro[3.3]heptan-2-yl.
[0267] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.5 is selected from hydrogen,
cyano, halogen, C.sub.1-6-alkyl, halo-C.sub.1-6-alkyl,
C.sub.1-6-alkoxy, 3- to 14-membered heterocycloalkyl,
C.sub.3-10-cycloalkyl, 5- to 14-membered heteroaryl, and
halo-C.sub.6-C.sub.14-aryl.
[0268] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.5 is selected from hydrogen,
cyano, halogen, C.sub.1-6-alkyl, halo-C.sub.1-6-alkyl, 3- to
14-membered heterocycloalkyl, C.sub.3-10-cycloalkyl and
halo-C.sub.6-C.sub.14-aryl.
[0269] In a particularly preferred embodiment, the present
invention provides a compound of formula (I) as described herein,
or a pharmaceutically acceptable salt thereof, wherein R.sup.5 is
selected from hydrogen, cyano, fluoro, chloro, methyl, CF.sub.3,
pyrrolidinyl, cyclopentyl, cyclopropyl and chlorophenyl.
[0270] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.7 is selected from hydrogen,
C.sub.1-6-alkyl, C.sub.6-C.sub.14-aryl, halo-C.sub.6-C.sub.14-aryl,
halo-C.sub.6-C.sub.14-aryloxy, and halo-C.sub.1-6-alkyl.
[0271] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.7 is C.sub.1-6-alkyl or
halo-C.sub.1-6-alkyl.
[0272] In a particularly preferred embodiment, the present
invention provides a compound of formula (I) as described herein,
or a pharmaceutically acceptable salt thereof, wherein R.sup.7 is
tert-butyl or CF.sub.3.
[0273] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.8 is selected from hydrogen,
halogen, C.sub.1-6-alkyl, and halo-C.sub.1-6-alkyl.
[0274] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.8 is hydrogen or
halo-C.sub.1-6-alkyl.
[0275] In a particularly preferred embodiment, the present
invention provides a compound of formula (I) as described herein,
or a pharmaceutically acceptable salt thereof, wherein R.sup.8 is
hydrogen or CF.sub.3.
[0276] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.4 is selected from
C.sub.1-6-alkyl, C.sub.1-6-alkoxy, and halogen.
[0277] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein R.sup.15 is hydrogen or
halogen.
[0278] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein: [0279] (i) X is C--R.sup.3; m is
0 or 1; n is selected from 0, 1 and 2; and L is selected from
--(CH.sub.2).sub.p--, --O--, --OCH.sub.2--,
--(CR.sup.16R.sup.17).sub.q--CH.sub.2O--, --CH.sub.2OCH.sub.2--,
--CF.sub.2CH.sub.2--, and --CH.sub.2.dbd.CH.sub.2--; or [0280] (ii)
X is N; m and n are both 1; and L is --(CH.sub.2).sub.p--; [0281] p
is 1 or 2; [0282] q is 0 or 1; [0283] A is selected from: [0284]
(i) C.sub.6-C.sub.14-aryl substituted with R.sup.4, R.sup.5 and
R.sup.6; [0285] (ii) 5- to 14-membered heteroaryl substituted with
R.sup.7, R.sup.8 and R.sup.9; and [0286] (iii) 3- to 14-membered
heterocycloalkyl substituted with R.sup.10, R.sup.11 and R.sup.12;
[0287] R.sup.1 is hydrogen or C.sub.1-6-alkyl; [0288] R.sup.2 is
hydrogen or C.sub.1-6-alkyl; [0289] R.sup.3 is selected from
hydrogen, halogen, C.sub.1-6-alkyl and halo-C.sub.1-6-alkyl; [0290]
R.sup.4 is selected from hydrogen, halogen, cyano, SF.sub.5,
C.sub.1-6-alkyl, C.sub.1-6-alkanoyl, C.sub.1-6-alkoxy,
halo-C.sub.1-6-alkoxy, halo-C.sub.1-6-alkyl, C.sub.3-10-cycloalkyl,
3- to 14-membered heterocycloalkyl, 3- to 14-membered
heterocycloalkyl substituted with R.sup.14 and R.sup.15, 5- to
14-membered heteroaryl, halo-C.sub.6-C.sub.14-aryl, and
C.sub.6-C.sub.14-aryloxy; [0291] R.sup.5 is selected from hydrogen,
cyano, halogen, C.sub.1-6-alkyl, halo-C.sub.1-6-alkyl,
C.sub.1-6-alkoxy, 3- to 14-membered heterocycloalkyl,
C.sub.3-10-cycloalkyl, 5- to 14-membered heteroaryl and
halo-C.sub.6-C.sub.14-aryl; [0292] R.sup.6 is hydrogen or halogen;
[0293] R.sup.7 is selected from hydrogen, C.sub.1-6-alkyl,
C.sub.6-C.sub.14-aryl, halo-C.sub.6-C.sub.14-aryl,
halo-C.sub.6-C.sub.14-aryloxy, and halo-C.sub.1-6-alkyl; [0294]
R.sup.8 is selected from hydrogen, halogen, C.sub.1-6-alkyl, and
halo-C.sub.1-6-alkyl; [0295] R.sup.9 is hydrogen; [0296] R.sup.10
is halogen; [0297] R.sup.11 is halogen; [0298] R.sup.12 is
hydrogen; [0299] R.sup.14 is selected from halogen,
C.sub.1-6-alkyl, and C.sub.1-6-alkoxy; [0300] R.sup.15 is hydrogen
or halogen; and [0301] R.sup.16 and R.sup.17, taken together with
the carbon atom to which they are attached, form a
C.sub.3-10-cycloalkyl.
[0302] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein: [0303] X is C--R.sup.3; [0304] m
and n are both 0; or [0305] m and n are both 1; [0306] L is
selected from --(CH.sub.2).sub.p--, --O--, --OCH.sub.2-- and
--CH.sub.2O--; [0307] p is 1 or 2; [0308] A is selected from:
[0309] (i) C.sub.6-C.sub.14-aryl substituted with R.sup.4, R.sup.5
and R.sup.6; and [0310] (ii) 5- to 14-membered heteroaryl
substituted with R.sup.7, R.sup.8 and R.sup.9; [0311] R.sup.1 is
hydrogen; [0312] R.sup.2 is hydrogen or C.sub.1-6-alkyl; [0313]
R.sup.3 is selected from hydrogen, halogen and C.sub.1-6-alkyl;
[0314] R.sup.4 is selected from halogen, SF.sub.5, C.sub.1-6-alkyl,
C.sub.1-6-alkoxy, halo-C.sub.1-6-alkoxy, halo-C.sub.1-6-alkyl,
C.sub.3-10-cycloalkyl, and 3- to 14-membered heterocycloalkyl;
[0315] R.sup.5 is selected from hydrogen, cyano, halogen,
C.sub.1-6-alkyl, halo-C.sub.1-6-alkyl, 3- to 14-membered
heterocycloalkyl, C.sub.3-10-cycloalkyl and
halo-C.sub.6-C.sub.14-aryl; [0316] R.sup.6 is hydrogen; [0317]
R.sup.7 is C.sub.1-6-alkyl or halo-C.sub.1-6-alkyl; [0318] R.sup.8
is hydrogen or halo-C.sub.1-6-alkyl; and [0319] R.sup.9 is
hydrogen.
[0320] In a particularly preferred embodiment, the present
invention provides a compound of formula (I) as described herein,
or a pharmaceutically acceptable salt thereof, wherein: [0321] X is
C--R.sup.3; [0322] m and n are both 0; or [0323] m and n are both
1; [0324] L is selected from --(CH.sub.2).sub.p--, --O--,
--OCH.sub.2-- and --CH.sub.2O--; [0325] p is 1 or 2; [0326] A is
selected from: [0327] (i) phenyl substituted with R.sup.4, R.sup.5
and R.sup.6; [0328] (ii) oxazolyl substituted with R.sup.7, R.sup.8
and R.sup.9; and [0329] (iii) pyridyl substituted with R.sup.7,
R.sup.8 and R.sup.9; [0330] R.sup.1 is hydrogen; [0331] R.sup.2 is
hydrogen or methyl; [0332] R.sup.3 is selected from hydrogen,
fluoro and methyl; [0333] R.sup.4 is selected from chloro,
SF.sub.5, methyl, methoxy, OCF.sub.3, CF.sub.3, cyclopropyl, and
2-azaspiro[3.3]heptan-2-yl; [0334] R.sup.5 is selected from
hydrogen, cyano, fluoro, chloro, methyl, CF.sub.3, pyrrolidinyl,
cyclopentyl, cyclopropyl and chlorophenyl; [0335] R.sup.6 is
hydrogen: [0336] R.sup.7 is selected from tert-butyl, methyl, and
CF.sub.3; [0337] R.sup.8 is hydrogen or CF.sub.3; and [0338]
R.sup.9 is hydrogen.
[0339] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein: [0340] X is C--R.sup.3; and
[0341] R.sup.3 is selected from hydrogen, halogen and
C.sub.1-6-alkyl.
[0342] In a particularly preferred embodiment, the present
invention provides a compound of formula (I) as described herein,
or a pharmaceutically acceptable salt thereof, wherein: [0343] X is
C--R.sup.3; and [0344] R.sup.3 is selected from hydrogen, fluoro
and methyl.
[0345] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein: [0346] (i) X is C--R.sup.3; m is
0 or 1; n is selected from 0, 1 and 2; and L is selected from
--(CH.sub.2).sub.p--, --O--, --OCH.sub.2--,
--(CR.sup.16R.sup.17).sub.q--CH.sub.2O--, --CH.sub.2OCH.sub.2--,
--CF.sub.2CH.sub.2--, and --CH.sub.2.dbd.CH.sub.2--; or [0347] (ii)
X is N; m and n are both 1; and L is --(CH.sub.2).sub.p--; [0348] p
is 1 or 2; [0349] q is 0 or 1; [0350] R.sup.3 is selected from
hydrogen, halogen and C.sub.1-6-alkyl; and [0351] to R.sup.16 and
R.sup.17, taken together with the carbon atom to which they are
attached, form a C.sub.3-10-cycloalkyl.
[0352] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein: [0353] X is C--R.sup.3; [0354] m
and n are both 0; or [0355] m and n are both 1; [0356] L is
selected from --(CH.sub.2).sub.p--, --O--, --OCH.sub.2-- and
--CH.sub.2O--: [0357] p is 1 or 2; and [0358] R.sup.3 is selected
from hydrogen, halogen and C.sub.1-6-alkyl.
[0359] In a particularly preferred embodiment, the present
invention provides a compound of formula (I) as described herein,
or a pharmaceutically acceptable salt thereof, wherein: [0360] X is
C--R.sup.3; [0361] m and n are both 0; or [0362] m and n are both
1; [0363] L is selected from --(CH).sub.p--, --O--, --OCH.sub.2--
and --CH.sub.2O--; [0364] p is 1 or 2; and [0365] R.sup.3 is
selected from hydrogen, fluoro and methyl.
[0366] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein: [0367] A is selected from: [0368]
(i) C.sub.6-C.sub.14-aryl substituted with R.sup.4, R.sup.5 and
R.sup.6; [0369] (ii) 5- to 14-membered heteroaryl substituted with
R.sup.7, R.sup.8 and R.sup.9; and [0370] (iii) 3- to 14-membered
heterocycloalkyl substituted with R.sup.10, R.sup.11 and R.sup.12;
[0371] R.sup.4 is selected from hydrogen, halogen, cyano, SF.sub.5,
C.sub.1-6-alkyl, C.sub.1-6-alkanoyl, C.sub.1-6-alkoxy,
halo-C.sub.1-6-alkoxy, halo-C.sub.1-6-alkyl, C.sub.3-10-cycloalkyl,
3- to 14-membered heterocycloalkyl, 3- to 14-membered
heterocycloalkyl substituted with R.sup.14 and R.sup.15, to
14-membered heteroaryl, halo-C.sub.6-C.sub.14-aryl, and
C.sub.6-C.sub.14-aryloxy [0372] R.sup.5 is selected from hydrogen,
cyano, halogen, C.sub.1-6-alkyl, halo-C.sub.1-6-alkyl,
C.sub.1-6-alkoxy, 3- to 14-membered heterocycloalkyl,
C.sub.3-10-cycloalkyl, 5- to 14-membered heteroaryl and
halo-C.sub.6-C.sub.14-aryl; [0373] R.sup.6 is hydrogen or halogen;
[0374] R.sup.7 is selected from hydrogen, C.sub.1-6-alkyl,
C.sub.6-C.sub.14-aryl, halo-C.sub.6-C.sub.14-aryl,
halo-C.sub.6-C.sub.14-aryloxy, and halo-C.sub.1-6-alkyl; [0375]
R.sup.8 is selected from hydrogen, halogen, C.sub.1-6-alkyl, and
halo-C.sub.1-6-alkyl; [0376] R.sup.9 is hydrogen; [0377] R.sup.10
is halogen; [0378] R.sup.11 is halogen; [0379] R.sup.12 is
hydrogen; [0380] R.sup.14 is selected from halogen,
C.sub.1-6-alkyl, and C.sub.1-6-alkoxy; and [0381] R.sup.15 is
hydrogen or halogen.
[0382] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein: [0383] A is selected from: [0384]
(i) C.sub.6-C.sub.14-aryl substituted with R.sup.4, R.sup.5 and
R.sup.6; and [0385] (ii) 5- to 14-membered heteroaryl substituted
with R.sup.7, R.sup.8 and R.sup.9; [0386] R.sup.4 is selected from
halogen, SF.sub.5, C.sub.1-6-alkyl, C.sub.1-6-alkoxy,
halo-C.sub.1-6-alkoxy, halo-C.sub.1-6-alkyl, C.sub.3-10-cycloalkyl,
and 3- to 14-membered heterocycloalkyl; [0387] R.sup.5 is selected
from hydrogen, cyano, halogen, C.sub.1-6-alkyl,
halo-C.sub.1-6-alkyl, 3- to 14-membered heterocycloalkyl,
C.sub.3-10-cycloalkyl and halo-C.sub.6-C.sub.14-aryl; [0388]
R.sup.6 is hydrogen; [0389] R.sup.7 is C.sub.1-6-alkyl or
halo-C.sub.1-6-alkyl; [0390] R.sup.8 is hydrogen or
halo-C.sub.1-6-alkyl; and [0391] R.sup.9 is hydrogen.
[0392] In a particularly preferred embodiment, the present
invention provides a compound of formula (I) as described herein,
or a pharmaceutically acceptable salt thereof, wherein: [0393] A is
selected from: [0394] (i) phenyl substituted with R.sup.4, R.sup.5
and R.sup.6; [0395] (ii) oxazolyl substituted with R.sup.7, R.sup.8
and R.sup.9; and [0396] (iii) pyridyl substituted with R.sup.7,
R.sup.8 and R.sup.9; [0397] R.sup.4 is selected from chloro,
SF.sub.5, methyl, methoxy, OCF.sub.3, CF.sub.3, cyclopropyl, and
2-azaspiro[3.3]heptan-2-yl; [0398] R.sup.5 is selected from
hydrogen, cyano, fluoro, chloro, methyl, CF.sub.3, pyrrolidinyl,
cyclopentyl, cyclopropyl and chlorophenyl; [0399] R.sup.6 is
hydrogen; [0400] R.sup.7 is tert-butyl, methyl, and CF.sub.3;
[0401] R.sup.8 is hydrogen or CF.sub.3; and [0402] R.sup.9 is
hydrogen.
[0403] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein: [0404] X is C--H; [0405] m and n
are both 0; [0406] L is --CH.sub.2O--; [0407] A is
C.sub.6-C.sub.14-aryl substituted with R.sup.4, R.sup.5 and
R.sup.6; [0408] R.sup.1, R.sup.2, and R.sup.6 are all hydrogen;
[0409] R.sup.4 is halo-C.sub.1-6-alkyl; and [0410] R.sup.5 is
halogen or C.sub.1-6-alkyl.
[0411] In a particularly preferred embodiment, the present
invention provides a compound of formula (I) as described herein,
or a pharmaceutically acceptable salt thereof, wherein: [0412] X is
C--H; [0413] m and n are both 0: [0414] L is --CH.sub.2O--: [0415]
A is C.sub.6-C.sub.14-aryl substituted with R.sup.4, R.sup.5 and
R.sup.6; [0416] R.sup.1, R.sup.2, and R.sup.6 are all hydrogen;
[0417] R.sup.4 is halo-C.sub.1-6-alkyl; and [0418] R.sup.5 is
halogen.
[0419] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, wherein: [0420] X is C--H; [0421] m and n
are both 0; [0422] L is --CH.sub.2O--; [0423] A is phenyl
substituted with R.sup.4, R.sup.5 and R.sup.6; [0424] R.sup.1,
R.sup.2, and R.sup.6 are all hydrogen; [0425] R.sup.4 is CF.sub.3;
and [0426] R.sup.5 is fluoro or methyl.
[0427] In a particularly preferred embodiment, the present
invention provides a compound of formula (I) as described herein,
or a pharmaceutically acceptable salt thereof, wherein: [0428] X is
C--H: [0429] m and n are both 0; [0430] L is --CH.sub.2O--; [0431]
A is phenyl substituted with R.sup.4, R.sup.5 and R.sup.6; [0432]
R.sup.1, R.sup.2, and R.sup.6 are all hydrogen; [0433] R.sup.4 is
CF.sub.3; and [0434] R.sup.5 is fluoro.
[0435] In one embodiment, the present invention provides a compound
of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, selected from the compounds disclosed in
Table 1.
[0436] In a preferred embodiment, the present invention provides a
compound of formula (I) as described herein, or a pharmaceutically
acceptable salt thereof, selected from: [0437]
(+)-(4aR,8aS)-6-(4-((4-(tert-Butyl)oxazol-2-yl)methyl)piperidine-1-carbon-
yl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; [0438]
(+)-(4aR,8aS)-6-[4-[[4-(Trifluoromethyl)phenyl]methyl]piperidine-1-carbon-
yl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; [0439]
(+)-(4aR,8aS)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)piperidine-1-carbony-
l)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; [0440]
rac-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)azetidine-1-c-
arbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; [0441]
(+)- or
(-)-(4aR,8aS)-6-(3-((2-Chloro-4-fluorobenzyl)oxy)azetidine-1-carbonyl)hex-
ahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; [0442] (+)- or
(-)-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)azetidine-1-c-
arbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; [0443]
(+)- or
(-)-(4aR,8aS)-6-(4-(4-(Trifluoromethoxy)benzyl)piperidine-1-carbonyl)hexa-
hydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; [0444] (+)- or
(-)-(4aR,8aS)-6-(4-(4-Chloro-3-fluorobenzyl)piperidine-1-carbonyl)hexahyd-
ro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; [0445] (+)- or
(-)-(4aR,8aS)-6-(4-(2-Chloro-4-(trifluoromethyl)phenoxy)piperidine-1-carb-
onyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; [0446] (+)-
or
(-)-(4aR,8aS)-6-(4-(3-(Trifluoromethyl)phenoxy)piperidine-1-carbonyl)hexa-
hydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; [0447] (+)- or
(-)-(4aR,8aS)-6-[4-[[2-Chloro-4-(trifluoromethoxy)phenoxy]methyl]piperidi-
ne-1-carbonyl]4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
[0448] (+)- or
(-)-(4aR,8aS)-6-(3-((2-Fluoro-4(trifluoromethyl)phenoxy)methyl)azetidine--
1-carbonyl)hexahydro-2H-pyrido[4,3-]1,4]oxazin-3(4H)-one; [0449]
(+)- or
(-)-(4aR,8aS)-6(4((4-Chloro-2-fluorophenoxy)methyl)piperidine-1-carbonyl)-
hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; [0450] (+)- or
(-)-(4aR,8aS)-6-(4-((4-Fluoro-2-(trifluoromethyl)phenoxy)methyl)piperidin-
e-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
[0451] (+)- or
(-)-(4aR,8aS)-6-(4-((2-Fluoro-4-(trifluoromethyl)phenoxy)methyl)piperi-
dine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
[0452] (+)- or
(-)-(4aR,8aS)-6-(4-(2-(Pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl-
)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
[0453] (+)- or
(-)-(4aR,8aS)-6-(4-((2-Chloro-4-(trifluoromethyl)phenoxy)methyl)piperidin-
e-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
[0454] (+)- or
(-)-(4aR,8aS)-6-[4-[[2-Cyclopentyl-4-(trifluoromethyl)phenyl]methyl]pi-
peridine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one-
; [0455] (+)- or
(-)-3-Chloro-4-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-
-6-carbonyl)piperidin-4-yl)methoxy)benzonitrile; [0456] (+)- or
(-)-(4aR,8aS)-6-(3-((2-Chloro-4(trifluoromethyl)phenoxy)methyl)azetidine--
1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; [0457]
(+)- or
(-)-(4aR,8aS)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)-4-fluoropiperidine--
1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; [0458]
(+)- or
(-)-(4aR,8aS)-6-(4-((4',6-Dichloro-[1,1'-biphenyl]-3-yl)oxy)piperidine-1--
carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; [0459]
(+)- or
(-)-(4aR,8aS)-6-(cis-4-((2-Chloro-4-(trifluorophenoxy)methyl)-3-methylpip-
eridine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
[0460] (+)- or
(-)-(4aR,8aS)-6-(3-((2-Chloro-4-(trifluoromethyl)benzyl)oxy)azeti-
dine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
[0461] (+)- or
(-)-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethoxy)benzyl)oxy)azet-
idine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
[0462] (+)- or
(-)-(4aR,8aS)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)-4-methylpip-
eridine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
[0463]
(4aR,8aS)-6-[3-[(2,4-Dichlorophenyl)methoxy]azetidine-1-carbonyl]-4,4a,5,-
7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; [0464]
(4aR,8aS)-6-[4-[[2-Fluoro-4-(trifluoromethyl)phenyl]methyl]piperidine-1-c-
arbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
[0465]
(4aR,8aS)-6-[4-[[2-Cyclopropyl-4-(trifluoromethyl)phenyl]methyl]piperidin-
e-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
[0466]
(4aR,8aS)-6-[3-[[3-Chloro-4-(trifluoromethyl)phenyl]methoxy]azetid-
ine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
[0467]
(4aR,8aS)-6-[3-[[2-Fluoro-5-(trifluoromethyl)phenyl]methoxy]azetid-
ine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
[0468]
(4aR,8aS)-6-[3-[2-[2-Fluoro-6-(trifluoromethyl)phenyl]methoxy]azet-
idine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
[0469]
(4aR,8aS)-6-(3-(2-fluoro-4-(trifluoromethyl)phenethyl)azetidine-1--
carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; [0470]
6-(3-((2,4-bis(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro--
2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; [0471]
(4aR,8aS)-6-[4-[3-chloro-4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl-
]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; [0472]
(4aR,8aS)-6-(3-methyl-4-(((5-methyl-6-(trifluoromethyl)pyridin-3-yl)oxy)m-
ethyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on-
e; [0473]
(4aR,8aS)-6-(3-((3,4-dichlorobenzyl)oxy)azetidine-1-carbonyl)hex-
ahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; [0474]
(4aR,8aS)-6-(3-((2,5-dichlorobenzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-
-pyrido[4,3-b][1,4]oxazin-3(4H)-one; [0475]
rac-(4aR,8aS)-6-(2-methyl-3-((4-methyl-3-(trifluoromethyl)benzyl)oxy)azet-
idine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
[0476]
(4aR,8aS)-6-(3-(((4,5-bis(trifluoromethyl)pyridin-2-yl)oxy)methyl)azetidi-
ne-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
[0477]
rac-(4aR,8aS)-6-(3-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)-2-methylazet-
idine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
[0478]
(4aR,8aS)-6-(3-((2-fluoro-4-(pentafluoro-16-sulfaneyl)benzyl)oxy)azetidin-
e-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxain-3(4H)-one; [0479]
(4aR,8aS)-6-(3-((4-methyl-2-(trifluoromethoxy)benzyl)oxy)azetidine-1-carb-
onyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; [0480]
(4aR,8aS)-6-[4-[3-cyclopropyl-4-(trifluoromethyl)phenoxy]piperidine-1-car-
bonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
[0481]
(4aR,8aS)-6-[3-[2-(2-fluoro-4-methyl-phenyl)ethyl]azetidine-1-carbonyl-4,-
4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; [0482]
(4aR,8aS)-6-[3-[2-[4-methoxy-2-(trifluoromethyl)phenyl]ethyl]azetidine-1--
carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
[0483]
(4aR,8aS)-6-[3-[3-(2-azaspiro[3.3]heptan-2-yl)-4-(trifluoromethyl)phenoxy-
]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-o-
ne; [0484]
(4aR,8aS)-6-[3-[2-[4-methy-2-(trifluoromethyl)phenyl]ethyl]azet-
idine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
[0485]
(4aR,8aS)-6-(3-((4-methyl-3-(trifluoromethyl)benzyl)oxy)azetidine--
1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxain-3(4H)-one; [0486]
(4aR,8aS)-6-(3-((2-methyl-3-(trifluoromethyl)benzyl)oxy)azetidine-1-carbo-
nyl)hexahydro-2H-pyrido[4,3-b[[1,4]oxazin-3(4H)-one; [0487]
rac-(4aR,8aS)-6-[2-methyl-3-[[2-methyl-4-(trifluoromethoxy)phenyl]methoxy-
]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-o-
ne; [0488]
rac-(4aR,8aS)-6-[2-methyl-3-[[2-methyl-3-(trifluoromethyl)pheny-
l]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]o-
xazin-3-one; [0489]
(4aR,8aS)-6-[3-(4-chloro-3-cyclopropyl-phenoxy)azetidine-1-carbonyl]-4,4#-
a!,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; [0490]
(4aR,8aS)-6-[4-[2-cloro-3-(trifluoroethyl)phenoxy]piperidine-1-carbonyl]--
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; [0491]
(4aR,8aS)-6-[3-(2-chloro-3-cyclopropyl-phenoxy)azetidine-1-carbonyl]-4,4a-
,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; [0492]
(4aR,8aS)-6-[3-[3-(2-azaspiro[3.3]heptan-2-yl)-2-chloro-phenoxy]azetidine-
-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
[0493]
(4aR,8aS)-6-[3-[2-chloro-3-(5-oxa-2-azaspiro[3.5]nonan-2-yl)phenoxy]azeti-
dine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
[0494]
(4aR,8aS)-6-[3-[(E)-2-(2-fluoro-4-methyl-phenyl)vinyl]azetidine-1--
carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
[0495]
(4aR,8aS)-6-(3-((E)-2-fluoro-6-(trifluoromethyl)styryl)azetidine-1-carbon-
yl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; and [0496]
(4aR,8aS)-6-(3-((4-methyl-3-(trifluoromethyl)benzyl)ox)azetidine-1-carbon-
yl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one.
[0497] In one embodiment, the present invention provides
pharmaceutically acceptable salts or esters of the compounds of
formula (I) as described herein. In a particular embodiment, the
present invention provides pharmaceutically acceptable salts of the
compounds according to formula (I) as described herein, especially
hydrochloride salts. In a further particular embodiment, the
present invention provides pharmaceutically acceptable esters of
the compounds according to formula (I) as described herein. In yet
a further particular embodiment, the present invention provides
compounds according to formula (I) as described herein.
[0498] In some embodiments, the compounds of formula (I) are
isotopically-labeled by having one or more atoms therein replaced
by an atom having a different atomic mass or mass number. Such
isotopically-labeled (i.e., radiolabeled) compounds of formula (I)
are considered to be within the scope of this disclosure. Examples
of isotopes that can be incorporated into the compounds of formula
(I) include isotopes of hydrogen, carbon, nitrogen, oxygen,
phosphorous, sulfur, fluorine, chlorine, and iodine, such as, but
not limited to, .sup.2H, .sup.3H, .sup.11C, .sup.13C, .sup.14C,
.sup.13N, .sup.15N, .sup.15O, .sup.17O, .sup.18O, .sup.31P,
.sup.32P, .sup.35S, .sup.18F, .sup.36CL, .sup.123I, and .sup.125I,
respectively. Certain isotopically-labeled compounds of formula
(I), for example, those incorporating a radioactive isotope, are
useful in drug and/or substrate tissue distribution studies. The
radioactive isotopes tritium, i.e. .sup.3H, and carbon-14, i.e.,
.sup.14C, are particularly useful for this purpose in view of their
ease of incorporation and ready means of detection. For example, a
compound of formula (I) can be enriched with 1, 2, 5, 10, 25, 50,
75, 90, 95, or 99 percent of a given isotope.
[0499] Substitution with heavier isotopes such as deuterium, i.e.
.sup.2H, may afford certain therapeutic advantages resulting from
greater metabolic stability, for example, increased in vivo
half-life or reduced dosage requirements.
[0500] Substitution with positron emitting isotopes, such as
.sup.11C, .sup.18F, .sup.15O and .sup.13N, can be useful in
Positron Emission Topography (PET) studies for examining substrate
receptor occupancy. Isotopically-labeled compounds of formula (I)
can generally be prepared by conventional techniques known to those
skilled in the art or by processes analogous to those described in
the Examples as set out below using an appropriate
isotopically-labeled reagent in place of the non-labeled reagent
previously employed.
[0501] Processes of Manufacturing
[0502] The preparation of compounds of formula (I) of the present
invention may be carried out in sequential or convergent synthetic
routes. Syntheses of the invention are shown in the following
general schemes. The skills required for carrying out the reaction
and purification of the resulting products are known to those
persons skilled in the art. The substituents and indices used in
the following description of the processes have the significance
given herein, unless indicated to the contrary.
[0503] If one of the starting materials, intermediates or compounds
of formula (I) contain one or more functional groups which are not
stable or are reactive under the reaction conditions of one or more
reaction steps, appropriate protective groups (as described e.g.,
in "Protective Groups in Organic Chemistry" by T. W. Greene and P.
G. M. Wutts, 5th Ed., 2014. John Wiley & Sons, N.Y.) can be
introduced before the critical step applying methods well known in
the art. Such protective groups can be removed at a later stage of
the synthesis using standard methods described in the
literature.
[0504] If starting materials or intermediates contain stereogenic
centers, compounds of formula (I) can be obtained as mixtures of
diastereomers or enantiomers, which can be separated by methods
well known in the art e.g., chiral HPLC, chiral SFC or chiral
crystallization. Racemic compounds can e.g., be separated into
their antipodes via diastereomeric salts by crystallization with
optically pure acids or by separation of the antipodes by specific
chromatographic methods using either a chiral adsorbent or a chiral
eluent. It is equally possible to separate starting materials and
intermediates containing stereogenic centers to afford
diastereomerically/enantiomerically enriched starting materials and
intermediates. Using such diastereomerically/enantiomerically
enriched starting materials and intermediates in the synthesis of
compounds of formula (I) will typically lead to the respective
diastereomerically/enantiomerically enriched compounds of formula
(I). A person skilled in the art will acknowledge that in the
synthesis of compounds of formula (I)--insofar not desired
otherwise--an "orthogonal protection group strategy" will be
applied, allowing the cleavage of several protective groups one at
a time each without affecting other protective groups in the
molecule. The principle of orthogonal protection is well known in
the art and has also been described in literature (e.g. Barany and
R. B. Merrifield, J. Am. Chem. Soc. 1977, 99, 7363; H. Waldmann et
al., Angew. Chem. Int. Ed. Engl. 1996, 35, 2056).
[0505] A person skilled in the art will acknowledge that the
sequence of reactions may be varied depending on reactivity and
nature of the intermediates.
[0506] In more detail, the compounds of formula (I) can be
manufactured by the methods given below, by the methods given in
the examples or by analogous methods. Appropriate reaction
conditions for the individual reaction steps are known to a person
skilled in the art. Also, for reaction conditions described in
literature affecting the described reactions see for example:
Comprehensive Organic Transformations: A Guide to Functional Group
Preparations, 2nd Edition, Richard C. Larock, John Wiley &
Sons, New York, N.Y. 1999). It was found convenient to carry out
the reactions in the presence or absence of a solvent. There is no
particular restriction on the nature of the solvent to be employed,
provided that it has no adverse effect on the reaction or the
reagents involved and that it can dissolve the reagents, at least
to some extent. The described reactions can take place over a wide
range of temperatures, and the precise reaction temperature is not
critical to the invention. It is convenient to carry out the
described reactions in a temperature range between -78.degree. C.
to reflux. The time required for the reaction may also vary widely,
depending on many factors, notably the reaction temperature and the
nature of the reagents. However, a period of from 0.5 hours to
several days will usually suffice to yield the described
intermediates and compounds. The reaction sequence is not limited
to the one displayed in the schemes, however, depending on the
starting materials and their respective reactivity, the sequence of
reaction steps can be freely altered.
[0507] If starting materials or intermediates are not commercially
available or their synthesis not described in literature, they can
be prepared in analogy to existing procedures for close analogues
or as outlined in the experimental section.
[0508] The following abbreviations are used in the present
text:
[0509] AcOH=acetic acid, ACN=acetonitrile, Bn=benzyl,
Boc=tert-butyloxycarbonyl, CAS RN=chemical abstracts registration
number, Cbz=benzyloxycarbonyl, Cs.sub.2CO.sub.3=cesium carbonate,
CO=carbon monoxide, CuCl=copper(I) chloride, CuCN=copper(I)
cyanide, CuI=copper(I) iodide, DAST=(diethylamino)sulfur
trifluoride, DBU=1,8-diazabicyclo[5,4,0]undec-7-ene,
DCM=dichloromethane, DEAD=diethyl azodicarboxylate,
DIAD=diisopropyl azodicarboxylate, DMAP=4-dimethylaminopyridine,
DME=dimethoxyethane, DMEDA=N,N'-dimethylethylenediamine,
DMF=N,N-dimethylformamide, DIPEA=N,N-diisopropylethylamine,
dppf=1,1 bis(diphenyl phosphino)ferrocene,
EDC.HCl=N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide
hydrochloride, EI=electron impact, ESI=electrospray ionization,
EtOAc=ethyl acetate, EtOH=ethanol, h=hour(s), FA=formic acid,
H.sub.2O=water, H.sub.2SO.sub.4=sulfuric acid,
HATU=1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-
-oxide hexafluorophosphate,
HBTU=O-benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate,
HCl=hydrogen chloride, HOBt=1-hydroxy-1H-benzotriazole; HPLC=high
performance liquid chromatography, iPrMgCl=isopropylmagnesium
chloride, I.sub.2=iodine, IPA=2-propanol, ISP=ion spray positive
(mode), ISN=ion spray negative (mode), K.sub.2CO.sub.3=potassium
carbonate, KHCO.sub.3=potassium bicarbonate, KI=potassium iodide,
KOH=potassium hydroxide, K.sub.3PO.sub.4=potassium phosphate
tribasic, LiAlH.sub.4 or LAH=lithium aluminium hydride,
LiHMDS=lithium bis(trimethylsilyl)amide, LiOH=lithium hydroxide,
MgSO.sub.4=magnesium sulfate, min=minute(s), mL=milliliter,
MPLC=medium pressure liquid chromatography, MS=mass spectrum,
nBuLi=n-butyllithium, NaBH.sub.3CN=sodium cyanoborohydride,
NaH=sodium hydride, NaHCO.sub.3=sodium hydrogen carbonate,
NaNO.sub.2=sodium nitrite, NaBH(OAc).sub.3=sodium
triacetoxyborohydride, NaOH=sodium hydroxide,
Na.sub.2CO.sub.3=sodium carbonate, Na.sub.2SO.sub.4=sodium sulfate,
Na.sub.2S.sub.2O.sub.3=sodium thiosulfate, NBS=N-bromosuccinimide,
nBuLi=n-butyllithium, NEt.sub.3=triethylamine (TEA),
NH.sub.4Cl=ammonium chloride, NMP=N-methyl-2-pyrrolidone,
OAc=Acetoxy, T.sub.3P=propylphosphonic anhydride, PE=petroleum
ether, PG=protective group, Pd--C=palladium on activated carbon,
PdCl.sub.2(dppf)-CH.sub.2Cl.sub.2=1,1'-bis(diphenylphosphino)ferrocene-pa-
lladium(II)dichloride dichloromethane complex,
Pd.sub.2(dba).sub.3=tris(dibenzylideneacetone)dipalladium(0),
Pd(OAc).sub.2=palladium(II) acetate, Pd(OH).sub.2=palladium
hydroxide,
Pd(PPh.sub.3).sub.4=tetrakis(triphenylphosphine)palladium(0),
PTSA=p-toluenesulfonic acid, R=any group, RT=room temperature,
SFC=Supercritical Fluid Chromatography,
S-PHOS=2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl, TBAI=tetra
butyl ammonium iodine, TEA=triethylamine, TFA=trifluoroacetic acid,
THF=tetrahydrofuran, TMEDA=N,N,N',N'-tetramethylethylenediamine,
ZnCl.sub.2=zinc chloride, Hal=halogen.
[0510] Compounds of formula I wherein A, L, X, m, n, R.sup.1 and
R.sup.2 are as described herein can be synthesized in analogy to
literature procedures and/or as depicted for example in Scheme
1.
##STR00010##
[0511] Accordingly,
4a,5,6,7,8,8a-hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-ones 1 are
reacted with intermediates 2 in the presence of a urea forming
reagent, such as bis(trichloromethyl) carbonate using a suitable
base and solvent such as, e.g. sodium bicarbonate in DCM, to give
compounds of formula I (step a). Further urea forming reagents
include but are not limited to phosgene, trichloromethyl
chloroformate, (4-nitrophenyl)carbonate or
1,1'-carbonyldiimidazole. Reactions of this type and the use of
these reagents are widely described in literature (e.g. G. Sartori
et al., Green Chemistry 2000, 2, 140). A person skilled in the art
will acknowledge that the order of the addition of the reagents can
be important in this type of reactions due to the reactivity and
stability of the intermediary formed carbamoyl chlorides, as well
as for avoiding formation of undesired symmetrical urea
by-products.
[0512] Intermediates 1 may be synthesized as depicted for example
in Scheme 2 and/or in analogy to methods described in
literature.
##STR00011##
[0513] Thus, 3-aminopiperidin-4-ol derivatives 3 in which "PG"
signifies a suitable protective group such as a Cbz or Boc
protective group can be acylated for example with acyl chlorides 4
in which R.sup.1 is as defined herein and "LG" signifies a suitable
leaving group (e.g., Cl or Br), using a suitable base such as
sodium or potassium carbonate, sodium hydroxide or sodium acetate
in an appropriate solvent such as THF, water, acetone or mixtures
thereof, to provide intermediates 5 (step a). Intermediates 4 are
either commercially available or can be prepared according to
literature methods in achiral (R.sup.1=H), racemic (R.sup.1 not H)
or enantiomerically pure form (R.sup.1 not H).
[0514] Intermediates 5 can be cyclized to intermediates 6 using
methods well known in the art, for example by treatment of 5 with
sodium hydride in THF or potassium tert-butoxide in IPA and water
(step b). Reactions of that type are described in literature (e.g.
Z. Rafinski et al., J. Org. Chem. 2015, 80, 7468; S. Dugar et al.,
Synthesis 2015, 47(5), 712; WO2005/066187).
[0515] Removal of the protective group in intermediates 6, applying
methods known in the art (e.g., a Boc group using TFA in DCM at
temperatures between 0.degree. C. and room temperature, a Cbz group
using hydrogen in the presence of a suitable catalyst such as Pd or
Pd(OH).sub.2 on charcoal in a suitable solvent such as MeOH, EtOH,
EtOAc or mixtures thereof and as described for example in
"Protective Groups in Organic Chemistry" by T. W. Greene and P. G.
M. Wuts, 4th Ed., 2006, Wiley N.Y.), furnishes intermediates 1
(step c).
[0516] Intermediates 1 can be obtained as mixtures of diastereomers
and enantiomers, respectively, or as single stereoisomers depending
on whether racemic mixtures or enantiomerically pure forms of cis-
or trans-3-aminopiperidin-4-ol derivatives 3 or intermediates 4 are
employed in their syntheses. Intermediates 3 are commercially
available and their synthesis has also been described in literature
(e.g. WO2005/066187; WO2011/0059118; WO2016/185279). Optically pure
cis-configured intermediates 1B and 1C can be obtained for example
according to Scheme 3 by chiral separation of commercially
available
rac-(4aR,8aS)-4a,5,6,7,8,8a-hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one
(1A) (optionally in form of a salt such as, e.g. a hydrochloride
salt) using methods known in the art, e.g. by diastereomeric salt
crystallization or by chiral chromatography (step a).
##STR00012##
[0517] In some embodiments, intermediates 2 are intermediates of
type B. Intermediates of type B in which A, m, n and R.sup.2 are as
described herein can be prepared by methods well known by a person
skilled in the art and as exemplified by the general synthetic
procedures outlined in Scheme 4.
##STR00013##
[0518] Ketones 7, either commercially available or prepared by
methods known in the art, can be subjected for example to a Wittig
reaction with alkylidene triphenylphosphoranes of type 8a in a
suitable solvent such as, e.g. THF. Methyl-THF or DMSO to give
intermediates 9 (step a). Phosphoranes 8a can be formed by treating
the corresponding phosphonium salts with a suitable base such as
BuLi. NaH, or KOtBu in a suitable solvent such as THF, dioxane or
Methyl-THF and may be isolated or used in situ. Phosphonium salts
in turn are readily available from an
aryl/heteroaryl/heterocyclic-substituted alkylhalide (with halide
being Cl, Br and iodo) and triphenylphosphine in a suitable solvent
such as toluene. Heating may be applied to accelerate the reaction
or drive the reaction to completion (e.g. H. J. Cristau, F. Plenat
in PATAI'S Chemistry of Functional Groups, Editor(s): Frank R.
Hartley, 07th August 2006, Series Editor(s): Prof Saul Patai).
[0519] Alternatively, intermediates 9 can be obtained using a
Homer-Wadsworth-Emmons (HWE) reaction using ketones 7 and
phosphonates 8b, wherein R.sup.a is alkyl, for example methyl or
ethyl. Phosphonates 8b are in situ .alpha.-metalated using a
suitable base and solvent such as NaH, nBuLi or KOtBu in THF (step
a). Phosphonates 8b are readily prepared using for example the
Arbuzov reaction by alkylation of an aryl/heteroaryl/heterocyclic
halide (with halide being Cl, Br and iodo) with commercially
available trialkyl phosphite (e.g. Chem. Rev. 1984, 84, 577).
[0520] Olefination reactions of both types are broadly described in
literature (e.g. Current Org. Chem. 2015, 19(9), page 744; Chem.
Rev. 1989, 89(4), 863; Org. React. 1977, 25, 73; Liebigs
Ann./Recueil 1997, 1283; Acc. Chem. Res. 1983, 16, 411).
[0521] Reduction of the double bond in intermediates 9 using, e.g.
hydrogen in the presence of a suitable catalyst such as palladium
on charcoal in an appropriate solvent or solvent mixture such as
EtOAc, MeOH or AcOH yields compounds 10 (step b).
[0522] Removal of the protective group from intermediates 10
applying methods known in the art (e.g., a Boc group using TFA in
DCM or 4M HCl in dioxane at temperatures between 0.degree. C. and
room temperature, a Cbz group using hydrogen in the presence of a
suitable catalyst such as Pd or Pd(OH).sub.2 on charcoal in a
suitable solvent such as MeOH, EtOH, EtOAc or mixtures thereof and
as described for example in "Protective Groups in Organic
Chemistry" by T. W. Greene and P. G. M. Wuts, 4th Ed., 2006. Wiley
N.Y.), furnishes intermediates B (step c).
[0523] In some embodiments, intermediates 2 are intermediates of
type C. Intermediates of type C in which A, R.sup.2 and p are as
described herein, r=0, 1 or 2 and (m+n)=2 or 3 can be prepared by
methods well known in the art and as exemplified by the general
synthetic procedures outlined in Scheme 5.
##STR00014##
[0524] Alkylation of optionally mono-protected piperazine or
1,4-diazepane derivatives 11a,b (commercially available or
synthesized in analogy to literature methods) with
aryl/heteroaryl/heterocyclyl-substituted alkyl derivatives 12,
either commercially available or synthesized according to
literature procedures and in which LG signifies a suitable leaving
group such as chlorine, bromine, iodine, OSO.sub.2alkyl (e.g.
mesylate (methanesulfonate), OSO.sub.2fluoroalkyl (e.g. triflate
(trifluoromethanesulfonate) or OSO.sub.2aryl (e.g. tosylate
(p-toluenesulfonate using a suitable base in an appropriate solvent
(e.g. sodium hydride in DMF) at temperatures between 0.degree. C.
and the boiling temperature of the solvent, gives intermediates
14a,b (step a).
[0525] Alternatively, compounds 11a,b can be subjected to a
reductive amination reaction with aldehydes of type 13 using a
suitable reducing agent and solvent such as NaBH.sub.3CN in MeOH,
AcOH or mixtures thereof to give intermediates 14a,b (step a).
[0526] Removal of the protective group from intermediates 14b
applying methods known in the art (e.g., a Boc group using TFA in
DCM or 4M HCl in dioxane at temperatures between 0.degree. C. and
room temperature, a Cbz group using hydrogen in the presence of a
suitable catalyst such as Pd or Pd(OH).sub.2 on charcoal in a
suitable solvent such as MeOH, EtOH, EtOAc or mixtures thereof and
as described for example in "Protective Groups in Organic
Chemistry" by T. W. Greene and P. G. M. Wuts, 4th Ed., 2006. Wiley
N.Y.), furnishes intermediates C (step c).
[0527] In some embodiments, compounds of formula I are compounds of
type Ie. Compounds Ie in which A, p, R.sup.1 and R.sup.2 are
defined as herein and (m+n)=2 or 3 can be prepared in analogy to
literature procedures or the methods described under Scheme 6
below.
##STR00015##
[0528] Compounds 1 can be coupled with piperazine or 1,4-diazepane
derivatives 11a applying for example the conditions outlined under
Scheme 1, step a, to give intermediates 15 (step a).
[0529] Intermediates 15 can be converted to compounds IC in analogy
to the procedure described under Scheme 5, step a (step b).
[0530] Alternatively, compounds 1 can be coupled with
mono-protected piperazine or 1,4-diazepane derivatives lib in which
PG signifies a suitable protective group such as a Cbz or Boc
protective group applying for example the conditions outlined under
Scheme 1, step a, to give intermediates 16 (step c).
[0531] Removal of the protective group by published methods or as
described under Scheme 5, step c, furnishes intermediates 15 (step
d).
[0532] In some embodiments, intermediates 2 are intermediates of
type D. Intermediates of type D in which A, m, n and R.sup.2 are as
described herein and R.sup.3 is selected from hydrogen, halogen,
C.sub.1-6-alkoxy, C.sub.1-6-alkyl and halo-C.sub.1-6-alkyl, can be
prepared by methods well known in the art and as exemplified by the
general synthetic procedures outlined in Scheme 7.
##STR00016##
[0533] Alcohols of type 17 can be subjected to a Mitsunobu reaction
with intermediates 18 in which PG is a suitable protective group
such as a Cbz, Boc or Bn, using an appropriate phosphine such as
triphenylphosphine and a dialkyl azodicarboxylate such as DEAD or
DIAD in a suitable solvent such as THF to give intermediates 19
(step a). Mitsunobu reactions of that type are broadly described in
literature (e.g. Org. Chem. Front. 2015, 2, 739; Chem. Rev. 2009,
109 (6), 2551).
[0534] Removal of the protective group from intermediates 19
applying literature methods and as described for example under
Scheme 3, step c, furnishes intermediates D (step b).
[0535] Alternatively, intermediates 19 may be prepared from
alcohols 17 that can be alkylated with compounds 20 in which LG is
a suitable leaving group such as chlorine, bromine, iodine.
OSO.sub.2alkyl (e.g. methanesulfonate), OSO.sub.2fluoroalkyl (e.g.
trifluoromethanesulfonate) or OSO.sub.2aryl (e.g.
p-toluenesulfonate using a suitable base in an appropriate solvent
(e.g. sodium hydride in DMF) at temperatures between 0.degree. C.
and the boiling temperature of the solvent (step c).
[0536] Furthermore, intermediates 19 may be synthesized via
alkylation of alcohols of type 18 with compounds 21 under the
conditions described under step c (step d).
[0537] In another embodiment, intermediates 2 are intermediates of
type E. Intermediates of type E in which A, m, n, R.sup.2 and
R.sup.3 are as described herein, can be prepared by methods well
known in the art and as exemplified by the general synthetic
procedures outlined in Scheme 8. In case R.sup.3 is a hydroxy group
a suitable protective group strategy known to those skilled in the
art may be applied.
##STR00017##
[0538] The carboxylic acid functionality in derivatives 22 in which
PG signifies a suitable protecting group such as, e.g. a Boc, Cbz
or Bn protecting group, either commercially available or prepared
by methods known in the art, can be converted into an acid chloride
(LG=Cl) or Weinreb amide (LG=NMeOMe) by applying methods broadly
described in literature to give intermediates 23 (step a).
[0539] Intermediates 23 can be reacted with compounds of type 24,
either commercially available or synthesized by methods known in
the art and as described below to yield intermediates 25 (step
b).
[0540] If compounds 24 are commercially not available they can be
prepared in analogy to literature methods. For example,
deprotonation of a reactive methyl group in optionally substituted
heterocycles 27 using an appropriate base such nBuLi or LiHMDS in a
suitable solvent, e.g. THF, hexane or mixtures thereof, at
temperatures ranging from -78.degree. C. to room temperature, gives
intermediates 24 in which MX=Li (step d).
[0541] Compounds 24 in which MX=MgHal with Hal being Cl, Br or I
(Grignard reagents) may be prepared by reaction of the
corresponding substituted benzyl halides 28 with magnesium in a
suitable solvent such as THF, optionally in the presence of
catalytic amounts of iodine at temperatures ranging from 0.degree.
C. to the boiling point of the solvent (step d).
[0542] Compounds 25 can be further converted into compounds 26 by a
deoxyfluorination reaction using a suitable fluorinating agent such
as DAST, Deoxo-Fluor (bis(2-methoxyethyl)aminosulfur trifluoride)
or aminodifluorosulfinium tetrafluoroborates (XtalFluor-E.RTM.,
XtalFluor-M.RTM. in the presence of, e.g. triethylamine
trihydrofluoride and TEA or DBU) in a suitable solvent such as DCM
or ACN (step d).
[0543] Removal of the protective group from intermediates 26
applying literature methods and as described for example under
Scheme 3, step c, furnishes intermediates E (step e).
[0544] In a further embodiment, intermediates 2 are intermediates
of type F. Intermediates F in which A, m, n, R.sup.2 and R.sup.3
are as described herein, can be prepared by methods well known in
the art and as exemplified by the general synthetic procedures
outlined in Scheme 9. In case R.sup.3 is a hydroxy group a suitable
protective group strategy known to those skilled in the art may be
applied.
##STR00018##
[0545] The carboxylic acid functionality in intermediates 29,
either commercially available or prepared by methods known in the
art, in which PG signifies a suitable protecting group such as,
e.g. a Boc, Cbz or Bn protecting group, can be converted for
example into an acid chloride (LG=Cl) or Weinreb amide (LG=NMeOMe)
by applying methods broadly described in literature to give
intermediates 30 (step a).
[0546] Intermediates 30 can be reacted with compounds of type 31,
either commercially available or synthesized by methods known in
the art and as described below to yield intermediates 32 (step
b).
[0547] In case compounds 31 are commercially not available they can
be prepared in analogy to literature methods. For example,
deprotonation of optionally substituted aryl or heteroaryl rings 33
using an appropriate base such n-BuLi, sec-BuLi, tert-BuLi, LiHMDS,
NaH, KH in a suitable solvent, such as THF, n-hexane or mixtures
thereof, at temperatures ranging from -78.degree. C. to room
temperature, gives intermediates 31 in which, depending on the base
used, MX=Li, Na or K (step c).
[0548] Compounds 31 in which MX=MgHal with Hal being Cl, Br or I
(Grignard reagents) may be prepared by reaction of the
corresponding optionally substituted aryl or heteroaryl halides 34
via direct insertion of magnesium (e.g. magnesium turnings
optionally in the presence of catalytic amounts of iodine, powder
in the presence of LiCl or Rieke magnesium, organic halides) or by
halogen-magnesium exchange by treating 34 in which Hal is
preferably bromine or iodine, with an alkylmagnesium halide such as
iPrMgCl (optionally in the presence of LiCl) in suitable solvents
such as diethyl ether or THF at temperatures ranging from 0.degree.
C. to the boiling point of the solvent (step d).
[0549] Compounds 32 can be further converted into compounds 35 by a
deoxyfluorination reaction using a suitable fluorinating agent such
as DAST, Deoxo-Fluor (bis(2-methoxyethyl)aminosulfur trifluoride)
or aminodifluorosulfinium tetrafluoroborates (XtalFluor-E.RTM.,
XtalFluor-M.RTM. in the presence of, e.g. triethylamine
trihydrofluoride and TEA or DBU) in a suitable solvent such as DCM
or ACN (step e).
[0550] Removal of the protective group from intermediates 35
applying literature methods and as described for example under
Scheme 3, step c, furnishes intermediates F (step f).
[0551] In some embodiments, intermediates 2 are intermediates of
type G. Intermediates of type G in which A, m, n, R.sup.2 are as
described herein and R.sup.3 is hydrogen, C.sub.1-6-alkoxy,
C.sub.1-6-alkyl and halo-C.sub.1-6-alkyl, can be prepared by
methods well known in the art and as exemplified by the general
synthetic procedures outlined in Scheme 10.
##STR00019##
[0552] Intermediates 38 may be prepared from alcohols 36 in which
PG is a suitable protective group such as a Cbz, Boc or Bn, that
can be alkylated with compounds 37 in which LG is a suitable
leaving group such as chlorine, bromine, iodine, OSO.sub.2alkyl
(e.g. methanesulfonate), OSO.sub.2fluoroalkyl (e.g.
trifluoromethanesulfonate) or OSO.sub.2aryl (e.g.
p-toluenesulfonate) using a suitable base, such as sodium hydride,
potassium tert-butoxide, in an appropriate solvent (e.g. in DMF or
THF) at temperatures between 0.degree. C. and the boiling
temperature of the solvent (step a).
[0553] Removal of the protective group from intermediates 38
applying literature methods and as described for example under
Scheme 4, step c, furnishes intermediates G (step b).
[0554] In some embodiments, intermediates 2 are intermediates of
type H. Intermediates of type H in which A, m, n, R.sup.2 and
R.sup.3 are as described herein, can be prepared by methods well
known in the art and as exemplified by the general synthetic
procedures outlined in Scheme 11.
##STR00020##
[0555] Alcohols of type 17 can be subjected to a Mitsunobu reaction
with intermediates 39 in which PG is a suitable protective group
such as a Cbz, Boc or Bn, using an appropriate phosphine such as
triphenylphosphine and a dialkyl azodicarboxylate such as DEAD or
DIAD in a suitable solvent such as THF to give intermediates 41
(step a). Mitsunobu reactions of that type are broadly described in
literature (e.g. Org. Chem. Front. 2015, 2, 739; Chem. Rev. 2009,
109 (6), 2551).
[0556] Removal of the protective group from intermediates 41
applying literature methods and as described for example under
Scheme 4, step c, furnishes intermediates H (step b).
[0557] Alternatively, intermediates 41 may be prepared from
alcohols 17 that can be alkylated with compounds 40 in which LG is
a suitable leaving group such as chlorine, bromine, iodine,
OSO.sub.2alkyl (e.g. methanesulfonate), OSO.sub.2fluoroalkyl (e.g.
trifluoromethanesulfonate) or OSO.sub.2aryl (e.g.
p-toluenesulfonate) using a suitable base such as Cs.sub.2CO.sub.3,
NaH, in an appropriate solvent, such as DMF at temperatures between
0.degree. C. and the boiling temperature of the solvent (step
c).
[0558] Reacting intermediates H with intermediates 1, for example
using the conditions described under scheme 1, step a, affords
compounds of type If, wherein A, R.sup.1, R.sup.2, R.sup.3, m and n
are as defined herein.
##STR00021##
[0559] Alternatively, compounds of type If may be prepared
according to Scheme 12.
##STR00022##
[0560] Alcohols of type 17 can be subjected to a Mitsunobu reaction
with intermediates 42, using an appropriate phosphine such as
triphenylphosphine and a dialkyl azodicarboxylate such as DEAD or
DIAD in a suitable solvent such as THF to give compounds ID (step
a). Mitsunobu reactions of that type are broadly described in
literature (e.g. Org. Chem. Front. 2015, 2, 739; Chem. Rev. 2009,
109 (6), 2551).
[0561] Alternatively, compounds ID may be directly prepared from
alcohols 17 that can be alkylated with compounds 43 in which LG is
a suitable leaving group such as chlorine, bromine, iodine,
OSO.sub.2alkyl (e.g. methanesulfonate), OSO.sub.2fluoroalkyl (e.g.
trifluoromethanesulfonate) or OSO.sub.2aryl (e.g.
p-toluenesulfonate) using a suitable base such as Cs.sub.2CO.sub.3,
NaH, in an appropriate solvent, such as DMF at temperatures between
0.degree. C. and the boiling temperature of the solvent (step
b).
[0562] In some embodiments, intermediates 2 are intermediates of
type J. Intermediates of type J in which A, m, n, R.sup.2 and
R.sup.3 are as described herein, can be prepared by methods well
known in the art and as exemplified by the general synthetic
procedures outlined in Scheme 13.
##STR00023##
[0563] Intermediates 46 may be prepared from heterocycloalkyls or
heteroaryls 45 that can be alkylated with compounds 44 in which LG
is a suitable leaving group such as chlorine, bromine, iodine,
OSO.sub.2alkyl (e.g. methanesulfonate), OSO.sub.2fluoroalkyl (e.g.
trifluoromethanesulfonate) or OSO.sub.2aryl (e.g.
p-toluenesulfonate) using a suitable base such as Cs.sub.2CO.sub.3,
K.sub.2CO.sub.3, NaH, in an appropriate solvent, such as DMF at
temperatures between 0.degree. C. and the boiling temperature of
the solvent (step a).
[0564] Removal of the protective group from intermediates 46
applying literature methods and as described for example under
Scheme 4, step c, furnishes intermediates J (step b).
[0565] Reacting intermediates J with intermediates 1 affords
compounds of type Ig, wherein A, R.sup.1, R.sup.2, R.sup.3, m and n
are as defined herein.
##STR00024##
[0566] Alternatively, compounds of type Ig may be directly prepared
from heterocycloalkyls or heteroaryls 45 that can be alkylated with
compounds 47 in which LG is a suitable leaving group such as
chlorine, bromine, iodine, OSO.sub.2alkyl (e.g. methanesulfonate),
OSO.sub.2fluoroalkyl (e.g. trifluoromethanesulfonate) or
OSO.sub.2aryl (e.g. p-toluenesulfonate) using a suitable base such
as Cs.sub.2CO.sub.3, K.sub.2CO.sub.3, NaH, in an appropriate
solvent, such as DMF at temperatures between 0.degree. C. and the
boiling temperature of the solvent (Scheme 14).
##STR00025##
[0567] In some embodiments, intermediates 2 are intermediates of
type K. Intermediates of type K in which A, m, n, R.sup.2 and
R.sup.3 are as described herein, can be prepared by methods well
known in the art and as exemplified by the general synthetic
procedures outlined in Scheme 15.
##STR00026##
[0568] Alcohols of type 48 can be subjected to a Mitsunobu reaction
with intermediates 39 in which PG is a suitable protective group
such as a Cbz, Boc or Bn, using an appropriate phosphine such as
triphenylphosphine and a dialkyl azodicarboxylate such as DEAD or
DIAD in a suitable solvent such as THF to give intermediates 49
(step a). Mitsunobu reactions of that type are broadly described in
literature (e.g. Org. Chem. Front. 2015, 2, 739; Chem. Rev. 2009,
109 (6), 2551).
[0569] Removal of the protective group from intermediates 49
applying literature methods and as described for example under
Scheme 4, step c, furnishes intermediates K (step b).
[0570] Alternatively, intermediates 49 may be prepared from
alcohols 48 that can be alkylated with compounds 40 in which LG is
a suitable leaving group such as chlorine, bromine, iodine,
OSO.sub.2alkyl (e.g. methanesulfonate), OSO.sub.2fluoroalkyl (e.g.
trifluoromethanesulfonate) or OSO.sub.2aryl (e.g.
p-toluenesulfonate) using a suitable base such as Cs.sub.2CO.sub.3,
NaH, in an appropriate solvent, such as DMF at temperatures between
0.degree. C. and the boiling temperature of the solvent (step
c).
[0571] In some embodiments, intermediates 2 are intermediates of
type L. Intermediates of type L in which A, m, n, R.sup.2 and
R.sup.3 are as described herein can be prepared by methods well
known by a person skilled in the art and as exemplified by the
general synthetic procedures outlined in Scheme 16.
##STR00027##
[0572] Intermediates 51 can be prepared for example from aldehydes
50, either commercially available or prepared by methods known in
the art, using a Wittig reaction or Homer-Wadsworth-Emmons (HWE)
reaction using alkylidene triphenylphosphoranes of type 8a and
phosphonates 8b, respectively, as described under step a in Scheme
4 (step a).
[0573] Reduction of the double bond in intermediates 51 applying
the conditions described under step b in Scheme 4 yields compounds
52 (step b).
[0574] Removal of the protective group from intermediates 52
applying methods known in the art and as outlined under step c in
Scheme 4 furnishes intermediates L (step c).
[0575] Removal of the protective group from intermediates 51
applying methods known in the art and as outlined under step c in
Scheme 4 furnishes intermediates M (step d).
[0576] In one aspect, the present invention provides a process of
manufacturing the urea compounds of formula (I) described herein,
comprising: [0577] reacting a first amine of formula 1, wherein
R.sup.1 is as described herein, preferably wherein R.sup.1 is
hydrogen,
[0577] ##STR00028## [0578] with a second amine 2, wherein A, L, m,
n, X and R.sup.2 are as described herein
[0578] ##STR00029## [0579] in the presence of a base and a urea
forming reagent,
[0580] to form said compound of formula (I).
[0581] In one embodiment, there is provided a process according to
the invention, wherein said base is sodium bicarbonate.
[0582] In one embodiment, there is provided a process according to
the invention, wherein said urea forming reagent is selected from
bis(trichloromethyl) carbonate, phosgene, trichloromethyl
chloroformate, (4-nitrophenyl)carbonate and
1,1'-carbonyldiimidazole, preferably wherein said urea forming
reagent is bis(trichloromethyl) carbonate.
[0583] In one aspect, the present invention provides a compound of
formula (I) as described herein, when manufactured according to any
one of the processes described herein.
[0584] MAGL Inhibitory Activity
[0585] Compounds of the present invention are MAGL inhibitors.
Thus, in one aspect, the present invention provides the use of
compounds of formula (I) as described herein for inhibiting MAGL in
a mammal.
[0586] In a further aspect, the present invention provides
compounds of formula (I) as described herein for use in a method of
inhibiting MAGL in a mammal.
[0587] In a further aspect, the present invention provides the use
of compounds of formula (I) as described herein for the preparation
of a medicament for inhibiting MAGL in a mammal.
[0588] In a further aspect, the present invention provides a method
for inhibiting MAGL in a mammal, which method comprises
administering an effective amount of a compound of formula (I) as
described herein to the mammal.
[0589] Compounds were profiled for MAGL inhibitory activity by
measuring the enzymatic activity of MAGL by following the
hydrolysis of 4-nitrophenylacetate resulting in 4-nitrophenol,
which absorbs at 405-412 nm (G. G. Muccioli, G. Labar, D. M.
Lambert, Chem. Bio. Chem. 2008, 9, 2704-2710). This assay is
hereinafter abbreviated "4-NPA assay".
[0590] The 4-NPA assay was carried out in 384 well assay plates
(black with clear bottom, non-binding surface treated, Coming Ref
3655) in a total volume of 40 .mu.L. Compound dilutions were made
in 100% DMSO (VWR Chemicals 23500.297) in a polypropylene plate in
3-fold dilution steps to give a final concentration range in the
assay from 25 .mu.M to 1.7 nM. 1 .mu.L compound dilutions (100%
DMSO) were added to 19 .mu.L MAGL (recombinant wild-type) in assay
buffer (50 mM TRIS (GIBCO, 15567-027), 1 mM EDTA (Fluka, 03690-100
ml)). The plate was shaked for 1 min at 2000 rpm (Variomag
Teleshake) and then incubated for 15 min at RT. To start the
reaction, 20 .mu.L 4-Nitrophenlyacetate (Sigma N-8130) in assay
buffer with 6% EtOH was added. The final concentrations in the
assay were 1 nM MAGL and 300 .mu.M 4-Nitrophenylacetate. After
shaking (1 min, 2000 rpm) and 5 min incubation at RT, the
absorbance at 405 nm was measured for a fist time (Molecular
Devices, SpectraMax Paradigm). A second measurement was then done
after incubation for 80 min at RT. From the two measurements, the
slope was calculated by subtracting the first from the second
measurement.
[0591] Alternatively, compounds were profiled for MAGL inhibitory
activity by determining the enzymatic activity by following the
hydrolysis of the natural substrate 2-arachidonoylglycerol
resulting in arachidonic acid, which can be followed by mass
spectrometry. This assay is hereinafter abbreviated "2-AG
assay".
[0592] The 2-AG assay was carried out in 384 well assay plates (PP.
Greiner Cat #784201) in a total volume of 20 .mu.L. Compound
dilutions were made in 100% DMSO (VWR Chemicals 23500.297) in a
polypropylene plate in 3-fold dilution steps to give a final
concentration range in the assay from 12.5 .mu.M to 0.8 .mu.M. 0.25
.mu.L compound dilutions (100% DMSO) were added to 9 .mu.L MAGL in
assay buffer (50 mM TRIS (GIBCO, 15567-027), 1 mM EDTA (Fluka,
03690-100 ml), 0.01% (v/v) Tween. After shaking, the plate was
incubated for 15 min at RT. To start the reaction, 10 .mu.L
2-arachidonoylglycerol in assay buffer was added. The final
concentrations in the assay was 50 pM MAGL and 8 .mu.M
2-arachidonoylglycerol. After shaking and 30 min incubation at RT,
the reaction was quenched by the addition of 40 .mu.L of
acetonitrile containing 4 .mu.M of d8-arachidonic acid. The amount
of arachidonic acid was traced by an online SPE system (Agilent
Rapidfire) coupled to a triple quadrupole mass spectrometer
(Agilent 6460). A C18 SPE cartridge (G9205A) was used in an
acetonitrile/water liquid setup. The mass spectrometer was operated
in negative electrospray mode following the mass transitions
303.1.fwdarw.259.1 for arachidonic acid and 311.1.fwdarw.267.0 for
d8-arachidonic acid. The activity of the compounds was calculated
based on the ratio of intensities [arachidonic acid/d8-arachidonic
acid].
TABLE-US-00001 TABLE 1 IC.sub.50 MAGL IC.sub.50 MAGL Ex.
[.mu.M].sup.[a] Ex. [.mu.M].sup.[a] 1 0.040 8 0.013 2 0.046 9 0.035
3 0.066 10 0.039 4 0.092 11 0.042 5 1.3 12 0.077 6 5.7 13 0.087 7
0.011 14 0.191 15 0.190 35 0.019 16 0.208 36 0.119 17 0.268 37 1.3
18 0.892 38 0.160 19 1.5 39 0.116 20 1.8 40 0.012 21 0.909 42 1.2
22 2.1 43 0.529 23 0.856 44 0.038 24 0.004 45 0.850 25 0.452 46
0.005 26 0.684 47 0.005 27 0.007 48 0.288 28 0.018 49 0.363 29
0.005 50 0.008 30 0.273 51 0.010 31 0.0 52 0.058 32 0.020 53 0.006
33 0.004 54 0.001 34 0.438 55 0.079 56 0.042 89 0.034.sup.[b] 57
0.049 90 0.168.sup.[b] 58 0.003 91 0.099.sup.[b] 59 0.012 92
0.014.sup.[b] 60 0.680 93 0.124 61 0.011 94 0.150 62 0.009 95 0.008
64 0.040 96 0.293 66 0.351 97 0.146 67 0.120 98 0.010 72 0.108 99
0.012 73 0.008 100 0.082 74 0.003 101 0.011 75 0.002 102 0.022 76
0.008 103 0.005 77 0.016 104 0.451 79 0.001 105 0.285 81 0.006 108
0.001 87 0.006.sup.[b] 109 0.223 88 0.005.sup.[b] 110 2.179 111
0.020 203 0.871.sup.[b] 112 0.012 204 0.100.sup.[b] 113 0.005 205
0.086.sup.[b] 114 0.005 206 0.023.sup.[b] 115 0.003 207
0.050.sup.[b] 116 0.004 208 0.003.sup.[b] 117 0.010 209
0.074.sup.[b] 118 0.132.sup.[b] 210 0.080.sup.[b] 119 0.014.sup.[b]
211 0.017.sup.[b] 120 0.007.sup.[b] 212 0.003.sup.[b] 121
0.151.sup.[b] 213 0.098.sup.[b] 122 0.008.sup.[b] 214 0.036.sup.[b]
123 0.082.sup.[b] 215 0.005.sup.[b] 124 1.035.sup.[b] 216
0.006.sup.[b] 139 0.002.sup.[b] 217 0.010.sup.[b] 140 0.059.sup.[b]
218 0.003.sup.[b] 141 0.040.sup.[b] 219 0.002.sup.[b] 142
0.075.sup.[b] 220 0.003.sup.[b] 201 0.239.sup.[b] 221
0.0007.sup.[b] 202 0.054.sup.[b] 222 0.143.sup.[b] 223
0.075.sup.[b] 243 0.010.sup.[b] 224 0.003.sup.[b] 244 0.030.sup.[b]
225 0.007.sup.[b] 245 1.7.sup.[b] 226 0.045.sup.[b] 246 1.0.sup.[b]
227 0.067.sup.[b] 247 1.1.sup.[b] 228 0.126.sup.[b] 248
0.607.sup.[b] 229 0.0009.sup.[b] 249 0.005.sup.[b] 230
0.073.sup.[b] 250 0.008.sup.[b] 231 0.005.sup.[b] 251 0.005.sup.[b]
232 0.061.sup.[b] 252 0.005.sup.[b] 233 0.022.sup.[b] 253
0.010.sup.[b] 234 0.002.sup.[b] 254 0.064.sup.[b] 235 0.033.sup.[b]
255 0.010.sup.[b] 236 0.175.sup.[b] 256 0.011.sup.[b] 237
0.254.sup.[b] 257 0.014.sup.[b] 238 0.002.sup.[b] 258 0.048.sup.[b]
239 0.0004.sup.[b] 259 0.015.sup.[b] 240 0.016.sup.[b] 260
0.018.sup.[b] 241 0.015.sup.[b] 261 0.048.sup.[b] 242 0.017.sup.[b]
262 0.181.sup.[b] 263 1.1.sup.[b] 279 0.001.sup.[b] 264
0.084.sup.[b] 280 0.041.sup.[b] 265 0.006.sup.[b] 281 0.035.sup.[b]
266 0.018.sup.[b] 282 0.136.sup.[b] 267 0.042.sup.[b] 283
0.179.sup.[b] 268 0.028.sup.[b] 284 0.072.sup.[b] 269 0.024.sup.[b]
285 2.6.sup.[b] 270 0.061.sup.[b] 286 0.128.sup.[b] 271
0.020.sup.[b] 287 0.006.sup.[b] 272 0.094.sup.[b] 288 0.053.sup.[b]
273 0.089.sup.[b] 289 0.003.sup.[b] 274 0.126.sup.[b] 290
0.044.sup.[b] 275 0.032.sup.[b] 291 0.078.sup.[b] 276 0.019.sup.[b]
292 0.005.sup.[b] 277 0.455.sup.[b] 293 0.030.sup.[b] 278
0.211.sup.[b] 294 3.0.sup.[b] .sup.[a]if not indicated otherwise
(see .sup.[b]), the activity was measured in 4-NPA assay;
.sup.[b]measured in 2-AG assay.
[0593] In one aspect, the present invention provides compounds of
formula (I) and their pharmaceutically acceptable salts or esters
as described herein, wherein said compounds of formula (I) and
their pharmaceutically acceptable salts or esters have IC.sub.50's
for MAGL inhibition below 25 .mu.M, preferably below 10 .mu.M, more
preferably below 5 .mu.M as measured in the MAGL assay described
herein.
[0594] In one embodiment, compounds of formula (I) and their
pharmaceutically acceptable salts or esters as described herein
have IC.sub.50 (MAGL inhibition) values between 0.0000001 .mu.M and
25 .mu.M, particular compounds have IC.sub.50 values between
0.000005 .mu.M and 10 .mu.M, further particular compounds have
IC.sub.50 values between 0.00005 .mu.M and 5 .mu.M, as measured in
the MAGL assay described herein.
[0595] In one embodiment, the present invention provides compounds
of formula (I) and their pharmaceutically acceptable salts or
esters as described herein, wherein said compounds of formula (I)
and their pharmaceutically acceptable salts or esters have an
IC.sub.50 for MAGL below 25 .mu.M, preferably below 10 .mu.M, more
preferably below 5 .mu.M as measured in an assay comprising the
steps of: [0596] a) providing a solution of a compound formula (I),
or a pharmaceutically acceptable salt or ester thereof, in DMSO:
[0597] b) providing a solution of MAGL (recombinant wild-type) in
assay buffer (50 mM tris(hydroxymethyl)aminomethane; 1 mM
ethylenediaminetetraacetic acid); [0598] c) adding 1 .mu.L of
compound solution from step a) to 19 .mu.L of MAGL solution from
step b); [0599] d) shaking the mixture for 1 min at 2000 rpm;
[0600] e) incubating for 15 min at RT; [0601] f) adding 20 .mu.L of
a solution of 4-nitrophenlyacetate in assay buffer (50 mM
tris(hydroxymethyl)aminomethane; 1 mM ethylenediaminetetraacetic
acid, 6% EtOH); [0602] g) shaking the mixture for 1 min at 2000
rpm; [0603] h) incubating for 5 min at RT; [0604] i) measuring the
absorbance of the mixture at 405 nm a fist time; [0605] j)
incubating a further 80 min at RT; [0606] k) measuring the
absorbance of the mixture at 405 nm a second time; [0607] l)
subtracting the absorbance measured under i) from the absorbance
measured under k) and calculating the slope of absorbance; [0608]
wherein: [0609] i) the concentration of the compound of formula
(I), or the pharmaceutically acceptable salt or ester thereof in
the assay after step f) is in the range of 25 .mu.M to 1.7 nM;
[0610] ii) the concentration of MAGL in the assay after step f) is
1 nM; [0611] iii) the concentration of 4-nitrophenylacetate in the
assay after step f) is 300 .mu.M; and [0612] iv) steps a) to l) are
repeated for at least 3 times, each time with a different
concentration of the compound of formula (I), or the
pharmaceutically acceptable salt or ester thereof.
[0613] Using the Compounds of the Invention
[0614] In one aspect, the present invention provides compounds of
formula (I) as described herein for use as therapeutically active
substance.
[0615] In a further aspect, the present invention provides the use
of compounds of formula (I) as described herein for the treatment
or prophylaxis of neuroinflammation, neurodegenerative diseases,
pain, cancer and/or mental disorders in a mammal.
[0616] In one embodiment, the present invention provides the use of
compounds of formula (I) as described herein for the treatment or
prophylaxis of neuroinflammation and/or neurodegenerative diseases
in a mammal.
[0617] In one embodiment, the present invention provides the use of
compounds of formula (I) as described herein for the treatment or
prophylaxis of neurodegenerative diseases in a mammal.
[0618] In one embodiment, the present invention provides the use of
compounds of formula (I) as described herein for the treatment or
prophylaxis of cancer in a mammal.
[0619] In one aspect, the present invention provides the use of
compounds of formula (I) as described herein for the treatment or
prophylaxis of multiple sclerosis. Alzheimer's disease, Parkinson's
disease, amyotrophic lateral sclerosis, traumatic brain injury,
neurotoxicity, stroke, epilepsy, anxiety, migraine, depression,
hepatocellular carcinoma, colon carcinogenesis, ovarian cancer,
neuropathic pain, chemotherapy induced neuropathy, acute pain,
chronic pain and/or spasticity associated with pain in a
mammal.
[0620] In a preferred embodiment, the present invention provides
the use of compounds of formula (I) as described herein for the
treatment or prophylaxis of multiple sclerosis, Alzheimer's disease
and/or Parkinson's disease in a mammal.
[0621] In a particularly preferred embodiment, the present
invention provides the use of compounds of formula (I) as described
herein for the treatment or prophylaxis of multiple sclerosis in a
mammal.
[0622] In one aspect, the present invention provides compounds of
formula (I) as described herein for use in the treatment or
prophylaxis of neuroinflammation, neurodegenerative diseases, pain,
cancer and/or mental disorders in a mammal.
[0623] In one embodiment, the present invention provides compounds
of formula (I) as described herein for use in the treatment or
prophylaxis of neuroinflammation and/or neurodegenerative diseases
in a mammal.
[0624] In one embodiment, the present invention provides compounds
of formula (I) as described herein for use in the treatment or
prophylaxis of cancer in a mammal.
[0625] In one embodiment, the present invention provides compounds
of formula (I) as described herein for use in the treatment or
prophylaxis of neurodegenerative diseases in a mammal.
[0626] In one aspect, the present invention provides compounds of
formula (I) as described herein for use in the treatment or
prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's
disease, amyotrophic lateral sclerosis, traumatic brain injury,
neurotoxicity, stroke, epilepsy, anxiety, migraine, depression,
hepatocellular carcinoma, colon carcinogenesis, ovarian cancer,
neuropathic pain, chemotherapy induced neuropathy, acute pain,
chronic pain and/or spasticity associated with pain in a
mammal.
[0627] In a preferred embodiment, the present invention provides
compounds of formula (I) as described herein for use in the
treatment or prophylaxis of multiple sclerosis, Alzheimer's disease
and/or Parkinson's disease in a mammal.
[0628] In a particularly preferred embodiment, the present
invention provides compounds of formula (I) as described herein for
use in the treatment or prophylaxis of multiple sclerosis in a
mammal.
[0629] In one aspect, the present invention provides the use of
compounds of formula (I) as described herein for the preparation of
a medicament for the treatment or prophylaxis of neuroinflammation,
neurodegenerative diseases, pain, cancer and/or mental disorders in
a mammal.
[0630] In one embodiment, the present invention provides the use of
compounds of formula (I) as described herein for the preparation of
a medicament for the treatment or prophylaxis of neuroinflammation
and/or neurodegenerative diseases in a mammal.
[0631] In one embodiment, the present invention provides the use of
compounds of formula (I) as described herein for the preparation of
a medicament for the treatment or prophylaxis of neurodegenerative
diseases in a mammal.
[0632] In one embodiment, the present invention provides the use of
compounds of formula (I) as described herein for the preparation of
a medicament for the treatment or prophylaxis of cancer in a
mammal.
[0633] In a further aspect, the present invention provides the use
of compounds of formula (I) as described herein for the preparation
of a medicament for the treatment or prophylaxis of multiple
sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic
lateral sclerosis, traumatic brain injury, neurotoxicity, stroke,
epilepsy, anxiety, migraine, depression, hepatocellular carcinoma,
colon carcinogenesis, ovarian cancer, neuropathic pain,
chemotherapy induced neuropathy, acute pain, chronic pain and/or
spasticity associated with pain in a mammal.
[0634] In a preferred embodiment, the present invention provides
the use of compounds of formula (I) as described herein for the
preparation of a medicament for the treatment or prophylaxis of
multiple sclerosis, Alzheimer's disease and/or Parkinson's disease
in a mammal.
[0635] In a particularly preferred embodiment, the present
invention provides the use of compounds of formula (I) as described
herein for the preparation of a medicament for the treatment or
prophylaxis of multiple sclerosis in a mammal.
[0636] In one aspect, the present invention provides a method for
the treatment or prophylaxis of neuroinflammation,
neurodegenerative diseases, pain, cancer and/or mental disorders in
a mammal, which method comprises administering an effective amount
of a compound of formula (I) as described herein to the mammal.
[0637] In one embodiment, the present invention provides a method
for the treatment or prophylaxis of neuroinflammation and/or
neurodegenerative diseases in a mammal, which method comprises
administering an effective amount of a compound of formula (I) as
described herein to the mammal.
[0638] In one embodiment, the present invention provides a method
for the treatment or prophylaxis of neurodegenerative diseases in a
mammal, which method comprises administering an effective amount of
a compound of formula (I) as described herein to the mammal.
[0639] In one aspect, the present invention provides a method for
the treatment or prophylaxis of multiple sclerosis, Alzheimer's
disease, Parkinson's disease, amyotrophic lateral sclerosis,
traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety,
migraine, depression and/or pain in a mammal, which method
comprises administering an effective amount of a compound of
formula (I) as described herein to the mammal.
[0640] In a preferred embodiment, the present invention provides a
method for the treatment or prophylaxis of multiple sclerosis,
Alzheimer's disease and/or Parkinson's disease in a mammal, which
method comprises administering an effective amount of a compound of
formula (I) as described herein to the mammal.
[0641] In a particularly preferred embodiment, the present
invention provides a method for the treatment or prophylaxis of
multiple sclerosis in a mammal, which method comprises
administering an effective amount of a compound of formula (I) as
described herein to the mammal.
[0642] Pharmaceutical Compositions and Administration
[0643] In one aspect, the present invention provides a
pharmaceutical composition comprising a compound of formula (I) as
described herein and a therapeutically inert carrier.
[0644] The compounds of formula (I) and their pharmaceutically
acceptable salts and esters can be used as medicaments (e.g. in the
form of pharmaceutical preparations). The pharmaceutical
preparations can be administered internally, such as orally (e.g.
in the form of tablets, coated tablets, dragees, hard and soft
gelatin capsules, solutions, emulsions or suspensions), nasally
(e.g. in the form of nasal sprays) or rectally (e.g. in the form of
suppositories). However, the administration can also be effected
parentally, such as intramuscularly or intravenously (e.g. in the
form of injection solutions).
[0645] The compounds of formula (I) and their pharmaceutically
acceptable salts and esters can be processed with pharmaceutically
inert, inorganic or organic adjuvants for the production of
tablets, coated tablets, dragees and hard gelatin capsules.
Lactose, corn starch or derivatives thereof, talc, stearic acid or
its salts etc. can be used, for example, as such adjuvants for
tablets, dragees and hard gelatin capsules.
[0646] Suitable adjuvants for soft gelatin capsules are, for
example, vegetable oils, waxes, fats, semi-solid substances and
liquid polyols, etc.
[0647] Suitable adjuvants for the production of solutions and
syrups are, for example, water, polyols, saccharose, invert sugar,
glucose, etc.
[0648] Suitable adjuvants for injection solutions are, for example,
water, alcohols, polyols, glycerol, vegetable oils, etc.
[0649] Suitable adjuvants for suppositories are, for example,
natural or hardened oils, waxes, fats, semi-solid or liquid
polyols, etc.
[0650] Moreover, the pharmaceutical preparations can contain
preservatives, solubilizers, viscosity-increasing substances,
stabilizers, wetting agents, emulsifiers, sweeteners, colorants,
flavorants, salts for varying the osmotic pressure, buffers,
masking agents or antioxidants. They can also contain still other
therapeutically valuable substances.
[0651] The dosage can vary in wide limits and will, of course, be
fitted to the individual requirements in each particular case. In
general, in the case of oral administration a daily dosage of about
0.1 mg to 20 mg per kg body weight, preferably about 0.5 mg to 4 mg
per kg body weight (e.g. about 300 mg per person), divided into
preferably 1-3 individual doses, which can consist, for example, of
the same amounts, should be appropriate. It will, however, be clear
that the upper limit given herein can be exceeded when this is
shown to be indicated.
[0652] In accordance with the invention, the compounds of formula
(I) or their pharmaceutically acceptable salts and esters can be
used for the treatment or prophylaxis of type 2 diabetes related
microvascular complications (such as, but not limited to diabetic
retinopathy, diabetic neuropathy and diabetic nephropathy),
coronary artery disease, obesity and underlying inflammatory
diseases, chronic inflammatory and autoimmune/inflammatory
diseases.
EXAMPLES
[0653] The invention will be more fully understood by reference to
the following examples. The claims should not, however, be
construed as limited to the scope of the examples.
[0654] In case the preparative examples are obtained as a mixture
of enantiomers, the pure enantiomers can be separated by methods
described herein or by methods known to the man skilled in the art,
such as e.g., chiral chromatography (e.g., chiral SFC) or
crystallization.
[0655] All reaction examples and intermediates were prepared under
an argon atmosphere if not specified otherwise.
Method A1
Example 11
rac-(4aR,aS)-6-[4-[[4-(Trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl-
]-4,4a,5,7,8,a-hexahydropyrido[4,3-b][1,4]oxazin-3-one
##STR00030##
[0657] To a solution of 4-nitrophenyl
4-(4-(trifluoromethyl)benzyl)piperidine-1-carboxylate (100 mg, 245
.mu.mol, BB2) in DMF (1.5 mL),
rac-(4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one
dihydrochloride (45.9 mg, 294 .mu.mol, ChemBridge Corporation, BB1)
and TEA (49.6 mg, 68.3 .mu.L, 490 .mu.mol) were added. The
resultant reaction mixture was heated at 80.degree. C. for 18 h.
The reaction mixture was diluted with EtOAc and washed three times
with H.sub.2O and NaHCO.sub.3. The combined organic layers were
washed with brine, dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo. The crude material was purified by flash
chromatography (silica gel, eluting with a gradient of MeOH/EtOAc
0-10%) to afford the title compound as an off-white oil (0.045 g;
43.2%). MS (ESI): m/z=426.4 [M+H].sup.+.
Method A2
Example 3
rac-(4aR,8aS)-6
[4-[(4-tert-Butylthiazol-2-yl)methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-
-hexahydropyrido[4,3-b][1,4]oxazin-3-one
##STR00031##
[0659] To an ice-cold suspension of bis(trichloromethyl) carbonate
(45.3 mg, 153 .mu.mol, CAS RN 32315-10-9) and NaHCO.sub.3(73.3 mg,
873 .mu.mol) in DCM (2 mL) was added in one portion
4-tert-butyl-2-(4-piperidylmethyl)thiazole hydrochloride (60 mg,
218 .mu.mol, Enamine Ltd) and the mixture was stirred at RT
overnight. The suspension was filtered and the filtrate was
evaporated. The residue was diluted in DCM (1 mL) and added
dropwise to an ice-cold solution of
rac-(4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one
dihydrochloride (50 mg, 218 .mu.mol, ChemBridge Corporation, BB1)
and DIPEA (152 .mu.L, 870 .mu.mol) in DCM (1 mL). The suspension
was stirred at RT for 19 h to become a solution. The reaction
mixture was poured on H.sub.2O and DCM and the layers were
separated. The aqueous layer was extracted three times with DCM.
The organic layers were washed twice with water, dried over
MgSO.sub.4, filtered, treated with silica gel and evaporated. The
compound was purified by silica gel chromatography on a 4 g column
using an MPLC system eluting with a gradient of DCM:MeOH (100:0 to
90:10) to provide the desired compound as a colorless foam (0.039
g; 42.5%). MS (ESI); m/z=421.2 [M+H].sup.+.
Method A3
Example 34
(+)- or
(-)-4-[[1-[(4aR,8aS)-3-Oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,-
4]oxazine-6-carbonyl]-4-piperidyl]methyl]benzonitrile
##STR00032##
[0661] To an ice-cold solution of bis(trichloromethyl) carbonate
(39.9 mg, 134 .mu.mol, CAS RN 32315-10-9) in DCM were added
NaHCO.sub.3(64.5 mg, 768 .mu.mol) and
(+)-cis-hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one (30 mg, 192
.mu.mol, BB a) and the mixture was stirred at RT overnight. To the
suspension was added 4-(piperidin-4-ylmethyl)benzonitrile (38.5 mg,
192 .mu.mol, CAS RN 333987-57-8) and DIPEA (99.3 mg, 134 .mu.L, 768
.mu.mol). The suspension was stirred at RT for 4.5 h. The reaction
mixture was poured on H.sub.2O and DCM and the layers were
separated. The aqueous layer was extracted three times with DCM.
The organic layers were washed twice with H.sub.2O, dried over
MgSO.sub.4, filtered, treated with silica gel and evaporated. The
compound was purified by silica gel chromatography on a 4 g column
using an MPLC system eluting with a gradient of DCM:MeOH (100:0 to
90:10) to furnish the desired compound as a colorless gum (0.023 g;
31.3%). MS (ESI): m/z=383.2 [M+H].sup.+.
Method A4
Example 79
(4aR,8aS)-6-(4-((2-chloro-4-fluorophenoxy)methyl)-4-methylpiperidine-1-car-
bonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one
##STR00033##
[0663] To a solution of 4-nitrophenyl
(4aR,8aS)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylate
(25 mg, 77.8 .mu.mol, BB7a) in NMP (1 mL) was added DIPEA (25.1 mg,
34 .mu.L, 195 .mu.mol) and
4-((2-chloro-4-fluorophenoxy)methyl)-4-methylpiperidine;
hydrochloride salt (19.5 mg, 66.1 .mu.mol, BB12). The reaction vial
was stirred at 140.degree. C. for 45 min. The crude material was
purified by reversed-phase HPLC to yield 23.2 mg of the desired
product. MS (ESI): m/z=440.2 [M+H].sup.+.
Method A5
Example 64
(4aR,8aS)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)-4-fluoropiperidine-1-car-
bonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one
##STR00034##
[0665] A microwave vial was heat gun-dried and charged with
bis(trichloromethyl) carbonate (26.6 mg, 89.6 .mu.mol) and sodium
bicarbonate (32.3 mg, 384 mol). The flask was placed under argon
and DCM (1 mL) was added to give a suspension. The suspension was
cooled by an ice-bath and
4-((2-chloro-4-fluorophenoxy)methyl)-4-fluoropiperidine;
hydrochloride salt (36.1 mg, 121 mol, BB15) was added. The mixture
was stirred at 0.degree. C. for 15 min and at RT overnight. The
reaction mixture was cooled down in an-ice bath and DCM (500 .mu.L)
and DIPEA (49.7 mg, 67.1 .mu.L, 384 .mu.mol) followed by
(4aR,8aS)-6-(4-((2-chloro-4-fluorophenoxy)methyl)-4-fluoropiperidine-1-ca-
rbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one (21.1 mg,
47.5 .mu.mol, BB1a) were added. The resulting off-white suspension
was stirred at room temperature for 7 h. The reaction mixture was
poured on water, DCM was added and the layers were separated. The
aqueous layer was extracted twice with DCM. The combined organic
layers were washed with brine, dried over MgSO.sub.4, filtered and
evaporated to afford a yellow oil (58 mg). The crude product was
purified by reverse-phase HPLC and lyophilized to provide the title
compound as a white solid (21.1 mg, 37.1% yield). MS (ESI):
m/z=444.2 [M+H].sup.+.
Method A6
Example 39
(4aR,8aS)-6-[4-[(2-Fluoro-4-methoxyphenoxy)methyl]piperidine-1-carbonyl]-4-
,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one
##STR00035##
[0667] To a solution of 2-fluoro-4-methoxyphenol (16.5 mg, 13
.mu.L, 116 .mu.mol),
(4aR,8aS)-6-[4-(hydroxymethyl)piperidine-1-carbonyl]-4,4a,5,7,8-
,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (34.5 mg, 116 .mu.mol,
BB16) and triphenylphosphine (33.5 mg, 128 .mu.mol) in DCM (580
.mu.L) was added DIAD (25.8 mg, 24.8 .mu.L, 128 .mu.mol) dropwise
and the reaction was stirred at room temperature for 22 h. The
reaction mixture was diluted with DCM and washed with 1M aq. NaOH.
The phases were separated and the aq. phase was extracted with DCM
twice. The combined organic layers were dried over sodium sulfate,
filtered and concentrated to dryness to give a red oil (99 mg). The
crude product was purified by reverse-phase HPLC and lyophilized to
afford the desired compound (20 mg, 40.9% yield) as a white solid.
MS (ESI): m/z=422.3[M+H].sup.+.
Method A7
Example 42 and 43
(4aS,8aR)-6-(4-(((6-(Trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidine-1--
carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one (Example
42) and
(4aR,8aS)-6-(4-(((6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidine-1-
-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one (Example
43)
##STR00036##
[0668] Step a)
rac-(4aR,8aS)-6-(4-(Chloromethyl)piperidine-1-carbonyl)hexahydro-2H-pyrid-
o[4,3-b][1,4]oxazin-3(4H)-one
##STR00037##
[0670] To a solution of
rac-(4aR,8aS)-6-(4-(hydroxymethyl)piperidine-1-carbonyl)hexahydro-2H-pyri-
do[4,3-b][1,4]oxazin-3(4H)-one (80 mg, 269 .mu.mol, BB16) in dry
DMF (2 mL) was added to DIPEA (52.2 mg, 70.5 .mu.L, 404 .mu.mol).
DMAP (1.64 mg, 13.5 .mu.mol) and methanesulfonyl chloride (46.2 mg,
404 .mu.mol) and the reaction mixture was stirred at room
temperature for 2 h. Addition of 4,4-difluoropiperidine;
hydrochloride salt (84.8 mg, 538 .mu.mol). DIPEA (139 mg, 188
.mu.L, 1.08 mmol) and the reaction mixture was stirred at room
temperature for 2 h. The reaction was then stirred at 70.degree. C.
for 14 h. The crude reaction was submitted for reversed-phase HPLC
purification to yield the title compound as a side product (35 mg).
MS (ESI): m/z=315.1 [M+H].sup.+.
Step b)
(4aS,8aR)-6-(4-(((6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piper-
idine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one
(Example 42) and (4aR
8aS)-6-(4-(((6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidine-1-carb-
onyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one (Example
43)
##STR00038##
[0672] To a solution of
rac-(4aR,8aS)-6-(4-(chloromethyl)piperidine-1-carbonyl)hexahydro-2H-pyrid-
o[4,3-b][1,4]oxazin-3(4H)-one (70 mg, 222 .mu.mol) in dry DMF (1
mL) was added 6-(trifluoromethyl)pyridin-3-ol (54.2 mg, 332
.mu.mol) and Cs.sub.2CO.sub.3 (108 mg, 332 .mu.mol). The reaction
mixture was stirred at 95.degree. C. for 18 h. Insolubles were
removed by filtration over Celite, the filtrate was concentrated
down to dryness and the crude residue was purified and the
enantiomers separated by chiral SFC to yield Example 42 (33.8 mg)
and Example 43 (32.5 mg). MS (ESI): m/z=443.2 [M+H].sup.+ for both
examples.
Method A8
Example 26
(4aS,8aR)-6-(4-((4-(Trifluoromethyl)-1H-pyrazol-1-yl)methyl)piperidine-1-c-
arbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one
##STR00039##
[0674] To a solution of
rac-(4aR,8aS)-6-(4-(hydroxymethyl)piperidine-1-carbonyl)hexahydro-2H-pyri-
do[4,3-b][1,4]oxazin-3(4H)-one (75 mg, 252 .mu.mol, BB16) in dry
DMF (2 mL) was added DIPEA (39.1 mg, 52.9 .mu.L, 303 .mu.mol), DMAP
(3.08 mg, 25.2 .mu.mol) and methanesulfonyl chloride (30.3 mg, 265
.mu.mol) and the reaction mixture was stirred at room temperature
for 2 h. 4-(Trifluoromethyl)-1H-pyrazole (68.6 mg, 504 .mu.mol) and
K.sub.2CO.sub.3 (87.1 mg, 631 .mu.mol) were added and the reaction
mixture was stirred at 90.degree. C. for 18 h. Insolubles were
removed by filtration over celite, the filtrate was concentrated to
dryness in vacuo and the crude residue was directly purified by
flash chromatography with an eluent mixture of DCM and MeOH (0% to
10%), to yield 90 mg of the desired product as a racemate. This was
submitted for SFC chiral separation to yield Example 26 (25 mg) as
a colorless oil and the enantiomer (31 mg) as a colorless oil. MS
(ESI): m/z=416.2 [M+H].sup.+.
Method A9
Example 37
(4aR,8aS)-6-(4-((4,4-Difluoropiperidin-1-yl)methyl)piperidine-1-carbonyl)h-
exahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one
##STR00040##
[0676] To a solution of
(4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one (40 mg,
256 .mu.mol, BB1a) in dry DMF (2 mL) cooled down to 0.degree. C.
was added DIPEA (39.7 mg, 53.7 .mu.L, 307 .mu.mol) and
4-nitrophenyl carbonochloridate (61.9 mg, 307 .mu.mol). The
reaction mixture was stirred at 0.degree. C. for 20 min. LCMS
control showed formation of the intermediate carbamate. DIPEA (116
mg, 157 .mu.L, 896 .mu.mol) and
4,4-difluoro-1-(piperidin-4-ylmethyl)piperidine; dihydrochloride
salt (89.5 mg, 307 .mu.mol, BB17) were added and the reaction
mixture was then stirred at room temperature for 30 min, then
stirred at 100.degree. C. for 14 h. Volatiles were removed in vacuo
and the crude residue was directly submitted for SFC purification
to yield the desired compound (9.5 mg) as a light orange oil. MS
(ESI): m/z=401.3 [M+H].sup.+.
Method A10
Example 125
(+)-(4aR,8aS)-6-[4-[2-(2-Chlorophenyl)ethynyl]piperidine-1-carbonyl]-4,4a,-
5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one
##STR00041##
[0678] In a sealed tube, 4-[2-(2-chlorophenyl)ethynyl]piperidine
(BB 18, 0.02 g, 0.078 mmol) and 4-nitrophenyl
(4aR,8aS)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylate
(BB7a, 0.025 g, 0.078 mmol) were mixed in ACN (0.6 mL). Then,
Huenig's base (0.041 mL, 0.234 mmol) was added, followed by DMAP
(0.005 g, 0.039 mmol) and the reaction mixture was heated to
90.degree. C. overnight. The mixture was evaporated to dryness and
the crude residue purified by reverse phase HPLC to give the title
compound (0.013 g, 41%) as a colorless solid. MS (ESI): m/z=402.2
[M+H].sup.+.
Method B1
Example 1
(+)-(4aR,8aS)-6-(4-((4-(tert-Butyl)thiazol-2-yl)methyl)piperidine-1-carbon-
yl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one
##STR00042##
[0680] The enantiomers of example 3 were separated by preparative
chiral HPLC (Chiralcel OD column) using an isocratic mixture of
EtOH (containing 0.05% of NH.sub.4OAc):n-heptane (20:80). The
fractions were evaporated to provide the desired compound as a
colorless solid (0.012 g; 34.3%). MS (ESI): m/z=421.2
[M+H].sup.+.
Method B2
Example 12
(+)- or
(-)-(4aR,8aS)-6-(4-(4-(Trifluoromethyl)phenoxy)piperidine-1-carbon-
yl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one
##STR00043##
[0682] The enantiomers of example 13 were separated using
preparative chiral HPLC (Chiralpak AD column) using an isocratic
mixture of EtOH (containing 0.05% of NH.sub.4OAc):n-heptane
(40:60). The fractions were evaporated to yield the desired
compound as a light brown oil (0.013 g: 28.4%). MS (ESI): m/z=428.2
[M+H].sup.+.
Method B3
Examples 103, 104 and 105
(4aR,aS)-6-[2-Methyl-3-[[4-(trifluoromethyl)phenyl]methoxy]azetidine-1-car-
bonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one
(Isomer A+B, Isomer C, Isomer D)
##STR00044##
[0684] The stereoisomers of example 117 were separated by
preparative chiral HPLC (Reprosil Chiral NR column) using an
isocratic mixture of EtOH (containing 0.05% of NH.sub.4OAc):
n-heptane (40:60) to provide examples 103 and 104 as single isomers
and example 105 as mixture of two stereoisomers. The fractions were
evaporated to provide the desired compounds as colorless
solids.
Method C
Example 21
rac-(4aR,8aS)-6(4-(4-(Trifluoromethyl)benzyl)piperazine-1-carbonyl)hexahyd-
ro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one
##STR00045##
[0686] A mixture of
rac-cis-6-(piperazine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(-
4H)-one (35 mg, 130 .mu.mol, BB3), 4-(trifluoromethyl)benzaldehyde
(22.7 mg, 17.4 .mu.L, 130 .mu.mol) and sodium triacetoxyborohydride
(27.6 mg, 130 .mu.mol) in DCM (1 mL) was stirred at RT for 15 h.
The reaction mixture was concentrated and the residue was purified
by preparative HPLC to give the desired compound as a white solid
(8 mg, 14.4%). MS (ESI): m/z=427.4 [M+H].sup.+.
[0687] If not indicated otherwise the following examples were
synthesized from
rac-(4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one
dihydrochloride (ChemBridge Corporation) and the suitable building
blocks in analogy to the reaction methods described herein.
TABLE-US-00002 Building Ex. Systematic Name/Structure block(s) MS,
m/z Method 2 ##STR00046## Example 4 405.3 [M + H].sup.+ B1 4
##STR00047## Supplier of building block: BCH Research (UK) and BB1
405.4 [M + H].sup.+ A2 5 ##STR00048## Example 3 421.2 [M + H].sup.+
B1 6 ##STR00049## Example 4 405.3 [M + H].sup.+ B1 7 ##STR00050##
Supplier of building block: UkrOrg- Syntez Ltd. and BB1 426.2 [M +
H].sup.+ A2 8 ##STR00051## Example 11 426.4 [M + H].sup.+ B1 9
##STR00052## 4-[(4- Chloro- phenoxy) methyl] piperi- dine (CAS RN
63608- 33-3) and BB1 408.3 [M + H].sup.+ A2 10 ##STR00053## 4-(4-
Chloro- benzyl)- piperi- dine hydro- chloride (CAS RN 36938- 76-8)
and BB1 392.2 [M + H].sup.+ A2 13 ##STR00054## 4-(4- Trifluoro-
methyl- phenoxy) piperi- dine hydro- chloride (CAS RN 28033- 37-6)
and BB1 428.2 [M + H].sup.+ A2 14 ##STR00055## Example 17 426.3 [M
+ H].sup.+ B1 15 ##STR00056## BB4 and BB1 374.4 [M + H].sup.+ A1 16
##STR00057## FCH Group and BB1 405.2 [M + H].sup.+ A2 17
##STR00058## 4-(4- Trifluoro- methyl benzyl) piperi- dine HCl (CAS
RN 192990- 03-7) and BB6 426.3 [M + H].sup.+ A2 18 ##STR00059##
3-Phenyl- 5-(piperi- din-4- ylmethyl)- 1,2,4- oxa- diazole (CAS RN
1239730- 22-3) and BB1 426.3 [M + H].sup.+ A2 19 ##STR00060##
Example 17 426.4 [M + H].sup.+ B1 20 ##STR00061## Example 11 426.4
[M + H].sup.+ B1 22 ##STR00062## 1-(4- Chlor- benzyl)- pipera- zine
(CAS RN 23145- 88-2) and BB1 393.2 [M + H].sup.+ A2 23 ##STR00063##
Example 7 426.2 [M + H].sup.+ B1 24 ##STR00064## Example 7 426.2 [M
+ H].sup.+ B1 25 ##STR00065## BB5 and BB1 427.2 [M + H].sup.+ A2 27
##STR00066## Supplier of building block: HDH Pharma, Inc. and BB1
432.2 [M + H].sup.+ A2 28 ##STR00067## Supplier of building block:
ZereneX Mole- cular Limi- ted and BB1a 398.1 [M + H].sup.+ A2 29
##STR00068## Example 27 432.2 [M + H].sup.+ B1 30 ##STR00069##
Example 27 432.2 [M + H].sup.+ B1 31 ##STR00070## 4-[4- (Trifluoro-
methoxy) benzyl] piperi- dine (CAS RN 681482- 50-8) and BB1a 442.2
[M + H].sup.+ A2 32 ##STR00071## 4-((2,4- Difluoro- phenoxy)
methyl) piperi- dine HCl CAS RN 614731- 39-4 and BB1a 410.2 [M +
H].sup.+ A5 33 ##STR00072## Building block prepared as des- cribed
in WO2013/ 179024 and BB1a 410.2 [M + H].sup.+ A2 35 ##STR00073##
4-(4- Chloro- benzyl)- piperi- dine hydro- chloride (CAS RN 36938-
76-8) and BB1a 392.2 [M + H].sup.+ A2 36 ##STR00074## 3-[[4-
(Trifluoro- methyl) phenyl] methyl] azetidine (CAS RN 937614- 88-5)
and BB1a 398.3 [M + H].sup.+ A1 38 ##STR00075## BB8 and BB1a 405.3
[M + H].sup.+ A2 40 ##STR00076## BB9 and BB1a 462.1 [M + H].sup.+
A2 41 ##STR00077## BB19 and BB1a 495.18 [M + H].sup.+ A3 44
##STR00078## 4-(3- (Trifluoro- methyl) phenoxy) piperi- dine (CAS
RN 337912- 66-0) and BB1a 428.2 [M + H].sup.+ A3 45 ##STR00079##
2-Chloro- 4-(tri- fluoro- methoxy) phenol (CAS: 35852- 58-5) and
BB1b 492.2 [M + H].sup.+ A6 46 ##STR00080## 2-Chloro- 4-(tri-
fluoro- methoxy) phenol (CAS RN: 35852- 58-5) and BB1a 492.2 [M +
H].sup.+ A6 47 ##STR00081## BB20 and BB1a 432.2 [M + H].sup.+ A5 48
##STR00082## BB12 and BB7b 440.2 [M + H].sup.+ A4 (1:1 ACN: iPrOH)
49 ##STR00083## 4-[(2,4- Difluoro- phenoxy) methyl] piperi- dine
hydro- chloride (CAS RN: 614731- 39-4) and BB7b 410.2 [M + H].sup.+
A4 50 ##STR00084## 4-Chloro- 2-fluoro- phenyl 4- piperi- dinyl-
methyl ether; hydro- chloride salt (CAS: 946680- 87-1) and BB7A
426.2 [M + H].sup.+ A4 (micro- wave heat- ing) 51 ##STR00085## BB21
and BB7a 460.2 [M + H].sup.+ A4 52 ##STR00086## BB22 and BB7a 460.2
[M + H].sup.+ A4 53 ##STR00087## BB91 and BB1a 495.3 [M + H].sup.+
A3 54 ##STR00088## BB23 and BB1a 476.3 [M + H].sup.+ A5 55
##STR00089## BB24 and BB1a 417.2 [M + H].sup.+ A5 56 ##STR00090##
1-[[2- (Pyrro- lidin- 1-yl)-4- (trifluoro- methyl) phenyl] methyl]
pipera- zine (synthe- sized accord- ing to WO2015/ 179559) and BB1a
496.26 [M + H].sup.+ A3 57 ##STR00091## BB25 and BB1a 398.2 [M +
H].sup.+ A5 58 ##STR00092## BB10 and BB1a 494.3 [M + H].sup.+ A3 59
##STR00093## BB26 and BB1a 433.2 [M + H].sup.+ A5 60 ##STR00094##
BB27 and BB1a 416.3 [M + H].sup.+ A9 61 ##STR00095## BB28 and BB1a
406.3 [M + H].sup.+ A5 62 ##STR00096## BB29 and BB1a 448.2 [M +
H].sup.+ A5 63 ##STR00097## BB30 and BB1a 445.24 [M + H].sup.+ A3
65 ##STR00098## BB31 and BB1a 401.22 [M + H].sup.+ A3 66
##STR00099## BB32 and BB1a 404.3 [M + H].sup.+ A9 (puri- fied by
RP- HPLC) 67 ##STR00100## 4-(4- Trifluoro- methyl benzyl) piperi-
dine HCl (CAS RN 192990- 03-7) and BB33 440.3 [M + H].sup.+ A3 68
##STR00101## BB34 and BB1a 495.18 [M + H].sup.+ A3 69 ##STR00102##
BB35 and BB1a 495.11 [M + H].sup.+ A3 fol- lowed by RP- HPLC 70
##STR00103## BB35 and BB1a 461.16 [M + H].sup.+ A3 fol- lowed by
RP- HPLC 71 ##STR00104## BB35 and BB1a 427.2 [M + H].sup.+ A3 fol-
lowed by RP- HPLC 72 ##STR00105## BB11 and BB7a 399.2 [M + H].sup.+
A1 73 ##STR00106## BB13 and BB7a 504.1 [M + H].sup.+ A1 74
##STR00107## BB36 and BB1a 440.1 [M + H].sup.+ A3 75 ##STR00108##
BB7a and BB37 448.2 [M + H].sup.+ A4 (sol- vent ACN instead of NMP)
76 ##STR00109## BB7a and BB38 414.2 [M + H].sup.+ A4 (sol- vent ACN
instead of NMP) 77 ##STR00110## BB7a and BB39 448.2 [M + H].sup.+
A4 (sol- vent ACN instead of NMP) 78 ##STR00111## BB7a and BB40
411.2 [M + H].sup.+ A4 (sol- vent ACN not NMP) 80 ##STR00112## BB41
and BB1a 509.2 [M + H].sup.+ A3 81 ##STR00113## BB14 and BB7a 492.2
[M + H].sup.+ A1 82 ##STR00114## BB42 and BB1a 509.2 [M + H].sup.+
A3 83 ##STR00115## BB43 and BB1a 517.18 [M + H].sup.+ A3 84
##STR00116## BB44 and BB1a 517.18 [M + H].sup.+ A3 85 ##STR00117##
N- methyl- N- (piperi- din-4-yl)- 4-(tri- fluoro- methyl) benza-
mide hydro- chloride (CAS RN 1580795- 67-0) and BB1a 469.20 [M +
H].sup.+ A3 86 ##STR00118## BB94 and BB1a 483.22 [M + H].sup.+ A3
87 ##STR00119## BB88 and BB1a 414.3 [M + H].sup.+ A5 88
##STR00120## BB45 and BB1a 444.3 [M + H].sup.+ A4 (ACN as sol-
vent) 89 ##STR00121## BB46 and BB1a 457.2 [M + H].sup.+ A3 90
##STR00122## 3-[(3- Chloro- phenoxy) methyl] pyrroli- dine (CAS RN
914299- 54-0) and BB1a 394.15 [M + H].sup.+ A4 (ACN as sol- vent)
91 ##STR00123## BB47 and BB1a 394.15 [M + H].sup.+ A4 (ACN as sol-
vent) 92 ##STR00124## BB48 and BB1a 444.2 [M + H].sup.+ A4 (ACN as
sol- vent) 93 ##STR00125## BB49 and BB1a 394.15 [M + H].sup.+ A4
(ACN as sol- vent) 94 ##STR00126## BB50 and BB1a 394.15 [M +
H].sup.+ A4 (ACN as sol- vent) 95 ##STR00127## BB51 and BB1a 466.23
[M + H].sup.+ A4 (ACN as sol- vent) 96 ##STR00128## BB52 and BB1a
394.15 [M + H].sup.+ A4 (ACN as sol- vent) 97 ##STR00129## BB53 and
BB1a 394.15 [M + H].sup.+ A4 (ACN as sol- vent) 98 ##STR00130##
BB54 and BB1a 440.4 [M + H].sup.+ A3 99 ##STR00131## BB55 and BB1a
460.16 [M + H].sup.+ A3 100 ##STR00132## 3-(4- Trifluoro- methyl-
benzyl) pyrroli- dine hydro- chloride salt (CAS RN: 957988- 84-4)
and BB1a 412.19 [M + H].sup.+ A3 101 ##STR00133## BB56 and BB1a
432.2 [M + H].sup.+ A4 (ACN as sol- vent) 102 ##STR00134## BB1a and
BB57 446.3 [M + H].sup.+ A4 (ACN as sol- vent) 103 ##STR00135##
Example 117 428.19 [M + H].sup.+ B3 104 ##STR00136## Example 117
428.19 [M + H].sup.+ B3 105 ##STR00137## Example 117 428.19 [M +
H].sup.+ B3 106 ##STR00138## BB58 and BB1a 445.19 [M + H].sup.+ A3
107 ##STR00139## BB59 and BB1a 523.22 [M + H].sup.+ A3 108
##STR00140## BB60 and BB1a 448.2 [M + H].sup.+ A4 (1:1 iPrOH: ACN
as sol- vent) 109 ##STR00141## BB61 and BB1a 416.2 [M + H].sup.+ A4
(1:1 iPrOH: ACN as sol- vent) 110 ##STR00142## BB62 and BB1a 500.2
[M + H].sup.+ A4 (ACN as sol- vent) 111 ##STR00143## BB63 and BB1a
446.2 [M + H].sup.+ A4 (ACN as sol- vent) 112 ##STR00144## BB64 and
BB1a 450.2 [M + H].sup.+ A4 (ACN as sol- vent)
113 ##STR00145## BB65 and BB1a 432.2 [M + H].sup.+ A4 (ACN as sol-
vent) 114 ##STR00146## BB66 and BB1a 432.2 [M + H].sup.+ A4 (ACN as
sol- vent) 115 ##STR00147## BB67 and BB1a 444.3 [M + H].sup.+ A4
(ACN as sol- vent) 116 ##STR00148## BB68 and BB1a 448.2 [M +
H].sup.+ A4 (1:1 iPrOH: ACN as sol- vent) 117 ##STR00149## BB69 and
BB1a 428.18 [M + H].sup.+ A3 118 ##STR00150## BB70 and BB1a 400.2
[M + H].sup.+ A4 (ACN as sol- vent) 119 ##STR00151## BB71 and BB1a
462.2 [M + H].sup.+ A4 (ACN as sol- vent) 120 ##STR00152## BB72 and
BB1a 434.1 [M + H].sup.+ A4 (ACN as sol- vent) 121 ##STR00153##
BB73 and BB1a 479.2 [M + H].sup.+ A4 (ACN as sol- vent) 122
##STR00154## BB74 and BB1a 442.1 [M + H].sup.+ Hans A4 (ACN as sol-
vent) 123 ##STR00155## BB75 and BB1a 453.0 [M + H].sup.+ Hans A4
(ACN as sol- vent) 124 ##STR00156## BB76 and BB1a 400.2 [M +
H].sup.+ A4 (ACN as sol- vent) 126 ##STR00157## BB77 403.3 [M +
H].sup.+ A10 127 ##STR00158## BB78 403.2 [M + H].sup.+ A10 128
##STR00159## BB79 420.3 [M + H].sup.+ A10 129 ##STR00160## BB80
402.3 [M + H].sup.+ A10 130 ##STR00161## BB81 402.3 [M + H].sup.+
A10 131 ##STR00162## BB82 436.3 [M + H].sup.+ A10 132 ##STR00163##
BB83 418.4 [M + H].sup.+ A10 133 ##STR00164## BB84 374.2 [M +
H].sup.+ A10 134 ##STR00165## BB85 408.3 [M + H].sup.+ A10 135
##STR00166## BB86 392.2 [M + H].sup.+ A10 136 ##STR00167## BB92
413.2 [M + H].sup.+ A1 (ACN as sol- vent DIPEA as base) 137
##STR00168## BB93 441.2 [M + H].sup.+ A1 (ACN as sol- vent DIPEA as
base) 139 ##STR00169## BB95 430.4 [M + H].sup.+ A1 (ACN as sol-
vent DIPEA as base) 140 ##STR00170## BB96 440.18 [M + H].sup.+ A3
fol- lowed by chiral SFC 141 ##STR00171## BB96 440.18 [M + H].sup.+
A3 fol- lowed by chiral SFC 142 ##STR00172## BB97 440.2 [M +
H].sup.+ A3 143 ##STR00173## BB98 and BB1a 450.1 [M + H].sup.+ A3
144 ##STR00174## BB99 and BB1a 482.2 [M + H].sup.+ A3 145
##STR00175## BB100 and BB1a 466.2 [M + H].sup.+ A3 146 ##STR00176##
Example 145 466.2 [M + H].sup.+ SFC, Chiral- pak AD, 40% MeOH 147
##STR00177## Example 145 466.2 [M + H].sup.+ SFC, Chiral- pak AD,
40% MeOH 148 ##STR00178## BB101 and BB1a 464.1 [M + H].sup.+ A3 152
##STR00179## BB104 and BB1a 496.1 [M + H].sup.+ A3 153 ##STR00180##
BB105 and BB1a 480.1 [M + H].sup.+ A3 154 ##STR00181## Example 153
480.1 [M + H].sup.+ A3, then HPLC Repro- sil Chiral NR, 60% hep-
tane, 40% EtOH + NH.sub.4Ac 155 ##STR00182## Example 153 480.1 [M +
H].sup.+ A3, then HPLC Repro- sil Chiral NR, 60% hep- tane, 40%
EtOH + NH.sub.4Ac 156 ##STR00183## BB106 and BB1a 448.1 [M +
H].sup.+ A3 157 ##STR00184## BB107 408.2 [M + H].sup.+ A10 158
##STR00185## BB108 426.3 [M + H].sup.+ A10 159 ##STR00186## BB109
376.3 [M + H].sup.+ A10 160 ##STR00187## BB110 442.3 [M + H].sup.+
A10 161 ##STR00188## BB111 392.3 [M + H].sup.+ A10 162 ##STR00189##
BB112 414.4 [M + H].sup.+ A10 163 ##STR00190## BB113 370.4 [M +
H].sup.+ A10 164 ##STR00191## BB114 442.3 [M + H].sup.+ A10 165
##STR00192## BB115 374.3 [M + H].sup.+ A10 166 ##STR00193## BB116
424.3 [M + H].sup.+ A10 167 ##STR00194## BB117 408.4 [M + H].sup.+
A10 168 ##STR00195## BB118 372.2 [M + H].sup.+ A10 169 ##STR00196##
BB119 368.4 [M + H].sup.+ A10 170 ##STR00197## BB120 424.3 [M +
H].sup.+ A10 171 ##STR00198## BB121 420.3 [M + H].sup.+ A10 172
##STR00199## BB122 392.3 [M + H].sup.+ A10 173 ##STR00200## BB123
354.3 [M + H].sup.+ A10 174 ##STR00201## BB124 392.3 [M + H].sup.+
A10 175 ##STR00202## BB125 406.3 [M + H].sup.+ A10 176 ##STR00203##
BB126 399.3 [M + H].sup.+ A10 177 ##STR00204## BB127 406.3 [M +
H].sup.+ A10 178 ##STR00205## BB128 405.4 [M + H].sup.+ A10 179
##STR00206## BB129 380.4 [M + H].sup.+ A10 180 ##STR00207## BB130
396.4 [M + H].sup.+ A10 181 ##STR00208## BB131 370.3 [M + H].sup.+
A10 182 ##STR00209## BB132 390.3 [M + H].sup.+ A10 183 ##STR00210##
BB133 384.3 [M + H].sup.+ A10 184 ##STR00211## BB134 388.3 [M +
H].sup.+ A10 185 ##STR00212## BB135 392.2 [M + H].sup.+ A10 186
##STR00213## BB136 418.3 [M + H].sup.+ A10 187 ##STR00214## BB137
380.2 [M + H].sup.+ A10 188 ##STR00215## BB138 380.2 [M + H].sup.+
A10 189 ##STR00216## BB139 460.3 [M + H].sup.+ A10 190 ##STR00217##
BB140 390.3 [M + H].sup.+ A10 191 ##STR00218## BB141 384.3 [M +
H].sup.+ A10 192 ##STR00219## BB143 436.4 [M + H].sup.+ A10 193
##STR00220## BB144 398.4 [M + H].sup.+ A10 194 ##STR00221## BB145
382.4 [M + H].sup.+ A10 195 ##STR00222## BB146 396.4 [M + H].sup.+
A10 196 ##STR00223## BB147 450.3 [M + H].sup.+ A10 197 ##STR00224##
BB148 434.4 [M + H].sup.+ A10 198 ##STR00225## BB149 330.3 [M -
H.sub.2O + H].sup.+ A10 199 ##STR00226## BB149 (Elimi- nation
product iso- lated during synthe- sis of example 198) 330.3 [M +
H].sup.+ A10 200 ##STR00227## BB142 442.3 [M + H].sup.+ A10 201
##STR00228## BB7a and BB98 494.2 [M + H].sup.+ A4 202 ##STR00229##
BB7a and BB99 524.2 [M + H].sup.+ A4 203 ##STR00230## BB7a and
BB100 495.2 [M + H].sup.+ A4 204 ##STR00231## BB7a and BB101 434.1
[M + H].sup.+ A4 205 ##STR00232## BB7a and BB102 460.2 [M +
H].sup.+ A4 206 ##STR00233## BB7a and BB103 513.3 [M + H].sup.+ A4
207 ##STR00234## BB7a and BB104 461.2 [M + H].sup.+ A4 208
##STR00235## BB7a and BB105 468.2 [M + H].sup.+ A4 209 ##STR00236##
BB7a and BB106 494.3 [M + H].sup.+ A4 210 ##STR00237## BB7a and
4-(4- Chloro- phen- noxy) piperi- dine hydro- chloride (CAS RN
63843- 53-8) 394.1 [M + H].sup.+ A4 211 ##STR00238## BB7a and BB107
462.2 [M + H].sup.+ A4 212 ##STR00239## BB7a and BB108 522.2 [M +
H].sup.+ A4 213 ##STR00240## BB7a and BB109 434.1 [M + H].sup.+ A4
214 ##STR00241## BB7a and BB110 432.1 [M + H].sup.+ A4 215
##STR00242## BB7a and BB111 376.0 [M + H].sup.+ A4 216 ##STR00243##
BB7a and BB112 442.3 [M + H].sup.+ A4 217 ##STR00244## BB7a and
BB113 428.3 [M + H].sup.+ A4 218 ##STR00245## BB7a and BB114 442.1
[M + H].sup.+ A4 219 ##STR00246## BB7a and BB115 426.1 [M +
H].sup.+ A4 220 ##STR00247## BB7a and BB116 454.3 [M + H].sup.+ A4
221 ##STR00248## BB7a and BB117 491.0 [M + H].sup.+ A4 224
##STR00249## BB170 and BB1a 414.1 [M + H].sup.+ A3 225 ##STR00250##
BB171 and BB1a 414.1 [M + H].sup.+ A3 226 ##STR00251## BB173 and
BB1a 429.4 [M + H].sup.+ A3 227 ##STR00252## BB173 and BB1a 442.2
[M + H].sup.+ A3 Chiral HPLC (Repro- sil Chiral NR, 60% n-hep-
tane, 40% EtOH + NH.sub.4Ac 228 ##STR00253## BB173 and BB1a 442.2
[M + H].sup.+ A3 Chiral HPLC (Repro- sil Chiral NR, 60% n-hep-
tane, 40% EtOH + NH.sub.4Ac 229 ##STR00254## BB173 and BB1a 442.2
[M + H].sup.+ A3 Chiral HPLC (Repro- sil Chiral NR, 60% n-hep-
tane, 40% EtOH + NH.sub.4Ac 230 ##STR00255## BB174 and BB1a 415.2
[M + H].sup.+ A3 231 ##STR00256## BB175 and BB1a 471.2 [M +
H].sup.+ A3 SFC: OD-H co- lumn, 20% EtOH 232 ##STR00257## BB175 and
BB1a 471.2 [M + H].sup.+ A3 SFC: OD-H co-
lumn, 20% EtOH 233 ##STR00258## BB176 and BB1a 464.2 [M + H].sup.+
A3 234 ##STR00259## BB177 and BB1a 483.2 [M + H].sup.+ A3 235
##STR00260## BB178 and BB1a 464.1 [M + H].sup.+ A3 HPLC: YMC-
Triart C18, 25- 45- 60- 100% ACN in water 236 ##STR00261## Example
233 464.4 [M + H].sup.+ Repro- sil Chiral NR, 70% Hep- tan, 30%
EtOH + NH.sub.4Ac 237 ##STR00262## Example 233 464.3 [M + H].sup.+
Repro- sil Chiral NR, 70% Hep- tan, 30% EtOH + NH.sub.4Ac 238
##STR00263## Example 233 464.4 [M + H].sup.+ Repro- sil Chiral NR,
70% n- hep- tane, 30% EtOH + NH.sub.4Ac 239 ##STR00264## BB179 and
BB1a 472.2 [M + H].sup.+ A3 240 ##STR00265## BB180 and BB1a 490.1
[M + H].sup.+ A3 241 ##STR00266## BB181 and BB1a 454.3 [M +
H].sup.+ A3 242 ##STR00267## BB182 and BB1a 525.3 [M + H].sup.+ A3
243 ##STR00268## BB183 and BB1a 525.3 [M + H].sup.+ A3 244
##STR00269## BB184 and BB1a 447.2 [M + H].sup.+ A3 245 ##STR00270##
BB185 and BB1a 514.2 [M + H].sup.+ A3 246 ##STR00271## BB186 and
BB1a 508.1 [M + H].sup.+ A3 247 ##STR00272## Example 246 508.0 [M +
H].sup.+ HPLC: Repro- sil Chiral NR, 60% n- hep- tane, 40% EtOH +
NH.sub.4Ac 248 ##STR00273## Example 246 508.0 [M + H].sup.+ HPLC:
Repro- sil Chiral NR, 60% n- hep- tane, 40% EtOH + NH.sub.4Ac 249
##STR00274## BB7a and BB187 482.1 [M + H].sup.+ A10 250
##STR00275## BB7a and BB188 428.3 [M + H].sup.+ A10 251
##STR00276## BB7a and BB189 444.2 [M + H].sup.+ A10 252
##STR00277## BB7a and BB190 458.2 [M + H].sup.+ A10 253
##STR00278## BB7a and BB191 442.3 [M + H].sup.+ A10 254
##STR00279## BB7a and BB192 446.3 [M + H].sup.+ A10 255
##STR00280## BB7a and BB193 462.3 [M + H].sup.+ A10 256
##STR00281## BB194 406.4 [M + H].sup.+ A10 257 ##STR00282## BB7a
and BB195 462.3 [M + H].sup.+ A10 258 ##STR00283## BB7a and BB196
446.0 [M + H].sup.+ A10 259 ##STR00284## BB7a and BB197 406.4 [M +
H].sup.+ A10 260 ##STR00285## BB7a and BB199 440.1 [M + H].sup.+
A10 261 ##STR00286## BB7a and BB200 434.1 [M + H].sup.+ A10 262
##STR00287## BB7a and BB202 453.4 [M + H].sup.+ A10 264
##STR00288## BB7a and BB205 444.2 [M + H].sup.+ A10 279
##STR00289## BB7a and BB206 430.2 [M + H].sup.+ A4 ACN as sol- vent
fol- lowed by prep- HPLC 280 ##STR00290## BB7a and BB207 432.2 [M +
H].sup.+ A4 ACN as sol- vent fol- lowed by prep- HPLC 281
##STR00291## BB7a and BB208 448.3 [M + H].sup.+ A4 ACN as sol- vent
fol- lowed by prep- HPLC 282 ##STR00292## BB7a and 3-(3- (Tri-
fluoro- methoxy) benzyl) aze- tidine hydro- chloride (CAS RN
1354963- 49-7) 414.3 [M + H].sup.+ A4 ACN as sol- vent fol- lowed
by prep- HPLC 283 ##STR00293## BB7a and BB209 432.2 [M + H].sup.+
A4 ACN as sol- vent fol- lowed by MPLC (n-hep- tane: EtOAc/ EtOH/
3/1 (70:30 to 10:90) 284 ##STR00294## BB7a and BB210 448.2 [M +
H].sup.+ A4 ACN as sol- vent fol- lowed by MPLC (n-hep- tane:
EtOAc/ EtOH/ 3/1 (70:30 to 10:90) 285 ##STR00295## Example 283
432.2 [M + H].sup.+ B3 286 ##STR00296## Example 283 432.2 [M +
H].sup.+ B3 287 ##STR00297## BB1a and BB211 374.2 [M + H].sup.+ A3
288 ##STR00298## BB7a and BB212 448.3 [M + H].sup.+ A4 289
##STR00299## BB1a and BB213 428.2 [M + H].sup.+ A3 290 ##STR00300##
BB7a and BB214 374.2 [M + H].sup.+ A4 (ACN as sol- vent) 291
##STR00301## BB7a and BB215 374.2 [M + H].sup.+ A4 (ACN as sol-
vent) 292 ##STR00302## BB7a and BB216 428.2 [M + H].sup.+ A4 (ACN
as sol- vent) 293 ##STR00303## Example 216 427.2 [M + H].sup.+ G
294 ##STR00304## BB217 428.2 [M + H].sup.+ A3 295 ##STR00305## BB1a
and BB218 448.1 [M + H].sup.+ A3
Example 222
(4aR,8aS)-6-[3-[[6-Fluoro-4-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidin-
e-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one
##STR00306##
[0688] Step a) tert-Butyl
3-[[6-chloro-4-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carboxyl-
ate
[0689] To a solution of tert-butyl
3-(hydroxymethyl)azetidine-1-carboxylate (CAS Nr. 142253-56-3)
(2.60 g, 13.9 mmol) and 2,6-dichloro-4-(trifluoromethyl)pyridine
(CAS Nr. 39890-98-7) (3.00 g, 13.9 mmol) in THF (60 mL) was added
NaH (60%, 1.11 g, 27.8 mmol) and the mixture was stirred 3 h at
25.degree. C. The solution was poured into sat. aq. NH.sub.4Cl (50
mL) and extracted with EtOAc (2.times.50 mL). The combined organic
layers were concentrated under vacuum to give crude tert-butyl
3-[[6-chloro-4-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carboxyl-
ate (3.00 g, 59%) as colorless oil, which was used directly in the
next step. LC-MS (ESI): m/z=367.1 [M+H].sup.+.
Step b)
2-(Azetidin-3-ylmethoxy)-6-chloro-4-(trifluoromethyl)pyridine
[0690] A solution of trifluoroacetic acid (6.3 mL, 81.8 mmol, 10
eq) and tert-butyl
3-[[6-chloro-4-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carboxyl-
ate (3.00 g, 8.18 mmol) in DCM (30 mL) was stirred at 25.degree. C.
for 4 h. The solution was concentrated under vacuum to give a
residue, which was purified by Prep-HPLC (HCl condition) to give
2-(azetidin-3-ylmethoxy)-6-chloro-4-(trifluoromethyl)pyridine (1.00
g, 46%) as white solid. LC-MS (ESI): m/z=267.0 [M+H].sup.+.
Step c)
(4aR,8aS)-6-[3-[[6-Chloro-4-(trifluoromethyl)-2-pyridyl]oxymethyl]-
azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on-
e
[0691] A solution of
2-(azetidin-3-ylmethoxy)-6-chloro-4-(trifluoromethyl)pyridine (150
mg, 0.560 mmol), N,N-diisopropylethylamine (0.29 mL, 1.69 mmol) and
4-nitrophenyl
(4aR,8aS)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylate
(BB7a) (199 mg, 0.620 mmol) in ACN (5 mL) was stirred at 25.degree.
C. for 16 h. The solution was concentrated under vacuum to give a
residue, which was purified by prep-HPLC (TFA conditions) to give
(4aR,8aS)-6-[3-[[6-chloro-4-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidi-
ne-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one
(10.times.) mg, 40%) as colorless oil. LC-MS (ESI): m/z=449.2
[M+H].sup.+.
Step d)
(4aR,8aS)-6-[3-[[6-Fluoro-4-(trifluoromethyl)-2-pyridyl]oxymethyl]-
azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on-
e
[0692] A solution of
(4aR,8aS)-6-[3-[[6-chloro-4-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidi-
ne-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one
(75 mg, 0.17 mmol) and cesium fluoride (101 mg, 0.670 mmol) in DMSO
(3 mL) was stirred at 80.degree. C. for 16 h. The solution was
filtered and purified by prep-HPLC (TFA conditions) to give
(4aR,8aS)-6-[3-[[6-fluoro-4-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidi-
ne-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one
(22 mg, 28%) as white solid. LC-MS (ESI): m/z=433.0
[M+H].sup.+.
Example 223
(4aR,8aS)-6-[3-[[6-Fluoro-5-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidin-
e-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one
##STR00307##
[0693] Step a) tert-Butyl
3-[[6-chloro-5-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carboxyl-
ate
[0694] To a solution of tert-butyl
3-(hydroxymethyl)azetidine-1-carboxylate (CAS Nr. 142253-56-3)
(1.56 g, 8.33 mmol) in THF (50 mL) was added NaH (60%. 741 mg, 18.5
mmol) followed by 2,6-dichloro-3-(trifluoromethyl)pyridine (CAS Nr.
55304-75-1) (2.00 g, 9.26 mmol). The resulting mixture was stirred
at 25.degree. C. for 3 h. The solution was poured into sat.aq.
NH.sub.4Cl (50 mL) and extracted with EtOAc (2.times.30 mL). The
combined organic layers were concentrated under vacuum to give a
residue, which was purified by flash column chromatography
(petroleum ether:EtOAc=5:1) to give tert-butyl
3-[[6-chloro-5-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carboxyl-
ate (1.10 g, 32%) as colorless oil. LC-MS (ESI): m/z=311.0
[M-56+H].sup.+.
Step b)
6-(Azetidin-3-ylmethoxy)-2-chloro-3-(trifluoromethyl)pyridine
[0695] A solution of trifluoroacetic acid (0.37 mL, 4.8 mmol) and
tert-butyl
3-[[6-chloro-5-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidine-1-carboxyl-
ate (1.1 g, 3.0 mmol) in DCM (30 mL) was stirred at 25.degree. C.
for 4 h. The solution was concentrated under vacuum to give a
residue, which was purified by Prep-HPLC (HCl condition) to give
6-(azetidin-3-ylmethoxy)-2-chloro-3-(trifluoromethyl)pyridine (600)
mg, 75%) as white solid. LC-MS (ESI): m/z=267.0 [M+H].sup.+.
Step c)
(4aR,8aS)-6-[3-[[6-Chloro-5-(trifluoromethyl)-2-pyridyl]oxymethyl]-
azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-on-
e
[0696] To a solution of
6-(azetidin-3-ylmethoxy)-2-chloro-3-(trifluoromethyl)pyridine (100
mg, 0.380 mmol) and 4-nitrophenyl
(4aR,8aS)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxane-6(5H)-carboxylate
(BB7a) (120 mg, 0.380 mmol) in ACN (5 mL) was added
N,N-diisopropylethylamine (0.13 mL, 0.75 mmol) with stirring at
25.degree. C. The solution was stirred at 25.degree. C. for 16 h.
The solution was concentrated under vacuum to give a residue, which
was purified by Prep-HPLC (TFA conditions) to give
(4aR,8aS)-6-[3-[[6-chloro-5-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidi-
ne-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one
(76 mg, 45%) as white solid. LC-MS (ESI): m/z=449.1
[M+H].sup.+.
Step d) (4aR,8aS)-6-[3-[[6-Fluoro-5-(trifluoromethyl)-2-pyridyl]ox
methyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxa-
zin-3-one
[0697] A solution of
(4aR,8aS)-6-[3-[[6-chloro-5-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidi-
ne-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one
(70 mg, 0.16 mmol) and cesium fluoride (95 mg, 0.62 mmol) in DMSO
(3 mL) was stirred at 60.degree. C. for 24 h. The solution was
filtered and then purified by Prep-HPLC (TFA conditions) to give
(4aR,8aS)-6-[3-[[6-fluoro-5-(trifluoromethyl)-2-pyridyl]oxymethyl]azetidi-
ne-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one
(38 mg, 49%) as white solid. LC-MS (ESI): m/z=433.3
[M+H].sup.+.
Synthesis of Building Blocks
BB1a & BB1b
(+)-cis-4a,5,6,7,8,8a-Hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one
and
(-)-cis-4a,5,6,7,8,8a-Hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one
[0698] The enantiomers of
rac-(4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one
dihydrochloride (BB 1, 500 mg, 2.18 mmol, ChemBridge Corporation)
were separated by preparative chiral HPLC (ReprosilChiral NR
column) using an isocratic mixture of EtOH (containing 0.05% of
NH.sub.4OAc):n-heptane (30:70).
[0699] First eluting enantiomer:
(+)-cis-4a,5,6,7,8,8a-Hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one
(BB1a). Yellow solid (0.150 g; 44.0%). MS (ESI): m/z=157.1
[M+H].sup.+.
[0700] Second eluting enantiomer:
(-)-cis-4a,5,6,7,8,8a-Hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one.
(BB1b). Yellow solid (0.152 g; 44.6%). MS (ESI): m/z=157.1
[M+H].sup.+.
BB2
(4-Nitrophenyl)
4-[[4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylate
[0701] To a solution of 4-(4-(trifluoromethyl)benzyl)piperidine
(10.times.) mg, 411 .mu.mol, CAS RN 192990-03-7) in DCM (1 mL), TEA
(83.2 mg, 115 .mu.L, 822 .mu.mol) was added. On cooling to
0.degree. C. 4-nitrophenyl carbonochloridate (91.1 mg, 452 .mu.mol,
CAS RN 7693-46-1) was added, the reaction mixture was allowed to
warm to RT and stirred for 18 hours. The reaction mixture was
diluted with DCM and subsequently washed with H.sub.2O and sat.
aqueous NaHCO.sub.3 solution. The combined organic layers were
washed with brine, dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo. The crude material was purified by flash
chromatography (silica 10 g, eluting with EtOAc/Heptane 0-50%), to
afford title compound as a light yellow solid. (0.165 g; 98.3%). MS
(ESI): m/z=409.3 [M+H].sup.+.
BB3
rac-(4aR,8aS)-6-(Piperazine-1-carbonyl)-4,4a,5,7,8,8a-hexahydropyrido[4,3--
b][1,4]oxazin-3-one
[0702] To a mixture of rac-tert-butyl
4-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)piper-
azine-1-carboxylate (100 mg, 271 .mu.mol) in DCM (3 mL) was added
TFA (155 mg, 105 .mu.L, 1.36 mmol) and the mixture was stirred at
RT for 15 h under an argon atmosphere.
[0703] The reaction mixture was washed with a saturated aqueous
NaHCO.sub.3 solution. The H.sub.2O layer was concentrated in vacuo
to give a white solid which was triturated with DCM for 30 min.
before it was filtered. The filtrate was concentrated to give a
light yellow gum (70 mg, 96.1%). MS (ESI): nm/z=269.3
[M+H].sup.+.
Step a) rac-tert-Butyl
4-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)piper-
azine-1-carboxylate
[0704] To a mixture of triphosgene (1.29 g, 4.36 mmol) and
Na.sub.2CO.sub.3 (1.98 g, 18.7 mmol) in THF (3 mL) at 0.degree. C.
were added dropwise a solution of tert-butyl
piperazine-1-carboxylate (1.16 g, 6.23 mmol, CAS RN 57260-71-6) in
THF (90 mL). The reaction mixture was stirred for 10 min. at
0.degree. C., then allowed to warm up to RT and stirring was
continued at RT for 5 h. The suspension was filtered off and the
filtrate was concentrated in vacuo. The residue was dissolved in
THF (40 mL) and added dropwise to a stirred suspension of
rac-(4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one
hydrochloride (1200 mg, 6.23 mmol, Chembridge Corporation) and
DIPEA (4.83 g, 6.53 mL, 37.4 mmol) in THF (40 mL) at 0.degree. C.
After 30 min. at 0.degree. C., the reaction mixture was allowed to
warm up to RT, and stirred at RT for 15 h. The mixture was filtered
and the filtrate concentrated in vacuo. The residue was diluted
with DCM and washed with water, aq. NaHCO.sub.3 solution and brine.
The organic layer was dried over Na.sub.2SO.sub.4, filtered and
concentrated to give a white solid (1.13 g, 58.6%). MS (ESI):
m/z=313.3 [M+H].sup.+.
BB4
(4-Nitrophenyl) 4-(phenoxymethyl)piperidine-1-carboxylate
[0705] The compound was prepared in analogy to BB2 using
4-(phenoxymethyl)piperidine (CAS N63614-86-8) to afford title
compound as a white solid which was used in the next step without
further purification.
BB5
2-(4-Piperidylmethyl)-5-(trifluoromethyl)pyridine; hydrochloride
salt
[0706] tert-Butyl
4-[[5-(trifluoromethyl)-2-pyridyl]methyl]piperidine-1-carboxylate
(320 mg, 0.930 mmol) was dissolved in 4 M HCl in EtOAc (10.0 mL, 40
mmol) and the solution stirred at 20.degree. C. for 2 h. The
mixture was concentrated to yield the desired compound as light
yellow solid (0.259, 94.8%). MS (ESI): m/z=245.0
[M-HCl+H].sup.+.
Step a) tert-Butyl
4-[[5-(trifluoromethyl)-2-pyridyl]methyl]piperidine-1-carboxylate
[0707] 2-Bromo-5-(trifluoromethyl)pyridine (500.0 mg, 2.21 mmol,
CAS RN 1000773-62-5) was degassed before 9-BBN solution 0.5 M in
THF (4.87 mL, 2.43 mmol, CAS RN 280-64-8) was added. The resulting
solution was refluxed for 1 h. After cooling to RT, the solution
was added to a solution of tert-butyl
4-methylenepiperidine-1-carboxylate (480.1 mg, 2.43 mmol, CAS RN
159635-49-1), [1,1'-bis(diphenylphosphino)ferrocene]palladium (II)
chloride (161.89 mg, 0.220 mmol, CAS RN 72287-26-4) and
K.sub.2CO.sub.3 (611.56 mg, 4.42 mmol) in DMF (5 mL) and water (0.5
mL). The resulting mixture was heated at 80.degree. C. for 4 h. The
mixture was cooled to RT and poured into water, the pH was adjusted
to 11 with 10% aqueous NaOH and the mixture was extracted with
EtOAc. The combined organic extracts were washed with brine, dried
over Na.sub.2SO.sub.4, filtered, and evaporated to give a crude
oil, which was purified by column chromatography (silica adsorbent;
gradient of PE:EtOAc 10:1 then 5:1) to yield the desired compound
as a light yellow oil (320 mg, 0.930 mmol, 42%). MS (ESI):
m/z=289.0 [M-C.sub.4H.sub.8+H].sup.+.
BB6
rac-(4aS,8aS)-Hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one
[0708] rac-Benzyl
(4aS,8aS)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylate
(125 mg, 431 .mu.mol) was dissolved in MeOH (5 mL). The reaction
solution was degassed in vacuo and backfilled with argon. Pd--C(20
mg, 188 .mu.mol) was added under an argon atmosphere. Argon was
evacuated from the reaction mixture and backfilled with hydrogen.
The reaction mixture was stirred at RT for 15 h under a hydrogen
atmosphere. The reaction mixture was filtered through a syringe
filter and concentrated in vacuo to afford the desired product as a
white solid (62 mg, 92.2%). MS (ESI): m/z=157.098 [M+H].sup.+.
Step a) rac-Benzyl
(3S,4S)-3-(2-chloroacetamido)-4-hydroxypiperidine-1-carboxylate
[0709] To a stirred suspension of rac-benzyl
(3S,4S)-3-amino-4-hydroxypiperidine-1-carboxylate (317 mg, 1.27
mmol, synthesized according to patent US 2011/59118 A1) and sodium
acetate (208 mg, 2.53 mmol, CAS RN 127-09-3) in a mixture of
acetone (4 mL)/H.sub.2O (0.5 mL) was added dropwise a solution of
chloroacetyl chloride (150 mg, 107 .mu.L, 1.33 mmol, CAS RN
79-04-9) in acetone (3 mL) between 0-5.degree. C. After the
addition the reaction mixture was stirred at RT for 1 h and
subsequently evaporated to dryness giving a yellow gum. The crude
product was purified by silica gel chromatography to afford the
desired product as a yellow solid (385 mg, 93%). MS (ESI):
m/z=325.2 [M-H].sup.+.
Step b) rac-Benzyl
(4aS,8aS)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylate
[0710] To a stirred solution of rac-Benzyl
(3S,4S)-3-(2-chloroacetamido)-4-hydroxypiperidine-1-carboxylate
(385 mg, 1.18 mmol) in dry THF (4 mL) was added NaH (67.9 mg, 1.7
mmol) at 0.degree. C. The mixture was allowed to reach RT and then
stirred for 90 min under an argon atmosphere. H.sub.2O (5 mL) was
added and stirring was continued for 10 min at RT. THF was removed
in vacuo from the reaction mixture. The residue was treated with
DCM and the organic phase was washed with H.sub.2O and brine, dried
over Na.sub.2SO.sub.4, filtered and then concentrated in vacuo. The
residue was purified by flash chromatography (12 g reversed phase
column, gradient 0-100% ACN (0.1% FA) in water (0.1% FA) to afford
the desired product as a white solid (133 mg, 38.9%). MS (ESI):
m/z=291.3 [M+H].sup.+.
BB7a and BB7b
4-Nitrophenyl
(4aR,8aS)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylate
BB7a
and
4-nitrophenyl
(4aS,8aR)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylate
BB7b
[0711] To a suspension of
rac-(4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
dihydrochloride salt (4.5 g, 19.6 mmol, BB1) in dry DCM (125 mL) at
0.degree. C. was added DIPEA (6.35 g, 8.58 mL, 49.1 mmol) followed
by 4-nitrophenyl carbonochloridate (4.35 g, 21.6 mmol). The
reaction mixture was stirred at 0.degree. C. for 10 min and at RT
for 2 h. The crude reaction was diluted with DCM and transferred
into a separating funnel for extraction with sat. aq.
Na.sub.2CO.sub.3 solution. The organic phase was collected and the
aqueous phase was back-extracted with DCM. The combined organic
phases were dried over Na.sub.2SO.sub.4 and evaporated down to
dryness to yield 6.62 g of a crude racemic product (BB7) as a
yellow solid. The crude material was directly submitted for a
chiral SFC separation to yield enantiomer BB7b (2.72 g, second
eluting to enantiomer) as a yellow solid and enantiomer BB7a (3.25
g, first eluting enantiomer) as a light beige solid but
contaminated with BB7b. A further SFC chiral separation was carried
out to yield 2.71 g of BB7a. MS (ESI): m/z=322.2 [M+H].sup.+ for
both enantiomers.
BB8
5-tert-Butyl-2-(4-piperidylmethyl)oxazole; hydrochloride salt
[0712] A solution of tert-butyl
4-[(5-tert-butyloxazol-2-yl)methyl]piperidine-1-carboxylate (167
mg, 518 .mu.mol) in HCl 2M in diethyl ether (2.59 mL, 5.18 mmol)
was stirred at RT for 5 h before another 1.29 mL (2.59 mmol) of HCl
2M in diethyl ether was added. The white suspension was stirred at
RT overnight. The mixture was cooled down in an ice-bath, then
filtered and washed with diethyl ether to get the desired compound
as a colorless solid (0.126 g, 94.0%). MS (ESI): m/z=223.2
[M+H].sup.+.
Step a) (5-tert-Butyloxazol-2-yl)methyl-triphenyl-phosphonium
bromide
[0713] To a solution of 2-(bromomethyl)-5-(tert-butyl)oxazole (600
mg, 2.75 mmol, CAS RN 1334492-54-4) in diethyl ether (5 mL) was
added triphenylphosphine (722 mg, 2.75 mmol, CAS RN 603-35-0) and
the mixture was stirred at RT for 64 h. The suspension was cooled
down in an ice-bath and then filtered. The filter cake was washed a
small volume of cold diethyl ether to give the desired compound as
a light yellow solid (0.864 g, 65.4%). MS (ESI): m/z=400.2
[M-Br+H].sup.+.
Step b) tert-Butyl
4-[(5-tert-butyloxazol-2-yl)methylene]piperidine-1-carboxylate
[0714] To an ice-cold suspension of
(5-tert-butyloxazol-2-yl)methyl-triphenyl-phosphonium bromide (355
mg, 739 .mu.mol) in THF (7 mL) was added potassium tert-butylate 1M
solution in THF (738 .mu.L, 738 .mu.mol) and the reaction stirred
at this temperature for 15 min. Then, tert-butyl
4-oxopiperidine-1-carboxylate (162 mg, 813 .mu.mol, CAS RN
79099-07-3) was added to the turbid, orange solution and stirring
was continued at 0.degree. C. for another 15 min., then at RT for
42 h. The reaction mixture was poured on half-saturated aqueous
NH.sub.4Cl solution and EtOAc and the layers were separated. The
aqueous layer was extracted twice with EtOAc. The combined organic
layers were dried over MgSO.sub.4, filtered, treated with silica
gel and evaporated. The compound was purified by silica gel
chromatography on a 12 g column using an MPLC system eluting with a
gradient of n-heptane:EtOAc (100:0 to 50:50) to provide the desired
compound as a colorless solid (0.180 mg; 76.0%). MS (ESI):
m/z=321.3 [M+H].sup.+.
Step c) tert-Butyl
4-[(5-tert-butyloxazol-2-yl)methyl]piperidine-1-carboxylate
[0715] To a solution of tert-butyl
4-[(5-tert-butyloxazol-2-yl)methylene]piperidine-1-carboxylate (180
mg, 562 .mu.mol) in MeOH (1 mL) and EtOAc (1 mL) was added Pd/C 10%
(17.9 mg, 16.9 .mu.mol) and the suspension was stirred under a
hydrogen atmosphere at 1.3 bar for 2 h. The suspension was filtered
over a microfilter and the filtrate was evaporated to get the
desired compound as a colorless oil (0.167 g; 92.2%). MS (ESI):
m/z=323.3 [M+H].sup.+.
BB12
4-[(2-Chloro-4-fluoro-phenoxy)methyl]-4-methyl-piperidine;
hydrochloride salt
[0716] To a solution of tert-butyl
4-[(2-chloro-4-fluoro-phenoxy)methyl]-4-methyl-piperidine-1-carboxylate
(186 mg, 0.520 mmol) in EtOAc (1.5 mL) was added HCl in EtOAc (4 M,
1.5 mL) at 0.degree. C. The solution was stirred at 15.degree. C.
for 3 h. The solution was concentrated under vacuum, then dried by
lyophilization to give desired product as a white solid (64.0 mg,
0.220 mmol, 40.3% yield). MS (ESI): m/z=258 [M+H].sup.+.
Step a) tert-Butyl
4-methyl-4-(methylsulfonyloxyethyl)piperidine-1-carboxylate
[0717] To a solution of tert-butyl
4-(hydroxymethyl)-4-methyl-piperidine-1-carboxylate (500 mg, 2.14
mmol, CAS RN: 614730-97-1) in DCM (5 mL) was added NEt.sub.3 (0.45
mL, 3.22 mmol) and methanesulfonyl chloride (0.23 mL, 3.0 mmol) at
0.degree. C. The mixture was stirred at 0.degree. C. for 2 h. The
mixture was washed twice with water (3 mL each) at 0.degree. C.,
and dried over Na.sub.2SO.sub.4. The organic layer was concentrated
in vacuum to yield the desired compound as colorless oil (766 mg,
2.46 mmol, 98.5%) which was used in the next step without further
purification. MS (ESI): m/z=256 [M-56+H].sup.+.
Step b) tert-Butyl
4-[(2-chloro-4-fluoro-phenoxy)methyl]-4-methyl-piperidine-1-carboxylate
[0718] To a solution of tert-butyl
4-methyl-4-(methylsulfonyloxymethyl)piperidine-1-carboxylate (450
mg, 1.46 mmol) in DMF (5 mL) was added Cs.sub.2CO.sub.3 (620 mg,
1.9 mmol) and 2-chloro-4-fluorophenol (0.14 mL, 1.46 mmol) at
15.degree. C. The mixture was heated to 90.degree. C. and stirred
for 16 h. The reaction solution was diluted by EtOAc (10 mL),
washed twice with brine (10 mL each), and dried over
Na.sub.2SO.sub.4. The organic layer was concentrated under vacuum
to give the crude product (0.7 g) as light yellow oil. The crude
product was purified by prep-HPLC and dried by lyophilization to
give the desired compound as colorless solid (186 mg, 0.520 mmol,
35.5% yield). MS (ESI): m/z=302 [M-56+H].sup.+.
BB15
4-[(2-Chloro-4-fluoro-phenoxy)methyl]-4-fluoro-piperidine;
hydrochloride salt
[0719] To a solution of tert-butyl 4-1
(2-chloro-4-fluoro-phenoxy)methyl-4-fluoro-piperidine-1-carboxylate
(220 mg, 0.610 mmol) in EtOAc (2 mL) was added HCl/EtOAc (0.4 mL,
3.6 mmol) at 0.degree. C. The solution was stirred at 15.degree. C.
for 2.5 h. The solution was concentrated in vacuo, then dried by
lyophilization to give desired product as a white solid (136.7 mg,
75.4%).
Step a) tert-Butyl
4-fluoro-4-(methylsulfonyloxymethyl)piperidine-1-carboxylate
[0720] To a solution of tert-butyl
4-fluoro-4-(hydroxymethyl)piperidine-1-carboxylate (500 mg, 2.14
mmol) in DCM (5 mL) was added NEt.sub.3 (0.45 mL, 3.22 mmol) and
methanesulfonyl chloride (0.23 mL, 3 mmol) at 0.degree. C. The
mixture was stirred at 0.degree. C. for 2 h. The mixture was washed
twice with H.sub.2O (3 mL each) at 0.degree. C., and dried over
Na.sub.2SO.sub.4. The organic layer was concentrated to provide the
compound as a colorless oil (766 mg, 98.5%) which was used in next
step without further purification. MS (ESI): m/z=256
[M-56+H].sup.+.
Step b) tert-Butyl
4-[(2-chloro-4-fluoro-phenoxy)methyl]-4-fluoro-piperidine-1-carboxylate
[0721] To a solution of tert-butyl
4-fluoro-4-(methylsulfonyloxymethyl)piperidine-1-carboxylate (383
mg, 1.23 mmol) in DMF (4 mL) was added Cs.sub.2CO.sub.3 (601 mg,
1.85 mmol), 2-chloro-4-fluorophenol (0.13 mL, 1.35 mmol) and
2-chloro-4-fluorophenol (0.13 mL, 1.35 mmol) at 15.degree. C. The
mixture was heated to 85.degree. C. and stirred for 16 h. The
mixture was extracted three times with EtOAc (5 mL each) at
15.degree. C., the combined organic layers washed three times with
brine (5 mL each), dried over Na.sub.2SO.sub.4, filtered and
evaporated. The crude product was purified by preparative HPLC and
dried by lyophilization to give the desired compound as light
yellow oil (275 mg, 0.760 mmol, 61.5%). MS (ESI): m/z=306
[M-56+H].sup.+.
BB16
rac-(4aR,8aS)-6-(4-(Hydroxymethyl)piperidine-1-carbonyl)hexahydro-2H-pyrid-
o[4,3-b][1,4]oxazin-3(4H)-one
[0722] To a suspension of
rac-(4aR,8aS)-hexahydro-2H-pyrido[4,3-b][14]oxazin-3(4H)-one;
dihydrochloride salt (450 mg, 1.96 mmol, BB1) in dry DMF (9 mL)
cooled down to 0.degree. C. under an inert atmosphere was added
DIPEA (787 mg, 1.06 mL, 6.09 mmol) and 4-nitrophenyl
carbonochloridate (475 mg, 2.36 mmol). The reaction mixture was
stirred at 0.degree. C. for 30 min. Piperidin-4-ylmethanol (271 mg,
2.36 mmol, CAS RN 6457-49-4) and DIPEA (381 mg, 515 .mu.L, 2.95
mmol) were added, and the reaction mixture was stirred at
100.degree. C. for 14 h. Volatiles were removed in vacuo and the
crude residue was purified by flash chromatography with a 24 g
SiO.sub.2 column using an eluent mixture of DCM and MeOH (5% to
25%). The crude product was submitted for SFC purification to yield
the desired compound as a light yellow oil (338 mg). MS (ESI):
m/z=298.3 [M+H].sup.+.
BB17
4,4-Difluoro-1-(piperidin-4-ylmethyl)piperidine; dihydrochloride
salt
[0723] To a solution of tert-butyl
4-((4,4-difluoropiperidin-1-yl)methyl)piperidine-1-carboxylate (453
mg, 1.07 mmol) in dioxane (2.5 mL) was added HCl (4.0M solution in
dioxane) (2.67 mL, 10.7 mmol) and the reaction mixture was stirred
at room temperature for 14 h. Volatiles were removed in vacuo to
yield the desired compound as a white solid (286 mg) which was used
in the next step without further purification. MS (ESI): m/z=219.3
[M+H].sup.+.
Step a) tert-Butyl
4-((4,4-difluoropiperidin-1-yl)methyl)piperidine-1-carboxylate
[0724] To a solution of a tert-butyl
4-(bromomethyl)piperidine-1-carboxylate (0.5 g, 1.8 mmol, CAS RN:
158407-04-6) in dry DMF (4 mL) was added 4,4-difluoropiperidine;
dihydrochloride salt (425 mg, 2.7 mmol) and Cs.sub.2CO.sub.3 (1.17
g, 3.59 mmol). The reaction mixture was then stirred at 80.degree.
C. under microwave radiation for 60 min. Insolubles were removed by
filtration, the filtrate was then concentrated in vacuo, and the
obtained crude residue was suspended in DCM and filtered through a
pad of Celite to give a crude yellow oil, which was purified by
flash chromatography on a SiO.sub.2 column, using an eluent mixture
of n-heptane and EtOAc (10% to 60%) to yield the desired product as
a colorless oil (453 mg). The compound was carried forwards to the
next step without further purification. MS (ESI): m/z=319.3
[M+H].sup.+.
BB19
N-(azetidin-3-ylmethyl)-22,2-trifluoro-1-(4-(trifluoromethyl)phenyl)ethan--
1-amine; bis(trifluoroacetate) salt
[0725] To a solution of tert-butyl
3-(((2,2,2-trifluoro-1-(4-(trifluoromethyl)phenyl)ethyl)amino)methyl)azet-
idine-1-carboxylate (1 g, 2.42 mmol) in DCM (10 mL) was added TFA
(5.53 g, 3.74 mL, 48.5 mmol). The resulting reaction mixture was
stirred at RT for 1 h. The reaction mixture was concentrated in
vacuo to yield the desired compound as colorless oil (1.29 g). MS
(ESI): m/z=313.5 [M+H].sup.+.
Step a) tert-Butyl
3-(((2,2,2-trifluoro-1-(4-trifluoromethyl)phenyl)ethyl)amino)methyl)azeti-
dine-1-carboxylate
[0726] To a dry flask with septum was added under nitrogen
tert-butyl 3-(aminomethyl)azetidine-1-carboxylate (0.852 g, 4.57
mmol), triethylamine (1.39 g, 1.91 mL, 13.7 mmol),
2,2,2-trifluoro-1-(4-(trifluoromethyl)phenyl)ethan-1-one (1.11 g,
780 .mu.L, 4.57 mmol), and dry DCM (28 mL). Titanium tetrachloride
1 M in DCM (2.29 mL, 2.29 mmol) was added via a syringe to the
ice-cooled flask (exothermic). The reaction was stirred overnight
at RT, then carefully quenched with a solution of NaCNBH.sub.3 (862
mg, 13.7 mmol) in MeOH (8.79 g, 11.1 mL, 274 mmol) and stirred
overnight. The reaction was basified with sat. NaHCO.sub.3
solution. The obtained insoluble material was filtered off over
celite. Extraction of the filtrate with DCM, the organic layers
were combined, washed with brine, dried over Na.sub.2SO.sub.4 and
concentrated. The crude material was purified by flash
chromatography (silica gel, 50 g, 0% to 50% EtOAc in n-heptane to
yield tert-butyl
3-(((2,2,2-trifluoro-1-(4-(trifluoromethyl)phenyl)ethyl)amino)methyl)azet-
idine-1-carboxylate which was used in the next step without further
purification.
BB26
3-Chloro-4-(4-piperidylmethoxy)benzonitrile; hydrochloride salt
[0727] To a solution of tert-butyl
4-[(2-chloro-4-cyano-phenoxy)methyl]piperidine-1-carboxylate (300
mg, 0.860 mmol) in EtOAc (3 mL) was added HCl in EtOAc (4M, 2.0 mL)
at 0.degree. C. The solution was stirred at 15.degree. C. for 3 h.
The solution was concentrated in vacuo, then dried by
lyophilization to give desired product as a white solid (238 mg,
0.830 mmol, 96% yield). MS (ESI): m/z=251 [M+H].sup.+.
Step a) tert-Butyl
4-(((methylsulfonyl)oxy)methyl)piperidine-1-carboxylate
[0728] To a solution of N-Boc-4-piperidinemethanol (10.0 g, 46.5
mmol, 1 eq) in DCM (200 mL) was added NEt.sub.3 (7.04 g, 69.7
mmol), then methanesulfonyl chloride (3.95 mL, 51.1 mmol) was added
at 0.degree. C. and the mixture was stirred at 0.degree. C. for 1
h. The mixture was poured into ice-water, the aqueous phase was
extracted twice with DCM (50 mL each). The combined organic layers
were washed with brine (50 mL), and concentrated under vacuum. The
residue was directly used without any purification. MS (ESI):
m/z=238.1 [M+H].
Step b) tert-Butyl
4-[(2-chloro-4-cyano-phenoxy)methyl]piperidine-1-carboxylate
[0729] To a solution of tert-butyl
4-(methylsulfonyloxymethyl)piperidine-1-carboxylate (700 mg, 2.39
mmol) in DMF (7 mL) was added Cs.sub.2CO.sub.3 (855 mg, 2.62 mmol)
and 3-chloro-4-hydroxybenzonitrile (0.25 mL, 2.39 mmol) at
15.degree. C. The mixture was heated to 85.degree. C. and stirred
for 16 h. The reaction mixture was diluted with EtOAc (8 mL) at
15.degree. C., washed three times with brine (8 mL each), the
combined organic layers were dried over Na.sub.2SO.sub.4 and
evaporated. The colorless residue (0.75 g) was purified by
prep-HPLC and dried by lyophilization to give the desired product
as a white solid (531 mg, 1.51 mmol, 53.4%). MS (ESI): m/z=295
[M-56+H].sup.+.
BB27
4-((4-(Trifluoromethyl)-1H-imidazol-1-yl)methyl)piperidine;
hydrochloride salt
[0730] To a solution of tert-butyl
4-((4-(trifluoromethyl)-1H-imidazol-1-yl)methyl)piperidine-1-carboxylate
(430 mg, 1.29 mmol) in dioxane (3 mL) was added HCl (4 M solution
in dioxane: 3.22 mL, 12.9 mmol) and the reaction mixture was
stirred at RT for 14 h. Volatiles were removed in vacuo to give the
crude product (362 mg) which was used in the next step without
further purification. MS (ESI): m/z=234.2 [M+H].sup.+.
Step a) tert-Butyl
4-((4-(trifluoromethyl)-1H-imidazol-1-yl)methyl)piperidine-1-carboxylate
[0731] To a solution of a tert-butyl
4-(bromomethyl)piperidine-1-carboxylate (0.5 g, 1.8 mmol, CAS RN:
158407-04-6) in dry DMF (4 mL) was added
4-(trifluoromethyl)-1H-imidazole (293 mg, 2.16 mmol) and
Cs.sub.2CO.sub.3 (1.17 g, 3.59 mmol). The reaction mixture was then
stirred at 80.degree. C. for 14 h. Insolubles were removed by
filtration, and the filtrate was concentrated in vacuo. The crude
residue was suspended in DCM and filtered through a pad of Celite
to give a yellow oil, which was purified by flash chromatography
with a SiO.sub.2 column, using an eluent mixture of n-heptane and
EtOAc (10% to 90.degree. 6). This yielded the first fraction (301
mg) of the desired product as a colorless oil, and a second
fraction (261 mg) of a mixture of the desired product with
impurities. The second fraction was submitted for SFC purification,
and the purified product was combined with the first fraction to
yield 430 mg of the desired product as a colorless oil. MS (ESI):
m/z=334.2 [M+H].sup.+.
BB29
3-((2-Chloro-4-(trifluoromethyl)phenoxy)methyl)azetidine
[0732] Trifluoroacetic acid (2 g, 1.35 mL, 17.5 mmol) was added to
a solution of tert-butyl
3-((2-chloro-4-(trifluoromethyl)phenoxy)methyl)azetidine-1-carboxylate
(320 mg, 875 .mu.mol) in DCM (4.37 mL) and the solution was stirred
at RT for 2 h. The solvent was removed under reduced pressure and
the resulting pale oil (470 mg) was diluted with EtOAc and washed
with aq. Na.sub.2CO.sub.3 solution. The aqueous phase was extracted
three times with EtOAc, and the combined organic layers were washed
with brine, dried over Na.sub.2SO.sub.4 and concentrated under
reduced pressure to afford the compound as a yellow oil (259 mg,
877 .mu.mol). MS (ESI): m/z=266.1 to [M+H].sup.+.
Step a) tert-Butyl
3-((2-chloro-4-(trifluoromethyl)phenoxy)methyl)azetidine-1-carboxylate
[0733] To a solution of 2-chloro-4-(trifluoromethyl)phenol (525 mg,
357 .mu.L, 2.67 mmol), tert-butyl
3-(hydroxymethyl)azetidine-1-carboxylate (500 mg, 2.67 mmol, CAS
RN: 142253-56-3) and triphenylphosphine (770 mg, 2.94 mmol) in DCM
(13.4 mL) was added DIAD (594 mg, 571 .mu.L, 2.94 mmol) dropwise
and the reaction was stirred at RT for 17 h. The reaction mixture
was quenched by addition of sat. aq. NaHCO.sub.3 solution (20 mL).
The phases were separated and the aq. phase was extracted with DCM
twice. The combined organic layers were dried over Na.sub.2SO.sub.4
and concentrated to dryness. The residue was dissolved in EtOH (7
mL) and a homogeneous solution of zinc chloride (218 mg, 1.6 mmol)
in EtOH (2 mL, 0.5 M) was added. The mixture was stirred for 30 min
during which a white solid precipitated. The white solid was
filtered off and washed with EtOH The filtrate was concentrated to
give a yellow oil with a white precipitate. The crude was
immobilized on Isolute and purified by column chromatography (40 g,
0 to 30% EtOAc in heptanes) to afford the title compound as a white
solid (764.6 mg, 1.99 mmol, 74.4%). MS (ESI): m/z=310.1
[M-56+H].sup.+.
BB30
N-benzyl-N-(2-hydroxyethyl)piperidine-4-carboxamide
hydrochloride
[0734] To a solution of tert-butyl
4-(benzyl(2-hydroxyethyl)carbamoyl)piperidine-1-carboxylate (0.080
g, 221 .mu.mol) in DCM (1 mL) was added HCl 2 M in diethyl ether
(1.1 mL, 2.21 mmol). The resultant reaction mixture was stirred at
RT for 1 h and then concentrated under vacuum at 22.degree. C. to
yield the desired compound as a colorless oil (63 mg) (BB30). MS
(ESI): m/z=263.18 [M+H].sup.+.
Step a) tert-Butyl
4-(benzyl(2-hydroxyethyl)carbamoyl)piperidine-1-carboxylate
[0735] In a 10 mL glastube, to
1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (0.1 g, 436
.mu.mol) in DMF (2 mL) was added 2-(benzylamino)ethan-1-ol (72.5
mg, 480 .mu.mol), DIPEA (169 mg, 229 .mu.L, 1.31 mmol) and HATU
(182 mg, 480 .mu.mol), stirred at RT for 1 h and extracted with
H.sub.2O/DCM. The crude material was purified by flash
chromatography (silica gel, 20 g, 50% to 100% EtOAc in n-heptane)
to yield the compound as a light yellow oil (156 mg).
BB31
N-benzylpiperidine-4-carboxamide hydrochloride
[0736] tert-Butyl 4-(benzylcarbamoyl)piperidine-1-carboxylate
(0.138 g, 433 .mu.mol) was dissolved in DCM (1 mL) and HCl 2M in
diethyl ether (2.17 mL, 4.33 mmol) was added. The reaction mixture
was stirred for 2 h. The residue was concentrated in vacuo to yield
the compound (108 mg) as a colorless oil. MS (ESI): m/z=219.15
[M+H].sup.+.
Step a) tert-Butyl 4-(benzylcarbamoyl)piperidine-1-carboxylate
[0737] In a 10 mL glastube, to
1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (0.1 g, 436
.mu.mol) in DMF (2 mL) was added phenylmethanamine (51.4 mg, 52.4
.mu.L, 480 .mu.mol), DIPEA (169 mg, 229 ML, 1.31 mmol) and HATU
(182 mg, 480 .mu.mol), stirred at RT for 2 h and extracted with
H.sub.2O/DCM. The crude material was purified by flash
chromatography (silica gel, 20 g, 50% to 100% EtOAc in n-heptane)
to yield the compound as a colorless oil (0.138 g).
BB32
4-((4-(tert-Butyl)-1H-pyrazol-1-yl)methyl)piperidine; hydrochloride
salt
[0738] To a solution of tert-butyl
4-((4-(tert-butyl)-1H-pyrazol-1-yl)methyl)piperidine-1-carboxylate
(100 mg, 311 .mu.mol) in dioxane (I mL) was added HCl (4.0M
solution in dioxane; 1.17 mL, 4.67 mmol) and the reaction mixture
was stirred at RT for 14 h. Volatiles were removed in vacuo to give
84 mg of a crude product which was used in the next step without
further purification. MS (ESI): m/z=222.3 [M+H].sup.+.
Step a) tert-Butyl
4-4-((4-tert-butyl)-1H-pyrazol-1-yl)methyl)piperidine-1-carboxylate
[0739] To a solution of a tert-butyl
4-(bromomethyl)piperidine-1-carboxylate (0.5 g, 1.8 mmol, CAS RN
158407-04-6) in dry DMF (4 mL) was added 4-(tert-butyl)-1H-pyrazole
(268 mg, 2.16 mmol) and NaH (86.3 mg, 2.16 mmol). The reaction
mixture was stirred at 80.degree. C. for 14 h. The reaction was
quenched by addition of few drops of sat. aq. NH.sub.4Cl solution,
and transferred into a separating funnel for partitioning between
DCM and sat. aq. NaHCO.sub.3 solution. The organic phase was
collected and the aqueous phase was back-extracted with DCM. The
combined organic phases were dried over Na.sub.2SO.sub.4 and
evaporated down to dryness. The crude material was purified by
flash chromatography with a SiO.sub.2 column, eluting with a
mixture of n-heptane and EtOAc (5% to 60%) to yield the desired
compound as a colorless oil (102 mg). MS (ESI): m/z=322.3
[M+H].sup.+.
BB33
(2R,4aR,8aS)-2-methyl-4a,5,6,7,8,8a-hexahydro-4H-pyrido[4,3-b][1,4]oxazin--
3-one
[0740] To a solution of
6-benzyl-2-methyl-5,6,7,8-tetrahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-on-
e (Isomer A, 1.10 g, 4.26 mmol) in EtOAc (16 mL) and MeOH (16 mL)
was added under argon Pd--C (227 mg, 213 .mu.mol) and the
suspension was stirred under a hydrogen atmosphere (balloon) at 1
bar for 24 h. The suspension was filtered over a microglass filter
and washed with 20 mL EtOAc under inert gas. The filtrate was
evaporated to give BB33 as a colorless solid (715 mg). MS (ESI):
m/z=170.8 [M+H].sup.+. Note: Only the single enantiomer formed
during the reduction.
Step a) 2-Methyl-4H-pyrido[4,3-b][1,4]oxazin-3-one
[0741] To a solution of 3-aminopyridin-4-ol (2.5 g, 22.7 mmol) in
DMF (100 mL) was added dropwise 2-chloropropanoyl chloride (3.03 g,
2.31 mL, 23.8 mmol) and the mixture was stirred at RT for 30 min.
After addition of K.sub.2CO.sub.3 (7.84 g, 56.8 mmol), the
suspension was heated to 100.degree. C. (oil bath) for 20 h. The
DMF was removed in vacuo, then 100 mL EtOAc were added and stirred
at RT for 10 min, and it was washed with 50 mL H.sub.2O, extracted
3 times with EtOAc. The organic phases were combined, dried with
MgSO.sub.4 and concentrated under vacuo to yield 3.72 g of
2-methyl-4H-pyrido[4,3-b][1,4]oxazin-3-one which was used in the
next step without further purification.
Step b)
6-Benzyl-2-methyl-3-oxo-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazin-6--
ium bromide
[0742] A suspension of
2-methyl-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one (3.72 g, 22.7 mmol)
in DCM (32 mL) and MeOH (8 mL) was treated with
(bromomethyl)benzene (4.65 g, 3.23 mL, 27.2 mmol) and the mixture
was stirred at RT for 60 h. A suspension formed, which was cooled
down to 0.degree. C., 20 mL n-hexane were added and then the
precipitate was filtered. The residue was washed with 15 mL of cold
DCM/n-hexan to yield the compound as an off-white solid (5.2 g). MS
(ESI): m/z=255 [M+H].sup.+.
Step c)
6-Benzyl-2-methyl-5,6,7,8-tetrahydro-2H-pyrido[4,3-b][1,4]oxazin-3-
(4H)-one
[0743] To a suspension of
6-benzyl-2-methyl-3-oxo-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazin-6-ium
bromide (5.2 g, 15.5 mmol) in EtOH (38 mL) was added in portions
NaBH.sub.4 (763 mg, 20.2 mmol) (exothermic, 22.degree. C. to
30.degree. C., yellow suspension). After the exothermic reaction
faded out the mixture was stirred at room temperature for 3 h, then
at 60.degree. C. for 1 h and at 22.degree. C. for 1 h. The reaction
mixture was evaporated, partitioned between H.sub.2O and EtOAc and
the layers were separated. The aqueous layer was extracted once
with EtOAc. The organic layers were washed twice with H.sub.2O,
dried over MgSO.sub.4, filtered, treated with silica gel and
evaporated. The compound was purified by silica gel chromatography
on a 120 g column using an MPLC system eluting with a gradient of
n-heptane:EtOAc (50 to 100 in 30 min.) to provide the compound as a
light yellow solid (2.48 g) which could be used in the following
step without further purification.
Step d)
6-Benzyl-2-methyl-5,6,7,8-tetrahydro-2H-pyrido[4,3-b][1,4]oxazin-3-
(4H)-one
[0744] The enantiomers were separated by preparative chiral HPLC
(Chiralcel OD column) using an isocratic mixture of EtOH
(containing 0.05% of NH.sub.4OAc):n-heptane (10:90). The fractions
were evaporated to provide the desired compounds as light yellow
solids (Isomer A 1.17 g, Isomer B 1.10 g).
BB34
N-(azetidin-3-ylmethyl)-2,2,2-trifluoro-1-(3-(trifluoromethyl)phenyl)ethan-
-1-amine
[0745] In a 100 mL two-necked flask, benzyl
3-(((2,2,2-trifluoro-1-(3-(trifluoromethyl)phenyl)ethyl)amino)methyl)azet-
idine-1-carboxylate (0.913 g, 2.05 mmol) was dissolved in a mixture
of THF (5 mL) and MeOH (5 mL). Pd/C 10% (109 mg, 102 .mu.mol) was
added under argon. The flask was purged and backfilled with H.sub.2
gas (3 times). The reaction mixture was then stirred at 25.degree.
C. for 4 h. The suspension was filtered over decalite, concentrated
and the resulting title compound (611 mg, colorless oil) used
directly for the next step. MS (ESI): m/z=313.4 [M+H].sup.+.
Step a) Benzyl
3-(((2,2,2-trifluoro-1-(3-(trifluoromethyl)phenyl)ethyl)amino)methyl)azet-
idine-1-carboxylate
[0746] To a dry flask with septum was added benzyl
3-(aminomethyl)azetidine-1-carboxylate (0.5 g, 2.27 mmol),
NEt.sub.3 (689 mg, 949 .mu.L, 6.81 mmol),
2,2,2-trifluoro-1-(3-(trifluoromethyl)phenyl)ethan-1-one (554 mg,
391 .mu.L, 2.27 mmol), and dry DCM (15 mL). Titanium tetrachloride
1M in DCM (1.13 mL, 1.13 mmol) was added via a syringe and the
flask was cooled in an ice bath (exothermic). The reaction was
stirred at RT overnight, carefully quenched with a solution of
NaCNBH.sub.3 (428 mg, 6.81 mmol) in MeOH (4.36 g, 5.51 mL, 136
mmol) and acetic acid (0.1 mL) and stirred at RT overnight. The
reaction was basified with sat. aq. NaHCO.sub.3 solution and the
insoluble material obtained was filtered away over celite. The
filtrate was extracted with DCM. The organic layers were combined,
washed with brine, dried over Na.sub.2SO.sub.4 and concentrated in
vacuo. The crude material was purified by flash chromatography
(silica gel, 50 g, 0% to 50% EtOAc in n-heptane) to yield the
desired compound as a colorless oil (913 mg). MS (ESI): m/z=447.2
[M+H].sup.+.
BB35
N-(azetidin-3-ylmethyl)-1-(2,4-dichlorophenyl)-2,2,2-trifluoroethan-1-amin-
e
[0747] In a 100 mL two-necked flask, benzyl
3-(((1-(2,4-dichlorophenyl)-2,2,2-trifluoroethyl)amino)methyl)azetidine-1-
-carboxylate (0.660 g, 1.48 mmol) was dissolved in EtOAc (20 mL) to
give a colorless solution. Pd/C 10% (78.5 mg, 73.8 .mu.mol) was
added under argon. The flask was purged and backfilled with H.sub.2
gas (3 times). The reaction mixture was stirred at 25.degree. C.
for 4 h. LC-MS showed a mixture of the title product
N-(azetidin-3-ylmethyl)-1-(2,4-dichlorophenyl)-2,2,2-trifluoroethan-1-ami-
ne together with the dehalogenated side-products
N-(azetidin-3-ylmethyl)-1-(2-chlorophenyl)-2,2,2-trifluoroethan-1-amine
and N-(azetidin-3-ylmethyl)-1-phenyl-2,2,2-trifluoroethan-1-amine.
The reaction mixture was filtered over decalite, concentrated in
vacuo and used directly for the next step.
Step a) Benzyl
3-[[[1-(2,4-dichlorophenyl)-2,2,2-trifluoro-ethylidene]amino]methyl]azeti-
dine-1-carboxylate
[0748] To a dry flask with septum was added under nitrogen benzyl
3-(aminomethyl)azetidine-1-carboxylate (0.500 g, 2.27 mmol, CAS RN
1016731-24-0), NEt.sub.3 (689 mg, 949 .mu.L, 6.81 mmol),
1-(2,4-dichlorophenyl)-2,2,2-trifluoroethan-1-one (556 mg, 2.27
mmol, and dry DCM (16.4 mL). Titanium tetrachloride (1 M solution
in DCM; 1.13 mL, 1.13 mmol) was added via a syringe to the
ice-cooled flask (exothermic). The reaction was stirred at RT
overnight, carefully quenched with a solution of NaCNBH.sub.3 (428
mg, 6.81 mmol) in MeOH (4.36 g, 5.51 mL, 136 mmol) and stirred for
6 h. LCMS indicated the reaction stopped at the imine.
[0749] The reaction was basified with sat. NaHCO.sub.3. The
obtained insoluble material was filtered over celite and the
filtrate was extracted with DCM. The organic layers were combined,
washed with brine, dried over Na.sub.2SO.sub.4 and concentrated.
The crude material was purified by flash chromatography (silica
gel, 50 g, 0% to 50% EtOAc in n-heptane) to give the desired
compound as a colorless oil (1 g).
Step b) Benzyl
3-(((1-(2,4-dichlorophenyl)-2,2,2-trifluoroethyl)amino)methyl)azetidine-1-
-carboxylate
[0750] In a 25 mL two-necked flask, benzyl
3-[[[1-(2,4-dichlorophenyl)-2,2,2-trifluoro-ethylidene]amino]methyl]azeti-
dine-1-carboxylate (1 g, 2.25 mmol) was dissolved in THF (10 mL)
and MeOH (1 mL) to give a colorless solution. Acetic acid (135 mg,
129 .mu.L, 2.25 mmol) and NaCNBH.sub.3 (423 mg, 6.74 mmol) were
added. The reaction mixture was stirred at 25.degree. C. for 6 h.
The reaction was basified with sat. NaHCO.sub.3. The obtained
insoluble material was filtered over celite and the filtrate was
extracted with DCM. The organic layers were combined, washed with
brine, dried over Na.sub.2SO.sub.4 and concentrated. The crude
material was purified by flash chromatography (silica gel, 50 g, 0%
to 50% EtOAc in heptane) to afford the title compound as a
colorless oil (660 mg) which used in the next step without further
purification.
BB36
cis-4-((2-Chloro-4-fluorophenoxy)methyl)-3-methylpiperidine;
hydrochloride salt
[0751] tert-Butyl
cis-4-((2-chloro-4-fluorophenoxy)methyl)-3-methylpiperidine-1-carboxylate
(115 mg, 321 .mu.mol) was dissolved in DCM (2 mL) and 2M HCl in
ether (161 .mu.L, 321 .mu.mol) was added. The reaction was stirred
at RT for 6 h, then the solvent was removed in vacuo. The crude
product (94 mg, colorless foam) was used in the next step without
purification. MS (ESI): m/z=258.2 [M+H].sup.+.
Step a) tert-Butyl
cis-4-((2-chloro-4-fluorophenoxy)methyl)-3-methylpiperidine-1-carboxylate
[0752] Mitsunobu reaction: In a 50 mL four-necked sulphonation
flask under argon, tert-butyl
cis-4-(hydroxymethyl)-3-methylpiperidine-1-carboxylate (840 mg,
3.66 mmol) was dissolved in THF (15 mL), 2-chloro-4-fluorophenol
(590 mg, 439 .mu.L, 4.03 mmol) and triphenylphosphine (1.06 g, 4.03
mmol) were added. The clear solution was stirred 5 min at RT, then
cooled to 0-2.degree. C. and DEAD (702 mg, 638 .mu.L, 4.03 mmol)
was added over 10 min. The reaction mixture was stirred at
2-4.degree. C. for 1 h, then stirred over night at RT. 50 mL
diethylether were added, the mixture was washed with 2.times.25 mL
water, 3.times.20 mL 1 N NaOH, 1.times.20 mL brine, the organic
phase was dried with Mg.sub.2SO.sub.4, after removing the solvent
in vacuo 2.7 g yellow oil were obtained. To remove the
triphenylphosphinoxide, the residue was stirred in
n-Heptane/diethylether for 30 min, the solids was filtered away,
the filtrate was concentrated in vacuo, to obtain 1.8 g crude
product that was purified by flash chromatography (silica gel, 50
g, 0% to 30% EtOAc in heptane, 40 min): tert-butyl
cis-4-((2-chloro-4-fluorophenoxy)methyl)-3-methylpiperidine-1-carboxylate-
, 1.21 g white solid.
BB39
3-((2-Fluoro-4-(trifluoromethoxy)benzyl)oxy)azetidine;
trifluoroacetate salt
[0753] To a solution of tert-butyl
3-((2-fluoro-4-(trifluoromethoxy)benzyl)oxy)azetidine-1-carboxylate
(415 mg, 1.14 mmol) in DCM (5 mL) was added TFA (1.3 g, 875 .mu.L,
11.4 mmol) and the reaction mixture was stirred at RT for 3 h.
Volatiles were removed in vacuo to yield 455 mg of a light yellow
oil that was used in the next step without further purification. MS
(ESI): m/z=266.1 [M+H].sup.+.
Step a) tert-Butyl
3-((2-fluoro-4-(trifluoromethoxy)benzyl)ox)azetidine-1-carboxylate
[0754] To a solution of tert-butyl 3-hydroxyazetidine-1-carboxylate
(200 mg, 1.15 mmol) in dry THF (5 mL) was added potassium
tert-butoxide (1.65 M solution in THF, 735 .mu.L, 1.21 mmol) and
the reaction mixture was stirred at RT for 15 min followed by
addition of l-(bromomethyl)-2-fluoro-4-(trifluoromethoxy)benzene
(315 mg, 1.15 mmol). The reaction mixture was then stirred at room
temperature for 14 h. The crude reaction was diluted with EtOAc and
extracted with aq. 1 M NaHCO.sub.3 solution, the organic phase was
collected and the aqueous phase was back-extracted with EtOAc. The
combined organic phases were dried over NaSO.sub.4 and evaporated
down to dryness to yield 418 mg of the crude product which was used
in the next step without further purification. MS (ESI): m/z=310.1
[M-56+H].sup.+.
BB40
N-(azetidin-3-yl)-2-chloro-4-fluoro-benzamide; trifluoroacetate
salt
[0755] To a solution of tert-butyl
3-[(2-chloro-4-fluoro-benzoyl)amino]azetidine-1-carboxylate (346
mg, 1.05 mmol) in DCM (3.5 mL) was added TFA (0.7 mL) at 0.degree.
C. The solution was stirred at 0.degree. C. for 2 h. The reaction
was concentrated in vacuum to give the crude product (600 mg) as
light yellow oil. The crude product was purified by prep-HPLC (0.1%
TFA in H.sub.2O and MeCN) and dried by lyophilization to give
desired compound as colorless solid (223 mg, 0.650 mmol, 59.2%
yield). MS (ESI): m/z=229 [M+H].sup.+.
Step a) tert-Butyl
3-[(2-chloro-4-fluoro-benzoyl)amino]azetidine-1-carboxylate
[0756] To a solution of 2-chloro-4-fluorobenzoic acid (500 mg, 2.86
mmol), 1-Boc-3-(amino)azetidine (493 mg, 2.86 mmol) and DMAP (35.0
mg, 0.290 mmol) in THF (10 mL) was added
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (714
mg, 3.72 mmol) at 0.degree. C. The mixture was heated to 30.degree.
C. and stirred for 16 h. The reaction was diluted with EtOAc (5
mL), washed three times with brine (10 mL each) and dried over
Na.sub.2SO.sub.4. The organic layer was concentrated in vacuum to
give the crude product (0.72 g) as yellow oil. The crude product
was purified by prep-HPLC and dried by lyophilization to give
desired compound as a colorless solid (546 mg, 1.66 mmol, 57.9%
yield). MS (ESI): m/z=273 [M-56+H].sup.+.
BB41
N-(azetidin-3-ylmethyl)-2,2,2-trifluoro-N-methyl-1-[4-(trifluoromethyl)pen-
tyl]ethanamine; trifluoroacetate salt
[0757] To a solution of tert-butyl
3-((methyl(2,2,2-trifluoro-1-(4-(trifluoromethyl)phenyl)ethyl)amino)methy-
l)azetidine-1-carboxylate (0.256 g, 600 .mu.mol) in DCM (5 mL) was
added TFA (1.37 g, 925 .mu.L, 12 mmol). The resulting reaction
mixture was stirred at RT for 1 h. The reaction mixture was
concentrated in vacuo to provide the desired compound as a
colorless oil (268 mg). MS (ESI): m/z=327.4 [M+H].sup.+.
Step a) tert-Butyl
3-((methyl(2,2,2-trifluoro-1-(4-(trifluoromethyl)phenyl)ethyl)amino)methy-
l)azetidine-1-carboxylate
[0758] To a dry flask with septum and 3 A molecular sieves was
added under nitrogen tert-butyl
3-((methylamino)methyl)azetidine-1-carboxylate (0.300 g, 293 .mu.L,
1.5 mmol), TEA (455 mg, 626 .mu.L, 4.49 mmol),
2,2,2-trifluoro-1-(4-(trifluoromethyl)phenyl)ethan-1-one (363 mg,
255 .mu.L, 1.5 mmol), and dry DCM (9.86 mL). Titanium tetrachloride
1 M in DCM (749 .mu.L, 749 .mu.mol) was added via a syringe to the
ice-cooled flask (exothermic). The reaction was stirred at RT
overnight, carefully quenched with a solution of NaCNBH.sub.3 (282
mg, 4.49 mmol) in MeOH (3.64 mL, 89.9 mmol) and stirred at RT for 2
h. The reaction was basified with sat. NaHCO.sub.3 solution. The
obtained insoluble material was filtered over celite and the
filtrate was extracted with DCM. The organic layers were combined,
washed with brine, dried over Na.sub.2SO.sub.4 and concentrated.
The crude material was purified by flash chromatography (silica
gel, 50 g, 0% to 50% EtOAc in n-heptane) and was used directly for
the next step.
BB42
N-methyl-N-(piperidin-4-yl)-1-(3-(trifluoromethyl)phenyl)cyclopropane-1-ca-
rboxamide hydrochloride
[0759] To a solution of tert-butyl
4-(N-methyl-1-(3-(trifluoromethyl)phenyl)cyclopropane-1-carboxamido)piper-
idine-1-carboxylate (0.301 g, 706 .mu.mol) in DCM (2 mL) was added
HCl 2M in diethyl ether (3.53 mL, 7.06 mmol). The resulting
reaction mixture was stirred at RT overnight and then concentrated
under vacuum at 22.degree. C. to give 256 mg of BB42 as off white
solid, MS (ESI): m/z=327.2 [M+H].sup.+
Step a) tert-butyl
4-(N-methyl-1-(3-(trifluoromethyl)phenyl)cyclopropane-1-carboxamido)piper-
idine-1-carboxylate
[0760] In a 20 mL glastube, to
1-(3-(trifluoromethyl)phenyl)cyclopropane-1-carboxylic acid (177
mg, 770 .mu.mol) in DMF (5 mL) was added HATU (293 mg, 770 .mu.mol)
and DIPEA (271 mg, 367 .mu.L, 2.1 mmol). The reaction mixture was
stirred for 15 min and then tert-butyl
4-(methylamino)piperidine-1-carboxylate (0.15 g, 700 .mu.mol) was
added. The reaction mixture was stirred at RT for 2 hours. The
reaction mixture was extracted with Water/DCM. The crude material
was purified by flash chromatography (silica gel, 20 g, 0% to 100%
EtOAc in heptane) to yield the desired compound as a light yellow
oil (301 mg). MS (ESI): m/z=371.2 [M-56+H].sup.+
BB43
2-(2-chloro-3-(trifluoromethyl)phenyl)-N-methyl-N-(piperidin-4-yl)acetamid-
e; hydrochloride salt
[0761] To a solution of tert-butyl
4-(2-(2-chloro-3-(trifluoromethyl)phenyl)-N-methylacetamido)piperidine-1--
carboxylate (0.301 g, 692 .mu.mol) in DCM (2 mL) was added HCl
(3.46 mL, 6.92 mmol). The resulting reaction mixture was stirred at
RT for 2 days and then concentrated under vacuum at 22.degree. C.
to yield 252 mg of BB43 as off white solid. MS (ESI): m/z=335.1
[M+H].sup.+.
Step a) tert-butyl
4-(2-(2-chloro-3-(trifluoromethyl)phenyl)-N-methylacetamido)piperidine-1--
carboxylate
[0762] In a 20 mL glass tube, to
2-(2-chloro-3-(trifluoromethyl)phenyl)acetic acid (184 mg, 770
.mu.mol) in DMF (5 mL) was added HATU (293 mg, 770 .mu.mol), DIPEA
(271 mg, 367 .mu.L, 2.1 mmol). The reaction mixture was stirred for
15 min and then tert-butyl 4-(methylamino)piperidine-1-carboxylate
(0.150 g, 700 .mu.mol) was added. The reaction mixture was stirred
at RT for 2 hours, and then extracted with Water/DCM. The crude
material was purified by flash chromatography (silica gel, 20 g, 0%
to 100% EtOAc in heptane) to yield tert-butyl
4-(2-(2-chloro-3-(trifluoromethyl)phenyl)-N-methylacetamido)piperidine-1--
carboxylate as light yellow oil, 301 mg, MS (ESI): m/z=379.1
[M-56+H].sup.+
BB44
2-(2-Chloro-5-(trifluoromethyl)phenyl)-N-methyl-N-(piperidin-4-yl)acetamid-
e; hydrochloride salt
[0763] Synthesized from
2-(2-chloro-5-(trifluoromethyl)phenyl)acetic and tert-butyl
4-(methylamino)piperidine-1-carboxylate. See synthesis of BB43 for
details. MS (ESI): m/z=335.1 [M+H].sup.+.
BB46
3-Methyl-5-(piperidin-4-ylmethoxy)-2-(trifluoromethyl)pyridine;
dihydrochloride salt
[0764] In a 25 mL tube tert-butyl
4-(((5-methyl-6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidine-1-car-
boxylate (87 mg, 232 .mu.mol) was dissolved in DCM (2 mL) and then
HCl in ether 2M (697 .mu.L, 1.39 mmol) was added, the reaction
mixture was stirred 12 h at RT. The mixture was concentrated in
vacuum, yielding 80 mg of BB46 as a white solid. MS (ESI):
m/z=275.2 [M+H].sup.+.
Step a) tert-Butyl
4-(((5-methyl-6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidine-1-car-
boxylate
[0765] In a 5 mL tube, tert-butyl
4-(hydroxymethyl)piperidine-1-carboxylate (80.7 mg, 375 .mu.mol)
was dissolved in DMF (1.5 mL), then NaH in Oil 60% (18 mg, 450
.mu.mol) was added at room temperature, the mixture was stirred for
20 min, then 5-bromo-3-methyl-2-(trifluoromethyl)pyridine (90 mg,
60 .mu.L, 375 .mu.mol) was added, and it was stirred for 2 hr at
RT, yielding a brown solution. 10 mL sat. NH.sub.4C were added, it
was extracted with water/ethyl acetate, dried over MgSO.sub.4, the
solvent was removed at 40.degree. C./150 mbar. The crude product
was purified by flash chromatography (silica gel, 20 g, 0 to 40%
EtOAc in n-heptane, in 35 min) to yield 87 mg of tert-butyl
4-(((5-methyl-6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidine-1-car-
boxylate. MS (ESI): m/z=319.2 [M-56+H].sup.+
BB58
N-(azetidin-3-ylmethyl)-2,2,2-trifluoro-1-(4-fluorophenyl)ethan-1-amine
[0766] In a 100 mL two-necked flask, benzyl
3-(((1-(2-chloro-4-fluorophenyl)-2,2,2-trifluoroethyl)amino)methyl)azetid-
ine-1-carboxylate (707 mg, 1.64 mmol) was combined with THF (5 mL)
and MeOH (5 mL) to give a colorless solution. Pd/C 10% (87.3 mg,
82.1 .mu.mol) was added under argon. The flask was purged and
backfilled with H.sub.2 (3 times). The reaction mixture was stirred
at 25.degree. C. for 1 h. The reaction mixture was filtered over
decalite, concentrated and used directly for the next step.
Colorless oil (472 mg). MS (ESI): m/z=263.2 [M+H].sup.+ (the
ortho-chlorine was lost during the hydrogenation).
Step a:) Benzyl
3-(((1-(2-chloro-4-fluorophenyl)-2,2,2-trifluoroethyl)amino)methyl)azetid-
ine-1-carboxylate
[0767] To a dry flask under a stream of nitrogen was added benzyl
3-(aminomethyl)azetidine-1-carboxylate (0.5 g, 2.27 mmol),
triethylamine (689 mg, 949 .mu.L, 6.81 mmol),
1-(2-chloro-4-fluoro-phenyl)-2,2,2-trifluoro-ethanone (519 mg, 2.27
mmol), and dry DCM (15 mL). Titanium tetrachloride 1M in DCM (1.13
mL, 1.13 mmol) was added via a syringe to the ice-cooled flask
(exothermic). The reaction was stirred overnight at RT, carefully
quenched with a methanolic solution of sodium cyanoborohydride (428
mg, 6.81 mmol) in methanol (4.36 g, 5.51 mL, 136 mmol)+Acetic Acid
(0.1 mL) and stirred overnight at RT. The reaction was basified
with sat. NaHCO.sub.3. The insoluble material obtained was filtered
away over celite, the filtrate was extracted with DCM, the organic
layers were combined, washed with brine, dried over
Na.sub.2SO.sub.4 and concentrated. Purification: The crude material
was purified by flash chromatography (silica gel, 50 g, 0% to 50%
EtOAc in heptane) to yield 707 mg of Benzyl
3-(((1-(2-chloro-4-fluorophenyl)-2,2,2-trifluoroethyl)amino)methyl)azetid-
ine-1-carboxylate as a colorless oil. MS (ESI): m/z=431.2
[M+H].sup.+.
BB59
2,2,2-Trifluoro-1-(piperidin-4-yl)-N-(3-(trifluoromethyl)benzyl)ethan-1-am-
ine; hydrochloride salt
[0768] To a solution of tert-butyl
4-(2,2,2-trifluoro-1-((3-(trifluoromethyl)benzyl)amino)ethyl)piperidine-1-
-carboxylate (0.140 g, 318 .mu.mol) in DCM (2 mL) was added HCl 2M
in diethyl ether (1.59 mL, 3.18 mmol). The resulting reaction
mixture was stirred at RT overnight and then concentrated under
vacuum at 22.degree. C. to yield 119 mg of the title compound as
off-white solid. MS (ESI): m/z=340.8 [M+H].sup.+.
Step a) tert-Butyl
4-(2,2,2-trifluoro-1-((3-(trifluoromethyl)benzyl)amino)ethyl)piperidine-1-
-carboxylate
[0769] A solution of tert-butyl
4-(1-amino-2,2,2-trifluoroethyl)piperidine-1-carboxylate (0.150 g,
531 .mu.mol) and 3-(trifluoromethyl)benzaldehyde (92.5 mg, 71.1
.mu.L, 531 .mu.mol) in 1,2-DCE (1 mL) was stirred for 1 hour at RT.
Sodium triacetoxyborohydride (225 mg, 1.06 mmol) was then added at
0.degree. C., and the reaction mixture was stirred at RT overnight.
The reaction mixture was poured onto sat. NaHCO.sub.3 and extracted
with DCM. The organic layers were combined, washed with brine,
dried over Na.sub.2SO.sub.4 and concentrated in vacuo. The crude
material was purified by flash chromatography (silica gel, 20 g, 0%
to 100% EtOAc in heptane) to yield 145 mg of the desired compound
as a colorless oil. MS (ESI): m/z=383.1 [M-56+H].sup.+
BB69
2-methyl-3-((4-(trifluoromethyl)benzyl)oxy)azetidine;
trifluoroacetate salt
[0770] To a solution of tert-butyl
2-methyl-3-((4-(trifluoromethyl)benzyl)oxy)azetidine-1-carboxylate
(0.36 g, 1.04 mmol) in DCM (4 mL) was added trifluoroacetic acid
(1.19 g, 10.4 mmol). The resulting reaction mixture was stirred at
RT for 1 hour. The reaction mixture was concentrated on high vacuum
to yield BB69 as a light yellow oil, 399 mg, mixture of all four
stereoisomers. MS (ESI): m/z=246.1 [M+H].sup.+.
Step a) tert-Butyl
2-methyl-3-((4-(trifluoromethyl)benzyl)oxy)azetidine-1-carboxylate
[0771] In a 25 mL two-necked flask,
tert-butyl-3-hydroxy-2-methylazetidine-1-carboxylate (215 mg, 1.15
mmol) was dissolved in DMF (5 mL) to give a colorless solution. At
0.degree. C., sodium hydride (60% dispersion in mineral oil) (41.8
mg, 1.05 mmol) was added. The reaction mixture was stirred at
0.degree. C. for 15 min. Then
1-(bromomethyl)-4-(trifluoromethyl)benzene (0.250 g, 1.05 mmol) was
added at 0.degree. C. The reaction mixture was stirred at RT
overnight. The reaction mixture was poured onto 20 mL sat.
NH.sub.4Cl and extracted with EtOAc (2.times.50 mL). The organic
layers were combined, washed with brine, dried over
Na.sub.2SO.sub.4 and concentrated in vacuo. The crude material was
purified by flash chromatography (silica gel, 20 g, 0% to 70% EtOAc
in heptane) to yield 360 mg of tert-butyl
2-methyl-3-((4-(trifluoromethyl)benzyl)oxy)azetidine-1-carboxylate
as a colorless oil. MS (ESI): m/z=290.1 [M-56+H].sup.+
BB87
3-Fluoro-5-(trifluoromethyl)benzyl 4-methylbenzenesulfonate
[0772] To a solution of
(3-fluoro-5-(trifluoromethyl)phenyl)methanol (100 mg, 72.5 .mu.L,
515 .mu.mol, Eq: 1) in DCM (2.58 mL) was added p-toluenesulfonic
anhydride (185 mg, 567 .mu.mol), DIPEA (79.9 mg, 108 .mu.L, 618
.mu.mol) and DMAP (6.29 mg, 51.5 .mu.mol). The reaction mixture was
stirred for 4 h at 0.degree. C. and for 2 days at room temperature.
The reaction mixture was taken up in EtOAc and washed with water
and brine. The organic layers were dried over MgSO.sub.4 and
concentrated in vacuo to give a yellow oil (178 mg) which was used
without further purification.
[0773] In analogy to BB39, and if not specified otherwise, the
intermediates shown in the following table were prepared from
commercially available benzyl bromides or the prepared tosylate
intermediates and the corresponding tert-butyl
3-hydroxyazetidine-1-carboxylate building blocks.
TABLE-US-00003 BB MS, No. Systematic Name Starting material m/z
BB37 3-((2-Chloro-4- 1-(Bromomethyl)-2-chloro-4- 266.1
(trifluoroinethyl)benzyl)oxy)azetidine; (trifluoromethyl)benzene [M
+ H].sup.+ trifluoroacetate salt BB38 3-((4- 1-(Bromomethyl)-4-
232.1 (Trifluoromethyl)benzyl)oxy)azetidine;
(trifluoromethyl)benzene [M + H].sup.+ trifluoroacetate salt BB45
3((3-Methoxy-4- 4-(Bromomethyl)-2-methoxy-1- 262.2
(trifluoromethyl)benzyl)oxy)azetidine; (trifluoromethyl)benzene [M
+ H].sup.+ trifluoroacetate salt BB56 3-((3-Fluoro-5- 3-Fluoro-5-
250.1 (trifluoromethyl)benzyl)oxy)azetidine;
(trifluoromethyl)benzyl 4- [M + H].sup.+ trifluoroacetate salt
methylbenzenesulfonate (BB87) BB60 3-((3-Chloro-4-
4-(Bromomethyl)-2-chloro-1- 266.1
(trifluoromethyl)benzyl)oxy)azetidine; (trifluoromethyl)benzene [M
+ H].sup.+ trifluoroacetate salt BB62 3-((2-Fluoro-4-
1-(Bromomethyl)-2-fluoro-4- 318.3 (trifluoromethyl)benzyl)oxy)-3-
(trifluoromethyl)benzene and [M + H].sup.+
(trifluoromethyl)azetidine; Tert-butyl 3-hydroxy-3-
trifluoroacetate salt trifluoromethyl)azetidine-1- carboxylate
(CAS: 398489-42-4) BB63 3-((2-Fluoro-4-
1-(Bromornethyl)-2-fluoro-4- 264.1 (trifluoromethyl)benzyl)oxy)-3-
(trifluoromethyl)benzene and [M + H].sup.+ methylazetidine;
trifluoroacetate salt Tert-butyl 3-hydroxy-3-
methylazetidine-1-carboxylate (CAS: 1104083-23-9) BB64
3-((2,4-Difluoro-5- 1-(Bromornethyl)-2,4-difluoro-5- 268.1
(trifluoromethypbenzyl)oxy)azetidine; (trifluoromethyl)benzene [M +
H].sup.+ trifluoroacetate salt BB65 3-((2-Fluoro-5-
2-(Bromomethyl)-1-fluoro-4- 250.1
(trifluoromethyl)benzyl)oxy)azetidine; (trifluoromethyl)benzene [M
+ H].sup.+ trifluoroacetate salt BB66 3-((2-Fluoro-5-
4-(Bromomethyl)-2-fluoro-1- 250.1
(trifluoromethyl)benzyl)oxy)azetidine; (trifluoromethyl)benzene [M
+ H].sup.+ trifluoroacetate salt BB67 3-((2-Methoxy-4-
1-(Bromomethyl)-2-methoxy-4- 262.2
(trifluoromethyl)benzyl)oxy)azetidine; (trifluoromethyl)benzene [M
+ H].sup.+ trifluoroacetate salt BB68 3-((4-Chloro-2-
1-(Bromomethyl)-4-chloro-2- 266.2
(trifluoromethyl)benzyl)oxy)azetidine; (trifluoromethyl)benzene [M
+ H].sup.+ trifluoroacetate salt BB88 3[(2,4-
1-(Bromomethyl)-2,4-dichloro- 232.1
dichlorophenyl)methoxy]azetidine benzene [M + H].sup.+ BB170
3((3,4- 4-(Bromomethyl)-1,2,dichloro- 232.1
Dichlorobenzyl)oxy)azetidine; 2,2,2- benzene [M + H].sup.+
trifluoroacetate BB171 3((2,5- 2-(Bromomethyl)-1,4-dichloro- 232.1
Dichlorobenzyl)oxy)azetidine; 2,2,2- benzene [M + H].sup.+
trifluoroacetate BB172 3-((3- 3-(Bromomethyl)- 248.1
(Trifluoromethoxy)benzyl)oxy)azetidine; trifluoromethoxy-benzene [M
+ H].sup.+ 2,2,2-trifluoroacetate BB173 2-Methyl-3-((4-methyl-3-
tert-Butyl-3-hydroxy -2- 266.2
(trifluoromethyl)benzyl)oxy)azetidine;
methylazetidine-1-carboxylate [M + H].sup.+ 2,2,2-trifluoroacetate
and 4-(bromomethyl)-1-methyl-2- trifluoromethyl)benzene BB178
3-(((2-Fluoro-4- tert-Butyl 3- 264.2 (trifluoromethyl)
benzyl)oxy)methyl) (hydroxymethyl)azetidine- 1- [M + H].sup.+
azetidine; 2,2,2-trifluoroacetate carboxylate and
1-(Bromomethyl)-2-fluoro-4- (trifluoromethyl)benzene BB180
[4-(Azetidin-3-yloxymethyl)-3- (4-(Bromomethyl)-3- 308.2
fluoro-phenyl]-pentafluoro-.quadrature.6-
fluorophenyl)pentafluoro-.quadrature.6- [M + H].sup.+ sulfane;
2,2,2-trifluoroacetate sulfane BB185 3-((2-Fluoro-4- tert-Butyl
3-hydroxy-3- 332.2 (trifluoromethyl)benzyl)oxy)-3-
(trifluoromethyl)pyrrolidine-1- [M + H].sup.+
(trifluoromethyl)pyrrolidine; 2,2,2- carboxylate and
trifluoroacetate 1-(Bromomethyl)-2-fluoro-4-
(trifluoromethyl)benzene BB187 3-[[2,4- 1-(Bromomethyl)-2,4- 336.2
bis(Trifluoromethyl)phenyl]methoxy] bis(trifluoromethy)benzene [M +
H].sup.+ azetidine BB188 3-[[2-Methyl-3-
1-(Bromomethyl)-2-methyl-3- 246.1 (trifluoromethyl)phenyl]methoxy]
(trifluoromethyl)benzene [M + H].sup.+ azetidine BB189
3[[2-Methyl-4- 1-(Bromornethyl)-2-methyl-4- 262.1
(trifluoromethoxy)phenyl]methoxy] (trifluoromethoxy)benzene [M +
H].sup.+ azetidine BB190 2-Methyl-3-[[2-methyl-4-
1-(Bromomethyl)-2-methyl-4- 276.2 (trifluoromethoxy)phenyl]methoxy]
(trifluoromethoxy)benzene [M + H].sup.+ azetidine and tert-butyl
3-hydroxy-2- methylazetidine-1-carboxylate BB191
2-Methyl-3-[[2-methyl-3- 1-(Bromomethyl)-2-methyl-3 260.2
(trifluoromethyl)phenyl]methoxy] (trifluoromethyl)benzene [M +
H].sup.+ azetidine and tert-Butyl 3-hydroxy-2-
methylazetidine-1-carboxylate BB207 3-[[4-Fluoro-2-
1-(Chloromethyl)-4-fluoro-2- 250.7 (trifluoromethyl)phenyl]methoxy]
trifluoromethyl)benzene (CAS [M + H].sup.+ azetidine;
4-methylbenzenesulfonate RN 248262-29-5) BB212 3-[[3-Fluoro-4-
4-(Bromornethyl)-2-fluoro-1- Used
('trifluoromethoxy)phenyl]methoxy] (trifluoromethoxy)benzene
without azetidine; 2,2,2-trifluoroacetate purification BB217
3-((4-Methyl-3- 4-(Bromomethyl)-1-methyl-2 246.2
(trifluoromethyl)benzyl)oxy)azetidine; (trifluoromethyl)benzene. [M
+ H].sup.+ 2,2,2-trifluoroacetate tBuOK as base
[0774] In analogy to BB29, intermediates BB20, BB25 and BB61 of the
following table were prepared from the commercially available
phen9ols. Where trifluoroacetate salts are indicated, the crude
product resulting from concentration of the reaction mixture was
used directly without further neutralization or purification.
TABLE-US-00004 BB MS, No. Systematic Name Starting material m/z
BB20 3-((2-Fluoro-4- 2-Fluoro-4- 250.1
(trifluoromethyl)phenoxy)methyl)azetidine; (trifluoromethyl)phenol
(CAS [M + H].sup.+ trifluoroacetate salt RN: 77227-78-2) BB25
3-[(2-Chloro-4- 2-Chloro-4-fluorophenol (CAS 216.1
fluorophenoxy)methyl]azetidine RN: 1996-41-4) [M + H].sup.+
(purified by RP- HPLC) BB61 3-((2-Chloro-4- 2-Chloro-4-fluorophenol
(CAS 234.1 fluorophenoxy)methyl)-3- RN: 1996-41-4) [M + H].sup.+
fluoroazetidine; trifluoroacetate salt and teft-Butyl 3-fluoro-3-
(hydroxymethyl)azetidine-1- carboxylate (CAS: 1126650-66-5)
[0775] In analogy to BB26, intermediates BB21-BB24 and BB28 of the
following table were prepared from the commercially available
phenols.
TABLE-US-00005 BB No. Systematic Name Starting material MS, m/z
BB21 4-((4-Fluoro-2- 4-Fluoro-2- 278.1
(trifluoromethyl)phenoxy)methyl)piperidine; (trifluoromethyl)phenol
(CAS: [M + H].sup.+ hydrochloride salt 130047-19-7 BB22
4[[2-Fluoro-4- 2-Fluoro-4- 278.0
(trifluoromethyl)phenoxy]methyl]piperidine; (trifluoromethol)phenol
(CAS: [M + H].sup.+ hydrochloride salt 77227-78-2) BB23
4-((2-Chloro-4- 2-Chloro-4- 294.1
(trifluoromethyl)phenoxy)methyl)piperidine; (trilluoromethyl)phenol
(CAS: [M + H].sup.+ hydrochloride salt 35852-58-5) BB24
5-Fluoro-2-(piperidin-4- 5-Fluoro-2-hydroxybenzonitrile 235.1
ylmethoxy)benzonitrile; (CAS: 91407-41-9) [M + H].sup.+
hydrochloride salt BB28 4-[(4-Fluoro-2-methyl-
4-Fluoro-2-methylphenol (CAS: 224.0 phenoxy)methyl]piperidine;
452-72-2) [M + H].sup.+ hydrochloride salt BB170 3((3,4-
4(Bromomethyl)-1,2-dichloro- 232.1 Dichlorobenzyl)oxy)azetidine
benzene [M + H].sup.+ 2,2,2-trifluoroacetate BB171 3-((2,5-
2(Bromomethyl)-1,4-dichloro- 232.1 Dichlorobenzyl)oxy)azetidine
benzene [M + H].sup.+ 2,2,2-trifluoroacetate BB172 3((3-
3(Bromomethyl)- 248.1 (Trifluoromethoxy)benzyl)oxy)azetidine
trifluoromethoxy-benzene [M + H].sup.+ 2,2,2-trifluoroacetate BB173
2-Methyl-3((4-methyl-3- tert-Butyl-3-hydroxy-2- 266.2
(triftuoromethyl)benzyl)oxy)azetidine methylazetidine-l-carboxylate
[M + H].sup.+ 2,2,2-trifluoroacetate and 4(Bromomethyl)-1-methyl-2
- (trifluoromethyl)benzene BB178 3-(((2-Fluoro-4- tert-Butyl 3-
264.2 (trifluoromethyl)benzyl)oxy)methyl)azetidine
(hydroxymethyl)azetidine-1- [M + H].sup.+ 2,2,2-trifluoroacetate
carboxylate and 1(Bromomethyl)-2-fluoro-4- (trifluoromethyl)benzene
BB180 [4(Azetidin-3-yloxylmethyl)-3- (4-Bromomethyl)-3- 308.2
fluoro-phenyl]-pentafluoro-.quadrature.6-
fluorophenyl)pentafluoro-.quadrature.6- [M + H].sup.+ sulfane
2,2,2-trifluoroacetic acid sulfane BB185 3((2-Fluoro-4- tert-Butyl
3-hydroxy-3- 332.2 (trifluoromethyl)benzyl)oxy)-3-
(trifluoromethyl)pyrrolidine-1- [M + H].sup.+
(trifluoromethyl)pyrrolidine 2,2,2- carboxylate and
trifluoroacetate 1(Bromomethyl)-2-fluoro-4-
(trifluoromethyl)benzene BB187 3-[[2,4- 1-(Bromomethyl)-2,4- 336.2
bis(Trifluoromethyl)phenyl]methoxy]azetidine
bis(trifluoromethyl)benzene [M + H].sup.+ BB188 3-[[2-Methyl-3-
1-(Bromomethyl)-2-methyl-3 - 246.1
(trifluoromethyl)phenyl]methoxy]azetidine (trifluoromethyl)benzene
[M + H].sup.+ BB189 3[[2-Methyl-4- 1-(Bromomethyl)-2-methyl-4-
262.1 (trifluoromethoxy)phenyl]methoxy]azetidine
(trifluoromethyl)benzene [M + H].sup.+ BB190
2-Methyl-3-[[2-methyl-4- 1-(Bromomethyl)-2-methyl-4- 276.2
(trifluoromethoxy)phenyl]methoxy]azetidine (trifluoromethyl)benzene
[M + H].sup.+ and tert-butyl 3-hydroxy-2-
methylazetidine-1-carboxylate BB191 2-Methyl-3-[[2-methyl-3-
1-(Bromomethyl)-2-methyl-3- 260.2
(trifluoromethoxy)phenyl]methoxy]azetidine (trifluoromethyl)benzene
[M + H].sup.+ and tert-Butyl 3-hydroxy-2-
methylazetidine-1-carboxylate BB207 3-[[4-Fluoro-2-
1-(Chloromethyl)-4-fluoro-2- 250.2
(trifluoromethoxy)phenyl]methoxy]azetidine;
(trifluoromethyl)benzene (CAS [M + H].sup.+
4-methylbenzenesulfonate RN 248262-29-5) BB212 3-[[3-Fluoro-4-
4-(Bromomethyl)-2-fluoro-1- Used
(trifluoromethoxy)phenyl]methoxy]azetidine
(trifluoromethoxy)benzene without 2,2,2-trifluoroacetate
purification BB217 3-((-Methyl-3- 4-(Bromomethyl)-1-methyl-2- 246.2
(trifluoromethyl)benzyl)oxy)azetidine; (trifluoromethyl)benzene. [M
+ H].sup.+ 2,2,2-trifluoroacetate tBuOK as base BB218
3-((2-Fluoro-6- tert-Butyl 3-mercaptoazetidine- 266.2
(trifluoromethyl)benzyl)thio)azetidine 1-carboxylate and [M +
H].sup.+ 2,2,2-trifluoroacetate 2-(Bromomethyl)-1-fluoro-3-
(trifluoromethyl)benzene
Method D1
BB9
4-[2-Chloro-4-(trifluoromethyl)phenoxy]piperidine; trifluoroacetate
salt
[0776] A mixture of tert-butyl
4-[2-chloro-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate
(750.0 mg, 1.97 mmol) in DCM (20 mL) and TFA (0.76 mL) was stirred
at 20.degree. C. for 12 h. The mixture was concentrated. The
residue was dissolved in H.sub.2O (20 mL) and washed twice with
PE:EA=10:1 (20 mL each). The aqueous layer was lyophilized to give
the desired product as light yellow solid (716 mg, 1.82 mmol,
87.8%). MS (ESI): m/z=280.1 [M+H].sup.+.
Step a) tert-Butyl
4-[2-chloro-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate
[0777] A mixture of 2-chloro-4-(trifluoromethyl)phenol (500 mg,
2.54 mmol), 1-Boc-4-hydroxypiperidine (768 mg, 3.82 mmol) and
triphenylphosphine (1334 mg, 5.09 mmol) in THF (10 mL) was stirred
at 0.degree. C. until completely dissolved. DIAD (1542 mg, 7.63
mmol) was slowly added dropwise at 0.degree. C. The mixture was
stirred at 20.degree. C. for 3 h and then concentrated under
vacuum. The residue was purified by prep-HPLC to give the desired
compound as light yellow solid (760 mg, 2 mmol, 78.7% yield). MS
(ESI): m/z=324.0 [M-56+H].sup.+.
BB57
3-(((2-Fluoro-6-(trifluoromethyl)benzyl)oxy)methyl)azetidine;
trifluoroacetate salt
[0778] To a solution of tert-butyl
3-(((2-fluoro-6-(trifluoromethyl)benzyl)oxy)methyl)azetidine-1-carboxylat-
e (158 mg, 435 .mu.mol) in DCM (1.74 mL) was added TFA (793 mg, 536
.mu.L, 6.96 mmol) and the reaction was stirred at room temperature
for 3 h. The reaction mixture was concentrated to give
3-(((2-fluoro-6-(trifluoromethyl)benzyl)oxy)methyl)azetidine;
trifluoroacetate salt (202 mg, 434 .mu.mol, 99.7% yield) as a
colorless oil. The crude was used without further purification. MS
(ESI): m/z=264.1 [M+H].sup.+.
Step a) Tert-butyl
3-(((2-fluoro-4-(trifluoromethyl)benzyl)oxy)methyl)azetidine-1-carboxylat-
e
[0779] To a solution of tert-butyl
3-(hydroxymethyl)azetidine-1-carboxylate (100 mg, 534 .mu.mol) in
dry THF (2.67 mL) was added potassium tert-butoxide 1.65 M solution
in THF (340 .mu.L, 561 .mu.mol) and the turbid reaction mixture was
stirred at RT for 15 min followed by addition of
1-(bromomethyl)-2-fluoro-6-(trifluoro-6-(trifluoromethyl)benzene
(137 mg, 534 .mu.mol). The reaction mixture was then stirred at
room temperature for 3 h. The crude reaction was diluted with ethyl
acetate and extracted with sat. aq. NaHCO.sub.3 solution, the
organic phase was collected and the aqueous phase was
back-extracted with ethyl acetate. The combined organic phases were
dried over sodium sulfate and evaporated down to dryness to yield a
clear oil. The crude was immobilized on Isolute and purified by
column chromatography eluting with 0 to 30% EtOAc in heptanes to
afford tert-butyl
3-(((2-fluoro-6-(trifluoromethyl)benzyl)oxy)methyl)azetidine-1-carboxylat-
e (158 mg, 413 .mu.mol, 77.3% yield) as a colorless oil. MS (ESI):
m/z=308.1 [M-56+H].sup.+
Method D2
BB10
4-[[2-Cyclopentyl-4-(trifluoromethyl)phenyl]methyl]piperidine;
formic acid salt
[0780] A mixture of tert-butyl
4-[[2-cyclopentyl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxyla-
te (440 mg, 0.610 mmol) and 5.0 mL of 4 M HCl in EtOAc in EtOAc (10
mL) was stirred at 20.degree. C. for 12 h. The mixture was
concentrated under vacuum. The residue was re-dissolved in H.sub.2O
(5 mL), washed twice with PE:EA (3:1; 10 mL each) and the layers
were separated. The aqueous layer was purified by prep-HPLC to give
the desired compound as light yellow solid (124 mg, 0.350 mmol,
65.3% yield). MS (ESI): m/z=312.2 [M+H].sup.+.
Step a) tert-Butyl
4-[[2-cyclopentyl-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carbox-
ylate
[0781] A solution of tert-butyl
4-[[2-bromo-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylate
(500 mg, 1.19 mmol), cyclopentyl bromide (266 mg, 1.78 mmol),
Ir(dF(CF.sub.3)ppy).sub.2(dtbbpy)PF.sub.6 (13.4 mg, 0.010 mmol, CAS
RN 870987-63-6), NiCl.sub.2.glyme (0.77 mg, 0.060 mmol), dtbbpy
(19.2 mg, 0.070 mmol, CAS RN 72914-19-3), TTMSS (296 mg, 1.19 mmol,
CAS RN 1873-77-4) and Na.sub.2CO.sub.3 (252 mg, 2.38 mmol) in DMF
(20 mL) was degassed by bubbling argon stream for 20 min. The
reaction mixture was irradiated with Blue LED (4.times.1) at
25.degree. C. for 16 h. The mixture was diluted with H.sub.2O and
then extracted three times with EtOAc (100 mL each). The combined
organic layer was washed with brine, dried over sodium sulfate,
filtered and concentrated. The residue was purified by prep-HPLC to
give the compound as a colorless oil (460 mg, 1.12 mmol, 53.8%). MS
(ESI): m/z=354.1 [M-56+H].sup.+.
Step b) tert-Butyl
4-[[2-cyclopentyl-4-(rifluoromethyl)phenyl]methyl]piperidine-1-carboxylat-
e
[0782] To a mixture of tert-butyl
4-[[2-cyclopentyl-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carbox-
ylate (460 mg, 0.640 mmol) in EtOAc (10 mL) was added wet Pd/C (40
mg), and then the mixture was stirred at 20.degree. C. for 12 h
under H.sub.2 (1520 mmHg). The mixture was filtered and the
filtrate was concentrated to give the compound as colorless oil
(460 mg, 1.12 mmol, 99.5%). MS (ESI): m/z=356.1 [M+H-56].sup.+.
BB11
2-(4-Piperidylmethyl)-1,3-benzoxazole; formic acid salt
[0783] A solution of 2-aminophenol (1.0 g, 9.16 mmol) and
1-Boc-4-piperidylacetic acid (2.68 g, 11 mmol) in polyphosphoric
acid (2.2 g) was stirred at 180.degree. C. for 2 h. The mixture was
diluted with a mixture of 12M aqueous NH.sub.4OH solution and ice
to reach pH>7, and then extracted three times with EtOAc (10 mL
each). The combined organic layers were washed with brine, dried
over Na.sub.2SO.sub.4, filtered and concentrated, and the residue
was purified by prep-HPLC to give the desired compound as a brown
oil (251 mg, 0.960 mmol, 9.7%). MS (ESI): m/z=217.2
[M+H].sup.+.
Method D3
BB13
4-[4-Chloro-3-(4-chlorophenyl)phenoxy]piperidine; hydrochloride
salt
[0784] A solution of tert-butyl
4-[4-chloro-3-(4-chlorophenyl)phenoxy]piperidine-1-carboxylate
(1000 mg, 2.37 mmol) in a 4 M solution of HCl in dioxane (50 mL)
was stirred at 20.degree. C. for 12 h. The mixture was concentrated
to give the title compound as a white solid (845 mg, 2.35 mmol,
96.2%). MS (ESI): m!z=322.0 [M+H].sup.+.
Step a) tert-Butyl 4-(3-bromo-4-chloro-phenoxy)
piperidine-1-carboxylate
[0785] A mixture of 3-bromo-4-chlorophenol (1000 mg, 4.82 mmol),
1-Boc-4-hydroxypiperidine (1164 mg, 5.78 mmol) and
triphenylphosphine (2529 mg, 9.64 mmol) was stirred in THF (10 mL)
until completely dissolved. Then DIAD (1948 mg, 9.64 mmol) was
slowly added drop wise at 0.degree. C.
[0786] The mixture was stirred at 20.degree. C. for 12 h,
concentrated and the residue was purified by reversed flash
chromatography to give the compound as yellow oil (1300 mg, 3.33
mmol, 69.0%). MS (ESI): m/z=336.0 [M-56+H].sup.+.
Step b) tert-Butyl
4-[4-chloro-3-(4-chlorophenyl)phenoxy]piperidine-1-carboxylate
[0787] To a solution of tert-butyl
4-(3-bromo-4-chloro-phenoxy)piperidine-1-carboxylate (1150 mg, 2.94
mmol) and 4-chlorophenylboronic acid (506 mg, 3.24 mmol),
Na.sub.2CO.sub.3 (1248 mg, 11.8 mmol) in 1,4-dioxane (20 mL) and
H.sub.2O (5 mL) was added tetrakis(triphenylphosphine)palladium(0)
(340 mg, 0.290 mmol, CAS RN 14221-01-3), and the mixture was
stirred at 110.degree. C. under N2 atmosphere for 12 h. The mixture
was filtered, the filtrate was concentrated, and the residue was
purified by silica gel column chromatography, eluting with a 5-20%
EtOAc-PE gradient to give the desired compound as light yellow oil
(1100 mg, 2.6 mmol, 88.5%). MS (ESI): m/z=366.1 [M-56+H].sup.+.
BB14
4-[[2-(1H-Pyrazol-4-yl)-4-(trifluoromethyl)phenyl]methyl)phenylmethyl]pipe-
ridine; trifluoroacetate salt
[0788] To a mixture of tert-butyl
4-[[2-(1-tert-butoxycarbonylpyrazol-4-yl)-4-(trifluoromethyl)
phenyl]methyl]piperidine-1-carboxylate (150.0 mg, 0.290 mmol) in
DCM (5 mL) was added TFA (1.0 mL). The mixture was stirred at
20.degree. C. for 15 h. The mixture was concentrated under vacuum
and then lyophilized to give the title compound as light yellow gum
(149 mg, 0.280 mmol, 85.1% yield). MS (ESI): m/z=310.0
[M+H].sup.+.
Step a) tert-Butyl
4-[[2-(1-tert-butoxycarbonylpyrazol-4-yl)-4-(trifluoromethyl)phenyl]methy-
lene]piperidine-1-carboxylate
[0789] A mixture of tert-butyl
4-[[2-bromo-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylate
(600 mg, 1.43 mmol), tert-butyl
4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)pyrazole-1-carboxylate
(846 mg, 2.86 mmol) and K.sub.2CO.sub.3 (592 mg, 4.28 mmol) in DMF
(10 mL) and H.sub.2O (0.5 mL) was stirred at 80.degree. C. for 12
h. The mixture was poured into H.sub.2O (30 mL) and extracted twice
with EtOAc (50 mL each). The combined organic layers were washed
with brine (30 mL), dried over Na.sub.2SO.sub.4 and filtered. The
filtrated was concentrated in vacuum to give the compound as light
yellow oil (520 mg, 1.02 mmol, 71.8% yield). MS (ESI): m/z=308.1
[M+H].sup.+.
Step b) tert-Butyl
4-[[2-(1-tert-butoxycarbonylpyrazol-4-yl)-4-(trifluoromethyl)
phenyl]methyl]piperidine-1-carboxylate
[0790] A mixture of tert-butyl
4-[[2-(1-tert-butoxycarbonylpyrazol-4-yl)-4-(trifluoromethyl)phenyl]methy-
lene]piperidine-1-carboxylate (180 mg, 0.350 mmol) and wet Pd/C (18
mg) in EtOAc (10 mL) was stirred at 30.degree. C. for 24 h under
H.sub.2 atmosphere (.about.1520 mm Hg). The mixture was filtered
and concentrated under vacuum to give the compound as brown oil
(150 mg, 0.290 mmol, 83%). MS (ESI): m/z=354.1
[M-56-100+H].sup.+.
BB18
4-[2-(2-Chlorophenyl)ethynyl]piperidine
[0791] To a suspension of tert-butyl
4-((2-chlorophenyl)ethynyl)piperidine-1-carboxylate (0.05 g, 0.156
mmol) in MeOH (3 mL) was added 4 M HCl in dioxane (0.391 mL, 1.56
mmol) and the reaction mixture was stirred at room temperature for
2 h. The mixture was evaporated to dryness and the residue
triturated in diisopropyl ether, filtered off and further dried
under high vacuum to give the title compound as a white solid as
the hydrochloride salt (0.02 g, 50%). MS (ESI): m/z=220.1
[M+H].sup.+.
Step a) tert-Butyl
4-[2-(2-chlorophenyl)ethyl]piperidine-1-carboxylate
[0792] In a sealed tube, a mixture of tert-butyl
4-ethynylpiperidine-1-carboxylate (0.1 g, 0.478 mmol, CAS RN
287192-97-6), 1-bromo-2-chlorobenzene (0.084 mL, 0.717 mmol),
copper (I) iodide (0.002 g, 0.009 mmol), TEA (0.666 mL, 4.78 mmol)
and bis(triphenylphosphine)palladium(II) chloride (0.027 g, 0.038)
in THF (2.8 mL) was degassed for 5 min under Argon. The reaction
mixture was then heated to 70.degree. C. and stirred for 4 h. The
mixture was filtered off over a pad of Dicalite, washed with EtOAc
and the mother liquors were evaporated to dryness. The residue was
purified by silica gel flash chromatography, eluting with a
gradient of 0-50% EtOAc/n-heptane to give the title compound as a
white solid (0.05 g, 33%). MS (ESI): m/z=264.1 [M-56+H].sup.+.
BB48a
tert-Butyl
4-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carb-
oxylate
[0793] A degassed solution of tert-butyl
4-methylenepiperidine-1-carboxylate (4465 mg, 22.6 mmol, CAS RN
159635-49-1) in 9-BBN (45.3 mL, 22.6 mmol) was refluxed for 1 h.
After cooling to room temperature, the solution was added into a
solution of 4-bromo-3-fluorobenzotrifluoride (5.0 g, 20.6 mmol, CAS
RN 40161-54-4), Pd(dppf)Cl.sub.2 (1514 mg, 2.06 mmol) and
K.sub.2CO.sub.3 (5687 mg, 41.1 mmol) in DMF (50 mL) and water (5
mL). The resulting mixture was heated at 80.degree. C. for 5 h.
After the mixture was cooled to room temperature and poured into
water, the pH was adjusted to 11 with 10% aqueous NaOH solution,
and the mixture was extracted with EtOAc. The combined organic
extracts were dried with brine and Na.sub.2SO.sub.4, filtered, and
evaporated to give a residue, which was further purified by column
chromatography (silica gel, PE:EtOAc=10:1 to 5:1) to give the
compound as light yellow solid (240 mg, 3.2%). MS (ESI): m/z=306
[M+H-56].sup.+.
BB51a
[0794] A mixture of tert-butyl
4-[[2-cyclopropyl-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carbox-
ylate (1000 mg, 2.62 mmol) and PtO.sub.2 (100 mg, 0.440 mmol) in
EtOAc (20 mL) was stirred at 20.degree. C. for 12 h under H.sub.2
atmosphere (1520 mmHg). The mixture was filtered and the filtrate
concentrated to furnish the compound as light yellow solid (940 mg,
93.5%). MS (ESI): m/z=328.2 [M+H].sup.+.
Step a) 2-Bromo-1-(bromomethyl)-4-(rifluoromethyl)benzene
[0795] A mixture of 2-bromo-1-methyl-4-(trifluoromethyl)benzene
(5.5 g, 23.0 mmol, CAS RN 128-08-5), benzoyl peroxide (835 mg, 3.45
mmol) and NBS (4.07 g, 23.01 mmol) in CCl.sub.4 (50.0 mL, 23.0
mmol) was stirred at 70.degree. C. for 5 h. The mixture was poured
into water (20 mL) and extracted twice with DCM (20 mL each). The
combined organic layer was washed with brine (20 mL), dried over
Na.sub.2SO.sub.4, filtered and concentrated in vacuum to give the
desired compound as light yellow oil which was used in the next
step without further purification (7.1 g, 97%).
Step b)
2-Bromo-1-(diethoxyphosphorylmethyl)-4-(trifluoromethyl)benzene
[0796] A mixture of
2-bromo-1-(bromomethyl)-4-(trifluoromethyl)benzene (7.1 g, 22.3
mmol) and triethyl phosphite (30 mL) was stirred at 155.degree. C.
for 5 h. The mixture was concentrated in vacuum to remove triethyl
phosphite, the residue was diluted with water (100 mL) and
extracted three times with EtOAc (100 mL each). The combined
organic layers were washed with brine (100 mL), dried over
Na.sub.2SO.sub.4, filtered and concentrated under vacuum. The
residue was purified by column chromatography (PE:EtOAc=100:1 to
10:1) to give the compound as light yellow oil which was used
without further purification in the next step (8 g, 95.5%).
Step c) tert-Butyl
4-(2-bromo-4-(trifluoromethyl)benzylidene)piperidine-1-carboxylate
[0797] To a mixture of
2-bromo-1-(diethoxyphosphorylmethyl)-4-(trifluoromethyl)benzene
(6.9 g, 18.4 mmol) in THF (100 mL) was added sodium hydride (2.21
g, 55.2 mmol) at 0.degree. C. The mixture was stirred at 0.degree.
C. for 1 h, then 1-Boc-4-piperidone (7.33 g, 36.79 mmol, CAS RN
79099-07-3) was added and the mixture was stirred at 20.degree. C.
for 12 h. The mixture was poured into water (100 mL) and extracted
three times with EtOAc (100 mL each). The combined organic layers
were washed with brine (100 mL), dried over Na.sub.2SO.sub.4,
filtered and concentrated in vacuum. The residue was purified by
column chromatography (PE:EA=100:1 to 50:1) to yield the desired
compound as off-white solid (4 g, 51.7%). MS (ESI): m/z=365.9
[M-56+H].
Step d) tert-butyl
4-[[2-cyclopropyl-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carbox-
ylate
[0798] A mixture of tert-butyl
4-[[2-bromo-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylate
(2.0 g, 4.76 mmol), cyclopropylboronic acid (818 mg, 9.52 mmol, CAS
RN 411235-57-9) and potassium carbonate (1973 mg, 14.3 mmol) in DMF
(10 mL) and water (0.5 mL) was stirred at 80.degree. C. under
nitrogen atmosphere for 12 h. The mixture was poured into water (50
mL), extracted three times with EtOAc (50 mL each). The combined
organic layers were washed with brine (50 mL), dried over
Na.sub.2SO.sub.4 and concentrated in vacuum. The residue was
purified by prep-HPLC to give the compound as light yellow oil
(1020 mg, 56.2% yield). MS (ESI): m/z=326.0 [M-56+H].sup.+.
BB53a
tert-Butyl 3-[(4-chlorophenyl)methoxy]pyrrolidine-1-carboxylate
[0799] A solution of N-Boc-3-hydroxypyrrolidine (1.0 g, 5.34 mmol)
and 4-chlorobenzyl bromide (1.32 g, 6.41 mmol) in ACN (10 mL) was
added potassium carbonate (1.48 g, 10.68 mmol). The mixture was
stirred at 80.degree. C. for 15 h. Then the mixture was
concentrated and diluted with water and extracted three times with
EtOAc (10 mL each). The combined organic layers were concentrated
to give the desired compound as colorless oil (326 mg, 19.6% yield)
MS (ESI): m/z=256.0 [M-56+H].sup.+.
Method D4
BB70
3-[4-(Trifluoromethyl)phenoxy]azetidine
[0800] To a solution of tert-butyl
3-[4-(trifluoromethyl)phenoxy]azetidine-1-carboxylate (500 mg, 1.58
mmol, BB70a) in DCM (3 mL) was added TFA (1.0 mL, 0.950 mmol) at
25.degree. C., the reaction was stirred at this temperature for 12
h. The mixture was concentrated and the residue was purified to via
prep-HPLC to provide the compound as colorless solid (150 mg, 0.690
mmol, 43.8%). MS (ESI): m/z=218.1 [M+H].sup.+.
BB72a
tert-Butyl
4-(4-chloro-3-cyclopropyl-phenoxy)piperidine-1-carboxylate
[0801] To a solution of tert-butyl
4-(3-bromo-4-chloro-phenoxy)piperidine-1-carboxylate (500 mg, 1.28
mmol, BB90), potassium carbonate (354 mg, 2.56 mmol) and
cyclopropylboronic acid (121 mg, 1.41 mmol) in 1,4-dioxane (5 mL)
and water (1 mL) was added
[1,1'-bis(diphenylphosphino)ferrocene]dichloro palladium(II)
(187.28 mg, 0.260 mmol). The mixture was stirred at 100.degree. C.
under nitrogen atmosphere for 12 h. The reaction mixture was
filtered and the filtrate was diluted with EtOAc (30 mL), washed
with water and then brine, the organic phase was dried over
Na.sub.2SO.sub.4, concentrated. The residue was purified by silica
gel column (eluting with a gradient of 5%-10% EtOAc-PE) to give the
compound as light yellow oil (220 mg, 48.9%). MS (ESI): m/z=296.1
[M-56+H].sup.+.
BB73a
tert-Butyl 4-(4-chloro-3-morpholino-phenoxy)
piperidine-1-carboxylate
[0802] To a solution of tert-butyl
4-(3-bromo-4-chloro-phenoxy)piperidine-1-carboxylate (500 mg, 1.28
mmol, BB90), cesium carbonate (834 mg, 2.56 mmol),
(R)-(+)-2,2'-bis(diphenylphosphino)-1,1'-binaphthalene (159 mg,
0.260 mmol) and morpholine (112 mg, 1.28 mmol) in DMF (10 mL) was
added tris(dibenzylideneacetone)dipalladium(0) (187 mg, 0.260 mmol)
and the mixture was stirred at 110.degree. C. under nitrogen
atmosphere for 12 h. The reaction mixture was filtered, the
filtrate was diluted with EtOAc (30 mL), washed with water and then
brine, the organic phase was dried over Na.sub.2SO.sub.4, and
concentrated. The residue was purified by silica gel column
(eluting with a gradient of 5%-10% EtOAc-PE) to give the desired
compound (360 mg, 70.9% yield) as light yellow oil. MS (ESI):
m/z=397.1 [M+H].sup.+.
BB74a
tert-Butyl
4-[2-methyl-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate
[0803] To a solution of tert-butyl
4-[2-bromo-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate (2.0
g, 4.71 mmol, BB74b) in THF (40 mL) was added lithium methide (11.8
mL, 18.9 mmol) dropwise at -70.degree. C. The mixture was stirred
at -70.degree. C. for 1 h and then stirred at 20.degree. C. for 12
h. The mixture was poured into ice water (100 mL) and extracted
three times with EtOAc (50 mL each). The combined organic layer was
washed with brine (100 mL), dried over Na.sub.2SO.sub.4 and
filtered. The filtrate was concentrated under vacuum to yield the
compound as light yellow solid (780 mg, 46%). MS (ESI): m/z=260.1
[M-100+H].sup.+.
BB75a
tert-Butyl
4-[2-cyano-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate
[0804] To a solution of zinc cyanide (2214 mg, 18.9 mmol) and
tert-butyl
4-[2-bromo-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate
(1600 mg, 3.77 mmol, BB74b) in DMA (30 mL) was added dppf (627 mg,
1.13 mmol), N,N-diisopropylethylamine (1.97 mL, 11.3 mmol), Zinc
dust (245 mg, 3.77 mmol) and Pd.sub.2(dba).sub.3 (1036 mg, 1.13
mmol) at 20.degree. C., then the mixture was stirred at 140.degree.
C. under nitrogen atmosphere for 4 h. The mixture was filtered. The
filtrate was poured into water (100 mL) and extracted three times
with EtOAc (50 mL each). The combined organic layer was washed with
brine (50 mL), dried over Na.sub.2SO.sub.4 and filtered. The
filtrate was concentrated over vacuum to give the title compound as
light brown solid (2.3 g, crude). MS (ESI): m/z=315.0
[M-56+H].sup.+.
BB76a
tert-Butyl
4-(oxazolo[5,4-c]pyridin-2-ylmethyl)piperidine-1-carboxylate
[0805] To a solution of hexachloroethane (2.47 g, 10.4 mmol) in
toluene (20 mL) was added triphenylphosphine (3.28 g, 12.5 mmol)
and NEt.sub.3 (4.65 mL, 33.4 mmol). The mixture was stirred at
80.degree. C. for 5 min, then tert-butyl
4-[2-[(3-hydroxy-4-pyridyl)amino]-2-oxo-ethyl]piperidine-1-carboxylate
(1.4 g, 4.17 mmol) was added and stirred at 80.degree. C. for 12 h.
The mixture was concentrated to remove toluene, then diluted with
water (100 mL) and extracted three times with EtOAc (50 mL each).
The combined organic layers were washed with brine, dried over
sodium sulfate, filtered and concentrated. The crude was purified
by silica gel chromatography (PE:EtOAc=10:1 to 1:0) to give the
compound as a yellow oil (814 mg, 21% yield). MS (ESI): m/z=318.1
[M+H].sup.+.
Step a) tert-Butyl
4-[2-[(3-hydroxy-4-pyridyl)amino]-2-oxo-ethyl]piperidine-1-carboxylate
[0806] A solution of 4-aminopyridin-3-ol (3.0 g, 27.3 mmol) and
1-Boc-4-piperidylacetic acid (7.95 g, 32.7 mmol) in DMF (30 mL) was
added HOBt (6.26 g, 40.9 mmol), EDCI (6.34 g, 40.87 mmol) and
NEt.sub.3 (11.39 mL, 81.74 mmol). The mixture was stirred at
20.degree. C. for 15 h. Then the mixture was concentrated, the
residue taken up in water (100 mL), and then extracted three times
with EtOAc (20 mL each). The organic phase was washed with brine,
dried over Na.sub.2SO.sub.4 and concentrated. The residue was
purified by reversed phase chromatography and lyophilized to give
two batches of the desired compound. Batch 1 as colorless solid
(1.2 g, 85% purity, 11.1%), and batch 2 as colorless solid (520 mg,
76.7% purity, 4.4% yield). MS (ESI): m/z=336.1 [M+H].sup.+ for both
batches.
BB77
4-Chloro-3-(2-piperidin-4-ylethynyl)pyridine
[0807] Intermediate BB77 was prepared in analogy to BB18, but using
3-bromo-4-chloro-pyridine in step a), to give the title compound as
an orange solid. MS (ESI): m/z=221.1 [M+H].sup.+.
BB78
3-Chloro-2-(2-piperidin-4-ylethynyl)pyridine
[0808] Intermediate BB78 was prepared in analogy to BB18, but using
2-bromo-3-chloro-pyridine in step a), to give the title compound as
a yellow solid. MS (ESI): m/z=221.1 [M+H].sup.+.
BB79
4-[2-(2-Chloro-4-fluorophenyl)ethynyl]piperidine
[0809] Intermediate BB79 was prepared in analogy to BB18, but using
1-bromo-2-chloro-4-fluoro-benzene in step a), to give the title
compound as a white solid. MS (ESI): m/z=238.1 [M+H].sup.+.
BB80
4-[2-(3-Chlorophenyl)ethynyl]piperidine
[0810] Intermediate BB80 was prepared in analogy to BB18, but using
1-bromo-3-chlorobenzene in step a), to give the title compound as a
colorless amorphous solid. MS (ESI): m/z=220.2 [M+H].sup.+.
BB81
4-[2-(4-Chlorophenyl)ethynyl]piperidine
[0811] Intermediate BB81 was prepared in analogy to BB18, but using
1-bromo-4-chlorobenzene in step a), to give the title compound as a
yellow amorphous solid. MS (ESI): m/z=220.2 [M+H].sup.+.
BB82
4-[2-(2-Chloro-4-chlorophenyl)ethynyl]piperidine
[0812] Intermediate BB82 was prepared in analogy to BB18, but using
1-bromo-2,4-dichloro-benzene in step a), to give the title compound
as a light yellow amorphous solid. MS (ESI): m/z=254.1
[M+H].sup.+.
BB83
4-[2-(2-Chlorophenyl)ethynyl]piperidin-4-ol
[0813] Intermediate BB83 was prepared in analogy to BB18, but using
tert-butyl 4-ethynyl-4-hydroxypiperidine-1-carboxylate (CAS RN
275387-83-2) in step a), to give the title compound as a yellow
amorphous solid. MS (ESI): m/z=218.1 [M-H.sub.2O+H].sup.+.
BB84
3-[2-(2-Chlorophenyl)ethynyl]azetidine
[0814] To a solution tert-butyl
3-[2-(2-chlorophenyl)ethynyl]azetidine-1-carboxylate (0.035 g,
0.120 mmol) in DCM (0.6 mL) was added TFA (0.92.4 mL, 1.2 mmol) and
the reaction mixture was stirred at room temperature for 2 h. The
mixture was diluted with DCM, poured into a saturated aq.
NaHCO.sub.3 solution and extracted with DCM. The combined organic
layers were washed with brine, dried over Na.sub.2SO.sub.4,
filtered, evaporated and further dried on the high vacuum to give
the crude title compound (0.02 g, 87%) as a light yellow oil. MS
(ESI): m/z=192.0 [M+H].sup.+.
Step a) tert-Butyl
3-[2-(2-chlorophenyl)ethyl]azetidine-1-carboxylate
[0815] The compound was prepared in analogy to intermediate BB 18,
but using tert-butyl 3-ethynylazetidine-1-carboxylate (CAS RN
287193-01-5) in step a), to give the title compound as a white
solid. MS (ESI): m/z=236.1 [M-56+H].sup.+.
BB85
3-[2-(2,4-Dichlorophenyl)ethynyl]azetidine
[0816] Intermediate BB85 was prepared in analogy to intermediate
BB84, but using 1-bromo-2,4-dichloro-benzene in step a), to give
the title compound as a light yellow oil. MS (ESI): m/z=226.1
[M+H].sup.+.
BB86
3-[2-(2-Chloro-4-fluoro-phenyl)ethynyl]azetidine
[0817] Intermediate BB86 was prepared in analogy to intermediate
BB84, but using 1-bromo-2-chloro-4-fluoro-benzene in step a), to
give the title compound as a yellow oil. MS (ESI): m/z=210.1
[M+H].sup.+.
[0818] In analogy to BB9a the following building blocks were
prepared from the respective building blocks
TABLE-US-00006 BB No. Systematic Name Starting materials MS, m/z
BB54a tert-Butyl 4-[[2-methyl-4- tert-Butyl 4- 302.1
(trifluoromethyl)phenyl]methyl] methylenepipendine-1- [M + H -
56].sup.+ piperidine-1-carboxylate carboxylate 4-Bromo-3-methyl
benzotrifluoride BB55a tert-Butyl 4-[[2-chloro-4- tert-Butyl 4-
322.0 (trifluoromethyl)phenyl]methyl] methylenepiperidine-1- [M + H
- 56].sup.+ piperidine-1-carboxylate carboxylate 4-Bromo-3-
chlorobenzotrifluoride
[0819] In analogy to BB15a the following building blocks were
prepared from the respective building blocks.
TABLE-US-00007 BB No. Systematic Name Starting materials MS, m/z
BB49a tert-Butyl 3-[(2- 2-Chlorobenzyl bromide 256.0
chlorophenyl)methoxy]pyrrolidine- N-Boc-3-hydroxypyrrolidine [M -
56 + H].sup.+ 1-carboxylate BB50a tert-Butyl 3[(3- 3-Chlorobenzyl
bromide 256.0 chlorophenyl)methoxy]pyrrolidine-
N-BOC-3-hydroxypyrrolidine [M - 56 + H].sup.+ 1-carboxylate
[0820] In analogy to BB9 step a, the following building blocks were
prepared from the respective starting materials.
TABLE-US-00008 BB No. Systematic Name Starting materials MS, m/z
BB47a tert-Butyl 3-[(2- 2-Chlorophenol 256.0
chlorophenoxy)methyl]pyrrolidine- tert-Butyl 3- [M - 56 + H].sup.+
1-carboxylate (hydroxymethyl)pyrrolidine-1- carboxylate BB52a
tert-Butyl 3-[(4- 4-Chlorophenol 256.0
chlorophenoxy)methyl]pyrrolidine- tert-Butyl 3- [M - 56 + H].sup.+
1-carboxylate (hydroxymethyl)pyrrolidine-1- carboxylate BB70a
tert-Butyl 3-[4- 4-(Trifluoromethyl)phenol Used
(trifluoromethyl)phenoxy]azetidine- tert-Butyl
3-hydroxyazetidine-1- without 1-carboxylate carboxylate further
purification BB71a tert-Butyl 4-[4-chloro-3- 1
-Boc-4-hydroxypiperidine 324.0 (trifluoromethyl)phenoxy]piperidine-
4-Chloro-3- [M - 56 + H].sup.+ 1-carboxylate
(trifluoromethyl)phenol BB74b tert-Butyl 4-[2-bromo-4- 2-Bromo-4-
369.9 (trifluoromethyl)phenoxy]piperidine- (trifluoromethyl)phenol
[M - 56 + H].sup.+ 1-carboxylate 1-BOC-4-hydroxypiperidine BB89a
tert-Butyl 3-[3- 3-Chlorophenol 256.0
chlorophenoxy)methyl]pyrrolidine- tert-Butyl 3- [M - 56 + H].sup.+
1-carboxylate (hydroxymethyl)pyrrolidine-1- carboxylate BB90
tert-Butyl 4-(3-bromo-4-chloro- 3-Bromo-4-chlorophenol 336.0
phenoxy) piperidine-1- 1-BOC-4-hydroxypiperidine [M - 56 + H].sup.+
carboxylate
Method D5
BB51
4-[[2-Cyclopropyl-4-(trifluoromethyl)phenyl]methyl]piperidine
formic acid salt
[0821] To a mixture of tert-butyl
4-[[2-cyclopropyl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxyla-
te (940 mg, 2.45 mmol, BB51a) in DCM (10 mL) was added TFA (2.0 mL,
2.45 mmol). The mixture was stirred at 20.degree. C. for 12 h. The
mixture was concentrated under vacuum. The residue was purified
twice by prep-HPLC to furnish the desired compound as light yellow
gum (111 mg, 12.4%). MS (ESI): m/z=284.2 [M+H].sup.+.
Step a) 2-Bromo-1-(bromomethyl)-4-(trifluoromethyl)benzene
[0822] A mixture of 2-bromo-1-methyl-4-(trifluoromethyl)benzene
(5.5 g, 23.0 mmol, CAS RN 128-08-5), benzoyl peroxide (835 mg, 3.45
mmol) and NBS (4.07 g, 23.0 mmol) in CCl.sub.4 (50.0 mL, 23.0 mmol)
was stirred at 70.degree. C. for 5 h. The mixture was poured into
water (20 mL) and extracted twice with DCM (20 mL each). The
combined organic layers were washed with brine (20 mL), dried over
Na.sub.2SO.sub.4, filtered and concentrated in vacuum to give the
compound as light yellow oil (7.1 g, 97%) which was used in the
next step without further purification.
Step b)
2-Bromo-1-(diethoxyphosphorylmethyl)-4-(trifluoromethyl)benzene
[0823] A mixture of
2-bromo-1-(bromomethyl)-4-(trifluoromethyl)benzene (7.1 g, 22.3
mmol) and triethyl phosphite (30.0 mL) was stirred at 155.degree.
C. for 5 h. The mixture was concentrated in vacuum to remove
triethyl phosphite. The residue was diluted with water (100 mL) and
extracted three times with EtOAc (100 mL each). The combined
organic layers were washed with brine (100 mL), dried over
Na.sub.2SO.sub.4, filtered and concentrated. The residue was
purified by column chromatography (PE:EA=100:1 to 10:1) to give the
title compound as light yellow oil (8 g, 21.3 mmol, 95.5%) which
was used in the subsequent step without further purification.
Step c) tert-Butyl
4-(2-bromo-4-(trifluoromethyl)benzylidene)piperidine-1-carboxylate
[0824] A mixture of
2-bromo-1-(diethoxyphosphorylmethyl)-4-(trifluoromethyl)benzene
(6.9 g, 18.4 mmol) in THF (100 mL) was added NaH (2.21 g, 55.2
mmol) at 0.degree. C. The mixture was stirred at 0.degree. C. for 1
h, then 1-Boc-4-piperidone (7.33 g, 36.8 mmol, CAS RN 79099-07-3)
was added and the mixture was stirred at 20.degree. C. for 12 h.
The mixture was poured into water (100 mL) and extracted three
times with EtOAc (100 mL each). The combined organic layer was
washed with brine (100 mL), dried over Na.sub.2SO.sub.4, filtered
and concentrated in vacuum. The residue was purified by column
chromatography (PE:EA=100:1 to 50:1) to yield the desired compound
as off-white solid (4 g, 9.52 mmol, 51.7%). MS (ESI): m/z=365.9
[M-56+H].sup.+.
Step d) tert-Butyl
4-[[2-cyclopropyl-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carbox-
ylate
[0825] A mixture of tert-butyl
4-[[2-bromo-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylate
(2.0 g, 4.76 mmol), cyclopropylboronic acid (818 mg, 9.52 mmol, CAS
RN 411235-57-9) and potassium carbonate (1973 mg, 14.3 mmol) in DMF
(10 mL) and water (0.5 mL) was stirred at 80.degree. C. for 12 h
under nitrogen atmosphere. The mixture was poured into water (50
mL) and extracted three times with EtOAc (50 mL each). The combined
organic layers were washed with brine (50 mL), dried over
Na.sub.2SO.sub.4 and concentrated in vacuum. The residue was
purified by prep-HPLC to give the compound as light yellow oil
(1020 mg, 56.2% yield) MS (ESI): m/z=326.0 [M-56+H].sup.+.
Step e) tert-Butyl
4-[[2-cyclopropyl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxyla-
te
[0826] A mixture of tert-butyl
4-[[2-cyclopropyl-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carbox-
ylate (1000 mg, 2.62 mmol) and PtO.sub.2 (100 mg, 0.440 mmol) in
EtOAc (20 mL) was stirred at 20.degree. C. for 12 h under hydrogen
atmosphere (1520 mm Hg). Then the mixture was filtered and the
filtrate was concentrated to yield the compound as light yellow
solid (940 mg, 93.5% yield). MS (ESI): m/z=328.2 [M+H].sup.+.
Method D6
BB92
N-methyl-N-[4-(trifluoromethyl)phenyl]piperidin-4-amine;
trifluoroacetate salt
[0827] To a solution of tert-butyl
4-[N-methyl-4-(trifluoromethyl)anilino]piperidine-1-carboxylate
(150 mg, 0.420 mmol) in DCM (1 mL) was added TFA (0.1 mL) at
0.degree. C. The mixture was stirred at 25.degree. C. for 12 h. The
reaction mixture was concentrated in vacuum. The residue was
purified by pre-HPLC (in the presence of TFA) to give the desired
product as yellow solid (120 mg, 77.0%). MS (ESI): m/z=259.2
[M+H].sup.+.
Step a) tert-Butyl
4-[4-(trifluoromethyl)anilino]piperidine-1-carboxylate
[0828] To a solution of p-trifluoromethylaniline (1.17 mL, 9.31
mmol, CAS RN 455-14-1) in DCM (30 mL) was added AcOH (0.560 g, 9.31
mmol) and 1-BOC-4-piperidone (2.78 g, 14.0 mmol, CAS RN
79099-07-3). Then 1M BH.sub.3/THF solution (27.9 mL, 27.9 mmol) was
added carefully at 0.degree. C. under nitrogen atmosphere. The
reaction mixture was stirred at 25.degree. C. for 12 h. The mixture
was poured into saturated aqueous NH.sub.4Cl solution (30 mL) and
extracted three times with EtOAc. The combined organic layers were
washed twice with water H.sub.2O, and then brine, dried over
Na.sub.2SO.sub.4 and concentrated in vacuum to afford yellow
residue, which was purified by silica gel column eluting with a
gradient of PE:EtOAc (20:1 to 5:1) to give the desired product as
white solid (2.0 g, 62.4%). MS (ESI): m/z=289.1 [M-56+H].sup.+.
Step b) tert-Butyl
4-[N-methyl-4-(trifluoromethyl)anilino]piperidine-1-carboxylate
[0829] To a solution of NaH (52.3 mg, 60.0% wt %, 1.31 mmol) in DMF
(5 mL) was added tert-butyl
4-[4-(trifluoromethyl)anilino]piperidine-1-carboxylate (300 mg,
0.870 mmol) at 0.degree. C. under nitrogen atmosphere. The mixture
was stirred at 0.degree. C. for 15 min, and then iodomethane (371
mg, 2.61 mmol) was added. The reaction mixture was stirred at
80.degree. C. for 12 hrs. The reaction mixture was poured into
water (20 mL) and extracted three times with EtOAc, the combined
organic layers were washed twice with water and brine, dried over
sodium sulfate and concentrated in vacuum to afford light yellow
residue, which was purified by silica gel column eluting with a
gradient of PE:EtOAc (20:1 to 5:1) to give the desired product as
white solid (160 mg, 51.3%). MS (ESI): m/z=303.1
[M-56+H].sup.+.
BB93
N-methyl-N-(4-(trifluoromethyl)phenyl)azetidin-3-amine
(trifluoroacetic acid salt)
[0830] The title compound was prepared in analogy to method D6 from
tert-butyl
3-[N-methyl-4-(trifluoromethyl)anilino]azetidine-1-carboxylate
(48%). MS (ESI): m/z=231.1 [M+H].sup.+.
Step a) tert-Butyl
3-[4-(trifluoromethyl)anilino]azetidine-1-carboxylate
[0831] To a solution of p-trifluoromethylaniline (0.780 mL, 6.21
mmol, CAS RN 455-14-1), AcOH (1.86 g, 31.0 mmol) and
1-BOC-3-azetidinone (2.13 g, 12.4 mmol, CAS RN 398489-26-4) in EtOH
(10 mL) was added NaBH.sub.3CN (1.95 g, 31.0 mmol) at 25.degree. C.
The mixture was stirred at 25.degree. C. for 12 h. The reaction
mixture was poured into saturated aqueous NH.sub.4Cl solution (20
mL) and extracted twice with EtOAc. The combined organic layers
were washed twice with H.sub.2O and brine, dried over sodium
sulfate and concentrated in vacuum to afford yellow residue, which
was purified by silica gel column eluting with a gradient of
PE:EtOAc (10:1 to 5:1) to give the desired product as white solid
(340 mg, 17.3%). MS (ESI): m/z=261.1 [M-56+H].sup.+.
Step b) tert-Butyl
3-[N-methyl-4-(trifluoromethyl)anilino]azetidine-1-carboxylate
[0832] To a solution of tert-butyl
3-[4-(trifluoromethyl)anilino]azetidine-1-carboxylate (300 mg,
0.950 mmol) in DMF (5 mL) was added NaH (45.5 mg, 60% wt %/o, 1.14
mmol) at 0.degree. C. The mixture was stirred for 15 min, and then
iodomethane (404 mg, 2.85 mmol) was added. The reaction mixture was
stirred at 25.degree. C. for 12 h. The reaction mixture was poured
into H.sub.2O (20 mL) and extracted twice with EtOAc. The combined
organic layers were washed three times with H.sub.2O and brine,
dried over Na.sub.2SO.sub.4 and concentrated in vacuum to afford
yellow residue. The residue was purified by silica gel column
eluting with a gradient of PE:EtOAc (10:1 to 5:1) to give the
desired product as white solid (310 mg, 98.9%). MS (ESI): m/z=275.2
[M-56+H].sup.+.
Method D7
BB94
N-methyl-N-(piperidin-4-yl)-2-(3-(trifluoromethyl)phenyl)acetamide
hydrochloride
[0833] To a solution of tert-butyl
4-[methyl-[2-[3-(trifluoromethyl)phenyl]acetyl]amino]piperidine-1-carboxy-
late (0.080 g, 200 .mu.mol) in DCM (I mL) was added a 2 M HCl
solution in diethyl ether (999 .mu.L, 2 mmol). The reaction mixture
was stirred at RT overnight and then concentrated in vacuo to
afford the title compound (67 mg, 199 .mu.mol) as an off-white
solid. MS (ESI): m/z=301.2 [M+H].sup.+.
Step a) tert-Butyl
4-[methyl-[2-[3-(rifluoromethyl)phenyl]acetyl]amino]piperidine-1-carboxyl-
ate
[0834] To a stirred mixture of 2-(3-(trifluoromethyl)phenyl)acetic
acid (105 mg, 513 .mu.mol, CAS RN 351-35-9) in DMF (5 mL) was added
HATU (195 mg, 513 .mu.mol) and DIPEA (181 mg, 244 .mu.L, 1.4 mmol).
After 15 min. stirring, tert-butyl
4-(methylamino)piperidine-1-carboxylate (0.100 g, 467 .mu.mol, CAS
RN 147539-41-1) was added and the reaction mixture was stirred at
RT for 2 h. The reaction mixture was diluted with DCM and washed
with H.sub.2O. The org, phase was concentrated to give a crude
product which was purified by flash chromatography on a 20 g
SiO.sub.2 column, using an eluent mixture of n-heptane and EtOAc
(0% to 100%) to afford the desired compound as a light yellow oil
(85 mg, 213 .mu.mol). MS (ESI): m/z=459.259
[M+CH.sub.3CN+NH.sub.4].sup.+.
Method D8
BB194
3-(4-Chloro-3-cyclopropylphenoxy)azetidine
[0835] To a solution of tert-butyl
3-(4-chloro-3-cyclopropylphenoxy)azetidine-1-carboxylate (0.023 g,
0.057 mmol) in DCM (1 mL) was added TFA (0.088 mL, 1.14 mmol) and
the reaction mixture stirred at room temperature for 18 hours. The
mixture was diluted with DCM, poured into a sat. aq. NaHCO.sub.3
solution and extracted with DCM. The combined organic layers were
washed with brine, dried over Na.sub.2SO.sub.4, filtered and
evaporated to dryness to yield the crude title compound (0.007 g,
35%) as a colorless oil. MS (ESI): m/z=224.1 [M+H].sup.+.
Step a) tert-Butyl
3-(3-bromo-4-chlorophenoxy)azetidine-1-carboxylate
[0836] In a sealed tube, 3-bromo-4-chlorophenol (0.1 mg, 0.482
mmol) and tert-butyl 3-hydroxyazetidine-1-carboxylate (0.083 g,
0.482 mmol) were dissolved in toluene (1.5 mL). The vial was
degassed with argon, then (tributylphosphoranylidene)acetonitrile
(CAS RN 157141-27-0, 0.195 mL, 0.723 mmol) was added and the
reaction mixture heated to 100.degree. C. for 30 minutes. The
mixture was diluted with EtOAc, poured into sat. aq. NaHCO.sub.3
solution and the aqueous layer was extracted with EtOAc. The
combined organic layers were washed with brine, dried over
Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The residue
was purified by silica gel flash chromatography eluting with a 0 to
20% EtOAc/heptane gradient to give the title compound (0.116 g,
53%) as a yellow oil. MS (ESI): m/z=308.1 [M-56+H].sup.+.
Step b) tert-Butyl
3-(4-chloro-3-cyclopropylphenoxy)azetidine-1-carboxylate
[0837] In a microwave vial, tert-butyl
3-(3-bromo-4-chlorophenoxy)azetidine-1-carboxylate (0.075 g, 0.165
mmol), cyclopropylboronic acid (0.021 g, 0.248 mmol) and
K.sub.2CO.sub.3 (0.046 g, 0.331 mmol) were mixed in dioxane (1.6
mL). Then, water (0.4 mL) was added followed by
bis(triphenylphosphine)palladium (II) chloride (0.012 g, 0.016
mmol) and the reaction mixture heated at 130.degree. C. under
microwave irradiation for 1 hour. The reaction mixture was diluted
with EtOAc, poured into water and extracted with EtOAc. The organic
layers were washed with brine, dried over Na.sub.2SO.sub.4,
filtered and concentrated in vacuo. The residue was purified by
silica gel flash chromatography, eluting with a 0 to 10%
EtOAc/heptane gradient to give the title compound (0.023 g, 43%) as
a colorless oil. MS (ESI): m/z=268.2 [M-56+H].sup.+.
Method D9
BB197
3-(2-Chloro-3-cyclopropylphenoxy)azetidine, trifluoroacetate
salt
[0838] To a solution of tert-butyl
3-(2-chloro-3-cyclopropyl-phenoxy)azetidine-1-carboxylate (0.1 g,
0.310 mmol) in DCM (2.5 mL) was added TFA (0.25 mL) and the
reaction mixture was stirred at room temperature for 2 hours. The
mixture was concentrated in vacuo to give the crude title compound
(0.083 g, 80% yield) as a dark brown oil. MS (ESI): m/z=224.6
[M+H].sup.+.
Step a) tert-Butyl
3-(3-bromo-2-chloro-phenoxy)azetidine-1-carboxylate
[0839] To a solution of tert-butyl 3-hydroxyazetidine-1-carboxylate
(0.5 g, 2.89 mmol) and 3-bromo-2-chloro-phenol (0.5 g, 2.41 mmol)
in THF (10 mL) were added PPh.sub.3 (0.948 g, 3.62 mmol) followed
by diethyl azodicarboxylate (0.47 mL, 3.62 mmol) and the reaction
mixture was stirred at room temperature for 12 hours. The mixture
was purified by reversed phase HPLC to give the title product (0.4
g, 46%) as a light yellow oil. MS (ESI): m/z=308.3
[M-56+H].sup.+.
Step b) tert-Butyl
3-(2-chloro-3-cyclopropylphenoxy)azetidine-1-carboxylate
[0840] In a sealed tube, cyclopropylboronic acid (0.071 g, 0.830
mmol), tert-butyl
3-(3-bromo-2-chloro-phenoxy)azetidine-1-carboxylate (0.2 g, 0.550
mmol) and Na.sub.2CO.sub.3 (0.117 g, 1.1 mmol) were mixed in
1,4-dioxane (5 mL) and water (1 mL). Then, Pd(dppf)Cl.sub.2 (0.040
g, 0.060 mmol) was added and the mixture was stirred to 110.degree.
C. for 12 hours. The mixture was purified by reversed phase HPLC to
give the title compound (0.12 g, 67%) as a light yellow oil. MS
(ESI): m/z=268.1 [M-56+H].sup.+.
Method D10
BB202
5-(4-Piperidyloxy)-2-(trifluoromethyl)benzonitrile,
trifluoroacetate
[0841] To a solution of tert-butyl
4-[3-cyano-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate
(0.05 g, 0.140 mmol) in DCM (1.5 mL) was added TFA (0.2 mL) and the
reaction mixture stirred at room temperature for 12 hours. The
mixture was concentrated in vacuo to give the crude title compound
(0.051 g, 98%) as a light brown oil. MS (ESI): m/z=271.6
[M+H].sup.+.
Step a) tert-Butyl
4-[3-bromo-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate
[0842] To a solution of 3-bromo-4-(trifluoromethyl)phenol (0.5 g,
2.54 mmol) and 1-Boc-4-hydroxypiperidine (0.512 g, 2.54 mmol) in
THF (8.5 mL) were added PPh.sub.3 (1 g, 3.82 mmol) followed by
diethyl azodicarboxylate (0.665 g, 3.82 mmol) and the reaction
mixture was stirred at room temperature for 12 hours. The mixture
was purified by silica gel flash chromatography, eluting with
PE:EtOAc 5:1 to give the title compound (0.5 g, 47%) as a light
yellow oil. MS (ESI): m/z=370.2 [M-56+H].sup.+.
Step b) tert-Butyl
4-[3-cyano-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate
[0843] In a sealed tube, tert-butyl
4-[3-bromo-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate (0.2
g, 0.470 mmol), Zn(CN).sub.2 (0.111 g, 0.940 mmol), CuI (0.09 g,
0.470 mmol) were mixed in DMF (10 mL). Then, Pd(PPh.sub.3).sub.4
(0.109 g, 0.090 mmol) was added and the reaction mixture stirred to
130.degree. C. for 16 hours. The mixture was purified by reversed
phase HPLC to give the title product (0.05 g, 29%) as a colorless
oil. MS (ESI): m/z=315.5 [M-56+H].sup.+.
Method E
Example 263
(+)-5-[1-[(4aR,8aS)-3-Oxo-4,4a,5,7,88a-hexahydropyrido[4,3-b][1,4]oxazine--
6-carbonyl]azetidin-3-yl]oxy-2-(trifluoromethyl)benzonitrile
##STR00308##
[0845] In a sealed tube,
(+)-(4aR,8aS)-6-[3-[3-bromo-4-(trifluoromethyl)phenoxy]azetidine-1-carbon-
yl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (BB 205,
0.2 g, 0.420 mmol), Zn(CN).sub.2 (0.098 g, 0.840 mmol), Zn (0.027
g, 0.420 mmol), dppf (0.232 g, 0.420 mmol). Hunig's base (0.108 g,
0.840 mmol) were mixed in DMA (10 mL) and the mixture was degassed.
Then, Pd.sub.2(dba).sub.3 (76.59 mg, 0.080 mmol) was added and the
reaction mixture was stirred at 130.degree. C. for 16 h. The
mixture was purified by reversed phase HPLC to give the title
compound (0.055 g, 30%) as a light yellow solid. MS (ESI):
m/z=425.3 [M+H].sup.+.
Method F
Example 265
(+)-(4aR,8aS)-6-[3-[3-(2-Azaspiro[3.3]heptan-2-yl)-4-(trifluoromethyl)phen-
oxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin--
3-one
##STR00309##
[0847] In a sealed tube,
(+)-(4aR,8aS)-6-[3-[3-bromo-4-(trifluoromethyl)phenoxy]azetidine-1-carbon-
yl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (BB203,
0.2 g, 0.420 mmol), 2-azaspiro[3.3]heptane (CAS RN 665-04-03, 0.117
g, 0.630 mmol), BINAP (0.052 g, 0.080 mmol) and K.sub.2CO.sub.3
(0.173 g, 1.25 mmol) were mixed in DMF (10 mL) and the mixture was
degassed. Then, Pd.sub.2(dba).sub.3 (76.59 mg, 0.080 mmol) was
added and the reaction mixture was stirred to 110.degree. C. for 16
hours. The reaction mixture was filtered off, the filtrate diluted
with water (50 mL) and extracted with EtOAc (3.times.20 mL).
Combined organics were washed with brine, dried over
Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The residue
was purified by reversed phase HPLC to give the title compound
(0.06 g, 29%) as a white solid. MS (ESI): m/z=495.1
[M+H].sup.+.
Method G
Example 293
(4aR,8aS)-6-(3-(4-Hydroxy-2-(trifluoromethyl)phenethyl)azetidine-1-carbony-
l)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one
##STR00310##
[0849] Boron tribromide (11.3 mg, 4.29 .mu.L, 45.3 .mu.mol) was
added to an ice cooled solution of
(4aR,8aS)-6-(3-(4-methoxy-2-(trifluoromethyl)phenethyl)azetidine-1-carbon-
yl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one (Example 216, 20
mg, 45.3 .mu.mol) in DCM (0.5 mL). The reaction mixture was stirred
at ambient temperature for 3 h. A saturated solution of aqueous
NaHCO.sub.3 was added and the mixture was extracted with AcOEt. The
layers were separated, the organic layer was dried over
Na.sub.2SO.sub.4, filtered and the solvent removed under reduced
pressure. The crude product was purified by prep. HPLC to give the
title compound (19%) as colorless solid. MS (ESI): m/z=427.2
[M+H].sup.+.
[0850] The following examples listed in the table below were
prepared in analogy to the procedure described for the preparation
of Example 265 by using the indicated intermediates and/or
commercially available compounds and using the mentioned
purification method such as reversed-phase HPLC or silica gel flash
chromatography.
TABLE-US-00009 Ex Systematic Name/Structure Intermediates MS, m/z
266 ##STR00311## BB203 BH66 and 3-Methylazetidine hydrochloride
(CAS RN 935669-28-6) 469.2 [M + H].sup.+ 267 ##STR00312## BB203 and
Difluoroazetidine hydrochloride (CAS RN 288315-03-7) 491.2 [M +
H].sup.+ 268 ##STR00313## BB203 and 3-Fluoro-3-methyl- azetidine
hydrochloride (CAS RN 1427379-42-7) 487.3 [M + H].sup.+ 269
##STR00314## BB203 and 6,6-Difluoro-2- azaspiro[3.3]heptane (CAS RN
1354952-05-8) 531.1 [M + H].sup.+ 270 ##STR00315## BB203 and
5-Oxa-2- azaspiro[3.5]nonane (CAS RN 138387-19-6) 525.3 [M +
H].sup.+ 271 ##STR00316## Example 258 and 2-Azaspiro[3.3]heptane
(CAS RN 665-04-03) 461.1 [M + H].sup.+ 272 ##STR00317## Example 258
and 3-Methylazetidine hydrochloride (CAS RN 935669-28-6) 435.1 [M +
H].sup.+ 273 ##STR00318## Example 258 and 3-Fluoro-3-methyl-
azetidine hydrochloride (CAS RN 1427379-42-7) 453.2 [M + H].sup.+
274 ##STR00319## Example 258 and 3-tert-Butoxyazetidine (CAS RN
1147530-63-9) 493.2 [M + H].sup.+ 275 ##STR00320## Example 258 and
5-Oxa-2- azaspiro[3.4]octane (CAS RN 145309-24-6) 477.2 [M +
H].sup.+ 276 ##STR00321## Example 258 and 5-Oxa-2-
azaspiro[3.5]nonane (CAS RN 138387-19-6) 491.2 [M + H].sup.+ 277
##STR00322## BB204 and 2-Azaspiro[3.3]heptane (CAS RN 665-04-03)
461.3 [M + H].sup.+ 278 ##STR00323## BB204 and Pyrrolidine 435.3 [M
+ H].sup.+
[0851] In analogy to the methods described herein above, the
following building blocks were prepared from the respective
starting material indicated in the table below.
TABLE-US-00010 BB No. Systematic Name Starting material Method MS,
m/z BB47 3-[(2- tert-Butyl 3-[(2- D3 212.1
Chlorophenoxy)methyl]pyrrolidine; chlorophenoxy)methyl]pyrrolidine-
[M + H].sup.+ hydrochloride salt 1-carboxylate BB47a BB48
4-[[2-Fluoro-4- tert-Butyl 4-[[2-fluoro-4- D2 262.1
(trifluoromethyl)phenyl]methyl]piperidine;
(trifluoromethyl)phenyl]methyl] [M + H].sup.+ formic acid salt
piperidine-1-carboxylate BB48a BB49 3-[(2- tert-Butyl 3-[(2- D3
212.1 Chlorophenyl)methoxy]pyrrolidine;
chlorophenyl)methoxy]pyrrolidine- [M + H].sup.+ hydrochloride salt
1-carboxylate BB49a BB50 3-[(3- tert-Butyl 3-[(3- D3 212.1
Chlorophenyl)methoxy]pyrrolidine; chlorophenyl)methoxy]pyrrolidine-
[M + H].sup.+ hydrochloride salt 1-carboxylate BB50a BB52 3-[(4-
tert-Butyl 3-[(4- D3 212.1 Chlorophenyl)methoxy]pyrrolidine;
chlorophenyl)methoxy]pyrrolidine- [M + H].sup.+ hydrochloride salt
1-carboxylate BB52a BB53 3-[(4- tert-Butyl 3-[(4- D2 Used
Chlorophenyl)methoxy]pyrrolidine chlorophenyl)methoxy]pyrrolidine-
without formic acid salt 1-carboxylate BB53a further purification
BB54 4-[[2-Methyl-4- tert-Butyl 4-[[2-methyl-4- D2 258.2
(trifluoromethyl)phenyl]methyl]piperidine;
(trifluoromethyl)phenyl]methyl] [M + H].sup.+ formic acid salt
piperidine-1-carboxylate BB54a BB55 4-[[2-Chloro-4- tert-Butyl
4-[[2-chloro-4- D1 278.0 (trifluoromethyl)phenyl]methyl]piperidine;
(trifluoromethyl)phenyl]methyl] [M + H].sup.+ trifluoroacetate salt
piperidine-1-carboxylate BB55a BB71 4-[4-Chloro-3- tert-Butyl
4-[4-chloro-3- D3 280.0 (trifluoromethyl)phenoxy]piperidine;
(trifluoromethyl)phenoxy]piperidine- [M + H].sup.+ hydrochloride
salt 1-carboxylate BB71a BB72 4-(4-Chloro-3-cyclopropyl- tert-Butyl
4-(4-chloro-3- D1 Used phenoxy) piperidine; cyclopropyl- without
trifluoroacetate salt phenoxy)piperidine-1- further carboxylate
BB72a purification BB73 4-[2-Chloro-5-(4-piperidyloxy)phenyl]
tert-Butyl 4-(4-chloro-3- D3 Used morpholine hydrochloride
morpholino- without phenoxy)piperidine-1- further carboxylate BB73a
purification BB74 4-[2-Methyl-4- tert-Butyl 4-+2-methyl-4- D1 260.2
(trifluoromethyl)phenoxy]piperidine;
(trifluoromethyl)phenoxy]piperidine- [M + H].sup.+ trifluoroacetate
salt 1-carboxylate BB74a BB75 2-(4-Piperidyloxy)-5- tert-Butyl
4-[2-cyano-4- D4 271.1 (trifluoromethyl)benzonitrile
(trifluoromethyl)phenoxy]piperidine- [M + H].sup.+ 1-carboxylate
BB75a BB76 2-(4- tert-Butyl 4-(oxazolo[5,4-c]pyridin- D1 218.1
Piperidylmethyl)oxazolo[5,4-c]pyridine; 2-ylmethyl)piperidine-1- [M
+ H].sup.+ trifluoroacetate salt carboxylate BB76a BB89 3-[(3-
tert-Butyl 3-[(3- D3 212.1 Chlorophenoxy)methyl]pyrrolidine;
chlorophenoxy)methyl]pyrrolidine- [M + H].sup.+ hydrochloride salt
1-carboxylate BB89a BB192 4-[2-Fluoro-4- tert-Butyl 4- D3 264.2
(trifluoromethyl)phenoxy]piperidine; hydroxypiperidine-1- [M +
H].sup.+ hydrochloride salt carboxylate BB193 4-[3-Chloro-4-
tert-Butyl 4-[3-chloro-4- D3 280.1
(trifluoromethyl)phenoxy]piperidine;
(trifluoromethyl)phenoxy]piperidine- [M + H].sup.+ hydrochloride
salt 1-carboxylate BB195 4-[2-Chloro-3- tert-Butyl 4-[2-chloro-3-
D8 280.1 (trifluoromethyl)phenoxy]piperidine;
(trifluoromethyl)phenoxy]piperidine [M + H].sup.+ hydrochloride
salt 1-carboxylate BB196 3-(3-Bromo-2-chloro- tert-Butyl
3-(3-bromo-2- D1 263.0 phenoxy)azetidine;
chloro-phenoxy)azetidine-1- [M + H].sup.+ trifluoroacetate salt
carboxylate BB198 3-[3-Bromo-4- tert-Butyl 3[3-bromo-4- D9 296.4
(trifluoromethyl)phenoxy]azetidine;
(trifluoromethyl)phenoxy]azetidine- [M + H].sup.+ trifluoroacetate
salt 1-carboxylate BB199 3-[3-Cyclopropyl-4- tert-Butyl
3-[3-cyclopropyl-4- D9 258.1 (trifluoromethyl)phenoxy]azetidine;
(trifluoromethyl)phenoxy]azetidine- [M + H].sup.+ trifluoroacetate
salt 1-carboxylate BB200 3-[3-Chloro-4- tert-Butyl 3-[3-chloro-4-
D1 252.5 (trifluoromethyl)phenoxy]azetidine;
(trifluoromethyl)phenoxy]azetidine- [M + H].sup.+ trifluoroacetate
salt 1-carboxylate BB201 3-(3-Bromo-5-chloro- tert-Butyl
3-(3-bromo-5- D1 263.9 phenoxy)azetidine; trifluoroacetate salt
chloro-phenoxy)azetidine-1- [M + H].sup.+ carboxylate BB205
3-(3-Bromo-4-chloro- tert-Butyl 3-(3-bromo-4- D1 263.9
phenoxy)azetidine; chlorophenoxy)azetidine-1- [M + H].sup.+
trifluoroacetate salt carboxylate
BB91
4-[[2-Pyrrolidin-1-yl-4-(trifluoromethyl)phenyl]methyl]piperidine;
formic acid salt
[0852] A solution of tert-butyl
4-[[2-pyrrolidin-1-yl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbo-
xylate (500 mg, 1.21 mmol) in 6 M HCl in MeOH solution (10.0 mL)
was stirred at 20.degree. C. for 1 h. The mixture was concentrated
under vacuum, purified by reversed phase column to give the title
compound as an orange oil (84.4 mg, 21.8% yield). MS (ESI):
m/z=313.2 [M+H]+.
Step a) Tert-butyl
4-[[2-pyrrolidin-1-yl-4-(trifluoromethyl)phenyl]methylene]piperidine-1-ca-
rboxylate
[0853] To a solution of tert-butyl
4-[[2-bromo-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylate
(800 mg, 1.90 mmol; BB51, step c), pyrrolidine (163 mg, 2.28 mmol),
Ruphos (4.25 mg, 0.010 mmol) and potassium tert-butoxide (320 mg,
2.86 mmol) in toluene (15 mL) was added palladium(II) acetate (1.28
mg, 0.010 mmol). The mixture was stirred at 80.degree. C. for 15 h
under N.sub.2 atmosphere. The mixture was filtered and concentrated
under vacuum to remove toluene. The mixture was diluted with
H.sub.2O (40 mL) and extracted three times with EtOAc (40 mL each).
The combined organic layers were washed with brine, dried over
Na.sub.2SO.sub.4, filtered and concentrated. The residue was
purified by silica gel chromatography (PE/EtOAc=1:0 to 8:1) to give
the compound as light yellow oil (552 mg, 1.34 mmol, 36.7%) MS
(ESI): m/z=411.1 [M+H].sup.+.
Step b) Tert-butyl
4-[[2-pyrrolidin-1-yl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbo-
xylate
[0854] To a solution of tert-butyl
4-[[2-pyrrolidin-1-yl-4-(trifluoromethyl)phenyl]methylene]piperidine-1-ca-
rboxylate (525 mg, 0.660 mmol) in MeOH (20 mL) was added wet Pd/C
(.about.52 mg) and the mixture was stirred at 20.degree. C. under
H.sub.2 atmosphere (balloon) for 1 h. The mixture was filtered and
concentrated under vacuum to give the desired compound as colorless
oil (500 mg) which was used in the next step without further
purification.
BB95
3-[2-[2-fluoro-6-(trifluoromethyl)phenyl)phenyl]ethyl]azetidine
4-methylbenzenesulfonate
[0855] To an solution of
3-[2-[2-fluoro-6-(trifluromethyl)phenyl]ethyl]azetidine-1-carboxylate
(50 mg, 144 .mu.mol, Eq: 1) in EtOAc (0.8 mL) was added
4-methylbenzenesulfonic acid monohydrate (29.7 mg, 173 .mu.mol, Eq:
1.2) and the mixture was heated at reflux for 1.5 hours. The clear,
colorless solution was allowed to cool down to RT. No precipitation
occurred. The solution was evaporated to give the desired product
as a colorless foam. MS (ESI): m/z=248.1 [M-TsOH+H]+.
Step a) tert-butyl
3-[(E)-2-[2-fluoro-6-(trifluoromethyl)phenyl]ethenyl]azetidine-1-carboxyl-
ate
[0856] To an ice-cold solution of diethyl
(2-fluoro-4-(trifluoromethyl)benzyl)phosphonate (300 mg, 955
.mu.mol) in THF (2 mL) was added sodium hydride 55% in mineral oil
(41.7 mg, 955 .mu.mol) and the mixture was stirred at this
temperature for 30 minutes. To the light brown mixture was added
dropwise a solution of tert-butyl 3-formylazetidine-1-carboxylate
(177 mg, 955 .mu.mol) in THF (1 mL). This led to an immediate
discolouration of the reaction mixture. Stirring was continued for
1 hours at ice-bath temperature followed by stirring at RT for 1.5
hours. The reaction mixture was poured into water and ethyl acetate
and the layers were separated. The aqueous layer was extracted
twice with ethyl acetate. The organic layers were washed once with
brine, dried over MgSO.sub.4, filtered, treated with silica gel and
evaporated. The compound was purified by silica gel chromatography
on a 12 g column using an MPLC system eluting with a gradient of
n-heptane:ethyl acetate (100:0 to 25:75) to get the desired
compound as a colorless solid (0.108 g; 32.8%). MS (ESI): m/z=290.2
[M-56+H]+.
Step b) tert-butyl
3-[2-[2-fluoro-6-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate
[0857] To a solution of tert-butyl
(E)-3-(2-fluoro-4-(trifluoromethyl)styryl)azetidine-1-carboxylate
(105 mg, 304 .mu.mol) in MeOH (1 mL) and Ethyl acetate (1 mL) was
added Pd/C 10% (11 mg, 304 .mu.mol) and the mixture was stirred
under a hydrogen atmosphere at 1.7 bar and RT for 30 minutes. The
suspension was filtered. The filtrate was evaporated to get the
desired compound as a colorless oil (0.104 g; 98.5%). MS (ESI):
m/z=292.2 [M-56+H]+.
BB96
4-((2-chloro-4-fluorophenoxy)methyl)azepane hydrochloride
[0858] To a solution of tert-butyl
4-((2-chloro-4-fluorophenoxy)methyl)azepane-1-carboxylate (620 mg,
1.73 mmol) in DCM (7.5 ml) was added HCl in ether 2M (10 ml, 20
mmol) and the reaction mixture was stirred overnight at rt. The
mixture was concentrated in vacuo, the crude material collected as
a white solid (490 mg, 1.67 mmol, 96.1%) and used directly on the
next step. LC-MS (ESI): m/z: 258.2 [M+H]+
Step a) tert-butyl
4-((2-chloro-4-fluorophenoxy)methyl)azepane-1-carboxylate
[0859] In a 25 ml four-necked sulphonation flask under argon,
tert-butyl 4-(hydroxymethyl)azepane-1-carboxylate (480 mg, 2.09
mmol) was dissolved in THF (10 ml). Subsequently,
2-chloro-4-fluorophenol (337 mg, 251 .mu.l, 2.3 mmol) and
triphenylphosphine (604 mg, 2.3 mmol) were added and the clear
solution was stirred for 5 min at rt. The mixture was cooled to
0.degree. C. and DEAD (401 mg, 365 .mu.l, 2.3 mmol) was added in
portions over 10 min. The mixture was stirred for 1 hr at 0.degree.
C., then overnight at rt. The mixture was taken up into EtOAc (50
ml), washed with water (2.times.25 ml), organic phase washed with
1M NaOH (3.times.25 ml), brine (20 ml), dried with
Na.sub.2SO.sub.4, filtered and concentrated in vacuo. Residue was
dissolved in n-Heptane/diethylether and the mixture stirred for 30
min, the TPPO precipitate filtered and the crude concentrated in
vacuo. The crude material was adsorbed on Isolute.RTM. and purified
by flash column chromatography (0-30% EtOAc/Heptane) over silica
gel (50 g) to afford the desired product (630 mg, 1.76 mmol, 84.1%)
as a yellow oil. LC-MS (ESI): m/z: 302.1 [M-56+H]+
BB97
4-[[4-(trifluoromethyl)phenyl]methyl]azepane hydrochloride
[0860] To a solution of tert-butyl
4-(4-(trifluoromethyl)benzyl)azepane-1-carboxylate (88 mg, 246
.mu.mol, Eq: 1) in DCM (1.5 ml) was added HCl in ether 2M (3.08 ml.
6.16 mmol) and the reaction mixture was stirred overnight at room
temperature. The mixture was concentrated in vacuo, the crude
material collected as a white solid (71 mg, 0.24 mmol, 98.2%) and
used directly on the next step. LC-MS (ESI): m/z: 258.2 [M+H]+
Step a: Triphenyl(4-(trifluoromethyl)benzyl)phosphonium bromide
[0861] Triphenylphosphine (1.84 g, 7 mmol) and
1-(bromomethyl)-4-(trifluoromethyl)benzene (1.61 g, 6.74 mmol) were
dissolved in xylene (35 ml). The reaction mixture was heated to
reflux at 155.degree. C. for 3.5 h and then cooled to room
temperature. The precipitated white crystalline solid was collected
by filtration, washed with diethyl ether and dried in vacuo. The
final compound (3.30 g, 6.58 mmol, 97.7% yield) was obtained as a
white powder and directly used on the next step. LC-MS (ESI): m/z:
421.2 [M+H]+
Step b: tert-butyl
(E)-4-(4-(trifluoromethyl)benzylidene)azepane-1-carboxylate
[0862] A suspension of sodium hydride (88.6 mg, 2.22 mmol) in DMF
(7.5 ml) was cooled in an ice bath, then
triphenyl(4-(trifluoromethyl)benzyl)phosphonium bromide (1.11 g,
2.22 mmol) was added. The suspension was stirred at 0.degree. C.
for 5 min. then for 25 min at rt. tert-butyl
4-oxoazepane-1-carboxylate (315 mg, 1.48 mmol) was added and the
resulting mixture was stirred at 80.degree. C. for 28 h. The
mixture was concentrated in vacuo, diluted with water (50 ml) and
EtOAc (40 ml) and extracted EtOAc (3.times.30 ml). The combined
organic fractions were washed with water, 10% LiCl solution, dried
with Na.sub.2SO.sub.4 and concentrated in vacuo. The residual oil
was treated with Et2O in order to precipitate the
triphenylphosphoxide that was filtered off The solution was
concentrated in vacuo and the residue was purified by flash column
chromatography (0-35% EtOAc/Heptane) over silica gel (50 g) to
afford the desired product (92 mg, 259 .mu.mol, 17.5% yield) as a
yellow oil. LC-MS (ESI): m/z: 300.2 [M-56+H]+
Step c: tert-butyl
4-(4-(trifluoromethyl)benzyl)azepane-1-carboxylate
[0863] A solution of tert-butyl
(E)-4-(4-(trifluoromethyl)benzylidene)azepane-1-carboxylate (90 mg,
253 .mu.mol) was dissolved in MeOH (2.5 ml). The reaction vessel
was evacuated and back-filled with argon 5 times. Under argon.
Pd--C (13.5 mg, 12.7 .mu.mol) was added and the atmosphere was
replaced with hydrogen three times. The reaction was stirred under
a hydrogen atmosphere at 1 bar for 24 h. The atmosphere was
replaced with argon and the reaction mixture was filtered over a
pad of Dicalite. The filter cake was washed with methanol. The
filtrate was concentrated in vacuo to give the desired product (89
mg, 249 .mu.mol, 98.3% yield) as a colorless oil which was used
without further purification. LC-MS (ESI): m/z: 302.2
[M-56+H].sup.+
BB98
3-((2-Chloro-4-(trifluoromethyl)phenyl)thio)azetidine
2,2,2-trifluoroacetate
[0864] tert-Butyl
3-((2-chloro-4-(trifluoromethyl)phenyl)thio)azetidine-1-carboxylate
(110 mg, 299 .mu.mol) was dissolved in DCM (2 mL) and TFA (273 mg,
184 .mu.L, 2.39 mmol) was added. The reaction mixture was stirred
at RT for 3 h. Volatiles were removed in vacuo to yield 110 mg of a
light yellow solid (96%). MS (ESI): m/z=268.1 [M+H].sup.+.
Step a) tert-Butyl
3-((2-chloro-4-(trifluoromethyl)phenyl)thio)azetidine-1-carboxylate
[0865] In a 20 mL glastube, a solution of
2-chloro-4-(trifluoromethyl)benzenethiol (440 mg, 2.07 mmol) in dry
THF (6 mL) was added potassium tert-butoxide IM solution in THF
(2.17 ml, 2.17 mmol) and the yellow reaction mixture was stirred at
RT for 15 min followed by addition of tert-butyl
3-bromoazetidine-1-carboxylate (489 mg, 2.07 mmol). The reaction
mixture was then stirred at RT for 5 h and over night at 70.degree.
C. The crude reaction was diluted with EtOAc and extracted with
H2O, the organic phase was collected and the aqueous phase was
back-extracted with EtOAc. The combined organic phases were dried
over Na.sub.2SO.sub.4 and evaporated down to dryness. The residue
was purified by chromatography (SiO.sub.2, n-eptane/EtOAc (0 to 40%
over 40 min) yielded the product as a viscous oil (467 mg, 61%). MS
(ESI): m/z=312.1 [M-56].sup.+.
BB99
3-((2-Chloro-4-(trifluoromethyl)phenyl)sulfonyl)azetidine
2,2,2-trifluoroacetate
[0866] tert-Butyl
3-((2-chloro-4-(trifluoromethyl)phenyl)sulfonyl)azetidine-1-carboxylate
(100 mg, 250 .mu.mol) was dissolved in DCM and TFA (228 mg, 154
.mu.L, 2 mmol) was added. The reaction mixture was stirred at RT
for 8 h. Volatiles were removed in vacuo to yield the desired
compound as light yellow solid (102 mg, 98%). MS (ESI): m/z=300.0
[M+H].sup.+.
Step a) tert-Butyl
3-((2-chloro-4-(trifluoromethyl)phenyl)thio)azetidine-1-carboxylate
[0867] In a 20 mL glastube, a solution of
2-chloro-4-(trifluoromethyl)benzenethiol (440 mg, 2.07 mmol) in dry
THF (6 mL) was added potassium tert-butoxide 1M solution in THF
(2.17 mL, 2.17 mmol) and the yellow reaction mixture was stirred at
r.t for 15 min followed by addition of tert-butyl
3-bromoazetidine-1-carboxylate (489 mg, 2.07 mmol). The reaction
mixture was then stirred at r.t for 5 h and over night at
70.degree. C. The crude reaction was diluted with EtOAc and
extracted with H2O, the organic phase was collected and the aqueous
phase was back-extracted with EtOAc. The combined organic phases
were dried over Na2SO4 and evaporated down to dryness. The residue
was purified by column chromatography (SiO.sub.2, n-eptane/EtOAc (0
to 40% over 40 min) to yield the desired product as a viscous oil
(467 mg, 61%). MS (ESI): m/z=312.1 [M-56+H].sup.+.
Step b) tert-Butyl
3-((2-chloro-4-(trifluoromethyl)phenyl)sulfonyl)azetidine-1-carboxylate
[0868] mCPBA (347 mg, 1.41 mmol) was added in one portion to a
stirred solution of tert-butyl
3-((2-chloro-4-(trifluoromethyl)phenyl)thio)azetidine-1-carboxylate
(345 mg, 938 .mu.mol) in DCM (6 mL) in an ice bath. The reaction
was stirred at RT for 20 min. The reaction mixture was poured into
5 mL saturated Na.sub.2CO.sub.3 solution and extracted twice with
DCM (20 mL each). The organic layers were combined, washed with
brine, dried over Na.sub.2SO.sub.4 and concentrated in vacuo. The
crude material was purified by preparative HPLC (YMC-Triart C 18,
ACN/H2O+0.1% HCOOH) to furnish the product as a white powder (253
mg, 67.5%) MS (ESI): m/z=344.0 [M-56+H].sup.+.
BB100
3-((2-Chloro-4-(trifluoromethyl)phenyl)sulfinyl)azetidine
2,2,2-trifluoroacetate
[0869] tert-Butyl
3-((2-chloro-4-(trifluoromethyl)phenyl)sulfinyl)azetidine-1-carboxylate
(50 mg, 130 .mu.mol) was dissolved in DCM (1.5 mL), TFA (149 mg,
100 .mu.L, 1.3 mmol) was added and the reaction mixture was stirred
at RT for 8 h. Volatiles were removed in vacuo to yield the
compound as white solid (51 mg, 98%). MS (ESI): m/z=284.1
[M+H].sup.+.
Step a) tert-Butyl
3-((2-chloro-4-(trifluoromethyl)phenyl)thio)azetidine-1-carboxylate
[0870] The compound was prepared in analogy to BB99, step a, and
used in the next step without further purification.
Step b) tert-Butyl
3-((2-chloro-4-(trifluoromethyl)phenyl)sulfinyl)azetidine-1-carboxylate
[0871] The sulfoxide intermediate was isolated from the synthesis
of the according sulfone building block BB99, step b. The product
was obtained as a white lyophilized powder (50 mg, 13.9%) MS (ESI):
m/z=328.1 [M-56+H].sup.+.
BB101
3-(((2-Chloro-4-(trifluoromethyl)phenyl)thio)methyl)azetidine
2,2,2-trifluoroacetate
[0872] To a solution of tert-butyl
3-(((2-chloro-4-(trifluoromethyl)phenyl)thio)methyl)azetidine-1-carboxyla-
te (0.200 g, 524 .mu.mol) in DCM (3 mL) was added TFA (478 mg, 323
.mu.L, 4.19 mmol) and the reaction mixture was stirred at RT for 3
h. Volatiles were removed in vacuo to yield the compound as light
yellow oil that was used in the next step without further
purification (267 mg). MS (ESI): m/z=282.2 [M+H].sup.+.
Step a) tert-Butyl
3-[[2-chloro-4-(trifluoromethyl)phenyl]sulfanylmethyl]azetidine-1-carboxy-
late
[0873] To a solution of 2-chloro-4-(trifluoromethyl)benzenethiol
(0.400 g, 1.88 mmol) in dry THF (6 mL) was added potassium
tert-butoxide IM solution in THF (1.98 mL, 1.98 mmol) and the
turbid reaction mixture was stirred at RT for 15 min followed by
addition of tert-butyl 3-(bromomethyl)azetidine-1-carboxylate (471
mg, 1.88 mmol). The reaction mixture was then stirred at RT for 19
h. The crude reaction was diluted with EtOAc and extracted with aq.
1 M NaHCO.sub.3 solution, the organic phase was collected and the
aqueous phase was back-extracted with EtOAc. The combined organic
phases were dried over Na.sub.2SO.sub.4 and evaporated down to
dryness to yield the crude product which was used in the next step
without further purification (762 mg). MS (ESI): m/z=326.1
[M-56+H].
BB102
3-((2-Fluoro-6-(trifluoromethyl)benzyl)sulfonyl)azetidine
2,2,2-trifluoroacetate
[0874] tert-Butyl
3-((2-fluoro-6-(trifluoromethyl)phenyl)methylsulfonyl)azetidine-1-carboxy-
late (0.047 g, 118 .mu.mol) was dissolved in DCM (0.5 mL) and TFA
(108 mg, 72.9 .mu.L, 946 .mu.mol) was added. The reaction mixture
was stirred at RT for 2 h. Volatiles were removed in vacuo to yield
the compound as a yellow oil (56 mg) that was used in the next step
without further purification. MS (ESI): m/z=298.2 [M+H].sup.+.
step a) tert-Butyl
3-((2-fluoro-6-(trifluoromethyl)benzyl)thio)azetidine-1-carboxylate
[0875] To a solution of tert-butyl
3-mercaptoazetidine-1-carboxylate (0.400 g, 2.11 mmol) in dry THF
(5 mL) was added potassium tert-butoxide 1M solution in THF (2.22
mL, 2.22 mmol) and the reaction mixture was stirred at RT for 15
min followed by addition of
2-(bromomethyl)-1-fluoro-3-(trifluoromethyl)benzene (CAS RN
239087-08-2). The reaction mixture was then stirred at RT for 14 h.
The crude reaction was diluted with EtOAc and extracted with aq. 1
M NaHCO.sub.3 solution, the organic phase was collected and the
aqueous phase was back-extracted with EtOAc. The combined organic
phases were dried over NaSO.sub.4 and evaporated down to dryness to
yield the crude product (805 mg) which was used in the next step
without further purification. MS (ESI): m/z=310.2
[M-56+H].sup.+.
Step b) tert-Butyl
3-[[2-fluoro-6-(trifluoromethyl)phenyl]methylsulfonyl]azetidine-1-carboxy-
late
[0876] 3-Chlorobenzoperoxoic acid (283 mg, 1.64 mmol) was added in
portion to a stirred solution of tert-butyl
3-((2-fluoro-6-(trifluoromethyl)benzyl)thio)azetidine-1-carboxylate
(0.300 g, 821 .mu.mol) in DCM (5 mL) in an ice bath. The reaction
mixture was stirred at RT for 15 min and poured into 5 mL saturated
aqueous NaHCO.sub.3 solution and extracted twice with DCM (10 mL
each). The organic layers were combined, washed with brine, dried
over Na2SO4 and concentrated in vacuo. The crude material was
purified by flash column chromatography (silica gel, 20 g, 0% to
100% EtOAc in n-heptane) to furnish the desired product as a
colorless oil (47 mg, 15%). MS (ESI): m/z=415.1
[M+NH.sub.4].sup.+.
BB103
3-((2-Fluoro-6-(trifluoromethyl)benzyl)sulfinyl)azetidine
2,2,2-trifluoroacetate
[0877] tert-Butyl
3-[[2-fluoro-6-(trifluoromethyl)phenyl]methylsulfinyl]azetidine-1-carboxy-
late (0.086 g, 225 .mu.mol) was dissolved in DCM (1 mL) and TFA
(206 mg, 139 .mu.L, 1.8 mmol) was added. The reaction mixture was
stirred at RT for 2 h. Volatiles were removed in vacuo to yield the
compound as a yellow oil (93 mg) that was used in the next step
without further purification. MS (ESI): m/z=282.2 [M+H].sup.+.
Step a) tert-Butyl
3-[[2-fluoro-6-(trifluoromethyl)phenyl]methylsulfinyl]azetidine-1-carboxy-
late
[0878] The sulfoxide intermediate was isolated from the synthesis
of BB 102, step b, as a colorless oil (86 mg, 28%). MS (ESI):
m/z=404.1 [M+Na].sup.+.
BB104
3-(((2-Chloro-4-(trifluoromethyl)phenyl)sulfonyl)methyl)azetidine
2,2,2-trifluoroacetate
[0879] tert-Butyl
3-(((2-chloro-4-(trifluoromethyl)phenyl)sulfonyl)methyl)azetidine-1-carbo-
xylate (0.145 g, 350 .mu.mol) was dissolved in DCM (2 mL) and TFA
(320 mg, 216 .mu.L, 2.8 mmol) was added. The reaction mixture was
stirred at RT for 2 h. Volatiles were removed in vacuo to yield the
compound as a yellow oil (181 mg) that was used in the next step
without further purification. MS (ESI): m/z=314.1 [M+H].sup.+.
Step a) tert-Butyl
3-(((2-chloro-4-(trifluoromethyl)phenyl)sulfonyl)methyl)azetidine-1-carbo-
xylate
[0880] 3-Chlorobenzoperoxoic acid (352 mg, 1.57 mmol) was added in
portions to a stirred solution of tert-butyl
3-(((2-chloro-4-(trifluoromethyl)phenyl)thio)methyl)azetidine-1-carboxyla-
te (BB 101, step a) (0.300 g, 786 .mu.mol) in DCM (5 mL) in an ice
bath. The reaction mixture was stirred at RT for 15 min and poured
into 5 mL saturated aqueous NaHCO.sub.3 solution and extracted
twice with DCM (10 mL each). The organic layers were combined,
washed with brine, dried over NaSO.sub.4 and concentrated in vacuo.
The crude material was purified by flash chromatography (silica
gel, 20 g, 0% to 100% EtOAc in n-heptane) to provide the desired
product as a colorless oil (145 mg, 45%). MS (ESI): m/z=314.0
[M-56+H].sup.+.
BB105
3-(((2-Chloro-4-(trifluoromethyl)phenyl)sulfinyl)methyl)azetidine
2,2,2-trifluoroacetate
[0881] tert-Butyl
3-(((2-chloro-4-(trifluoromethyl)phenyl)sulfinyl)methyl)azetidine-1-carbo-
xylate (0.086 g, 216 .mu.mol) was dissolved in DCM (1 mL) and TFA
(197 mg, 133 .mu.L, 1.73 mmol) was added. The reaction mixture was
stirred at RT for 2 h. Volatiles were removed in vacuo to yield the
compound as a yellow oil (99 mg) that was used in the next step
without further purification. MS (ESI): m/z=298.1 [M+H].sup.+.
Step a) tert-Butyl
3-(((2-chloro-4-(trifluoromethyl)phenyl)sulfinyl)methyl)azetidine-1-carbo-
xylate
[0882] The sulfoxide intermediate was isolated from the synthesis
of BB104, step a. The desired product was obtained as a yellow oil
(80 mg, 25.6%). MS (ESI): m/z=398.1 [M+H].sup.+.
BB106
3-((2-Fluoro-4-(trifluoromethyl)benzyl)thio)azetidine
2,2,2-trifluoroacetate
[0883] To a solution of tert-butyl
3-((2-fluoro-4-(trifluoromethyl)benzyl)thio)azetidine-1-carboxylate
(0.282 g, 772 .mu.mol) in DCM (3 mL) was added TFA (880 mg, 595
.mu.L, 7.72 mmol) and the reaction mixture was stirred at RT for 3
h. Volatiles were removed in vacuo to yield the desired compound as
a colorless oil (302 mg) that was used in the next step without
further purification. MS (ESI): m/z=266.2 [M+H].sup.+.
Step a) tert-Butyl
3-[[2-fluoro-4-(trifluoromethyl)phenyl]methylsulfonyl]azetidine-1-carboxy-
late
[0884] To a solution of tert-butyl
3-mercaptoazetidine-1-carboxylate (0.200 g, 1.06 mmol) in dry THF
(2 mL) was added potassium tert-butoxide 1M solution in THF (1.11
mL, 1.11 mmol) and the reaction mixture was stirred at RT for 15
min followed by addition of
1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene (272 mg, 1.06
mmol, CAS RN 239087-07-1). The reaction mixture was then stirred at
RT for 14 h. The crude reaction was diluted with EtOAc and
extracted with aq. 1 M NaHCO.sub.3 solution, the organic phase was
collected and the aqueous phase was back-extracted with EtOAc. The
combined organic phases were dried over NaSO.sub.4 and evaporated
down to dryness and purified by flash chromatography (silica gel,
20 g, 0% to 80% EtOAc in n-heptane) to furnish the desired product
as a colorless oil (288 mg, 75%). MS (ESI): m/z=310.2
[M-56+H].sup.+.
[0885] In analogy to BB84, the following intermediates were
prepared from the respective commercially available starting
materials.
TABLE-US-00011 BB No. Systematic Name Starting material MS, m/z
BB107 3-[2-(2,6- 1,3-Dichloro-2-iodobenzene 226.1
Dichlorophenyl)ethynyl]azetidine [M + H].sup.+ BB108
3-[2-[2-Fluoro-4- 1-Bromo-2-fluoro-4- 244.2
(trifluoromethyl)phenyl]ethynyl]azetidine (trifluoromethyl)benzene
[M + H].sup.+ BB109 3-[2-(2,6- 1,3-Difluoro-2-iodobenzene 194.2
Difluorophenyl)ethynyl]azetidine [M + H].sup.+ BB110
3-[2-[3-Chloro-4- 4-Bromo-2-chloro-1- 260.2
(trifluoromethyl)phenyl]ethynyl]azetidine (trifluoromethyl)benzene
[M + H].sup.+ BB111 3-[2-(2-Chloro-6-fluoro- 2-Bromo-1-chloro-3-
210.1 phenyl)ethynyl]azetidine fluorobenzene [M + H].sup.+ BB112
3-[2-(2-Chloro-4-cyclopropyl- 1-Bromo-2-chloro-4- 232.2
phenyl)ethynyl]azetidine cyclopropylbenzene [M + H].sup.+ BB113
3-[2-(2- 1-Bromo-2-methoxybenzene 188.2
Methoxyphenyl)ethynyl]azetidine [M + H].sup.+ BB114
3-[2-[4-Chloro-2- 4-Chloro-1-iodo-2- 260.1
(trifluoromethyl)phenyl]ethynyl]azetidine (trifluoromethyl)benzene
[M + H].sup.+ BB115 3-[2-(3-Chlorophenyl)ethynyl]azetidine
1-Bromo-3-chlorobenzene 192.1 [M + H].sup.+ BB116 3-[2-[4-
1-bromo-4- 242.2 (Trifluoromethoxy)phenyl]ethynyl]azetidine
(Trifluoromethoxy)benzene [M + H].sup.+ BB117 3-[2-[4- 1-Bromo-4-
226.2 (Trifluoromethoxy)phenyl]ethynyl]azetidine
(trifluoromethyl)benzene [M + H].sup.+ BB118
3-[2-(3-Fluoro-2-methyl- 1-Bromo-3-fluoro-2- 190.2
phenyl)ethynyl]azetidine methylbenzene [M + H].sup.+ BB119
3-[2-(2,6- 2-Iodo-1,3-dimethylbenzene 186.2
Dimethylphenyl)ethynyl]azetidine [M + H].sup.+ BB120 3-[2-[2-
1-Bromo-2- 242.2 (Trifluoromethoxy)phenyl]ethynyl]azetidine
(trifluoromethoxy)benzene [M + H].sup.+ BB121
3-[2-(2-Bromophenyl)ethynyl]azetidine 1-Bromo-2-iodobenzene 236.1
[M + H].sup.+ BB122 3-[2-(2-Chloro-3-fluoro- 1-Bromo-2-chloro-3-
210.1 phenyl]ethynyl]azetidine fluorobenzene [M + H].sup.+ BB123
3-[2-(o-Tolyl)ethynyl]azetidine 1-Bromo-2-methylbenzene 172.2 [M +
H].sup.+ BB124 3-[2-(4-Chloro-2-fluoro- 4-Chloro-2-fluoro-1- 210.1
phenyl)ethynyl]azetidine iodobenzene [M + H].sup.+ BB125 3-[2-[2-
1-(Difluoromethoxy)-2- 224.2
(Difluorormethoxy)phenyl]ethynyl]azetidine iodobenzene [M +
H].sup.+ BB126 2-[2-(Azetidin-3-yl)ethynyl]-3-chloro- 2-Bromo-3-
217.2 benzonitrile chlorobenzonitrile [M + H].sup.+ BB127 3-[2-[4-
1-(Difluoromethoxy)-4- 224.2
(Difluorormethoxy)phenyl]ethynyl]azetidine iodobenzene [M +
H].sup.+ BB128 1-[4-[2-(Azetidin-3- 1-(4- 223.2
yl)ethynyl]phenyl]cyclopropartecarbonitrile
Bromophenyl)cyclopropane- [M + H].sup.+ 1-carbonitrile BB129
3-[2-(4-Cyclopropylphenyl)prop-1- 1-Bromo-4-cyclopropyl- 198.2
ynyl]lazetidine benzene [M + H].sup.+ BB130 1-[4-[2-(Azetidin-3-
1-(4- 214.2 yl)ethynyl]phenyl]cyclopropanol
Bromophenyl]cyclopropanol [M + H].sup.+ BB131 3[2-(3-
1-Iodo-3-methoxybenzene 188.2 Methoxyphenyl)ethynyl]azetidine [M +
H].sup.+ BB132 3-[2-[2- 1-Bromo-2- 208.2
(Difluoromethyl)phenyl]ethynyl]azetidine (difluoromethyl)benzene [M
+ H].sup.+ BB133 3-[2-[3-Methoxy-2-methyl- 1-Iodo-3-methoxy-2-
202.2 phenyl)ethynyl]azetidine methylbenzene [M + H].sup.+ BB134
3-[2-[2-Chloro-6-methyl- 1-Chloro-2-iodo-3- 206.1
phenyl)ethynyl]azetidine methylbenzene [M + H].sup.+ BB135
3-[2-(2-Chloro-5-fluoro- 2-Bromo-1-chloro-4- 210.1
phenyl)ethynyl]azetidine fluorobenzene [M + H].sup.+ BB136 3-[2-(4-
1-Bromo-4-methylsulfonyl- 236.2
Methylsulfonylphenyl)ethynyl]azetidine benzene [M + H].sup.+ BB137
3-[2-(5-Chloro-2- 2-Bromo-5-chlorothiophene 198.1
thienyl)ethynyl]azetidine [M + H].sup.+ BB138 3-[2-(5-Chloro-3-
4-Bromo-2-chlorothiophene 198.1 thienyl)ethynyl]azetidine [M +
H].sup.+ BB139 3-[2-[2-Chloro-6-fluoro-4-
2-Bromo-1-chloro-3-fluoro- 278.1
(trifluoromethyl)phenyl]ethynyl]azetidine
5-(trifluoromethyl)benzene [M + H].sup.+ BB140
3[2-(2-Chlorophenyl)ethynyl]azetidin-3-ol Chloro-2-iodobenzene
208.1 and [M + H].sup.+ tert-butyl 3-ethynyl-3- hydroxyazetidine-1-
carboxylate (CAS RN 1259034-35-9) BB141 3-[2-[2- 1-Iodo-2- 202.2
(Methoxymethyl)phenyl]ethynyl]lazetidine (methoxymethyl)benzene [M
+ H].sup.+ BB142 3-[2-[2-Chloro-4- 2-Chloro-1-iodo-4- 260.2
(trifluoromethyl)phenyl]ethynyl]azetidine (tritluoromethyl)benzene
[M + H].sup.+
[0886] In analogy to BB18, the following intermediates were
prepared from the respective commercially available starting
materials.
TABLE-US-00012 BB No. Systematic Name Starting material MS, m/z
BB143 4-[2-[2- 1-Bromo-2- 254.3
(Trifluoromethyl)phenyl]ethynyl]piperidine (trifluoromethyl)benzene
[M + H].sup.+ BB144 4-[2-(2- 1-Bromo-2-methoxybenzene 216.3
Methoxyphenyl)ethynyl]piperidine [M + H].sup.+ BB145
4-[2-(o-Tolyl)ethynyl]piperidine 1-Bromo-2-methylbenzene 200.3 [M +
H].sup.+ BB146 4-[2-(2,6- 2-Iodo-1,3-dimethytbenzene 214.3
Dimethylphenyl)ethynyl]piperidine [M + H].sup.+ BB147
4-[2-(2,4-Dichlorophenyl)ethynyl]-4- Bromo-2,4-dichlorobenzene
268.2 methyl-piperidine and tert-Butyl 4-ethynyl-4- [M + H].sup.+
methylpiperidine- 1-carboxylate (CAS RN 1363383-17-8) BB148
4-[2-(2-Chloro-4-fluoro- 2-Chloro-4-fluoro-1- 252.2
phenyl)ethynyl]-4-methyl-piperidine iodobenzene and [M + H].sup.+
tert-Butyl 4-ethynyl-4- methylpiperidine- 1-carboxylate (CAS RN
1363383-17-8)
BB149
1-[2-(Azetidin-3-yl)ethynyl]cyclopentanol hydrochloride
[0887] To a solution of tert-butyl
3-[2-(1-hydroxycyclopentyl)ethynyl]azetidine-1-carboxylate (0.02 g,
0.075 mmol) in dioxane (0.5 mL) was added 4 M HCl in dioxane (0.094
mL, 0.377 mmol) and the reaction mixture was stirred at RT for 18
h. The mixture was evaporated to dryness and the residue triturated
in diisopropyl ether, filtered off and further dried under high
vacuum to give the title compound as a white solid as the
hydrochloride salt (0.013 g, 87%). MS (ESI): m/z=166.1
[M+H].sup.+.
Step a) tert-Butyl
3-[2-(1-hydroxycyclopentyl)ethynyl]azetidine-1-carboxylate
[0888] To a solution of tert-butyl 3-ethynylazetidine-1-carboxylate
(0.2 g, 1.1 mmol) in THF (6.5 mL) at -78.degree. C. was added nBuLi
(0.759 mL, 1.21 mmol) dropwise and the reaction mixture was stirred
at this temperature for 1 h. Then, cyclopentanone (0.107 mL, 1.21
mmol) in THF (3 mL) was added dropwise to the mixture which was
stirred at -78.degree. C. for 2 h. The mixture was allowed to warm
up to 0.degree. C., poured into a sat. NH.sub.4OH aqueous solution
and extracted with EtOAc. The combined organic layers were washed
with brine, dried over Na.sub.2SO.sub.4, filtered and evaporated.
The residue was purified by silica gel flash chromatography,
eluting with a gradient of EtOAc:n-heptane (0 to 100%) to yield the
title compound as a light yellow oil (0.020 g, 7%). MS (ESI):
m/z=192.2 [M-56-18+H].sup.+.
BB150
4-[3-Pyrazol-1-yl-5-(trifluoromethyl)phenoxy]piperidine formate
[0889] A mixture of tert-butyl
4-[3-pyrazol-1-yl-5-(trifluoromethyl)phenoxy]piperidine-1-carboxylate
(400.0 mg, 0.970 mmol) and TFA (1.0 mL, 0.970 mmol) in DCM (10 mL)
was stirred at 20.degree. C. for 12 h. The mixture was purified by
prep-HPLC (ACN and water containing 0.225% v/v FA) to give the
desired product (300 mg, 94.4%) as colorless gum. MS (ESI):
m/z=312.1 [M+H].sup.+.
Step a: tert-Butyl
4-[3-bromo-5-(trifluoromethyl)phenoxy]piperidine-1-carboxylate
[0890] To a solution of 3-bromo-5-(trifluoromethyl)phenol (2.0 g,
8.3 mmol), 1-BOC-4-hydroxypiperidine (1.84 g, 9.13 mmol, CAS RN
106-52-5) and PPh.sub.3 (2.61 g, 9.96 mmol) in THF (32.6 mL) was
added diisopropyl azodicarboxylate (1.96 mL, 9.96 mmol) and the
mixture was stirred at 20.degree. C. for 15 h. The mixture was
concentrated under vacuum. The residue was purified by prep-HPLC
(ACN and water containing 0.225% v/v FA) and concentrated under
vacuum to give the desired product (2.6 g, 73.9% yield) as light
yellow oil. MS (ESI): m/z=367.9 [M-56+H].sup.+.
Step b) tert-Butyl
4-[3-pyrazol-1-yl-5-(trifluoromethyl)phenoxy]piperidine-1-carboxylate
[0891] A mixture of tert-butyl
4-[3-bromo-5-(trifluoromethyl)phenoxy]piperidine-1-carboxylate
(500.0 mg, 1.18 mmol), pyrazole (160.47 mg, 2.36 mmol), CuI (22.37
mg, 0.120 mmol), cesium carbonate (1152 mg, 3.54 mmol) and
N,N'-dimethylethylenediamine (519.15 mg, 5.89 mmol) in DMF (5 mL)
was stirred at 110.degree. C. for 12 h. The mixture was poured into
H.sub.2O water (30 mL) and extracted three times with EtOAc (50
mL). The combined organic layer was washed with ammonia (10 mL),
brine (50 mL), dried over Na.sub.2SO.sub.4 and filtered. The
filtrate was concentrated under vacuum to give the desired product
(400 mg, 82.5% yield) as light yellow oil. MS (ESI): m/z=356.2
[M-56+H].sup.+.
BB51
4-[[2-(2,2,2-Trifluoroethoxy)-4-(trifluoromethyl)phenyl]methyl]piperidine
[0892] A mixture of
4-[[2-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]methylene]piperid-
ine (250.0 mg, 0.740 mmol) and Pd/C (50.0 mg, wt. 10%) in THF (10
mL) was stirred at 20.degree. C. for 12 h under H.sub.2 (1520
mmHg). The mixture was filtered and concentrated under vacuum to
give the desired compound (240 mg, 95.4%) as light brown gum. MS
(ESI): m/z=342.1 [M+H].sup.+.
Step a) tert-Butyl
4-(p-tolylsulfonylhydrazone)piperidine-1-carboxylate
[0893] To a solution of 4-methylbenzenesulfonhydrazide (9.35 g,
50.19 mmol, CAS RN 1576-35-8) in MeOH (100 mL) was added
1-BOC-4-piperidone (10.0 g, 50.19 mmol, CAS RN 17502-28-8) and the
mixture was stirred at 25.degree. C. for 12 h. The mixture was
concentrated to give the desired product (18.4 g. 99.8%) as
off-white solid. MS (ESI): m/z=368.2 [M+H].sup.+.
Step b)
2-(2,2,2-Trifluoroethoxy)-4-(trifluoromethyl)benzaldehyde
[0894] A mixture of NaH (187.39 mg, 60% dispersion in mineral oil,
4.68 mmol) in 2,2,2-trifluoroethanol (16.67 mL, 228.74 mmol, CAS
RN75-89-8) was stirred at 0.degree. C. The cooling bath was removed
and the mixture was stirred at 20.degree. C. for 2 h, and then
2-fluoro-4-(trifluoromethyl)benzaldehyde (1.0 g, 5.21 mmol, CAS RN
763-93-9) was added and the mixture was stirred at 20.degree. C.
for 12 h. The mixture was poured into H.sub.2O (30 mL) and
extracted twice with EtOAc (30 mL each). The combined organic
layers were washed with brine (30 mL), dried over Na.sub.2SO.sub.4
and filtered. The filtrate was concentrated under vacuum to give
the desired product (1.2 g, 84.7%) as light yellow solid. .sup.1H
NMR (400 MHz, DMSO-d6) .delta. 10.44-10.34 (m, 1H), 7.93 (d, J=8.1
Hz, 1H), 7.75 (s, 1H), 7.55 (d, J=8.1 Hz, 1H), 5.11 (q, J=8.7 Hz,
2H).
Step c) tert-Butyl
4-[2-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)benzoyl]piperidine-1-carb-
oxylate
[0895] A mixture of
2-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)benzaldehyde (1000.0
mg, 3.67 mmol), tert-butyl
4-(p-tolylsulfonylhydrazone)piperidine-1-carboxylate (1350.3 mg,
3.67 mmol) and cesium carbonate (1795.9 mg, 5.51 mmol) in
1,4-dioxane (30 mL) was stirred at 110.degree. C. for 12 h under
N.sub.2 atmosphere. The mixture was poured into H.sub.2O (50 mL)
and extracted three times with EtOAc (50 mL each). The combined
organic layers were washed with brine (50 mL), dried over
Na.sub.2SO.sub.4 and filtered. The filtrate was concentrated under
vacuum and the residue was purified by prep-HPLC (MeCN and water
containing 0.225% v/v FA) to give the desired product (980 mg,
58.6%) as light yellow gum. MS (ESI): m/z=400.1 [M-56+H].sup.+.
Step d) tert-Butyl
4-[hydroxy-[2-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]methyl]pi-
peridine-1-carboxylate
[0896] To a solution of tert-butyl
4-[2-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)benzoyl]piperidine-1-carb-
oxylate (900.0 mg, 1.98 mmol) in MeOH (45 mL) was added NaBH.sub.4
(149.54 mg, 3.95 mmol) at 0.degree. C. and the mixture was stirred
at 20.degree. C. for 12 h. The mixture was purified by prep-HPLC
(MeCN and water containing 0.225% v/v FA) (650 mg, 71.9%) as light
yellow oil. MS (ESI): m/z=384.0 [M-56-OH+H].sup.+.
Step e)
4-[[2-(2,2,2-Trifluoroethoxy)-4-(trifluoromethyl)phenyl]methylene]-
piperidine
[0897] A mixture of tert-butyl
4-[hydroxy-[2-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]methyl]pi-
peridine-1-carboxylate (400.0 mg, 0.870 mmol) and MsOH (840.43 mg,
8.74 mmol) in DCM (4 mL) was stirred at 40.degree. C. for 24 h. The
mixture was poured into saturated aqueous Na.sub.2CO.sub.3 solution
(5 mL) and extracted three times with EtOAc (10 mL each). The
combined organic layers were washed with brine (10 mL), dried over
Na.sub.2SO.sub.4 and filtered. The filtrate was concentrated under
vacuum to give the desired compound as light yellow oil (260 mg,
76.2%). MS (ESI): m/z=340.1 [M+H].sup.+.
BB152
4-[3-(1,2,4-Triazol-1-yl)-5-(trifluoromethyl)phenoxyl]piperidine
trifluoroacetate
[0898] To a mixture of tert-butyl
4-[3-(1,2,4-triazol-1-yl)-5-(trifluoromethyl)phenoxypiperidine-1-carboxyl-
ate (240.0 mg, 0.580 mmol) in DCM (10 mL) was added TFA (1.0 mL).
The mixture was stirred at 20.degree. C. for 12 h and then
concentrated under vacuum to give
4-13-(1,2,4-triazol-1-yl)-5-(trifluoromethyl)phenoxy]piperidine
2,2,2-trifluoroacetic acid salt (240 mg, 96.7%) as light yellow
gum. MS (ESI): m/z=313.1 [M+H].sup.+.
Step a) tert-Butyl
4-[3-(1,2,4-triazol-1-yl)-5-(trifluoromethyl)phenoxy]piperidine-1-carboxy-
late
[0899] A mixture of tert-butyl
4-[3-bromo-5-(trifluoromethyl)phenoxy]piperidine-1-carboxylate
(500.0 mg, 1.18 mmol, BB98, intermediate a). 1,2,4-triazole (162.8
mg, 2.36 mmol) and CuI (22.37 mg, 0.120 mmol) in DMF (5 mL) was
stirred at 110.degree. C. for 12 h. The mixture was poured into
H.sub.2O (20 mL) and extracted three times with EtOAc (30 mL each).
The combined organic layers were washed with ammonia (20 mL), brine
(20 mL, three times), dried over Na.sub.2SO.sub.4 and filtered. The
filtrate was concentrated under vacuum and the residue was purified
by column chromatography (PE:EA=50:1-3:1) to give the desired
product (240 mg, 49.4%) as light yellow solid. MS (ESI): m/z=357.1
[M-56+H].sup.+.
BB153
3-[4-Chloro-3-(trifluoromethyl)phenoxy]azetidine
trifluoroacetate
[0900] To a solution of tert-butyl
3-[4-chloro-3-(trifluoromethyl)phenoxy]azetidine-1-carboxylate
(300.0 mg, 0.530 mmol) in DCM (7.5 mL) was added TFA (1.04 mL) at
0.degree. C. and the mixture was stirred at 20.degree. C. for 2 h.
The mixture was concentrated to give the title compound as yellow
oil (280 mg, 97%). MS (ESI): m/z=252.0 [M+H].sup.+.
Step a) tert-Butyl
3-[4-chloro-3-(trifluoromethyl)phenoxy]azetidine-1-carboxylate
[0901] To a solution of 2-chloro-5-hydroxybenzotrifluoride (1 g,
5.1 mmol CAS RN 6294-93-5), ten-butyl
3-hydroxyazetidine-1-carboxylate (0.97 g, 5.6 mmol CAS RN
141699-55-0) and triphenylphosphine (1.6 g, 6.11 mmol) in THF (20
mL) was added diisopropyl azodicarboxylate (1.2 mL, 6.11 mmol) and
the mixture was stirred at 20.degree. C. for 15 h. The mixture was
concentrated and purified by reversed phase chromatography (MeCN
and water containing 0.225% v/v FA) to give the title compound (820
mg, 28.7%) as brown solid. MS (ESI): m/z=295.9 [M-56+H].sup.+.
BB154
4-(4-Chloro-3-pyrazol-1-yl-phenoxy)piperidine trifluoroacetate
[0902] To a solution of tert-butyl
4-(4-chloro-3-pyrazol-1-yl-phenoxy)piperidine-1-carboxylate (260.0
mg, 0.690 mmol) in DCM (5.38 mL) was added TFA (1.34 mL, 17.46
mmol) at 0.degree. C. and the mixture was stirred at 20.degree. C.
for 1 h. The mixture was concentrated to give the title compound as
an orange oil (250 mg, 92.7 yield). MS (ESI): m/z=278.1
[M+H].sup.+.
Step a) tert-Butyl
4-(3-bromo-4-chloro-phenoxy)piperidine-1-carboxylate
[0903] To a solution of 1-BOC-4-hydroxypiperidine (2.04 g, 10.12
mmol, CAS RN 106-52-5), 3-bromo-4-chlorophenol (2.0 g, 9.64 mmol,
CAS RN 2402-82-6) and triphenylphosphine (3.03 g, 11.57 mmol) in
THF (50 mL) was added diisopropyl azodicarboxylate (2.28 mL, 11.57
mmol) and the mixture was stirred at 20.degree. C. for 15 h. Then
the mixture was concentrated and the residue was purified by
reversed flash chromatography (MeCN and water containing 0.1% v/v
FA) to give the desired product (2.8 g, 74.3%) as light yellow oil.
MS (ESI): m/z=335.9 [M-56+H].sup.+.
Step b) tert-Butyl
4-(4-chloro-3-pyrazol-1-yl-phenoxy)piperidine-1-carboxylate
[0904] To a mixture of tert-butyl
4-(3-bromo-4-chloro-phenoxy)piperidine-1-carboxylate (1.0 g, 2.56
mmol), pyrazole (139.4 mg, 2.05 mmol), cesium carbonate (2501.8 mg,
7.68 mmol) and 1,10-phenanthroline (225.49 mg, 2.56 mmol) in DMF
(20 mL) was added CuI (48.59 mg, 0.260 mmol) and the mixture was
stirred at 110.degree. C. for 12 h under N.sub.2 atmosphere. The
mixture was concentrated, diluted with H.sub.2O (20 mL) and
extracted three times with EtOAc (10 mL). The combined organic
layers were concentrated and the residue purified by reversed phase
chromatography (ACN and water containing 0.1% v/v FA) to give the
desired product (265 mg, 22.5%, 82% purity) as yellow oil. MS
(ESI): m/z=378.1 [M+H].sup.+.
BB55
4-[5-(4-Piperidyloxy)-2-(trifluoromethyl)phenyl]morpholine
trifluoroacetate
[0905] To a solution of tert-butyl
4-[3-morpholino-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate
(400.0 mg, 0.93 mmol) in DCM (3 mL) was added TFA (1.0 mL) and the
reaction mixture was stirred at 25.degree. C. for 12 h. The
reaction was concentrated in vacuum to provide the crude product
(300 mg) as yellow oil, which was used in next step without further
purification. MS (ESI): m/z=331.2 [M+H].sup.+.
Step a) tert-Butyl
4-(3-bromo-4-(trifluoromethyl)phenoxy)piperidine-1-carboxylate
[0906] To a solution of 3-bromo-4-(trifluoromethyl)phenol (500.0
mg, 2.54 mmol, CAS RN1214385-56-4) and 1-BOC-4-hydroxypiperidine
(512 mg, 2.54 mmol, CAS RN 106-52-5) in THF (8.5 mL) was added
PPh.sub.3 (1000.9 mg, 3.82 mmol) and diethyl azodicarboxylate
(664.53 mg, 3.82 mmol) and the mixture was stirred at 25.degree. C.
for 12 h. The mixture was purified by silica gel chromatography
using PE:EA=5:1 as eluant to provide the desired product (503 mg,
46.6% yield) as light yellow oil. MS (ESI): m/z=369.2
[M-56+H].sup.+.
Step b) tert-Butyl
4-(3-morpholino-4-(trifluoromethyl)phenoxy)piperidine-1-carboxylate
[0907] A mixture of tert-butyl
4-[3-bromo-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate
(500.0 mg, 1.18 mmol), morpholine (154 mg, 1.77 mmol, CAS RN
110-91-8), (R)-(+)-2,2'-bis(diphenylphosphino)-1,1'-binaphthalene
(146.77 mg, 0.24 mmol, CAS RN 76189-55-4), cesium carbonate (1.15
g, 3.54 mmol) and tris(dibenzylideneacetone)dipalladium(0) (172.47
mg, 0.240 mmol, CAS RN 76971-72-7) in DMF (10 mL) was stirred at
110.degree. C. for 12 h. The mixture was poured into H.sub.2O and
extracted three times with EtOAc. The combined organic layers were
washed with brine, dried over Na2SO4 and filtered. The filtrate was
concentrated under vacuum and the residue was purified by column
chromatography (gradient of EtOAc in PE 5% to 33%) to give the
desired product (480 mg, 94.6%) as light yellow solid. MS (ESI):
m/z=431.1 [M+H].sup.+.
BB156
4-(4-Chloro-3-(1,2,4-triazol-1-yl)phenoxy)piperidine
trifluoroacetate
[0908] To a solution of tert-butyl
4-[4-chloro-3-(1,2,4-triazol-1-yl)phenoxy]piperidine-1-carboxylate
(196.0 mg, 0.520 mmol) in DCM (5 mL) was added TFA (1.01 mL, 13.13
mmol) at 0.degree. C. and the mixture was stirred at 20.degree. C.
for 1 h. The mixture was concentrated to give the title compound
(178 mg, 87.6%) as brown oil. MS (ESI): m/z=279.1 [M+H].sup.+.
Step a) tert-Butyl
4-[4-chloro-3-(1,2,4-triazol-1-yl)phenoxy]piperidine-1-carboxylate
[0909] A mixture of tert-butyl
4-(3-bromo-4-chloro-phenoxy)piperidine-1-carboxylate (500.0 mg,
1.28 mmol. BB102, intermediate a). 1,2,4-triazole (176.8 mg, 2.56
mmol), CuI (24.3 mg, 0.130 mmol) and cesium carbonate (1250.9 mg,
3.84 mmol) and dimethyl glycine (1.0 mL, 1.28 mmol) in DMF (10 mL)
was stirred at 120.degree. C. for 12 h. The mixture was
concentrated to remove the DMF, diluted with H.sub.2O (50 mL) and
extracted three times with EtOAc (20 mL each). The combined organic
layers were evaporated and the residue purified by reverse phase
flash chromatography (ACN and water containing 0.1% v/v FA) to give
the title compound (196 mg, 37.1%) as colorless oil. MS (EST):
m/z=323.0 [M-56+H].sup.+.
BB157
4-[3-Cyclopropyl-4-(trifluoromethyl)phenoxy]piperidine
trifluoroacetate
[0910] To a mixture of tert-butyl
4-[3-cyclopropyl-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate
(360.0 mg, 0.930 mmol) in DCM (18 mL) was added TFA (1.8 mL). The
mixture was stirred at 25.degree. C. for 12 h. The mixture was
concentrated under vacuum to provide the desired compound as light
yellow gum (370 mg, 99.2%). MS (ESI): m/z=286.2 [M+H].sup.+.
Step a) tert-Butyl
4-[3-cyclopropyl-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate
[0911] A mixture of tert-butyl
4-[3-bromo-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate
(500.0 mg, 1.18 mmol, BB103, intermediate b), cyclopropylboronic
acid (151.86 mg, 1.77 mmol), Na2CO3 (374.74 mg, 3.54 mmol) and
Pd(PPh3)4 (13.6 mg, 0.010 mmol) in 1,4-dioxane (10 mL) and H2O (1
mL) was stirred at 95.degree. C. for 12 h. The mixture was poured
into H.sub.2O (50 mL) and extracted three times with EtOAc (50 mL
each). The combined organic layers were washed with brine (50 mL),
dried over Na2SO4 and filtered. The filtrate was concentrated under
vacuum and purified by column chromatography (PE:EtOAc=20:1-5:1) to
give the desired product (380 mg, 83.7%) as colorless gum. MS
(ESI): m/z=330.1 [M-56+H].sup.+.
BB358
4-[3-Pyrazol-1-yl-4-(trifluoromethyl)phenoxy]piperidine
trifluoroacetate
[0912] To a solution of tert-butyl
4-[3-pyrazol-1-yl-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate
(180.0 mg, 0.440 mmol) in DCM (5 mL) was added TFA (0.5 mL). The
mixture was stirred at 25.degree. C. for 12 h and then concentrated
under vacuum to give the desired product (180 mg, 96.7%) as light
yellow gum. MS (ESI): m/z=312.1 [M+H].sup.+.
Step a) tert-Butyl
4-[3-pyrazol-1-yl-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate
[0913] A mixture of tert-butyl
4-[3-bromo-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylate
(500.0 mg, 1.18 mmol, BB103, intermediate b), pyrazole (120.35 mg,
1.77 mmol), CuI (22.37 mg, 0.120 mmol),
N,N'-dimethylethylenediamine (519.45 mg, 5.89 mmol) and Cs2CO3
(767.99 mg, 2.36 mmol) in DMF (10 mL) was stirred at 110.degree. C.
for 12 h. The mixture was poured into H.sub.2O (30 mL) and
extracted three times with EtOAc (50 mL each). The combined organic
layers were washed with ammonia (20 mL), brine (50 mL), dried over
Na.sub.2SO.sub.4 and filtered. The filtrate was concentrated and
the crude product was purified by prep-TLC (PE:EA=5:1) to give the
desired product (190 mg, 39.2%) as colorless oil. MS (ESI):
m/z=356.1 [M-56+H].sup.+.
BB159
4-[[2,6-Difluoro-4-(trifluoromethyl)phenyl]methyl]piperidine
trifluoroacetate
[0914] To a solution of tert-butyl
4-[[2,6-difluoro-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylat-
e (70.0 mg, 0.180 mmol) in DCM (1 mL) was added TFA (0.2 mL) and
the mixture was stirred at 20.degree. C. for 1 h. The mixture was
concentrated to give the title compound (50 mg, 68.9%) as brown
oil. MS (ESI): m/z=280.1 [M+H].sup.+.
Step a)
2-(Diethoxyphosphorylmethyl)-1,3-difluoro-5-(trifluoromethyl)benze-
ne
[0915] A solution of
2-(bromomethyl)-1,3-difluoro-5-(trifluoromethyl)benzene (1.29 mL,
3.27 mmol, CAS RN 493038-91-8) in triethyl phosphite (5.44 g, 32.73
mmol) was stirred at 160.degree. C. for 5 h. The mixture was
concentrated under vacuum to provide the title compound (600 mg,
55.2%, colorless oil) which was used in the next step without
further purification.
Step b) tert-Butyl
4-[[2,6-difluoro-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxy-
late
[0916] A mixture of
2-(diethoxyphosphorylmethyl)-1,3-difluoro-5-(trifluoromethyl)benzene
(400.0 mg, 1.2 mmol) in THF (4 mL) was added to sodium hydride
(144.49 mg, 3.61 mmol) in THF (4 mL) at 0.degree. C. The mixture
was stirred at 0.degree. C. for 1 h, and then 1-BOC-4-piperidone
(479.83 mg, 2.41 mmol, CAS RN 79099-07-3) was added to the above
mixture. The mixture was stirred at 20.degree. C. for 12 h. The
mixture was poured into H2O (50 mL) and extracted three times with
EtOAc (20 mL each). The combined organic layers were washed with
brine, dried over Na2SO4, filtered and concentrated under vacuum.
The residue was purified by column chromatography (PE:EA=1:0 to
2:1) to give the title compound (100 mg, 22.0%) as colorless oil.
MS (ESI): m/z=322.0 [M-56+H].sup.+.
Step c) tert-Butyl
4-[[2,6-difluoro-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylat-
e
[0917] To a solution of tert-butyl
4-[[2,6-difluoro-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxy-
late (100.0 mg, 0.270 mmol) in MeOH (8 mL) was added Pd/C (10.0 mg,
wt. 10%). The mixture was stirred at 20.degree. C. for 1 h under H2
atmosphere, then filtered and concentrated to give the title
compound as colorless oil (70 mg, 69.6%). MS (ESI):
m/z=324.1[M-56+H].sup.+.
BB160
4-[4-Chloro-3-(4-chlorophenyl)-2-fluoro-phenoxyl]piperidine
trifluoroacetate
[0918] To a mixture of tert-butyl
4-[4-chloro-3-(4-chlorophenyl)-2-fluoro-phenoxy]piperidine-1-carboxylate
(145.0 mg, 0.330 mmol) in DCM (10 mL) was added TFA (1.0 mL). The
mixture was stirred at 20.degree. C. for 5 h. The mixture was
concentrated under vacuum to give the desired product (149 mg,
99.6%) as light brown gum. MS (ESI): m/z=340.1 [M+H].sup.+.
Step a) 1-Chloro-2-(4-chlorophenyl)-3-fluoro-4-methoxy-benzene
[0919] A mixture of 4-bromochlorobenzene (1.41 g, 7.34 mmol, CAS RN
106-39-8), (6-chloro-2-fluoro-3-methoxy-phenyl) boronic acid (1.0
g, 4.89 mmol, CAS RN 867333-04-8) and K2CO3 (2.03 g, 14.68 mmol) in
1,4-dioxane (15 mL) and H2O (1.5 mL) was stirred under N2
atmosphere at 110.degree. C. for 1 h in a microwave oven. The
mixture was poured into H2O (20 mL) and extracted three times with
EtOAc (20 mL each). The combined organic layers were washed with
brine (20 mL), dried over Na2SO4 and filtered. The filtrate was
concentrated under vacuum and the residue was purified by column
chromatography using PE as eluant to give the desired product (110
mg, 8.3%) as colorless oil which was used in the next step without
further purification.
Step b) 4-chloro-3-(4-chlorophenyl)-2-fluoro-phenol
[0920] To a mixture of
1-chloro-2-(4-chlorophenyl)-3-fluoro-4-methoxy-benzene (215.0 mg,
0.790 mmol) in DCM (7 mL) was added a solution of BBr3 (993.36 mg,
3.97 mmol) in DCM (7 mL) drop wise at -78.degree. C. The mixture
was stirred at 20.degree. C. for 12 h. The reaction was quenched by
adding MeOH (1 mL) followed by water (10 mL), and the mixture was
extracted three times with DCM (10 mL each). The combined organic
layers were washed with brine (10 mL), dried over Na2SO4 and
filtered. The filtrate was concentrated under vacuum to give the
desired product (120 mg, 57.5%) as light brown solid which was used
in the next step without further purification.
Step c) tert-Butyl
4-[4-cloro-3-(4-chlorophenyl)-2-fluoro-phenoxy]piperidine-1-carboxylate
[0921] A mixture of 4-chloro-3-(4-chlorophenyl)-2-fluoro-phenol
(120.0 mg, 0.470 mmol), 1-BOC-4-hydroxypiperidine (187.88 mg, 0.930
mmol, CAS RN 106-52-5). PPh3 (244.85 mg, 0.930 mmol) and DIAD (0.18
mL, 0.930 mmol) in THF (12 mL) was stirred at 20.degree. C. for 12
h. The mixture was poured into H2O and extracted three times with
EtOAc. The combined organic layer was washed with brine, dried over
Na2SO4 and filtered. The filtrate was concentrated under vacuum and
the residue purified by column chromatography
(PE:EA=1:0.about.20:1) to give the desired product as light yellow
gum (150 mg, 73%). MS (ESI): m/z=384.0 [M-56+H].sup.+.
BB161
3-[2-Chloro-4-(Trifluoromethyl)phenoxy]azetidine
trifluoroacetate
[0922] To a solution of tert-butyl
3-[2-chloro-4-(trifluoromethyl)phenoxy]azetidine-1-carboxylate
(400.0 mg, 1.14 mmol) in DCM (10 mL) was added TFA (2.0 mL) at
20.degree. C. After stirring for 2 h the mixture was concentrated
to give the crude product (410 mg, 98.6%) as light yellow oil which
was used in the next step without further purification.
Step a) tert-Butyl
3-[2-chloro-4-(trifluoromethyl)phenoxy]azetidine-1-carboxylate
[0923] To a solution of 2-chloro-4-(trifluoromethyl)phenol (100(0.0
mg, 5.09 mmol, CAS RN 35852-58-5) and tert-butyl
3-hydroxyazetidine-1-carboxylate (1057.5 mg, 6.11 mmol, CAS RN
141699-55-0) in THF (20 mL) was added PPh3 (1999.49 mg, 7.63 mmol)
and diethyl azodicarboxylate (1329.05 mg, 7.63 mmol), the mixture
was stirred at 25.degree. C. for 12 h. The reaction mixture
solution was evaporated in vacuum, the residue was purified by
reverse-phase flash (0.1% v/v FA) to afford the desired product
(800 mg, 2.27 mmol, 44.7% yield) as light yellow oil. MS (ESI):
m/z=296.0 [M-56+H].sup.+.
BB162
3-((2-Fluoro-6-(trifluoromethyl)benzyl)oxy)azetidine
trifluoroacetate
[0924] To a solution of tert-butyl
3-[[2-fluoro-6-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxylate
(400.0 mg, 1.15 mmol) in dry DCM (10 mL) was added TFA (2.0 mL) at
25.degree. C. and the mixture was stirred at 25.degree. C. for 12
h. The solvent was stripped off and the residue was dried under
vacuum to afford the desired compound as yellow oil (300 mg, 22%).
MS (ESI): m/z=250.0 [M+H].sup.+.
Step a) tert-Butyl
3-[[2-fluoro-6-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxylate
[0925] To a solution of 2-fluoro-6-(trifluoromethyl)benzyl bromide
(1000.0 mg, 3.89 mmol, CAS RN 239087-08-2) and tert-butyl
3-hydroxyazetidine-1-carboxylate (673.92 mg, 3.89 mmol, CAS RN
141699-55-0) in dry THF (10 mL) at 25.degree. C. was added t-BuOK
(5.84 mL, 5.84 mmol; 1.0 M in dry THF) and the mixture was stirred
at 25.degree. C. for 12 h. The mixture was poured into H2O (10 mL)
and extracted three times with EA (20 mL each). The combined
organic layers were combined, dried over anhydrous Na2SO4 and
filtered. The filtrate was concentrated under reduced pressure,
purified by flash chromatography on silica gel (gradient PE:EA=10:1
to 2:8) to give the title compound as colorless oil (1100 mg,
80.9%). MS (ESI): m/z=294.0 [M-56+H].sup.+.
BB163
3-[2-(2-Fluoro-4-methyl-phenyl)ethyl]azetidine trifluoroacetate
[0926] To a solution of tert-butyl
3-[2-(2-fluoro-4-methyl-phenyl)ethyl]azetidine-1-carboxylate (350.0
mg, 1.19 mmol) in dry DCM (10 mL) at 25.degree. C., was added TFA
(1.0 mL, 1.19 mmol) and the mixture was stirred at 25.degree. C.
for 12 h. The reaction mixture was concentrated by reduced pressure
and the residue was dried in vacuum to provide the desired compound
as colorless oil (260 mg, 70.9%). MS (ESI): m/z=194.0
[M+H].sup.+.
Step a) tert-Butyl
3-(2-trimethylsilylethynyl)azetidine-1-carboxylate
[0927] To a solution of trimethylsilylacetylene (9.97 g, 101.55
mmol, CAS RN 1066-54-2) in dry THF (200 mL) at 25.degree. C. was
added i-PrMgCl (48.57 mL, 97.14 mmol; 1.0 M in dry THF) and the
mixture was stirred at 25.degree. C. for 15 mins. Then a solution
of 1-BOC-3-iodoazetidine (25.0 g, 88.3 mmol, CAS RN 254454-54-1)
was added followed by FeCl2 (0.34 g, 2.65 mmol) in dry DMF (606 mL)
and the mixture was stirred at 25.degree. C. for 12 hrs. The
mixture was poured into saturated aq. NH4Cl solution (200 mL) and
extracted three times with EtOAc (150 mL each). The organic layers
were combined, dried with anhydrous Na2SO4, filtered and the
filtrate was concentrated under reduced pressure. The residue was
purified by flash chromatography on silica gel (PE:EA=20:1 to 10:1)
to give the desired product as black oil (18 g, 80.4%). 1H NMR (400
MHz, CHLOROFORM-d) .delta.=4.11 (t, J=8.4 Hz, 2H), 3.92 (dd, J=6.5,
8.1 Hz, 2H), 3.51-3.17 (m, 1H), 1.44 (s, 10H), 0.16 (s, 9H).
Step b) tert-Butyl 3-ethynylazetidine-1-carboxylate
[0928] To a solution of tert-butyl
3-(2-trimethylsilylethynyl)azetidine-1-carboxylate (6243 mg, 24.64
mmol) in dry MeOH (40 mL) was added potassium carbonate (1700 mg,
12.32 mmol) at 25.degree. C. and the reaction mixture was stirred
at 25.degree. C. for 2 h. The mixture was filtered, the filtrate
was poured into saturated aq. NH4Cl solution (100 mL) and extracted
with EA (100 mL three times). The combined organic layers were
dried with anhydrous Na2SO4, filtered and the filtrate concentrated
under reduced pressure. The residue was purified by flash
chromatography on silica gel (PE:EA=50:1 to 15:1) to afford the
title compound as light yellow oil (4100 mg, 91.8%). 1H NMR (400
MHz, CHLOROFORM-d) .delta.=4.16-4.11 (m, 2H), 3.93 (dd, J=6.5, 8.2
Hz, 2H), 3.37-3.20 (m, 1H), 2.28 (d, J=2.4 Hz, 1H), 1.43 (s,
9H).
Step c) tert-Butyl
3-[2-(2-fluoro-4-methyl-phenyl)ethynyl]azetidine-1-carboxylate
[0929] To a solution of tert-butyl 3-ethynylazetidine-1-carboxylate
(1000.0 mg, 5.52 mmol) and 4-bromo-3-fluorotoluene (1251.58 mg,
6.62 mmol, CAS RN 452-74-4) in dry THF (20 mL) were added Pd(PPh3)4
(530.63 mg, 0.460 mmol). CuI (87.83 mg, 0.460 mmol) and TEA (4644.2
mg, 46.0 mmol) at 25.degree. C. The mixture was purged with N2 for
1 min and then stirred at 60.degree. C. under N2 atmosphere for 12
h. The mixture was poured into saturated aq. NH4Cl solution (50 mL)
and extracted three times with EtOAc (30 mL each). The combined
organic layers were dried with anhydrous Na2SO4, filtered, the
filtrate was concentrated under reduced pressure. The residue was
purified by flash chromatography on silica gel (PE:EA=20:1 to 10:1)
to provide the desired compound as colorless oil (650 mg, 40.7%).
1H NMR (400 MHz, CHLOROFORM-d) .delta.=7.33-7.28 (m, 1H), 6.94-6.85
(m, 2H), 4.26-4.19 (m, 2H), 4.05 (dd, J=6.4, 8.1 Hz, 2H), 3.66-3.49
(m. 1H). 2.36 (s, 3H), 1.46 (s, 9H).
Step d) tert-Butyl
3-[2-(2-fluoro-4-methyl-phenyl)ethyl]azetidine-1-carboxylate
[0930] Batch a: To a solution of tert-butyl
3-[2-(2-fluoro-4-methyl-phenyl)ethynyl]azetidine-1-carboxylate
(50.0 mg, 0.170 mmol, 1 eq) in EtOAc (5 mL) was added Pd/C (50.0
mg, wt. 10%) at 25.degree. C. The mixture was stirred at 40.degree.
C. under a balloon of hydrogen gas for 12 h. LCMS analysis found
79.8% of desired product.
[0931] Batch b: To a solution of tert-butyl
3-[2-(2-fluoro-4-methyl-phenyl)ethynyl]azetidine-1-carboxylate
(500.0 mg, 1.73 mmol) in EtOAc (10 mL) was added Pd/C (250.0 mg,
wt. 10%) at 25.degree. C. and the mixture was stirred at 40.degree.
C. under a balloon of hydrogen gas for 6 h. LCMS found 80.4% of
desired product. Batch a and b were combined, the reaction mixture
was filtered through a pad of celite, the filtrate was concentrated
under reduced pressure and the residue was dried in vacuum to give
the compound as colorless oil (350 mg, 69.0%). MS (ESI): m/z=238.1
[M-56+H].sup.+.
BB164
3-[2-[4-Methoxy-2-(trifluoromethyl)phenyl]ethyl]azetidine
trifluoroacetate
[0932] To a solution of tert-butyl
3-[2-(2-fluoro-4-methyl-phenyl)ethyl]azetidine-1-carboxylate (180.0
mg, 0.5 mmol) in dry DCM (10 mL) was added TFA (1.0 mL, 1.19 mmol)
at 25.degree. C. and the mixture was stirred at 25.degree. C. for
12 h. The reaction mixture was concentrated under reduced pressure
and the residue was dried in vacuum to give the title compound (150
mg, 80.2%) as colorless oil. MS (ESI): m/z=260.1 [M+H].sup.+.
Step a) tert-Butyl
3-[2-[4-methoxy-2-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate
[0933] To a solution of tert-butyl 3-ethynylazetidine-1-carboxylate
(800.0 mg, 4.41 mmol, BB111, intermediate b) and
3-trifluoromethyl-4-bromoanisole (1350.9 mg, 5.3 mmol, CAS RN
400-72-6) in dry THF (30 mL) at 25.degree. C., was added
Pd(PPh.sub.3).sub.4 (509.41 mg, 0.440 mmol), CuI (84.31 mg, 0.440
mmol) and TEA (4458.42 mg, 44.14 mmol). The mixture was purged with
N.sub.2 for 1 min and then stirred at 60.degree. C. under N.sub.2
atmosphere for 12 h. The mixture was poured into saturated aq.
NH.sub.4Cl solution (100 mL) and extracted three times with EtOAc
(50 mL each). The organic layers were combined, dried with
anhydrous Na.sub.2SO.sub.4, filtered, the filtrate was concentrated
with reduced pressure. The residue was purified by flash
chromatography on silica gel (PE:EA=20:1 to 10:1) to provide the
product as colorless oil (160 mg, 8.2%). MS (ESI): m/z=300.1
[M-56+H].sup.+.
Step b) tert-Butyl
3-[2-[4-methoxy-2-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate
[0934] To a solution of tert-butyl
3-[2-(2-fluoro-4-methyl-phenyl)ethynyl]azetidine-1-carboxylate
(230.0 mg, 0.65 mmol) in EtOAc (10 mL) at 25.degree. C., was added
Pd/C (150.0 mg, wt. 10%), the mixture was stirred at 40.degree. C.
under a balloon of H.sub.2 (about 15 psi) for 12 h. The reaction
mixture was filtered through a pad of celite and the filtrate was
concentrated under reduced pressure. The residue was dried under
vacuum to furnish the desired compound as colorless oil (180 mg,
77.4%). MS (ESI): m/z=304.1 [M-56+H].sup.+.
BB165
3-[[4-Methyl-2-(trifluoromethyl)phenyl]methoxy]azetidine
trifluoroacetate
[0935] To a solution of tert-butyl
3-[[4-methyl-2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxylate
(130.0 mg, 0.380 mmol) in DCM (6.5 mL) was added TFA (1.3 mL, 16.87
mmol) and the reaction was stirred at 20.degree. C. After 12 h the
mixture was evaporated to give the desired crude product as light
brown oil (130 mg, 96.1%). MS (ESI): m/z=246.5 [M+H].sup.+.
Step a) 4-Bromo-1-(Bromomethyl)-2-(trifluoromethyl)benzene
[0936] The solution of 5-bromo-2-methylbenzotrifluoride (2000 mg,
8.37 mmol, CAS RN 86845-27-4), N-bromosuccinimide (1489 mg, 8.37
mmol, CAS RN 128-08-5) and benzoyl peroxide (101.34 mg, 0.420 mmol,
CAS RN 2685-64-5) in carbon tetrachloride (30 mL) was stirred at
90.degree. C. for 12 h. The mixture was evaporated and the residue
was purified by silica gel column chromatography (100% PE) to give
the desired product as light brown oil (690 mg, 25.9%) which was
used in the next step without further purification.
Step b) tert-Butyl
3-[[4-bromo-2-(Trifluoromethyl)phenyl]methoxy]azetidine-1-carboxylate
[0937] To a solution of tert-butyl 3-hydroxyazetidine-1-carboxylate
(337.5 mg, 1.95 mmol, CAS RN 22214-30-8) in THF (9 mL) was added
t-BuOK (1.95 mL, 1.95 mmol), then
4-bromo-1-(bromomethyl)-2-(trifluoromethyl) benzene (590.0 mg, 1.86
mmol) was added and the mixture was stirred at 20.degree. C. for 12
h. The mixture was poured into aq. NH.sub.4Cl solution (200 mL) and
extracted three times with EtOAc (50 mL). The combined organic
layers were washed with brine, dried over Na.sub.2SO.sub.4 and
concentrated. The residue was purified by prep-HPLC (ACN and water
containing 0.225% v/v FA) to give the desired product as light
brown oil (300 mg, 39.4%). MS (ESI): m/z=356.3 [M-56+H].sup.+.
Step c) tert-Butyl
3-[[4-Methyl-2-(rifluoromethyl)phenyl]methoxy]azetidine-1-carboxylate
[0938] To a solution of tert-butyl
3-[[4-bromo-2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxylate
(250.0 mg, 0.610 mmol), trimethylboroxine (114.8 mg, 0.910 mmol).
K.sub.2CO.sub.3 (168.5 mg, 1.22 mmol) in 1,4-dioxane (10 mL) and
H2O (2.5 mL) was added Pd(dppf)Cl.sub.2 (89.18 mg, 0.120 mmol). The
reaction was stirred at 100.degree. C. for 12 h. The mixture was
filtered, concentrated, and the residue was purified by reversed
flash chromatography (ACN and water containing 0.1% v/v FA) to give
the desired product as light brown oil (146 mg, 69.4%). MS (ESI):
m/z=290.4 [M-56+H].sup.+.
BB166
3-[2-[2-Methoxy-6-(trifluoromethyl)phenyl]ethyl]azetidine
trifluoroacetate
[0939] To a solution of tert-butyl
3-[2-[2-methoxy-6-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate
(300.0 mg, 0.830 mmol) in DCM (5 mL), TFA (1.0 mL) was added and
stirred at 25.degree. C. for 1 h. The reaction mixture was
evaporated under reduced pressure to give the desired product (300
mg, 96.3%) as colorless oil. MS (ESI): m/z=260.1 [M+H].sup.+.
Step a) tert-Butyl
3-[2-[2-methoxy-6-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate
[0940] To a solution of tert-butyl 3-ethynylazetidine-1-carboxylate
(710.6 mg, 3.92 mmol, B111, intermediate b) and
2-bromo-1-methoxy-3-(trifluoromethyl)benzene (500.0 mg, 1.96 mmol)
in dry DMSO (17.5 mL) at 25.degree. C., was added
Pd(PPh.sub.3).sub.2Cl.sub.2 (137.6 mg, 0.200 mmol) and
Cs.sub.2C.sub.3 (1278 mg, 3.92 mmol). The mixture was purged with
N.sub.2 for 1 min and then stirred at 110.degree. C. under N.sub.2
atmosphere for 12 h. The mixture was filtered, the filtrate was
concentrated and the residue was purified by silica gel
(PE:EtOAc=20:1) to give the desired product as light yellow oil
(600 mg, 86.1%) that was used in the next step without further
purification.
Step b) tert-Butyl 3-[2-[2-methoxy-6-(trifluoromethyl)
phenyl]ethynyl]azetidine-1-carboxylate
[0941] To a solution of tert-butyl
3-[2-[2-methoxy-6-(trifluoromethyl)phenyl]ethynyl]azetidine-1-carboxylate
(400.0 mg, 1.13 mmol) in EtOAc (20 mL), wet Pd/C (50 mg, 10 wt. %)
was added. The mixture was purged with H.sub.2 3 times and then
stirred at 40.degree. C. under H.sub.2 atmosphere (balloon) for 12
h. The mixture was filtered and the filtrate was concentrated to
give the desired product as light yellow oil (300 mg, 74.2% yield)
which was used in the next step without further purification.
BB167
3-[2-[4-Methyl-2-(trifluoromethyl)phenyl]ethyl]azetidine
trifluoroacetate
[0942] To a solution of tert-butyl
3-[2-[4-methyl-2-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate
(100.0 mg, 0.290 mmol) in DCM (4 mL) was added TFA (0.5 mL) and the
mixture was stirred at 20.degree. C. for 12 h. The reaction mixture
was evaporated under reduced pressure to give the desired product
as yellow oil (98 mg, 94.2%). MS (ESI): m/z=244.1 [M+H].sup.+.
Step a) tert-Butyl
3-[2-[4-methyl-2-(trifluoromethyl)phenyl]ethynyl]azetidine-1-carboxylate
[0943] To a solution of tert-butyl 3-ethynylazetidine-1-carboxylate
(606.6 mg, 3.35 mmol) and 2-bromo-5-methylbenzotrifluoride (400.0
mg, 1.67 mmol) in dry DMSO (14.9 mL) at 25.degree. C., was added
Pd(PPh.sub.3).sub.2Cl.sub.2 (117.46 mg, 0.170 mmol) and
Cs.sub.2CO.sub.3 (1091 mg, 3.35 mmol). The mixture was purged with
N.sub.2 for 1 min and then stirred at 110.degree. C. under N.sub.2
atmosphere for 12 h. The reaction mixture was poured into H.sub.2O
and extracted with EtOAc. The organic layer was evaporated and the
residue was purified by silica gel column chromatography
(PE:EtOAc=20:1) to give the desired compound as a yellow oil (390
mg, 68.7% yield). MS (ESI): m/z=284.1 [M-56+H].sup.+.
Step b) tert-Butyl
3-[2-[4-methyl-2-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate
[0944] To a solution of tert-butyl
3-[2-[4-methyl-2-(trifluoromethyl)phenyl]ethynyl]azetidine-1-carboxylate
(390.0 mg, 1.15 mmol) in EtOAc (19.5 mL), wet Pd/C (150 mg, 10 wt.
%) was added, the mixture was purged 3 times with H.sub.2 and
stirred at 40.degree. C. under H.sub.2 atmosphere (balloon) for 12
h. The mixture was filtered and the filtrate was concentrated to
give the desired product as light yellow oil (295 mg, 72.9% yield).
MS (ESI): m/z=288.1 [M-56+H].sup.+.
BB68
1-[2-[2-(Azetidin-3-yl)ethyl]-5-(trifluoromethyl)phenyl]ethanone
trifluoroacetate
[0945] To a solution of tert-butyl
3-[2-[2-acetyl-4-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate
(50.0 mg, 0.130 mmol) in DCM (1 mL) was added TFA (0.2 mL) and the
solution was stirred at 20.degree. C. for 12 h. The mixture was
concentrated to give the desired product as light brown oil (50 mg,
96.4% yield). MS (ESI): m/z=272.1 [M+H].sup.+.
Step a) 2-Bromo-1-(bromomethyl)-4-(trifluoromethyl)benzene
[0946] To a solution of [2-bromo-4-(trifluoromethyl)phenyl]methanol
(500.0 mg, 1.96 mmol, CAS RN 497959-33-8) and PPh3 (770.5 mg, 2.94
mmol) in THF (10 mL) was added carbon tetrabromide (975.3 mg, 2.94
mmol), and the mixture was stirred at 25.degree. C. for 12 h. The
reaction was concentrated in vacuum and the residue was purified by
silica gel column chromatography (PE:EA=0:1-20:1) to yield the
desired product as colorless oil (600 mg, 96.3% yield). .sup.1H NMR
(400 MHz, CHLOROFORM-d) .delta.=7.78 (s, 1H), 7.55-7.46 (m, 2H).
4.53 (s, 2H).
Step b)
2-Bromo-1-(diethoxyphosphorylmethyl)-4-(trifluoromethyl)benzene
[0947] A solution of
2-bromo-1-(bromomethyl)-4-(trifluoromethyl)benzene (600.0 mg, 1.89
mmol) in triethyl phosphite (3136 mg, 18.87 mmol) was stirred at
160.degree. C. for 5 h. The mixture was concentrated at 100.degree.
C. under reduced pressure to remove most of the triethyl phosphite
to give the crude product (700 mg) as light yellow oil. MS (ESI):
m/z=375.2 [M+H].sup.+.
Step c) tert-Butyl
3-[(E)-2-[2-bromo-4-(trifluoromethyl)phenyl]vinyl]azetidine-1-carboxylate
[0948] A mixture of
2-bromo-1-(diethoxyphosphorylmethyl)-4-(trifluoromethyl)benzene
(600.0 mg, 1.6 mmol) in THF (10 mL) was added to another suspension
of NaH (191.9 mg, 4.8 mmol, 60% dispersion in mineral oil) in THF
(10 mL) at 0.degree. C. The mixture was stirred at 0.degree. C. for
1 h. Then tert-butyl 3-formylazetidine-1-carboxylate (296.3 mg, 1.6
mmol) was added and the mixture was stirred at 20.degree. C. for 11
h. The reaction mixture was poured into aq. NH.sub.4Cl solution
(100 mL) and extracted three times with EtOAc (50 mL each). The
combined organic layers were washed with brine (100 mL), dried over
Na.sub.2SO.sub.4, filtered and concentrated. The residue was
purified by silica gel column chromatography (PE:EtOAc=20:1) to
give the desired product as light yellow oil (450 mg, 69.3%). MS
(ESI): m/z=352.0 [M56+H].sup.+. .sup.1H NMR (400 MHz, CHLOROFORM-d)
.delta.=7.74 (d, J=0.8 Hz, 1H), 7.58-7.51 (m, 1H), 7.49-7.41 (m,
1H), 6.71 (d, J=15.8 Hz, 1H), 6.36 (dd, J=8.4, 15.8 Hz, 1H), 4.13
(t, J=8.5 Hz, 2H), 3.78 (dd, J=5.8, 8.6 Hz, 2H), 3.44-3.31 (m, 1H),
1.39 (s, 9H).
Step d) tert-Butyl
3-[(E)-2-[2-acetyl-4-(trifluoromethyl)phenyl]vinyl]azetidine-1-carboxylat-
e
[0949] A solution of tributyl(1-ethoxyvinyl)tin (426.7 mg, 1.18
mmol), tert-butyl
3-[(E)-2-[2-bromo-4-(trifluoromethyl)phenyl]vinyl]azetidine-1-carboxylate
(400.0 mg, 0.980 mmol) and Pd(Ph.sub.3P).sub.2Cl.sub.2 (138.2 mg,
0.200 mmol) in THF (16 mL) was stirred at 80.degree. C. under
N.sub.2 atmosphere for 4 h. The mixture was cooled down to room
temperature and aq. KF solution (10 mL) was added. The mixture was
stirred for 10 mins. extracted three times with EtOAc (20 mL each)
and the combined organic layers were concentrated. The residue was
dissolved in THF (20 mL) and aq. HCl (0.6 N, 20 mL) was added. The
mixture was stirred at 20.degree. C. for 0.5 h, extracted three
times with EtOAc (20 mL each) and the combined organic layers were
concentrated. The residue was purified by silica gel column
chromatography (PE:EtOAc=20:1) to give the desired product (280 mg,
77% yield) as light yellow oil. MS (ESI): m/z=314.1
[M-56+H].sup.+.
Step e) tert-Butyl
3-[2-[2-acetyl-4-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate
[0950] To a solution of tert-butyl
3-[(E)-2-[2-acetyl-4-(trifluoromethyl)phenyl]vinyl]azetidine-1-carboxylat-
e (50.0 mg, 0.140 mmol) in EtOAc (5 mL) was added wet Pd/C (20.0
mg, 10 wt. %) and the mixture was stirred at 20.degree. C. under
H.sub.2 (balloon) atmosphere for 12 h. The reaction was then warmed
up to 50.degree. C. and stirred for another 12 h. The mixture was
filtered and the filtrate was concentrated to give the desired
product (50 mg, 99.5%) as light yellow oil. MS (ESI): m/z=316.2
[M-56+H].sup.+.
BB169
3-[2-[2-Bromo-4-(trifluoromethyl)phenyl]ethyl]azetidine
trifluoroacetate
[0951] To a solution of tert-butyl
3-[2-[2-bromo-4-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate
(400.0 mg, 0.980 mmol) in DCM (10 mL) was added TFA (1.0 mL) and
the mixture was stirred at 20.degree. C. for 12 h. The reaction
mixture was evaporated under reduced pressure to give the desired
product (413 mg, 99.8% yield) as yellow oil. MS (ESI): m/z=308.1
[M+H].sup.+.
Step a) tert-Butyl
3-[2-[2-bromo-4-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate
[0952] To a suspension of tert-butyl
3-[(E)-2-[2-bromo-4-(trifluoromethyl)
phenyl]vinyl]azetidine-1-carboxylate (600.0 mg, 1.48 mmol, BB116,
intermediate c) and MgO (118.1 mg, 2.95 mmol) in EtOAc (20 mL) was
added Pd/C (300.0 mg, 10 wt. %), the mixture was stirred at
25.degree. C. under H.sub.2 atmosphere (balloon) for 1 h. The
reaction mixture was filtered and the filtrate was evaporated under
reduced pressure to give the desired product (500 mg, 82.9%) as
light yellow oil. MS (ESI): m/z=352.0 [M-56+H].sup.+.
BB174
2-(Azetidin-3-ylmethoxy)-5-(trifluoromethyl)pyridine
2,2,2-trifluoroacetate
[0953] Synthesis of BB174 was performed in analog) to BB57,
starting from tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate
and 2-bromo-5-(trifluoromethyl)pyridine. MS (ESI): m/z=233.1
[M+H].sup.+.
BB75
3-Methyl-5-[[rac-(3R,4R)-3-methyl-4-piperidyl]methoxy]-2-(trifluoromethyl)-
pyridine dihydrochloride
[0954] tert-Butyl
(rac-3R,4R)-3-methyl-4-(((5-methyl-6-(trifluoromethyl)pyridin-3-yl)oxy)me-
thyl)piperidine-1-carboxylate (198 mg, 510 .mu.mol) was dissolved
in DCM (2 mL) and HCl 2M in ether (1.53 mL, 3.06 mmol) was added.
The reaction mixture was stirred at RT for 8 h. The reaction
mixture was concentrated in vacuo to yield 180 mg of desired
product as white solid (98%) MS (ESI): m/z=289.3 [M+H].sup.+.
a) tert-Butyl (rac-3R,
4R)-4-(hydroxymethyl)-3-methylpiperidine-1-carboxylate
[0955] To a stirred solution of
cis-N-BOC-3-methylpiperidine-4-carboxylic acid methyl ester (2 g,
7.77 mmol) in THF (10 ml) was added lithium borohydride (5.83 mL,
11.7 mmol) at 2-5.degree. C. The reaction mixture was then heated
at reflux for 3 h and then cooled to 2-5.degree. C. Water was added
and the aqueous layer was extracted twice with EtOAc (30 mL each).
The organic layer was washed with water, NaHCO.sub.3 and brine, the
layers were separated, and the organics dried over Na.sub.2SO.sub.4
and concentrated in vacuum. Purification by flash chromatography
(gradient of EtOAc in n-heptane, 0 to 65%) provided the product as
a colorless oil (930 mg, 50%). MS (ESI): m/z=174.1
[M-56+H].sup.+.
b) tert-Butyl (rac-3R,
4R)-3-methyl-4-(((5-methyl-6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)pip-
eridine-1-carboxylate
[0956] tert-butyl
(3R,4R)-4-(hydroxymethyl)-3-methylpiperidine-1-carboxylate (239 mg,
1.04 mmol) was dissolved in DMF (4.17 mL) and NaH in mineral oil
(60%, 45.8 mg, 1.15 mmol) was added at RT. The reaction was stirred
for 20 min, then 5-bromo-3-methyl-2-(trifluoromethyl)pyridine (250
mg, 167 .mu.L, 1.04 mmol) was added and stirring continued for 12 h
at RT. The reaction was quenched with 10 mL sat. NH.sub.4Cl
solution and extracted three times with water/EtOAc. The organic
phases were combined and dried over MgSO.sub.4 and the solvent was
removed in vacuo. Flash chromatography (gradient of EtOAc in
n-heptane, 0 to 50%) yielded the product as white solid (148 mg,
49%). MS (ESI): m/z=333.2 [M-56+H].sup.+.
BB176
3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)-2-methylazetidine
2,2,2-trifluoroacetate
[0957] To a solution of tert-butyl
3-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)-2-methylazetidine-1-carboxyla-
te (0.265 g, 729 .mu.mol) in DCM (4 mL) was added TFA (832 mg, 562
.mu.L, 7.29 mmol). The resultant reaction mixture was stirred at RT
for 1 h. The reaction mixture was concentrated to give the title
compound as a colorless oil. The crude product was used without
further purification. MS (ESI): m/z=264.2 [M+H].sup.+.
Step a) [2-Fluoro-4-(trifluoromethyl)phenyl]methyl
methanesulfonate
[0958] To an ice-cold solution of
(2-fluoro-4-(trifluoromethyl)phenyl)methanol (840 mg, 4.33 mmol)
and triethylamine (1.31 g, 1.81 mL, 13 mmol) in DCM (8 mL) was
added dropwise methanesulfonyl chloride (496 mg, 337 .mu.L, 4.33
mmol) and the mixture was stirred at 0.degree. C. for 1 h. The
reaction mixture was poured on saturated aqueous NaHCO.sub.3
solution (10 mL) and DCM (20 mL) and the layers were separated. The
aqueous layer was extracted once with DCM (20 mL). The organic
layers were washed once with brine, dried over MgSO.sub.4, filtered
and evaporated to yield the desired compound as a yellow oil (1.13
g, 96%).
Step b) tert-Butyl
3-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]-2-methyl-azetidine-1-carb-
oxylate
[0959] To an ice-cold solution of tert-butyl
3-hydroxy-2-methylazetidine-1-carboxylate (250 mg, 1.34 mmol) in
DMF (3 mL) was added NaH (60% in mineral oil, 58.7 mg, 1.47 mmol)
in portions and the mixture was stirred at ice-bath temperature for
5 min followed by stirring at RT for 40 min. A solution of
2-fluoro-4-(trifluoromethyl)benzyl methanesulfonate (436 mg, 1.6
mmol) in DMF (1 mL) was added dropwise to the mixture at RT.
Stirring of the slurry was continued at RT for 16 h. The reaction
mixture was poured on saturated aqueous NH.sub.4C solution (10 mL)
and EtOAc (20 mL) and the layers were separated. The aqueous layer
was extracted once with EtOAc (50 mL). The organic layers were
washed twice with water, dried over Na.sub.2SO.sub.4, filtered, and
concentrated. The crude compound was purified by silica gel
chromatography (gradient of n-heptane:EtOAc 100:0 to 0:100) to get
tert-butyl
3-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]-2-methyl-azetidine-1-carb-
oxylate as a colorless oil (0.265 g, 54.6% yield). MS (ESI):
m/z=308.2 [M-56+H].sup.+.
BB 177
2-(Azetidin-3-ylmethoxy)-4,5-bis(trifluoromethyl)pyridine
2,2,2-trifluoroacetate
[0960] Synthesis of BB 177 was performed in analogy to BB57,
starting from tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate
and 2-chloro-4,5-bis(trifluoromethyl)pyridine. MS (ESI): m/z=301.2
[M+H].sup.+.
BB179
3-((4-Chloro-2-phenoxybenzyl)oxy)azetidine
2,2,2-trifluoroacetate
[0961] Synthesis of BB179 was done in analogy to BB39, starting
from tert-butyl 3-hydroxyazetidine-1-carboxylate and
1-(bromomethyl)-4-chloro-2-phenoxybenzene (synthesis described
below). MS (ESI): m/z=290.2 [M+H].sup.+.
1-(Bromomethyl)-4-chloro-2-phenoxybenzene
[0962] i) In a 10 mL round-bottomed flask, methyl
4-chloro-2-phenoxybenzoate (547 mg, 2.08 mmol) was diluted in
toluene (3.82 mL) and the reaction mixture was cooled in an ice
bath. Sodium bis(2-methoxyethoxy)aluminum hydride 70% in toluene
(649 mg, 637 .mu.L, 2.25 mmol) was added dropwise slowly at max.
15.degree. C. to give a light yellow solution. The reaction mixture
was stirred at r.t. for 30 min. The crude reaction mixture,
containing the product (4-chloro-2-phenoxyphenyl)methanol was used
directly in the next step.
[0963] ii) In a 25 mL round-bottomed flask, hydrobromic acid 48% in
H.sub.2O (6.49 g, 4.35 mL, 38.5 mmol) was cooled in an ice bath.
Then 4-chloro-2-phenoxyphenyl)methanol (crude, 488 mg, 2.08 mmol)
was added dropwise slowly and the mixture was stirred at 50.degree.
C. for 2 h. Hydrobromic acid 48% in H.sub.2O (6.25 g, 2.18 mL,
19.25 mmol) was added and the mixture was stirred at 60.degree. C.
for 1 h, then cooled to RT. The aqueous phase was separated, the
organic phase was washed four times with H.sub.2O and evaporated.
The crude material was purified by flash column chromatography
(gradient 0% to 25% EtOAc in hexanes) and was used in the next step
without further purification. Yield: 85%.
BB 181
3-((1-(2,4-Dichlorophenyl)cyclopropyl)methoxy)azetidine
2,2,2-trifluoroacetate
[0964] To a solution of tert-Butyl
3-((1-(2,4-dichlorophenyl)cyclopropyl)methoxy)azetidine-1-carboxylate
(165 mg, 443 .mu.mol) in DCM (2 mL) was added TFA (202 mg, 137
.mu.L, 1.77 mmol) and the reaction stirred at RT for 8 h. The
mixture was concentrated in vacuo (azeotrop with toluene, EtOAc and
n-heptane) to provide the compound as a colorless oil (170 mg,
99%). MS (ESI): m/z=272.2 [M+H].sup.+.
Step a) 1-(2,4-Dichlorophenyl)cyclopropyl)methanol
[0965] In a 50 mL three-necked flask,
1-(2,4-dichlorophenyl)cyclopropane-1-carboxylic acid (1 g, 4.33
mmol) was combined with THF (20 mL) to give a colorless solution.
At 0.degree. C., borane tetrahydrofuran complex solution 1.0 M in
THF (6.49 mL, 6.49 mmol) was added dropwise over a period of 15
min. The reaction was stirred at RT for 2 h. MeOH (2 mL) was added
dropwise followed by 1M aq. HCl solution and stirred for 30 min.
The reaction mixture was extracted twice with EtOAc (40 mL each)
and the organic layers were washed with 10% aq Na.sub.2CO.sub.3
solution (40 mL) followed by brine (40 mL). The organic fractions
were combined and dried over Na.sub.2SO.sub.4 and concentrated in
vacuo. The crude material was purified by flash column
chromatography (gradient EtOAc in n-heptane, 0% to 30%) to yield
the compound as colorless oil (90%) MS (ESI): m/z=201.0
[M-16+H].sup.+.
Step b) 1-(2,4-Dichlorophenyl)cyclopropyl]methyl
methanesulfonate
[0966] To an ice-cold solution of
(1-(2,4-dichlorophenyl)cyclopropyl)methanol (350 mg, 1.61 mmol) and
TEA (326 mg, 449 .mu.L, 3.22 mmol) in DCM (6 mL) was added dropwise
methanesulfonyl chloride (185 mg, 126 .mu.L, 1.61 mmol) and the
mixture was stirred at 0.degree. C. for 1 h, then at RT overnight.
The reaction mixture was poured on saturated aqueous NaHCO.sub.3
solution (10 mL) and DCM (10 mL) and the layers were separated. The
aqueous layer was extracted once with DCM (10 mL). The organic
layers were washed with brine, dried over MgSO.sub.4, filtered and
evaporated to furnish the desired intermediate mesylate compound as
a yellow oil (435 mg, 91%). MS (ESI): m/z=201.0
[M-mesyl+H].sup.+.
Step c) tert-Butyl
3-((1-(2,4-dichlorophenyl)cyclopropyl)methoxy)azetidine-1-carboxylate
[0967] To an ice-cold solution of tert-butyl
3-hydroxyazetidine-1-carboxylate (220 mg, 1.27 mmol) in DMF (4 mL)
was added sodium hydride in mineral oil (60%, 61 mg, 1.52 mmol) in
portions and the mixture was stirred at ice-bath temperature for 5
min followed by stirring at RT for 40 min. A solution of
1-(2,4-dichlorophenyl)cyclopropyl)methyl methanesulfonate (431 mg,
1.46 mmol) was dissolved in DMF (1 mL) and added dropwise to the
mixture at RT. Stirring of the slurry was continued at RT for 16 h,
then at 55.degree. C. for 2.5 h. The reaction mixture was poured on
saturated aqueous NH.sub.4Cl solution (10 mL) and EtOAc (20 mL) and
the layers were separated. The aqueous layer was extracted once
with EtOAc (50 mL). The organic layers were washed twice with
water, dried over MgSO.sub.4, filtered and evaporated. Flash
Chromatography (gradient of EtOAc in n-heptane 0 to 40%) yielded
the product as colorless oil (165 mg, 35%) MS (ESI): m/z=316.2
[M-56+H].sup.+.
BB182
2-((Azetidin-3-yloxy)methyl)-6-(4-fluorophenoxy)-4-(trifluoromethyl)pyridi-
ne 4-methylbenzenesulfonate
[0968] Tert-butyl
3-((6-(4-fluorophenoxy)-4-(trifluoromethyl)pyridin-2-yl)methoxy)azetidine-
-1-carboxylate (150 mg, 339 .mu.mol) was dissolved under argon in
EtOAc (2 mL), p-toluenesulfonic acid monohydrate (77.4 mg, 407
.mu.mol) was added and the mixture was stirred at RT for 5 min,
then for 80.degree. C. 3 h at and at RT over night. The reaction
mixture was evaporated to provide the compound as 180 mg of a
yellow oil which was used in the next step without further
purification. MS (ESI): m/z=343.2 [M+H].sup.+.
Step a) tert-Butyl
3-((6-bromo-4-(trifluoromethyl)pyridin-2-yl)methoxy)azetidine-1-carboxyla-
te
[0969] To a solution of tert-butyl 3-hydroxyazetidine-1-carboxylate
(272 mg, 1.57 mmol) in dry THF (8 mL) was added potassium
tert-butoxide IM in THF (1.57 mL, 1.57 mmol) and the turbid
reaction mixture was stirred at RT for 30 min.
2-Bromo-6-(bromomethyl)-4-(trifluoromethyl)pyridine (500 mg, 1.57
mmol) was added at 0-2.degree. C. and the reaction stirred at
0-2.degree. C. for 20 min. The reaction mixture was then stirred at
RT for 16 h. The reaction mixture was diluted with EtOAc, extracted
with water, the organic phase was collected and the aqueous phase
was back-extracted with EtOAc. The combined organic layers were
dried over sodium sulfate and evaporated down to dryness. The crude
material was purified by flash column chromatography (gradient of
EtOAc in n-heptane, 0% to 40%) to provide the product as light
yellow oil (41%) MS (ESI): m/z=355.1 [M-56+H].sup.+.
Step b) tert-Butyl
3-[[6-(4-fluorophenoxy)-4-(trifluoromethyl)-2-pyridyl]methoxy]azetidine-1-
-carboxylate
[0970] tert-Butyl
3-((6-bromo-4-(trifluoromethyl)pyridin-2-yl)methoxy)azetidine-1-carboxyla-
te (260 mg, 632 .mu.mol) and 4-fluorophenol (70.9 mg, 632 .mu.mol)
were dissolved in DMF (2 mL), then K.sub.2CO.sub.3 (131 mg, 948
.mu.mol) was added and the mixture was stirred at 80.degree. for 30
h. The reaction mixture was evaporated under vacuum and the residue
was dissolved in EtOAc and extracted with water and brine. The
organic layers were dried over MgSO.sub.4, filtered and the solvent
was removed under vacuum. The residue was purified by flash
chromatography (gradient of EtOAc in n-heptane, 0 to 30%) to yield
the product as a light yellow oil (93%). MS (ESI): m/z=443.4
[M+H].sup.+.
BB183
6-((Azetidin-3-yloxy)methyl)-2-(4-fluorophenoxy)-3-(trifluoromethyl)pyridi-
ne 4-methylbenzenesulfonate
[0971] tert-Butyl
3-((6-(4-fluorophenoxy)-5-(trifluoromethyl)pyridin-2-yl)methoxy)azetidine-
-1-carboxylate (170 mg, 384 .mu.mol) was dissolved under argon
atmosphere in EtOAc (2.27 mL) and p-toluenesulfonic acid
monohydrate (87.7 mg, 461 .mu.mol) was added. The reaction was
stirred at RT for 5 min, then at 80.degree. C. for 3 h and stirred
at RT over night. The reaction mixture was evaporated under reduced
pressure to dryness to provide the desired product as light yellow
oil (89%) MS (ESI): m/z=343.2 [M+H].sup.+.
Step a) Methyl
6-(4-fluorophenoxy)-5-(trifluoromethyl)picolinate
[0972] Methyl 6-chloro-5-(trifluoromethyl)picolinate (800 mg, 3.34
mmol), 4-fluorophenol (412 mg, 3.67 mmol) and K.sub.2CO.sub.3 (692
mg, 5.01 mmol) were dissolved in DMF (6 mL) and stirred at
80.degree. C. for 6 h. The reaction mixture was cooled to RT and
extracted three times with water (20 mL each), twice with EtOAc (30
mL each), brine (20 mL), dried over MgSO.sub.4, filtered and
evaporated in vacuo. The crude residue was purified by flash column
chromatography (gradient of EtOAc in n-heptane, 0 to 50%) to
provide the product as white solid (67%). MS (ESI): m/z=316.1
[M+H].sup.+.
Step b)
(6-(4-Fluorophenoxy)-5-(trifluoromethyl)pyridin-2-yl)methanol
[0973] To a stirred solution of methyl
6-(4-fluorophenoxy)-5-(trifluoromethyl)picolinate (705 mg, 2.24
mmol) in THF (8 mL) was added lithium borohydride 2M in THF (1.34
mL, 2.68 mmol) at 2-5.degree. C. The reaction mixture was stirred
at RT for 3 h and then cooled to 2-4.degree. C. and quenched with
10 mL water (slowly added). The aqueous layer was extracted twice
with EtOAc (30 mL each) and the combined organic layers were washed
with water, 10 mL NaHCO.sub.3 solution and 10 mL brine. The organic
layer was dried over Na.sub.2SO.sub.4 and concentrated in vacuum.
Purification by flash column chromatography (gradient of EtOAc in
n-heptane, 0 to 50%) yielded the product as a colorless solid
(95%). MS (ESI): m/z=288.2 [M+H].sup.+.
Step c)
6-(Bromomethyl)-2-(4-fluorophenoxy)-3-(trifluoromethyl)pyridine
[0974] To a solution of
(6-(4-fluorophenoxy)-5-(trifluoromethyl)pyridin-2-yl)methanol (330
mg, 1.15 mmol) in dry DCM (5 mL) was added tetrabromomethane (457
mg, 1.38 mmol). The mixture was cooled to 0-3.degree. C. and over
10 min triphenylphosphine (392 mg, 1.49 mmol) in 1 mL dry DCM was
added. The mixture was stirred 1 hr at 2-4.degree. C., then 20 mL
DCM and silica gel was added. The solvent was removed in vacuo and
the residue subjected to column flash chromatography (gradient of
EtOAC in n-heptane. 0 to 40%) to yield the desired product as a
colorless oil (94%). MS (ESI): m/z=350.0 [M+H]+.
Step d) tert-Butyl
3-((6-(4-fluorophenoxy)-5-(trifluoromethyl)pyridin-2-yl)methoxy)azetidine-
-1-carboxylate
[0975] To a solution of tert-butyl 3-hydroxyazetidine-1-carboxylate
(183 mg, 1.06 mmol) in dry THF (5 mL) was added potassium
tert-butoxide 1M in THF (1.11 mL, 1.11 mmol) and the reaction
mixture was stirred at RT for 15 min. Then,
6-(bromomethyl)-2-(4-fluorophenoxy)-3-(trifluoromethyl)pyridine
(370 mg, 1.06 mmol) was added. The reaction mixture was stirred at
RT for 1 h and then diluted with EtOAc and extracted with 1M aq.
NaHCO.sub.3 solution. The organic phase was collected and the
aqueous phase was back-extracted with EtOAc. The combined organic
phases were dried over sodium sulfate and evaporated down to
dryness. The residue was purified by column flash chromatography
(gradient of EtOAc in n-heptane, 0 to 30%) to furnish the product
as a colorless oil (34%). MS (ESI): m/z=387.2 [M-56+H].sup.+.
BB184
2-((Azetidin-3-yloxy)methyl)-4-(4-fluorophenyl)thiazole
2,2,2-trifluoroacetate
[0976] To a solution of tert-butyl
3-((4-(4-fluorophenyl)thiazol-2-yl)methoxy)azetidine-1-carboxylate
(150 mg, 412 .mu.mol) in dry DCM (1.5 mL) under argon atmosphere
was added TFA (282 mg, 190 .mu.L, 2.47 mmol) and the solution was
stirred at RT for 8 h. The reaction mixture was concentrated in
vacuo (azeotrop with toluene, EtOAc and heptane) to yield the
desired product as a yellow solid (98%). MS (ESI): m/z=265.2
[M+H].sup.+.
Step a) (4-(4-Fluorophenyl)thiazol-2-yl)methanol
[0977] To a stirred solution of ethyl
4-(4-fluorophenyl)thiazole-2-carboxylate (835 mg, 3.32 mmol) in dry
THF (10 mL) was added lithium borohydride 2M in THF (1.99 mL, 3.99
mmol) at 2-5.degree. C. The reaction mixture was stirred at RT for
3 h, then cooled to 2-4.degree. C. and quenched with water (10 mL
slowly added). The aqueous layer was extracted twice with EtOAc (30
mL each) and the organic layers were washed with water, 10 mL
NaHCO.sub.3 solution and 10 mL brine. The combined organic layers
were dried over Na.sub.2SO.sub.4 and concentrated in vacuum. The
residue was purified by column flash chromatography (gradient of
EtOAc in n-heptane, 0 to 60%) to yield the desired product as a
white solid (94%) MS (ESI): m/z=210.1 [M+H].sup.+.
Step b) 2-(Bromomethyl)-4-(4-fluorophenyl)thiazole
[0978] To a solution of (4-(4-fluorophenyl)thiazol-2-yl)methanol
(400 mg, 1.91 mmol) in dry DCM (7 mL) was added tetrabromomethane
(761 mg, 2.29 mmol), the solution was cooled to 0-3.degree. C. and
triphenylphosphine (652 mg, 2.49 mmol) in 1 mL dry DCM was added
over 10 min. The mixture was stirred at 2-4.degree. C. for 1 h,
then 20 mL DCM were added. The reaction mixture was extracted with
water, saturated NH.sub.4Cl solution and brine. The organic phase
was dryed over MgSO.sub.4, filtered and evaporated. The residue was
purified by flash chromatography (gradient of EtOAc in n-heptane, 0
to 40%) to provide 480 mg of the title compound as a light yellow
oil (83%). MS (ESI): m/z=273.9 [M+H].sup.+.
Step c) tert-Butyl
3-((4-(4-fluorophenyl)thiazol-2-yl)methoxy)azetidine-1-carboxylate
[0979] To a solution of tert-butyl 3-hydroxyazetidine-1-carboxylate
(293 mg, 1.69 mmol) in dry THF (6 mL) was added potassium
tert-butoxide IM in THF (1.77 mL, 1.77 mmol) and the reaction
mixture was stirred at RT for 15 min. After cooling down to
2-4.degree. C. 2-(bromomethyl)-4-(4-fluorophenyl)thiazole (460 mg,
1.69 mmol) in 1 mL THF was added. The reaction mixture was stirred
at RT for 1 h, diluted with EtOAc and extracted with 1M aq.
NaHCO.sub.3 solution. The organic phase was collected and the
aqueous phase was back-extracted with EtOAc. The combined organic
phases were dried over Na.sub.2SO.sub.4 and evaporated down to
dryness. The residue was purified by column flash chromatography
(gradient of EtOAc in n-heptane, 0 to 40%) to furnish the desired
product as a light yellow solid (89%/). MS (ESI): m/z=365.2
[M+H].sup.+.
BB186
rac-(2R,3S)-3-(2-Bromo-5-(trifluoromethyl)phenoxy)-2-methylpyrrolidine
2,2,2-trifluoroacetate
[0980] To a solution of rac-tert-butyl
(2R,3S)-3-(2-bromo-5-(trifluoromethyl)phenoxy)-2-methylpyrrolidine-1-carb-
oxylate (225 mg, 530 .mu.mol) in dry DCM (2 mL) under argon
atmosphere was added TFA (242 mg, 163 .mu.L, 2.12 mmol) and the
solution was stirred at RT over night. The reaction mixture was
concentrated in vacuo to dryness (azeotrop with n-heptane) to
provide 233 mg of the title compound as a colorless oil (97%). MS
(ESI): m/z=324.1 [M+H].sup.+.
Step a) rac-tert-Butyl
(2R,3S)-3-(2-bromo-5-(trifluoromethyl)phenoxy)-2-methylpyrrolidine-1-carb-
oxylate
[0981] To a solution of rac-tert-butyl
(2R,3S)-3-hydroxy-2-methylpyrrolidine-1-carboxylate (CAS:
1807941-04-3, 150 mg, 745 .mu.mol) in dry THF (4 mL) under argon
atmosphere was added potassium tert-butoxide 1M in THF (783 .mu.L,
783 .mu.mol). The mixture was stirred at RT for 15 min, then cooled
down to 2-4.degree. C. and a solution of
1-bromo-2-fluoro-4-(trifluoromethyl)benzene (181 mg, 745 .mu.mol)
in 0.5 mL dry THF was added slowly. The mixture was stirred at RT
for 2 h and then extracted with EtOAc and aqueous 5% NaHCO.sub.3
solution followed by water and brine. The organic phase was dried
over MgSO.sub.4, filtered off and evaporated to dryness. The
residue was purified by column flash chromatography (gradient of
EtOAc in n-heptane, 0 to 40%) to yield the product as light yellow
oil (71%). MS (ESI): m/z=368 [M-56+H].sup.+.
[0982] The following intermediates were synthesized from
4-nitrophenyl
(4aR,8aS)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylate
(BB7a) and the suitable building blocks in analogy to the reaction
methods described herein.
TABLE-US-00013 BB No. Building block(s) MS, m/z Method BB203 BB198
480.1 [M + H].sup.+ A10 without DMAP BB204 BB201 445.1 [M +
H].sup.+ A10 without DMAP
BB206
3-[2-[2-Fluoro-4-(trifluoromethyl)phenyl]ethyl]azetidine;
4-methylbenzenesulfonic acid
[0983] The compound was prepared in analogy to BB95 from tert-butyl
3-(2-fluoro-4-(trifluoromethyl)phenethyl)azetidine-1-carboxylate
and 4-methylbenzenesulfonic acid monohydrate. Upon cooling a
suspension formed which was filtered. The filter cake was washed
with a small volume of EtOAc to provide the desired product as a
colorless solid (71.6%). MS (ESI): m/z=248.2 [M+H].sup.+.
Step a) Diethyl (2-fluoro-4-(trifluoromethyl)benzyl)phosphonate
[0984] The compound was prepared in analogy to BB159, step a, from
1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene and triethyl
phosphite. Colorless oil (83.4%). MS (ESI): m/z=315.2
[M+H].sup.+.
Step b) tert-Butyl
3-[(E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]vinyl]azetidine-1-carboxylat-
e
[0985] The compound was prepared in analogy to BB95, step a, from
diethyl (2-fluoro-4-(trifluoromethyl)benzyl)phosphonate and
tert-butyl 3-formylazetidine-1-carboxylate to yield the compound as
a colorless oil (69.9%). MS (ESI): m/z=290.1 [M-56+H].sup.+.
Step c) tert-Butyl
3-[2-[2-fluoro-4-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate
[0986] The compound was prepared in analogy to BB95, step b, from
tert-butyl
3-[(E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]vinyl]azetidine-1-carboxylat-
e. Colorless oil (92.0%). MS (ESI): m/z=292.2 [M-56+H].sup.+.
BB208
3-[2,2-Difluoro-2-[4-(trifluoromethyl)phenyl]ethyl]azetidine;
4-methylbenzenesulfonic acid
[0987] The compound was prepared in analogy to BB95 from tert-butyl
3-(2,2-difluoro-2-(4-(trifluoromethyl)phenyl)ethyl)azetidine-1-carboxylat-
e and 4-methylbenzenesulfonic acid monohydrate and using the
material isolated from the filtrate after evaporation, which was
used without further purification (30%). MS (ESI): m/z=266.2
[M+H].sup.+.
Step a) tert-Butyl
3-[2-[methoxy(methyl)amino]-2-oxo-ethyl]azetidine-1-carboxylate
[0988] To a suspension of
2-(1-(tert-butoxycarbonyl)azetidin-3-yl)acetic acid (2 g, 9.29
mmol) and HATU (3.89 g, 10.2 mmol) in DCM (65 mL) was added DIPEA
(2.64 g, 3.57 mL, 20.4 mmol) and the mixture was stirred at RT for
30 min before N,O-dimethylhydroxylamine hydrochloride (906 mg, 9.29
mmol) was added. Stirring was continued at RT overnight. The
reaction mixture was poured on saturated aqueous NH.sub.4Cl
solution and EtOAc and the layers were separated. The aqueous layer
was extracted twice with EtOAc. The organic layers were washed
twice with water, dried over MgSO.sub.4, filtered, treated with
silica gel and evaporated. The compound was purified by silica gel
chromatography on a 25 g column using an MPLC system eluting with a
gradient of n-heptane:EtOAc (100:0 to 0:100) to furnish the desired
compound as a colorless oil (100%) which was used in the next step
without further purification. MS (ESI): m/z=203.2
[M-56+H].sup.+.
Step b) tert-Butyl
3-[2-oxo-2-[4-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylate
[0989] To an ice-cold solution of tert-butyl
3-(2-(methoxy(methyl)amino)-2-oxoethyl)azetidine-1-carboxylate (0.8
g, 3.1 mmol) in THF (5 mL) in an argon-flushed and heat-dried
2-neck flask was added dropwise a turbid solution of
(4-(trifluoromethyl)phenyl)magnesium bromide 2.22 M in THF (1.95
mL, 4.34 mmol). The brown solution was stirred in an ice-bath for
2.5 h allowing the temperature to rise to RT. The reaction mixture
was poured on saturated aqueous NH.sub.4Cl solution and EtOAc and
the layers were separated. The aqueous layer was extracted twice
with EtOAc. The organic layers were dried over MgSO.sub.4,
filtered, treated with silica gel and evaporated. The compound was
purified by silica gel chromatography on a 25 g column using an
MPLC system eluting with a gradient of n-heptane:EtOAc (100:0 to
0:100) to provide the desired compound as a colorless solid
(25.9%). MS (ESI): m/z=342.3 [M-H].sup.-.
Step c) tert-Butyl
3-[2,2-difluoro-2-[4-(trifluoromethyl)phenyl]ethyl]azetidine-1-carboxylat-
e
[0990] To a solution of tert-butyl
3-(2-oxo-2-(4-(trifluoromethyl)phenyl)ethyl)azetidine-1-carboxylate
(50 mg, 146 .mu.mol) in toluene (0.3 mL) under argon was added
bis(2-methoxyethyl)aminosulphur trifluoride (50% solution in THF,
387 mg, 379 .mu.L, 874 .mu.mol) and the mixture was stirred at
80.degree. C. for 19 h. The dark mixture was allowed to cool down
and another batch of bis(2-methoxyethyl)aminosulphur trifluoride
(50% solution in THF, 387 mg, 379 .mu.L, 874 .mu.mol) was added.
Heating was continued at 80.degree. C. for another 4 h. The
reaction mixture was poured on saturated aqueous NaHCO.sub.3
solution and EtOAc and the layers were separated. The aqueous layer
was extracted twice with EtOAc. The organic layers were dried over
MgSO.sub.4, filtered, treated with silica gel and evaporated. The
compound was purified by silica gel chromatography on a 4 g column
using an MPLC system eluting with a gradient of n-heptane:EtOAc
(100:0 to 50:50) to yield the desired compound as a light brown oil
(45.1%). MS (ESI): m/z=266.1 [M+H].sup.+.
BB209
3-[2-Fluoro-5-(trifluoromethyl)phenoxyl]pyrrolidine;
4-methylbenzenesulfonic acid
[0991] The compound was prepared in analogy to BB95 from tert-butyl
3-[2-fluoro-5-(trifluoromethyl)phenoxy]pyrrolidine-1-carboxylate.
Colorless oil which was used in the next step without further
purification. MS (ESI): m/z=250.1 [M+H].sup.+.
Step a) tert-Butyl
3-[2-fluoro-5-(trifluoromethyl)phenoxy]pyrrolidine-1-carboxylate
[0992] To a solution of 2-fluoro-5-(trifluoromethyl)phenol (321 mg,
1.78 mmol), tert-butyl 3-hydroxypyrrolidine-1-carboxylate (334 mg,
1.78 mmol, CAS RN: 103057-44-9) and triphenylphosphine (467 mg,
1.78 mmol) in THF (5 mL) was added
(E)-diazene-1,2-diylbis(piperidin-1-ylmethanone) (450 mg, 1.78
mmol, CAS RN 10465-81-3) in portions and the mixture was stirred at
RT for 40 h. Silica gel was added to the suspension and it was
evaporated. The compound was purified by silica gel chromatography
on a 24 g column using an MPLC (ISCO) system eluting with a
gradient of n-heptane:EtOAc (100:0 to 75:25) to provide the desired
compound as a colorless oil (8.3%) which was used in the next step
without further purification. MS (ESI): m/z=294.1
[M-56+H].sup.+.
BB210
3-[2-Chloro-5-(trifluoromethyl)phenoxy]pyrrolidine;
4-methylbenzenesulfonic acid
[0993] The compound was prepared in analogy to BB95 from tert-butyl
3-[2-chloro-5-(trifluoromethyl)phenoxy]pyrrolidine-1-carboxylate.
Colorless oil. MS (ESI): m/z=266.1 [M+H].sup.+.
Step a) tert-Butyl
3-[2-chloro-5-(trifluoromethyl)phenoxy]pyrrolidine-1-carboxylate
[0994] The compound was prepared in analogy to BB209, step a, from
2-chloro-5-(trifluoromethyl)phenol and tert-butyl
3-hydroxypyrrolidine-1-carboxylate. Colorless solid which was used
after chromatography without further purification. MS (ESI):
m/z=310.1 [M-56+H].sup.+.
BB211
3-[(E)-2-(2-fluoro-4-methyl-phenyl)vinyl]azetidine;
4-methylbenzenesulfonic acid
[0995] The compound was prepared in analogy to BB95 from tert-butyl
3-[(E)-2-(2-fluoro-4-methyl-phenyl)vinyl]azetidine-1-carboxylate
and 4-methylbenzenesulfonic acid monohydrate. Colorless solid
(87%). MS (ESI): m/z=192.2 [M+H].sup.+.
Step a) 1-(Diethoxyphosphorylmethyl)-2-fluoro-4-methyl-benzene
[0996] The compound was prepared in analogy to BB206, step a, from
1-(bromomethyl)-2-fluoro-4-methylbenzene and triethyl phosphite
followed by silica gel chromatography on a 40 g column using an
MPLC (ISCO) system eluting with a gradient of n-heptane:EtOAc
(100:0 to 0:100). Colorless liquid (85%). MS (ESI): m % z=261.1
[M+H].sup.+.
Step b) tert-Butyl
3-[(E)-2-(2-fluoro-4-methyl-phenyl)vinyl]azetidine-1-carboxylate
[0997] The compound was prepared in analogy to example BB206, step
b, from tert-butyl 3-formylazetidine-1-carboxylate and
1-(diethoxyphosphorylmethyl)-2-fluoro-4-methyl-benzene. Colorless
oil (7%). MS (ESI): m % z=236.2 [M-56+H].sup.+.
* * * * *